{"a0699820f33dbd624c609d225a0061fa081a7a8a": [["I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd (\"BMJ\") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.", [["CC", "CHEMICAL", 284, 286], ["right", "ANATOMY_MODIFIER", 33, 38]]]], "566e6fb2a6614c633a6418075d45114634ed8d01": [["The identification of most of the genes in the human genome has spawned varying estimates of the number of potential new drug targets that await discovery (Drews, 2000; Hopkins & Groom, 2002) .", [["human", "ORGANISM", 47, 52], ["human genome", "DNA", 47, 59], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 47, 52], ["human genome", "OBSERVATION", 47, 59], ["new", "OBSERVATION_MODIFIER", 117, 120]]], ["However, translating this genomic information into drug therapies is still a major challenge facing pharmaceutical companies.", [["drug therapies", "TREATMENT", 51, 65]]], ["Providing support for the concept that drug modulation of a given target is likely to produce a therapeutic response in patients is a key step in this progression from ''gene to screen'' (Hardy & Peet, 2004) .", [["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128]]], ["The main limitations are knowing which gene products are functionally involved in the pathology of a disease (target validation) and the druggability of the gene products by small molecule compounds.", [["a disease", "PROBLEM", 99, 108], ["the gene products", "TREATMENT", 153, 170], ["small molecule compounds", "PROBLEM", 174, 198], ["main", "OBSERVATION_MODIFIER", 4, 8], ["disease", "OBSERVATION", 101, 108], ["small", "OBSERVATION_MODIFIER", 174, 179], ["molecule compounds", "OBSERVATION", 180, 198]]], ["For over a decade now, targeting mRNA for both target validation and as a therapeutic strategy has been actively pursued using ribozymes (Breaker, 2004) or antisense (Crooke, 2004) approaches.", [["mRNA", "RNA", 33, 37], ["a therapeutic strategy", "TREATMENT", 72, 94], ["ribozymes (Breaker", "TREATMENT", 127, 145]]], ["To date, only antisense technology has produced a marketed drug: Vitravene\u00a0for cytomegalovirus-induced retinitis (Winkler, 2004) .", [["Vitravene", "CHEMICAL", 65, 74], ["cytomegalovirus-induced retinitis", "DISEASE", 79, 112], ["Vitravene", "CHEMICAL", 65, 74], ["Vitravene", "SIMPLE_CHEMICAL", 65, 74], ["cytomegalovirus", "ORGANISM", 79, 94], ["Vitravene", "TREATMENT", 65, 74], ["cytomegalovirus", "PROBLEM", 79, 94], ["retinitis", "PROBLEM", 103, 112], ["retinitis", "OBSERVATION", 103, 112]]], ["Hailed as the ''Scientific Breakthrough of the Year'' for 2002 by the journal Science (Couzin, 2002) , double-stranded RNA (dsRNA) reagents are used to bind to and promote the degradation of target RNAs by harnessing an endogenous biological pathway.", [["target RNAs", "RNA", 191, 202], ["double-stranded RNA (dsRNA) reagents", "TREATMENT", 103, 139]]], ["In the context of drug discovery, the value of RNAi is based on the premise that knocking down the expression of putative drug targets can be used to rapidly and specifically simulate the biological and pharmacological effects of target inhibition by low-molecular-weight compounds in cellular assays and animal models of the disease.", [["cellular", "ANATOMY", 285, 293], ["cellular", "CELL", 285, 293], ["putative drug targets", "TREATMENT", 113, 134], ["cellular assays", "TEST", 285, 300], ["the disease", "PROBLEM", 322, 333], ["disease", "OBSERVATION", 326, 333]]], ["Although still in its infancy with respect to drug development, August 2004 brought a filing by Acuity Pharmaceuticals with the U.S. Food and Drug Administration for the first clinical trial of an RNAi therapeutic: Cand5 for treatment of a common form of blindness (http://www. acuitypharma.com/page4.html).", [["Cand5", "CHEMICAL", 215, 220], ["blindness", "DISEASE", 255, 264], ["Cand5", "SIMPLE_CHEMICAL", 215, 220], ["page4.html", "PROTEIN", 295, 305], ["Drug Administration", "TREATMENT", 142, 161], ["treatment", "TREATMENT", 225, 234], ["blindness", "PROBLEM", 255, 264], ["blindness", "OBSERVATION", 255, 264]]], ["In this article, we will review and assess the use of RNAi reagents for both target validation and their potential as therapeutics.The mechanism of RNA interferenceRNAi was first observed by plant biologists in the late 1980s, but its molecular mechanism remained unclear until the late 1990s, when elegant work in the nematode Caenorhabditis elegans showed that RNAi is an evolutionary conserved gene-silencing mechanism (Fire et al., 1998; Reinhart et al., 2000) .", [["nematode Caenorhabditis elegans", "ORGANISM", 319, 350], ["Caenorhabditis elegans", "SPECIES", 328, 350], ["Caenorhabditis elegans", "SPECIES", 328, 350], ["RNAi reagents", "TREATMENT", 54, 67], ["RNA interferenceRNAi", "PROBLEM", 148, 168], ["RNA interferenceRNAi", "OBSERVATION", 148, 168]]], ["The sequence-specific posttranscriptional gene silencing by double-stranded RNA is conserved in a range of organisms: plants, Neurospora, Drosophila, C. elegans, and mammals.", [["Neurospora, Drosophila", "ORGANISM", 126, 148], ["C. elegans", "ORGANISM", 150, 160], ["double-stranded RNA", "RNA", 60, 79], ["Drosophila", "SPECIES", 138, 148], ["C. elegans", "SPECIES", 150, 160], ["Drosophila", "SPECIES", 138, 148], ["C. elegans", "SPECIES", 150, 160], ["The sequence", "TEST", 0, 12], ["double-stranded RNA", "PROBLEM", 60, 79]]], ["This process is related to a normal defense against viruses and the mobilisation of transposable genetic elements (transposons; Tijsterman et al., 2002) .", [["transposable genetic elements", "DNA", 84, 113], ["transposons", "DNA", 115, 126], ["viruses", "PROBLEM", 52, 59]]], ["The dsRNAs produced by integrated transposons, replicating viruses, or one of the newly identified class of regulatory noncoding microRNAs (miRNAs; Bartel, 2004) are processed into short dsRNAs.", [["dsRNAs", "DNA", 4, 10], ["transposons", "DNA", 34, 45], ["regulatory noncoding microRNAs", "DNA", 108, 138], ["miRNAs", "DNA", 140, 146], ["2004", "DNA", 156, 160], ["short dsRNAs", "DNA", 181, 193], ["The dsRNAs", "PROBLEM", 0, 10], ["short dsRNAs", "PROBLEM", 181, 193], ["dsRNAs", "OBSERVATION", 4, 10], ["viruses", "OBSERVATION", 59, 66], ["noncoding microRNAs", "OBSERVATION", 119, 138], ["short dsRNAs", "OBSERVATION", 181, 193]]], ["These short RNAs trigger a cascade of biochemical events (Fig. 1) involving a cytoplasmic ribonuclease III (RNase III)-like protein known as Dicer and the partially characterised multiprotein complex known as the RNA-induced silencing complex (RISC), leading ultimately to the degradation of mRNAs (posttranscriptional gene silencing).", [["cytoplasmic", "ANATOMY", 78, 89], ["cytoplasmic", "ORGANISM_SUBSTANCE", 78, 89], ["ribonuclease III", "GENE_OR_GENE_PRODUCT", 90, 106], ["RNase III", "GENE_OR_GENE_PRODUCT", 108, 117], ["Dicer", "GENE_OR_GENE_PRODUCT", 141, 146], ["RNA-induced silencing complex", "GENE_OR_GENE_PRODUCT", 213, 242], ["RISC", "GENE_OR_GENE_PRODUCT", 244, 248], ["cytoplasmic ribonuclease III", "PROTEIN", 78, 106], ["RNase III)-like protein", "PROTEIN", 108, 131], ["Dicer", "PROTEIN", 141, 146], ["multiprotein complex", "PROTEIN", 179, 199], ["RNA-induced silencing complex", "PROTEIN", 213, 242], ["RISC", "PROTEIN", 244, 248], ["mRNAs", "RNA", 292, 297], ["These short RNAs", "PROBLEM", 0, 16], ["biochemical events", "PROBLEM", 38, 56], ["a cytoplasmic ribonuclease III (RNase III)", "PROBLEM", 76, 118], ["the partially characterised multiprotein complex", "PROBLEM", 151, 199], ["the RNA", "PROBLEM", 209, 216], ["the degradation of mRNAs (posttranscriptional gene silencing", "PROBLEM", 273, 333], ["multiprotein complex", "OBSERVATION", 179, 199]]], ["The naturally occurring miRNAs are synthesized in the nucleus in large precursor forms.", [["nucleus", "ANATOMY", 54, 61], ["nucleus", "CELLULAR_COMPONENT", 54, 61], ["naturally", "OBSERVATION_MODIFIER", 4, 13], ["occurring miRNAs", "OBSERVATION", 14, 30], ["nucleus", "ANATOMY_MODIFIER", 54, 61], ["large", "OBSERVATION_MODIFIER", 65, 70], ["precursor forms", "OBSERVATION", 71, 86]]], ["An enzyme known as Drosha mediates the processing of the primary miRNA transcripts into pre-miRNAs (\u00a870mers), which are then exported to the cytoplasm .", [["cytoplasm", "ANATOMY", 141, 150], ["Drosha", "GENE_OR_GENE_PRODUCT", 19, 25], ["\u00a870mers", "GENE_OR_GENE_PRODUCT", 100, 107], ["cytoplasm", "ORGANISM_SUBSTANCE", 141, 150], ["Drosha", "PROTEIN", 19, 25], ["primary miRNA transcripts", "RNA", 57, 82], ["pre-miRNAs", "RNA", 88, 98], ["An enzyme", "TEST", 0, 9], ["Drosha mediates", "PROBLEM", 19, 34], ["Drosha", "OBSERVATION", 19, 25], ["primary miRNA transcripts", "OBSERVATION", 57, 82], ["cytoplasm", "OBSERVATION_MODIFIER", 141, 150]]], ["In the cytoplasm, Dicer is responsible for cleaving doublestranded molecules, whether derived from endogenous miRNAs or from replicating viruses, into small RNA duplexes of 19 -25 base pairs (bp) with characteristic 3Vdinucleotide overhangs (Bernstein et al., 2001) .", [["cytoplasm", "ANATOMY", 7, 16], ["cytoplasm", "ORGANISM_SUBSTANCE", 7, 16], ["Dicer", "GENE_OR_GENE_PRODUCT", 18, 23], ["Dicer", "PROTEIN", 18, 23], ["doublestranded molecules", "PROTEIN", 52, 76], ["endogenous miRNAs", "RNA", 99, 116], ["small RNA duplexes", "RNA", 151, 169], ["19 -25 base pairs", "DNA", 173, 190], ["3Vdinucleotide overhangs", "DNA", 216, 240], ["cleaving doublestranded molecules", "PROBLEM", 43, 76], ["endogenous miRNAs", "PROBLEM", 99, 116], ["replicating viruses", "PROBLEM", 125, 144], ["small RNA duplexes", "TEST", 151, 169], ["bp", "TEST", 192, 194], ["characteristic 3Vdinucleotide overhangs", "PROBLEM", 201, 240], ["responsible for", "UNCERTAINTY", 27, 42]]], ["The small interfering RNA (siRNA) duplex is incorporated into the RISC, whereupon an ATP-dependent helicase unwinds the duplex, enabling either one of the 2 strands to independently recognize mRNAs (Kisielow et al., 2002) .", [["RISC", "ANATOMY", 66, 70], ["ATP", "CHEMICAL", 85, 88], ["ATP", "CHEMICAL", 85, 88], ["RISC", "GENE_OR_GENE_PRODUCT", 66, 70], ["ATP", "SIMPLE_CHEMICAL", 85, 88], ["small interfering RNA (siRNA) duplex", "DNA", 4, 40], ["RISC", "CELL_TYPE", 66, 70], ["ATP-dependent helicase", "PROTEIN", 85, 107], ["mRNAs", "RNA", 192, 197], ["The small interfering RNA (siRNA) duplex", "PROBLEM", 0, 40], ["an ATP", "TEST", 82, 88], ["the duplex", "TEST", 116, 126], ["small", "OBSERVATION_MODIFIER", 4, 9], ["interfering RNA", "OBSERVATION", 10, 25], ["RISC", "ANATOMY", 66, 70]]], ["The extent of complementarity between the guiding strand and the target mRNA determines whether mRNA silencing is achieved via site-specific cleavage of the message in the region of the siRNA -mRNA duplex (Caudy et al., 2003) or through an miRNA-like mechanism of translational repression (Doench et al., 2003) .", [["guiding strand", "RNA", 42, 56], ["target mRNA", "RNA", 65, 76], ["siRNA -mRNA duplex", "DNA", 186, 204], ["the guiding strand", "TREATMENT", 38, 56], ["mRNA silencing", "PROBLEM", 96, 110], ["translational repression", "PROBLEM", 264, 288], ["extent", "OBSERVATION_MODIFIER", 4, 10], ["complementarity", "OBSERVATION", 14, 29], ["siRNA", "ANATOMY", 186, 191]]], ["For siRNA-mediated silencing, the cleavage products are released and degraded, leaving the disengaged RISC complex to further survey the mRNA pool.Ribonucleic acid interference in mammalian cellsAlthough genomic approaches such as gene expression analysis using ''gene chips'' (Archacki & Wang, 2004) or disease gene mapping (Whittaker, 2003a) can associate genes with disease phenotypes, these data alone cannot define the disease-associated role for the protein encoded by the gene.", [["mammalian cells", "ANATOMY", 180, 195], ["Ribonucleic acid", "CHEMICAL", 147, 163], ["Ribonucleic acid", "CHEMICAL", 147, 163], ["RISC", "GENE_OR_GENE_PRODUCT", 102, 106], ["Ribonucleic acid", "SIMPLE_CHEMICAL", 147, 163], ["mammalian cells", "CELL", 180, 195], ["cleavage products", "PROTEIN", 34, 51], ["RISC complex", "PROTEIN", 102, 114], ["mammalian cells", "CELL_TYPE", 180, 195], ["disease gene", "DNA", 304, 316], ["siRNA-mediated silencing", "TREATMENT", 4, 28], ["the cleavage products", "TREATMENT", 30, 51], ["Ribonucleic acid interference in mammalian cells", "PROBLEM", 147, 195], ["genomic approaches", "TREATMENT", 204, 222], ["''gene chips", "TREATMENT", 262, 274], ["disease gene mapping", "TREATMENT", 304, 324], ["disease phenotypes", "PROBLEM", 369, 387], ["the disease", "PROBLEM", 420, 431], ["acid interference", "OBSERVATION", 159, 176], ["mammalian cells", "OBSERVATION", 180, 195]]], ["Knockout mice have proved to be a powerful way of studying a gene's biological/disease relevance (Rosahl, 2003) to the extent that knockout phenotypes show a good correlation with drug efficacy (Zambrowicz et al., 2003) .", [["mice", "ORGANISM", 9, 13], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 9, 13], ["knockout phenotypes", "PROBLEM", 131, 150]]], ["However, the cost and time implications of developing such models mean there has been a drive to develop methods that enable target validation in vitro (particularly when working with novel targets) before embarking on in vivo studies.", [["vivo studies", "TEST", 222, 234]]], ["Given the success of RNAi in assigning gene function in lower eukaryotes, such as the nematode worm C. elegans (Sugimoto, 2004) and the fruitfly Drosophila melanogaster (Kuttenkeuler & Boutros, 2004) , it is not surprising that the approach has been adopted for analysing gene function (particularly target validation) in mammalian systems.Small interfering RNAThe specific and effective silencing of genes by RNAi in C. elegans and D. melanogaster can be achieved using long (> 500 bp) dsRNAs (Mello & Conte, 2004) .", [["nematode", "ORGANISM", 86, 94], ["worm C. elegans", "ORGANISM", 95, 110], ["fruitfly", "ORGANISM", 136, 144], ["Drosophila melanogaster", "ORGANISM", 145, 168], ["C. elegans", "ORGANISM", 418, 428], ["D. melanogaster", "ORGANISM", 433, 448], ["C. elegans", "SPECIES", 100, 110], ["Drosophila melanogaster", "SPECIES", 145, 168], ["C. elegans", "SPECIES", 418, 428], ["D. melanogaster", "SPECIES", 433, 448], ["C. elegans", "SPECIES", 100, 110], ["Drosophila melanogaster", "SPECIES", 145, 168], ["C. elegans", "SPECIES", 418, 428], ["D. melanogaster", "SPECIES", 433, 448], ["RNAi", "TREATMENT", 21, 25], ["analysing gene function", "PROBLEM", 262, 285], ["Small interfering RNAThe", "PROBLEM", 340, 364], ["interfering", "OBSERVATION", 346, 357]]], ["Furthermore, dsRNAs can be introduced into worms by direct injection, feeding them bacteria expressing dsRNA, or by soaking the worms in a solution of dsRNA (Wang & Barr, 2005) .", [["worms", "ANATOMY", 43, 48], ["dsRNAs", "DNA", 13, 19], ["worms", "SPECIES", 43, 48], ["worms", "SPECIES", 128, 133], ["dsRNAs", "TREATMENT", 13, 19], ["direct injection", "TREATMENT", 52, 68], ["feeding them bacteria expressing dsRNA", "PROBLEM", 70, 108]]], ["Firstly, dsRNAs > 30 bp trigger the g-interferon (IFN) pathway (the interferon pathway is one arm of the innate immune system triggered partly by dsRNA, a common replicative intermediate in viral infections), thus, 21 -23 bp double-stranded small interfering RNAs (siRNAs) generated by chemical synthesis (Elbashir et al., 2001) , enzymatic cleavage (Kittler et al., 2004) , or expression systems (Zheng et al., 2004) have to be used.", [["viral infections", "DISEASE", 190, 206], ["g-interferon", "GENE_OR_GENE_PRODUCT", 36, 48], ["IFN", "GENE_OR_GENE_PRODUCT", 50, 53], ["dsRNAs", "DNA", 9, 15], ["IFN", "PROTEIN", 50, 53], ["interferon", "PROTEIN", 68, 78], ["double-stranded small interfering RNAs", "RNA", 225, 263], ["siRNAs", "DNA", 265, 271], ["dsRNAs", "TEST", 9, 15], ["the g-interferon (IFN) pathway", "TREATMENT", 32, 62], ["the interferon pathway", "TREATMENT", 64, 86], ["dsRNA", "PROBLEM", 146, 151], ["a common replicative intermediate in viral infections", "PROBLEM", 153, 206], ["bp", "TEST", 222, 224], ["double-stranded small interfering RNAs (siRNAs", "TREATMENT", 225, 271], ["enzymatic cleavage", "PROBLEM", 331, 349], ["viral infections", "OBSERVATION", 190, 206], ["small", "OBSERVATION_MODIFIER", 241, 246], ["interfering RNAs", "OBSERVATION", 247, 263]]], ["These molecules elude the stress response by mimicking Dicer products and entering the RNAi pathway further downstream.", [["Dicer", "GENE_OR_GENE_PRODUCT", 55, 60], ["Dicer products", "PROTEIN", 55, 69], ["the stress response", "PROBLEM", 22, 41], ["mimicking Dicer products", "TREATMENT", 45, 69]]], ["Secondly, the siRNA duplexes have to be transfected into mammalian cells using either lipid-based formulations (Brazas & Hagstrom, 2005) , electroporation (Gresch et al., 2004) , or by linking to peptides (Muratovska & Eccles, 2004) .", [["cells", "ANATOMY", 67, 72], ["mammalian cells", "CELL", 57, 72], ["lipid", "SIMPLE_CHEMICAL", 86, 91], ["mammalian cells", "CELL_TYPE", 57, 72], ["the siRNA duplexes", "TREATMENT", 10, 28], ["lipid-based formulations", "TREATMENT", 86, 110], ["mammalian cells", "OBSERVATION", 57, 72]]], ["As siRNAs have become more widely used, the basic structure of effective siRNAs has been defined ( Fig. 2) , including the need for a 19-bp RNA duplex with a 2-nucleotide overhang on the 3Vends.", [["2-nucleotide", "CHEMICAL", 158, 170], ["2-nucleotide", "CHEMICAL", 158, 170], ["2-nucleotide overhang", "DNA", 158, 179], ["3Vends", "DNA", 187, 193], ["siRNAs", "PROBLEM", 3, 9], ["effective siRNAs", "TREATMENT", 63, 79], ["a 19-bp RNA duplex", "TREATMENT", 132, 150], ["more widely", "OBSERVATION_MODIFIER", 22, 33], ["effective siRNAs", "OBSERVATION", 63, 79]]], ["It has also become clear that the effectiveness of siRNA silencing is sequence specific, hence, rules for siRNA design have been developed (Mittal, 2004; Reynolds et al., 2004) .", [["siRNA silencing", "TREATMENT", 51, 66], ["siRNA design", "PROBLEM", 106, 118], ["clear", "OBSERVATION", 19, 24]]], ["Despite this, siRNA duplexes still have to be experimentally assessed and optimised for the knockdown of individual mRNA molecules, as not all duplexes matching the design criteria are potent (Kumar et al., 2003; Hsieh et al., 2004) .", [["mRNA molecules", "RNA", 116, 130], ["siRNA duplexes", "PROBLEM", 14, 28], ["individual mRNA molecules", "PROBLEM", 105, 130]]], ["It should also be emphasised that gene expression is knocked down rather than knocked out. siRNA has been successfully applied to mammalian cell lines (Caplen et al., 2001; Elbashir et al., 2001) , primary cells (Kao et al., 2004; Krick et al., 2005) , and embryonic stem cells (Ikeda et al., 2004; Hoelters et al., in press ).Stable induction of small interfering RNA by short hairpin RNA (shRNA)In contrast to C. elegans, where RNAi effects are stable, long lasting, and are passed onto the offspring (Grishok & Mello, 2002) , gene silencing by transfected siRNA duplexes in mammalian cells is transient.", [["cell lines", "ANATOMY", 140, 150], ["primary cells", "ANATOMY", 198, 211], ["embryonic stem cells", "ANATOMY", 257, 277], ["cells", "ANATOMY", 587, 592], ["mammalian cell lines", "CELL", 130, 150], ["cells", "CELL", 206, 211], ["embryonic stem cells", "CELL", 257, 277], ["C. elegans", "ORGANISM", 412, 422], ["mammalian cells", "CELL", 577, 592], ["mammalian cell lines", "CELL_LINE", 130, 150], ["primary cells", "CELL_TYPE", 198, 211], ["embryonic stem cells", "CELL_TYPE", 257, 277], ["small interfering RNA", "RNA", 347, 368], ["short hairpin RNA", "RNA", 372, 389], ["mammalian cells", "CELL_TYPE", 577, 592], ["C. elegans", "SPECIES", 412, 422], ["C. elegans", "SPECIES", 412, 422], ["siRNA", "TREATMENT", 91, 96], ["mammalian cell lines", "TREATMENT", 130, 150], ["small interfering RNA", "PROBLEM", 347, 368], ["short hairpin RNA (shRNA)", "PROBLEM", 372, 397], ["RNAi effects", "PROBLEM", 430, 442], ["gene silencing", "TREATMENT", 529, 543], ["transfected siRNA duplexes in mammalian cells", "PROBLEM", 547, 592], ["mammalian cell lines", "OBSERVATION", 130, 150], ["stem cells", "OBSERVATION", 267, 277], ["small", "OBSERVATION_MODIFIER", 347, 352], ["interfering RNA", "OBSERVATION", 353, 368], ["stable", "OBSERVATION_MODIFIER", 447, 453], ["siRNA duplexes", "OBSERVATION", 559, 573], ["mammalian cells", "OBSERVATION", 577, 592], ["transient", "OBSERVATION_MODIFIER", 596, 605]]], ["This is because mammalian cells lack the RNA-dependent RNA polymerases that amplify siRNAs in C. elegans.", [["cells", "ANATOMY", 26, 31], ["mammalian cells", "CELL", 16, 31], ["C. elegans", "ORGANISM", 94, 104], ["mammalian cells", "CELL_TYPE", 16, 31], ["RNA-dependent RNA polymerases", "PROTEIN", 41, 70], ["C. elegans", "SPECIES", 94, 104], ["C. elegans", "SPECIES", 94, 104], ["mammalian cells", "PROBLEM", 16, 31], ["the RNA", "PROBLEM", 37, 44], ["dependent RNA polymerases", "PROBLEM", 45, 70], ["mammalian cells", "OBSERVATION", 16, 31]]], ["As a result, gene silencing is dependent on the number of siRNA molecules transfected into the cells and the duplexes become progressively diluted as cells divide.", [["cells", "ANATOMY", 95, 100], ["cells", "ANATOMY", 150, 155], ["cells", "CELL", 95, 100], ["cells", "CELL", 150, 155], ["siRNA molecules", "PROTEIN", 58, 73], ["gene silencing", "PROBLEM", 13, 27], ["siRNA molecules", "TREATMENT", 58, 73], ["the duplexes", "PROBLEM", 105, 117]]], ["The persistence of siRNA activity in mammalian cells varies with the proliferative status of the cells, such that siRNA activity lasts for 3 -7 days in proliferating cells, but can persist for 3 weeks or more in terminally differentiated cells, such as neurons (Omi et al., 2004) .", [["mammalian cells", "ANATOMY", 37, 52], ["cells", "ANATOMY", 97, 102], ["cells", "ANATOMY", 166, 171], ["cells", "ANATOMY", 238, 243], ["neurons", "ANATOMY", 253, 260], ["mammalian cells", "CELL", 37, 52], ["cells", "CELL", 97, 102], ["cells", "CELL", 166, 171], ["cells", "CELL", 238, 243], ["neurons", "CELL", 253, 260], ["mammalian cells", "CELL_TYPE", 37, 52], ["proliferating cells", "CELL_TYPE", 152, 171], ["terminally differentiated cells", "CELL_TYPE", 212, 243], ["siRNA activity in mammalian cells", "PROBLEM", 19, 52], ["the cells", "PROBLEM", 93, 102], ["siRNA activity", "PROBLEM", 114, 128], ["proliferating cells", "PROBLEM", 152, 171], ["persistence", "OBSERVATION_MODIFIER", 4, 15], ["siRNA activity", "OBSERVATION", 19, 33], ["mammalian cells", "OBSERVATION", 37, 52], ["proliferative", "OBSERVATION_MODIFIER", 69, 82], ["cells", "ANATOMY", 97, 102], ["siRNA activity", "OBSERVATION", 114, 128]]], ["To get around this problem, vector-based systems for the introduction and stable expression of siRNA in target cells have been developed (Tuschl, 2002) .", [["cells", "ANATOMY", 111, 116], ["cells", "CELL", 111, 116], ["target cells", "CELL_TYPE", 104, 116], ["vector-based systems", "TREATMENT", 28, 48], ["the introduction", "TREATMENT", 53, 69], ["siRNA in target cells", "PROBLEM", 95, 116], ["stable", "OBSERVATION_MODIFIER", 74, 80], ["siRNA", "OBSERVATION", 95, 100]]], ["These vectors contain RNA polymerase III promoters that either express sense and antisense strands from separate promoters (tandem type) or express short hairpin RNAs (shRNAs) that are cleaved by the Dicer to produce siRNA (shRNA type; Fig. 3 ).", [["RNA polymerase III", "GENE_OR_GENE_PRODUCT", 22, 40], ["short hairpin RNAs", "GENE_OR_GENE_PRODUCT", 148, 166], ["shRNAs", "GENE_OR_GENE_PRODUCT", 168, 174], ["Dicer", "GENE_OR_GENE_PRODUCT", 200, 205], ["RNA polymerase III promoters", "DNA", 22, 50], ["promoters", "DNA", 113, 122], ["short hairpin RNAs", "RNA", 148, 166], ["shRNAs", "DNA", 168, 174], ["Dicer", "PROTEIN", 200, 205], ["These vectors", "TREATMENT", 0, 13], ["RNA polymerase III promoters", "TREATMENT", 22, 50], ["antisense strands", "PROBLEM", 81, 98], ["short hairpin RNAs (shRNAs)", "PROBLEM", 148, 175], ["RNA polymerase", "OBSERVATION", 22, 36]]], ["Stably transfected cell lines can be generated by selecting for a drug resistance marker (expressed either on the vector or on a co-transfected plasmid).", [["cell lines", "ANATOMY", 19, 29], ["plasmid", "ANATOMY", 144, 151], ["Stably", "CELL", 0, 6], ["cell lines", "CELL", 19, 29], ["cell lines", "CELL_LINE", 19, 29], ["co-transfected plasmid", "DNA", 129, 151], ["Stably transfected cell lines", "TREATMENT", 0, 29], ["a drug resistance marker", "TREATMENT", 64, 88], ["a co-transfected plasmid", "TREATMENT", 127, 151], ["transfected cell lines", "OBSERVATION", 7, 29]]], ["Such vector systems have been successfully used to obtain efficient and stable knockdown of target genes in mammalian cells (Mittal, 2004) .", [["mammalian cells", "ANATOMY", 108, 123], ["mammalian cells", "CELL", 108, 123], ["target genes", "DNA", 92, 104], ["mammalian cells", "CELL_TYPE", 108, 123], ["Such vector systems", "PROBLEM", 0, 19], ["mammalian cells", "OBSERVATION", 108, 123]]], ["Although it is difficult to say which of these 2 vector systems are more efficient at silencing gene expression, work does suggest that the shRNA system is more effective than the tandem system is (Miyagishi & Taira, 2003) .", [["the shRNA system", "PROBLEM", 136, 152]]], ["Recent work also indicates that shRNAs are more potent inducers of RNAi than is siRNA (Siolas et al., 2005) .Stable induction of small interfering RNA by short hairpin RNA (shRNA)The limitations of using plasmid vectors in terms of efficiency of transfection and difficulty in transfecting primary cells (Dykxhoorn et al., 2003) have resulted in workers developing retroviral (Brummelkamp et al., 2002) , lentiviral (Rubinson et al., 2003) , and adenoviral (Arts et al., 2003) vector systems for shRNA delivery.", [["primary cells", "ANATOMY", 290, 303], ["cells", "CELL", 298, 303], ["retroviral", "ORGANISM", 365, 375], ["lentiviral", "ORGANISM", 405, 415], ["adenoviral", "ORGANISM", 446, 456], ["shRNAs", "DNA", 32, 38], ["small interfering RNA", "RNA", 129, 150], ["short hairpin RNA", "RNA", 154, 171], ["primary cells", "CELL_TYPE", 290, 303], ["shRNAs", "PROBLEM", 32, 38], ["small interfering RNA", "PROBLEM", 129, 150], ["short hairpin RNA (shRNA)", "PROBLEM", 154, 179], ["plasmid vectors", "TREATMENT", 204, 219], ["transfection", "PROBLEM", 246, 258], ["difficulty in transfecting primary cells", "PROBLEM", 263, 303], ["vector systems", "TREATMENT", 477, 491], ["shRNA delivery", "TREATMENT", 496, 510], ["shRNAs", "OBSERVATION", 32, 38], ["more potent", "OBSERVATION_MODIFIER", 43, 54], ["small", "OBSERVATION_MODIFIER", 129, 134], ["interfering RNA", "OBSERVATION", 135, 150], ["short hairpin", "OBSERVATION_MODIFIER", 154, 167], ["transfection", "OBSERVATION", 246, 258]]], ["Viral vectors permit the efficient delivery and stable expression of shRNA constructs in a range of mammalian cells (including primary cells) and a variety of animal species.", [["mammalian cells", "ANATOMY", 100, 115], ["primary cells", "ANATOMY", 127, 140], ["mammalian cells", "CELL", 100, 115], ["cells", "CELL", 135, 140], ["shRNA constructs", "DNA", 69, 85], ["mammalian cells", "CELL_TYPE", 100, 115], ["primary cells", "CELL_TYPE", 127, 140], ["Viral vectors", "TREATMENT", 0, 13], ["the efficient delivery", "TREATMENT", 21, 43], ["shRNA constructs", "PROBLEM", 69, 85], ["mammalian cells", "PROBLEM", 100, 115], ["primary cells", "PROBLEM", 127, 140], ["animal species", "PROBLEM", 159, 173], ["stable", "OBSERVATION_MODIFIER", 48, 54], ["mammalian cells", "OBSERVATION", 100, 115]]], ["Retroviral vectors are based on murine stem cell virus or Moloney murine leukemia virus and permit the stable introduction of shRNA into dividing cells (transformed and primary).", [["stem cell", "ANATOMY", 39, 48], ["cells", "ANATOMY", 146, 151], ["Moloney murine leukemia virus", "DISEASE", 58, 87], ["Retroviral", "ORGANISM", 0, 10], ["murine stem cell virus", "ORGANISM", 32, 54], ["Moloney murine leukemia virus", "ORGANISM", 58, 87], ["cells", "CELL", 146, 151], ["dividing cells", "CELL_TYPE", 137, 151], ["murine", "SPECIES", 32, 38], ["murine", "SPECIES", 66, 72], ["Retroviral", "SPECIES", 0, 10], ["Moloney murine leukemia virus", "SPECIES", 58, 87], ["Retroviral vectors", "TREATMENT", 0, 18], ["murine stem cell virus", "PROBLEM", 32, 54], ["Moloney murine leukemia virus", "PROBLEM", 58, 87], ["stem cell virus", "OBSERVATION", 39, 54], ["Moloney murine leukemia virus", "OBSERVATION", 58, 87], ["stable", "OBSERVATION_MODIFIER", 103, 109]]], ["They have been used to suppress gene expression in stem cells and reconstituted organs derived from those cells (Hemann et al., 2003) .", [["stem cells", "ANATOMY", 51, 61], ["organs", "ANATOMY", 80, 86], ["cells", "ANATOMY", 106, 111], ["stem cells", "CELL", 51, 61], ["organs", "ORGAN", 80, 86], ["cells", "CELL", 106, 111], ["stem cells", "CELL_TYPE", 51, 61], ["gene expression in stem cells", "PROBLEM", 32, 61], ["stem cells", "OBSERVATION", 51, 61]]], ["Lentiviral vectors are derived from human immunodeficiency virus (HIV)-1 and can infect both dividing and nondividing postmitotic cells (e.g., neurones) and have been used to generate transgenic animals that display loss-offunction phenotypes and vector transmission to offspring (Rubinson et al., 2003; Tiscornia et al., 2003) .", [["postmitotic cells", "ANATOMY", 118, 135], ["neurones", "ANATOMY", 143, 151], ["human immunodeficiency virus", "DISEASE", 36, 64], ["Lentiviral", "ORGANISM", 0, 10], ["human immunodeficiency virus (HIV)-1", "ORGANISM", 36, 72], ["postmitotic cells", "CELL", 118, 135], ["neurones", "CELL", 143, 151], ["dividing and nondividing postmitotic cells", "CELL_TYPE", 93, 135], ["human immunodeficiency virus (HIV", "SPECIES", 36, 69], ["Lentiviral", "SPECIES", 0, 10], ["human immunodeficiency virus", "SPECIES", 36, 64], ["HIV)-1", "SPECIES", 66, 72], ["Lentiviral vectors", "TREATMENT", 0, 18], ["human immunodeficiency virus", "PROBLEM", 36, 64], ["loss-offunction phenotypes", "PROBLEM", 216, 242], ["nondividing postmitotic cells", "OBSERVATION", 106, 135]]], ["Adenoviral vectors based on adeno-associated viruses (AAV) can infect both dividing and nondividing cells, and because they integrate site specifically into the AAVS1 region of chromosome 19, they are safer than retroviral or lentiviral vectors, which are associated with insertional mutagenesis (Mittal, 2004) .", [["cells", "ANATOMY", 100, 105], ["chromosome 19", "ANATOMY", 177, 190], ["Adenoviral", "ORGANISM", 0, 10], ["adeno-associated viruses", "ORGANISM", 28, 52], ["AAV", "ORGANISM", 54, 57], ["cells", "CELL", 100, 105], ["AAVS1", "GENE_OR_GENE_PRODUCT", 161, 166], ["chromosome 19", "CELLULAR_COMPONENT", 177, 190], ["retroviral", "ORGANISM", 212, 222], ["lentiviral", "ORGANISM", 226, 236], ["dividing and nondividing cells", "CELL_TYPE", 75, 105], ["AAVS1 region", "DNA", 161, 173], ["chromosome 19", "DNA", 177, 190], ["Adenoviral", "SPECIES", 0, 10], ["adeno-associated viruses", "SPECIES", 28, 52], ["AAV", "SPECIES", 54, 57], ["Adenoviral vectors", "TREATMENT", 0, 18], ["adeno-associated viruses", "PROBLEM", 28, 52], ["viruses", "OBSERVATION", 45, 52], ["nondividing cells", "OBSERVATION", 88, 105], ["lentiviral vectors", "OBSERVATION", 226, 244]]], ["AAV vectors have been successfully used to silence genes, both in vitro and in vivo (Xia et al., 2002 Boden et al., 2004) .RNA interference in vivoRNAi is being used for the knockdown of gene expression in animals and promises to provide a quicker and cheaper way to generate knockout animals.", [["AAV", "ORGANISM", 0, 3], ["AAV vectors", "DNA", 0, 11], ["AAV", "SPECIES", 0, 3], ["AAV vectors", "TREATMENT", 0, 11], ["RNA interference in vivoRNAi", "PROBLEM", 123, 151], ["a quicker and cheaper way", "TREATMENT", 238, 263], ["interference", "OBSERVATION", 127, 139]]], ["The delivery of siRNA into model mammalian organisms has been achieved by intravenous injection or by electroporation of synthetic siRNAs directly into target tissues and organs (Dillon et al., 2004) .", [["intravenous", "ANATOMY", 74, 85], ["tissues", "ANATOMY", 159, 166], ["organs", "ANATOMY", 171, 177], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 74, 85], ["tissues", "TISSUE", 159, 166], ["organs", "ORGAN", 171, 177], ["The delivery of siRNA into model mammalian organisms", "TREATMENT", 0, 52], ["intravenous injection", "TREATMENT", 74, 95], ["synthetic siRNAs", "TREATMENT", 121, 137], ["organs", "ANATOMY", 171, 177]]], ["However, efficient and stable silencing has been most effectively obtained using retroviral and lentiviral vectors to transduce stem cells and embryos (Hemann et al., 2003; Rubinson et al., 2003) .", [["stem cells", "ANATOMY", 128, 138], ["embryos", "ANATOMY", 143, 150], ["retroviral", "ORGANISM", 81, 91], ["lentiviral", "ORGANISM", 96, 106], ["stem cells", "CELL", 128, 138], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 143, 150], ["stem cells", "CELL_TYPE", 128, 138], ["retroviral and lentiviral vectors", "TREATMENT", 81, 114], ["stable", "OBSERVATION_MODIFIER", 23, 29], ["silencing", "OBSERVATION", 30, 39], ["stem cells", "OBSERVATION", 128, 138]]], ["The results of experiments in a number of laboratories show that siRNA-mediated gene silencing functions in a range of cell and tissue types from blastocysts to adult animals and is both heritable and stable.", [["cell", "ANATOMY", 119, 123], ["tissue", "ANATOMY", 128, 134], ["blastocysts", "ANATOMY", 146, 157], ["cell", "CELL", 119, 123], ["tissue", "TISSUE", 128, 134], ["blastocysts", "DEVELOPING_ANATOMICAL_STRUCTURE", 146, 157], ["siRNA-mediated gene silencing functions", "PROBLEM", 65, 104], ["blastocysts", "OBSERVATION", 146, 157], ["heritable", "OBSERVATION_MODIFIER", 187, 196], ["stable", "OBSERVATION_MODIFIER", 201, 207]]], ["Kunath et al. (2003) transfected mouse ES cells with constructs expressing shRNAs for Ras GTPase-activating protein (RasGAP) and were able to produce mice that died during embryogenesis, with defects similar to those of RasGAP knockout mice produced by homologous recombination.", [["ES cells", "ANATOMY", 39, 47], ["mouse", "ORGANISM", 33, 38], ["ES cells", "CELL", 39, 47], ["Ras GTPase-activating protein", "GENE_OR_GENE_PRODUCT", 86, 115], ["RasGAP", "GENE_OR_GENE_PRODUCT", 117, 123], ["mice", "ORGANISM", 150, 154], ["RasGAP", "GENE_OR_GENE_PRODUCT", 220, 226], ["mice", "ORGANISM", 236, 240], ["mouse ES cells", "CELL_LINE", 33, 47], ["shRNAs", "DNA", 75, 81], ["Ras GTPase-activating protein", "PROTEIN", 86, 115], ["RasGAP", "PROTEIN", 117, 123], ["RasGAP", "PROTEIN", 220, 226], ["mouse", "SPECIES", 33, 38], ["mice", "SPECIES", 150, 154], ["mice", "SPECIES", 236, 240], ["mouse", "SPECIES", 33, 38], ["mice", "SPECIES", 150, 154], ["mice", "SPECIES", 236, 240], ["transfected mouse ES cells", "TREATMENT", 21, 47], ["Ras GTPase", "TEST", 86, 96], ["defects", "PROBLEM", 192, 199], ["RasGAP knockout mice", "TREATMENT", 220, 240]]], ["In another study, CD8 mRNA levels in T-cells were reduced in transgenic mice made using Fig. 3 .", [["T-cells", "ANATOMY", 37, 44], ["CD8", "GENE_OR_GENE_PRODUCT", 18, 21], ["T-cells", "CELL", 37, 44], ["mice", "ORGANISM", 72, 76], ["CD8 mRNA", "RNA", 18, 26], ["T-cells", "CELL_TYPE", 37, 44], ["mice", "SPECIES", 72, 76], ["mice", "SPECIES", 72, 76], ["another study", "TEST", 3, 16], ["CD8 mRNA levels", "TEST", 18, 33]]], ["Tandem and hairpin-type expression vectors for RNAi.", [["Tandem and hairpin-type expression vectors", "DNA", 0, 42], ["Tandem and hairpin-type expression vectors", "TREATMENT", 0, 42], ["hairpin", "OBSERVATION", 11, 18]]], ["In tandem-type vectors, the sense and antisense strands are expressed by separate polymerase III promoters and the strands anneal inside the cells to form duplex siRNA molecules.", [["cells", "ANATOMY", 141, 146], ["cells", "CELL", 141, 146], ["tandem-type vectors", "DNA", 3, 22], ["polymerase III promoters", "DNA", 82, 106], ["duplex siRNA molecules", "PROTEIN", 155, 177], ["antisense strands", "TREATMENT", 38, 55], ["siRNA molecules", "OBSERVATION", 162, 177]]], ["In the hairpin-type vectors, sense and antisense strands are connected by a loop and are expressed as a single molecule, which rapidly forms a hairpin structure with a stem and a loop that are processed to siRNA by Dicer.RNA interference in vivoa lentiviral vector expressing a hairpin (Rubinson et al., 2003) .", [["stem", "ANATOMY", 168, 172], ["Dicer", "GENE_OR_GENE_PRODUCT", 215, 220], ["hairpin-type vectors", "DNA", 7, 27], ["Dicer", "PROTEIN", 215, 220], ["antisense strands", "TREATMENT", 39, 56], ["a loop", "TREATMENT", 74, 80], ["a loop", "TREATMENT", 177, 183], ["RNA interference", "PROBLEM", 221, 237], ["vivoa lentiviral vector", "TREATMENT", 241, 264], ["hairpin", "OBSERVATION", 7, 14], ["antisense strands", "OBSERVATION", 39, 56], ["loop", "OBSERVATION_MODIFIER", 76, 80], ["hairpin structure", "OBSERVATION", 143, 160], ["stem", "OBSERVATION_MODIFIER", 168, 172], ["lentiviral vector", "OBSERVATION", 247, 264]]], ["Generating these mice is technically easier than generating knockout mice by the traditional route.", [["mice", "ORGANISM", 17, 21], ["mice", "ORGANISM", 69, 73], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 69, 73], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 69, 73]]], ["Furthermore, the finding that the approach can be applied to species not amenable to embryonic stem cell gene targeting, such as the rat (Hasuwa et al., 2002) , is particularly useful.RNA interference in vivoIndications that the knockdown phenotype produced by RNAi may be more ''variegated'' than the traditional knockout phenotype (Kunath et al., 2003; Rubinson et al., 2003) may be useful in modelling complex human diseases, where susceptibility or resistance is encoded by gene variants that display relative rather than absolute differences in expression.RNA interference in vivoCell-specific targeting of si/shRNA expression is an important consideration, particularly when considering RNAi for therapeutic applications (van Haaften et al., 2004) or as an alternative to low-molecular-weight molecules for target validation in vivo.", [["embryonic stem cell", "ANATOMY", 85, 104], ["embryonic stem cell", "CELL", 85, 104], ["rat", "ORGANISM", 133, 136], ["human", "ORGANISM", 413, 418], ["rat", "SPECIES", 133, 136], ["human", "SPECIES", 413, 418], ["rat", "SPECIES", 133, 136], ["human", "SPECIES", 413, 418], ["embryonic stem cell gene targeting", "TREATMENT", 85, 119], ["RNA interference in vivoIndications", "PROBLEM", 184, 219], ["the knockdown phenotype", "PROBLEM", 225, 248], ["modelling complex human diseases", "PROBLEM", 395, 427], ["RNA interference", "PROBLEM", 561, 577], ["vivoCell", "TREATMENT", 581, 589], ["si/shRNA expression", "TREATMENT", 612, 631], ["therapeutic applications", "TREATMENT", 702, 726], ["stem cell", "OBSERVATION", 95, 104]]], ["To get around the lethal effects of knocking out genes that are crucial for development, inducible knockout systems are used (Kwak et al., 2004) .Vectors that carry inducible promoters to allow the controlled expression of shRNA in response to an inducer based on the pol III promoters controlled by tetracycline (Matsukura et al., 2003) , ecdysone (Gupta et al., 2004) , or causes recombination (Cre) recombinase (Wiznerowicz & Trono, 2003; Fritsch et al., 2004; Kasim et al., 2004; Tiscornia et al., 2004) have been developed.", [["tetracycline", "CHEMICAL", 300, 312], ["tetracycline", "CHEMICAL", 300, 312], ["pol III", "GENE_OR_GENE_PRODUCT", 268, 275], ["tetracycline", "SIMPLE_CHEMICAL", 300, 312], ["Cre", "GENE_OR_GENE_PRODUCT", 397, 400], ["inducible promoters", "DNA", 165, 184], ["shRNA", "DNA", 223, 228], ["pol III promoters", "DNA", 268, 285], ["knocking out genes", "PROBLEM", 36, 54], ["inducible knockout systems", "PROBLEM", 89, 115], ["Vectors", "TREATMENT", 146, 153], ["inducible promoters", "TREATMENT", 165, 184], ["an inducer", "TREATMENT", 244, 254], ["the pol III promoters", "TREATMENT", 264, 285], ["tetracycline", "TREATMENT", 300, 312]]], ["An siRNA system that combines Cre -loxP for tissue-specific expression and tetracycline-on for inducible expression has been described recently .", [["tissue", "ANATOMY", 44, 50], ["tetracycline", "CHEMICAL", 75, 87], ["tetracycline", "CHEMICAL", 75, 87], ["Cre", "GENE_OR_GENE_PRODUCT", 30, 33], ["loxP", "GENE_OR_GENE_PRODUCT", 35, 39], ["tissue", "TISSUE", 44, 50], ["tetracycline", "SIMPLE_CHEMICAL", 75, 87], ["Cre -loxP", "DNA", 30, 39], ["An siRNA system", "TEST", 0, 15], ["Cre", "TEST", 30, 33], ["tetracycline", "TREATMENT", 75, 87], ["inducible expression", "PROBLEM", 95, 115], ["siRNA system", "OBSERVATION", 3, 15]]], ["By mating one mouse (carrying the siRNA/loxP plasmid) with another mouse carrying the Cre recombinase in specific tissues, siRNA in the offspring is induced by tetracycline.", [["tissues", "ANATOMY", 114, 121], ["tetracycline", "CHEMICAL", 160, 172], ["tetracycline", "CHEMICAL", 160, 172], ["mouse", "ORGANISM", 14, 19], ["loxP", "GENE_OR_GENE_PRODUCT", 40, 44], ["mouse", "ORGANISM", 67, 72], ["Cre", "GENE_OR_GENE_PRODUCT", 86, 89], ["tissues", "TISSUE", 114, 121], ["tetracycline", "SIMPLE_CHEMICAL", 160, 172], ["siRNA/loxP plasmid", "DNA", 34, 52], ["Cre recombinase", "DNA", 86, 101], ["mouse", "SPECIES", 14, 19], ["mouse", "SPECIES", 67, 72], ["mouse", "SPECIES", 14, 19], ["mouse", "SPECIES", 67, 72], ["the siRNA/loxP plasmid", "TREATMENT", 30, 52], ["siRNA", "PROBLEM", 123, 128], ["tetracycline", "TREATMENT", 160, 172]]], ["Using this method, an ABCA1-deficient mouse line that mimicked Tangier disease was produced, without the need to use embryonic stem cells or gene targeting.RNA interference in vivoAlthough the production of transgenic mice by RNAi potentially provides a speedy way of producing knockout animals, it is not as well characterised as the knockout approach.", [["embryonic stem cells", "ANATOMY", 117, 137], ["Tangier disease", "DISEASE", 63, 78], ["ABCA1", "GENE_OR_GENE_PRODUCT", 22, 27], ["mouse", "ORGANISM", 38, 43], ["Tangier disease", "CANCER", 63, 78], ["embryonic stem cells", "CELL", 117, 137], ["mice", "ORGANISM", 218, 222], ["ABCA1", "PROTEIN", 22, 27], ["embryonic stem cells", "CELL_TYPE", 117, 137], ["mouse", "SPECIES", 38, 43], ["mice", "SPECIES", 218, 222], ["mouse", "SPECIES", 38, 43], ["mice", "SPECIES", 218, 222], ["this method", "TREATMENT", 6, 17], ["an ABCA1-deficient mouse line", "TREATMENT", 19, 48], ["Tangier disease", "PROBLEM", 63, 78], ["embryonic stem cells", "TREATMENT", 117, 137], ["gene targeting", "TREATMENT", 141, 155], ["RNA interference", "PROBLEM", 156, 172], ["mouse line", "OBSERVATION", 38, 48], ["stem cells", "OBSERVATION", 127, 137], ["interference", "OBSERVATION_MODIFIER", 160, 172]]], ["It is unclear if the technology is robust enough to be a general approach for in vivo studies.", [["vivo studies", "TEST", 81, 93]]], ["Detailed analyses have not been performed to determine how reliably gene function can be knocked down in all tissues at all times throughout the life of the animal and what level of knockdown is required to result in a phenotype.", [["tissues", "ANATOMY", 109, 116], ["tissues", "TISSUE", 109, 116], ["Detailed analyses", "TEST", 0, 17], ["a phenotype", "PROBLEM", 217, 228]]], ["The lentiviral approach often results in multiple integration events (Rubinson et al., 2003; Tiscornia et al., 2003) , and mosaic expression of the shRNA might be expected.High-throughput analysis of gene functionOne of the most exciting opportunities offered by RNAi is the facility to identify all the genes required for certain physiological processes using genome-wide RNAi screens (Carpenter & Sabatini, 2004; Silva et al., 2004) .", [["lentiviral", "ORGANISM", 4, 14], ["shRNA", "DNA", 148, 153], ["The lentiviral approach", "TREATMENT", 0, 23], ["multiple integration events", "PROBLEM", 41, 68], ["mosaic expression of the shRNA", "PROBLEM", 123, 153], ["mosaic expression", "OBSERVATION", 123, 140]]], ["Highthroughput screens to identify genes involved in develop-ment and carcinogenesis have been successfully carried out in C. elegans (Lettre et al., 2004; Poulin et al., 2004) and D. melanogaster (Lum et al., 2003; Dasgupta & Perrimon, 2004) , and web databases that archive and distribute RNAi data for these organisms have been developed (www.RNAi.org and www.flyRNAi.org).The ability to extend such screens to mammalian systems is potentially very powerful, as most genes have now been identified to some level of accuracy, hence, it should be possible to define the role of genes in cell-based phenotypic assays by systematic inhibition of gene expression.", [["cell", "ANATOMY", 588, 592], ["carcinogenesis", "DISEASE", 70, 84], ["C. elegans", "ORGANISM", 123, 133], ["D. melanogaster", "ORGANISM", 181, 196], ["cell", "CELL", 588, 592], ["C. elegans", "SPECIES", 123, 133], ["D. melanogaster", "SPECIES", 181, 196], ["C. elegans", "SPECIES", 123, 133], ["D. melanogaster", "SPECIES", 181, 196], ["Highthroughput screens", "TEST", 0, 22], ["RNAi data", "TEST", 291, 300], ["these organisms", "PROBLEM", 305, 320]]], ["Although synthetic siRNAs are compatible with high-throughput formats (Vanhecke & Janitz, 2004a) , genome-scale libraries of chemically synthesized siRNA have not been reported, however, smaller collections for the screening of between 30 and 500 genes have been (Aza-Blanc et al., 2003; Hsieh et al., 2004 ).", [["Aza", "CHEMICAL", 264, 267], ["genome-scale libraries", "DNA", 99, 121], ["synthetic siRNAs", "TEST", 9, 25], ["Vanhecke & Janitz", "TREATMENT", 71, 88], ["chemically synthesized siRNA", "PROBLEM", 125, 153], ["smaller collections", "PROBLEM", 187, 206], ["the screening", "TEST", 211, 224], ["synthetic siRNAs", "OBSERVATION", 9, 25], ["high", "OBSERVATION_MODIFIER", 46, 50], ["smaller", "OBSERVATION_MODIFIER", 187, 194], ["collections", "OBSERVATION", 195, 206]]], ["An siRNA library that targeted > 8000 human genes based on an expression system in which siRNA duplexes are generated upon transfection into mammalian cells was used to identify regulators of nuclear factor-kappaB (NF-nB) signalling (Zheng et al., 2004) .High-throughput analysis of gene functionMost of the efforts in this area have concentrated on the use of vector-based shRNA libraries (Vanhecke & Janitz, 2005) .", [["mammalian cells", "ANATOMY", 141, 156], ["human", "ORGANISM", 38, 43], ["mammalian cells", "CELL", 141, 156], ["nuclear factor-kappaB", "GENE_OR_GENE_PRODUCT", 192, 213], ["NF-nB", "GENE_OR_GENE_PRODUCT", 215, 220], ["human genes", "DNA", 38, 49], ["mammalian cells", "CELL_TYPE", 141, 156], ["nuclear factor-kappaB", "PROTEIN", 192, 213], ["NF", "PROTEIN", 215, 217], ["nB", "PROTEIN", 218, 220], ["shRNA libraries", "DNA", 374, 389], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 38, 43], ["An siRNA library", "TEST", 0, 16], ["an expression system", "TREATMENT", 59, 79], ["siRNA duplexes", "TREATMENT", 89, 103], ["transfection into mammalian cells", "TREATMENT", 123, 156], ["nuclear factor", "TEST", 192, 206], ["gene function", "PROBLEM", 283, 296], ["vector-based shRNA libraries", "TREATMENT", 361, 389], ["siRNA library", "OBSERVATION", 3, 16]]], ["Large-scale gene-knockdown studies using retroviral vectors to express shRNAs have been reported in mammalian cells (Berns et al., 2004; Paddison et al., 2004) .", [["mammalian cells", "ANATOMY", 100, 115], ["retroviral", "ORGANISM", 41, 51], ["mammalian cells", "CELL", 100, 115], ["shRNAs", "DNA", 71, 77], ["mammalian cells", "CELL_TYPE", 100, 115], ["Large-scale gene-knockdown studies", "TREATMENT", 0, 34], ["retroviral vectors", "TREATMENT", 41, 59], ["shRNAs", "PROBLEM", 71, 77]]], ["Both studies included ''molecular bar codes'' in the vectors so that individual shRNAs in the cells could be easily detected.", [["cells", "ANATOMY", 94, 99], ["cells", "CELL", 94, 99], ["shRNAs", "DNA", 80, 86], ["Both studies", "TEST", 0, 12], ["individual shRNAs in the cells", "PROBLEM", 69, 99], ["bar codes", "OBSERVATION", 34, 43], ["vectors", "ANATOMY", 53, 60], ["individual shRNAs", "OBSERVATION", 69, 86]]], ["The screens identified new members of the pathways analysed, however, the failure to detect certain known members of the pathways highlights the current limitations of these approaches.", [["The screens", "TEST", 0, 11], ["the failure", "PROBLEM", 70, 81]]], ["Adenoviral vectors have been used to generate an shRNA library aimed at knocking down nearly 5000 transcripts encoding ''druggable'' proteins (http:// www.galadeno.com).", [["Adenoviral", "ORGANISM", 0, 10], ["druggable'' proteins", "PROTEIN", 121, 141], ["www.galadeno.com", "PROTEIN", 151, 167], ["Adenoviral", "SPECIES", 0, 10], ["Adenoviral vectors", "TREATMENT", 0, 18], ["an shRNA library", "TREATMENT", 46, 62]]], ["Potentially, genome-wide screens could be carried out for any process for which a tissue culture model exists.", [["tissue culture", "ANATOMY", 82, 96], ["tissue", "TISSUE", 82, 88], ["wide screens", "TEST", 20, 32], ["any process", "PROBLEM", 58, 69], ["a tissue culture model", "TEST", 80, 102]]], ["Furthermore, the development of transfected cell arrays in which si/shRNAs are printed onto a modified glass surface (Vanhecke & Janitz, 2004b) provides a way of reducing reagent usage and costs in such large screens (Erfle et al., 2004) .", [["cell", "ANATOMY", 44, 48], ["cell", "CELL", 44, 48], ["shRNAs", "GENE_OR_GENE_PRODUCT", 68, 74], ["shRNAs", "DNA", 68, 74], ["transfected cell arrays", "TREATMENT", 32, 55], ["si/shRNAs", "TREATMENT", 65, 74], ["a modified glass surface (Vanhecke & Janitz", "TREATMENT", 92, 135], ["reducing reagent usage", "TREATMENT", 162, 184], ["transfected cell arrays", "OBSERVATION", 32, 55], ["shRNAs", "ANATOMY", 68, 74]]], ["The large amounts of phenotypic data arising from such large-scale knockdown studies will require the development of bioinformatics tools to transform these complex datasets into ''digitised'' formats that can be readily mined (Gunsalus & Piano, 2005) .High-throughput analysis of gene function4.", [["gene function4", "DNA", 281, 295], ["phenotypic data", "PROBLEM", 21, 36], ["such large-scale knockdown studies", "PROBLEM", 50, 84], ["gene function4", "PROBLEM", 281, 295], ["large", "OBSERVATION_MODIFIER", 4, 9], ["amounts", "OBSERVATION_MODIFIER", 10, 17], ["large", "OBSERVATION_MODIFIER", 55, 60]]], ["The use of RNA interference for the study of disease-associated genes siRNA has been widely used in mammalian cells to define the functional roles of individual genes, particularly in disease (Dykxhoorn et al., 2003; Dillon et al., 2004) . siRNAs have been extensively used in cell-based studies for pathway dissection (Semizarov et al., 2004; Sun et al., 2004; Siripurapu et al., 2005) and to knockdown the expression of genes involved in a range of cellular processes, including endocytosis (Huang et al., 2004a) , signal transduction (Debes et al., 2002; Shu et al., 2002) , apoptosis (Kartasheva et al., 2002; Lassus et al., 2002) , and the cell cycle (Chen et al., 2002) , as well as genes relevant to neurodegenerative disease (Alberi et al., 2004; Buckingham et al., 2004; Thakker et al., 2004; Yokota et al., 2004) and xenotransplantation (Karlas et al., 2004) .", [["cells", "ANATOMY", 110, 115], ["cell", "ANATOMY", 277, 281], ["cellular", "ANATOMY", 451, 459], ["cell", "ANATOMY", 645, 649], ["neurodegenerative disease", "DISEASE", 707, 732], ["mammalian cells", "CELL", 100, 115], ["cell", "CELL", 277, 281], ["cellular", "CELL", 451, 459], ["cell", "CELL", 645, 649], ["mammalian cells", "CELL_TYPE", 100, 115], ["RNA interference", "TREATMENT", 11, 27], ["the study", "TEST", 32, 41], ["disease", "PROBLEM", 45, 52], ["associated genes siRNA", "PROBLEM", 53, 75], ["siRNAs", "TREATMENT", 240, 246], ["pathway dissection", "PROBLEM", 300, 318], ["neurodegenerative disease", "PROBLEM", 707, 732], ["xenotransplantation", "TREATMENT", 827, 846], ["genes siRNA", "OBSERVATION", 64, 75], ["dissection", "OBSERVATION", 308, 318], ["cellular processes", "OBSERVATION", 451, 469], ["neurodegenerative disease", "OBSERVATION", 707, 732]]], ["In this section, we will concentrate on the use of RNAi to study diseaserelevant genes in cancer, infection, and respiratory disease.CancerThe success of the drug Gleevec (imatinib) has shown the effectiveness of directly targeting cancer-promoting proteins for cancer therapy by revolutionizing drug therapy of chronic myelogenous leukemia (CML; Deininger et al., 2004) .", [["cancer", "ANATOMY", 90, 96], ["respiratory", "ANATOMY", 113, 124], ["Cancer", "ANATOMY", 133, 139], ["cancer", "ANATOMY", 232, 238], ["cancer", "ANATOMY", 262, 268], ["chronic myelogenous leukemia", "ANATOMY", 312, 340], ["CML", "ANATOMY", 342, 345], ["cancer", "DISEASE", 90, 96], ["infection", "DISEASE", 98, 107], ["respiratory disease", "DISEASE", 113, 132], ["Cancer", "DISEASE", 133, 139], ["Gleevec", "CHEMICAL", 163, 170], ["imatinib", "CHEMICAL", 172, 180], ["cancer", "DISEASE", 232, 238], ["cancer", "DISEASE", 262, 268], ["chronic myelogenous leukemia", "DISEASE", 312, 340], ["CML", "DISEASE", 342, 345], ["Gleevec", "CHEMICAL", 163, 170], ["imatinib", "CHEMICAL", 172, 180], ["cancer", "CANCER", 90, 96], ["Cancer", "CANCER", 133, 139], ["Gleevec", "SIMPLE_CHEMICAL", 163, 170], ["imatinib", "SIMPLE_CHEMICAL", 172, 180], ["cancer", "CANCER", 232, 238], ["cancer", "CANCER", 262, 268], ["chronic myelogenous leukemia", "CANCER", 312, 340], ["CML", "CANCER", 342, 345], ["diseaserelevant genes", "DNA", 65, 86], ["cancer-promoting proteins", "PROTEIN", 232, 257], ["Cancer", "SPECIES", 133, 139], ["RNAi", "TREATMENT", 51, 55], ["cancer", "PROBLEM", 90, 96], ["infection", "PROBLEM", 98, 107], ["respiratory disease", "PROBLEM", 113, 132], ["Cancer", "PROBLEM", 133, 139], ["the drug Gleevec (imatinib", "TREATMENT", 154, 180], ["directly targeting cancer", "PROBLEM", 213, 238], ["cancer therapy", "TREATMENT", 262, 276], ["revolutionizing drug therapy", "TREATMENT", 280, 308], ["chronic myelogenous leukemia", "PROBLEM", 312, 340], ["CML", "PROBLEM", 342, 345], ["cancer", "OBSERVATION", 90, 96], ["infection", "OBSERVATION", 98, 107], ["respiratory disease", "OBSERVATION", 113, 132], ["cancer", "OBSERVATION", 232, 238], ["chronic", "OBSERVATION_MODIFIER", 312, 319], ["myelogenous leukemia", "OBSERVATION", 320, 340]]], ["However, drug resistance is common in advanced phases of the disease because of mutations in the kinase domain of the BCR -ABL fusion protein that impair imatinib binding.", [["imatinib", "CHEMICAL", 154, 162], ["imatinib", "CHEMICAL", 154, 162], ["BCR", "GENE_OR_GENE_PRODUCT", 118, 121], ["ABL", "GENE_OR_GENE_PRODUCT", 123, 126], ["imatinib", "SIMPLE_CHEMICAL", 154, 162], ["kinase domain", "PROTEIN", 97, 110], ["BCR -ABL fusion protein", "PROTEIN", 118, 141], ["drug resistance", "PROBLEM", 9, 24], ["the disease", "PROBLEM", 57, 68], ["mutations in the kinase domain", "PROBLEM", 80, 110], ["the BCR", "PROBLEM", 114, 121], ["ABL fusion protein", "TREATMENT", 123, 141], ["imatinib binding", "PROBLEM", 154, 170], ["drug resistance", "OBSERVATION", 9, 24], ["imatinib binding", "OBSERVATION", 154, 170]]], ["These fusion proteins are attractive candidates for RNAi.", [["fusion proteins", "PROTEIN", 6, 21], ["These fusion proteins", "TREATMENT", 0, 21], ["RNAi", "PROBLEM", 52, 56]]], ["It has been shown that siRNA molecules targeting the junction fusion sequence attenuated the proliferation of transformed haematopoietic cells, sensitised cells to imatinib, and also inhibited an imatinib mutant .", [["haematopoietic cells", "ANATOMY", 122, 142], ["cells", "ANATOMY", 155, 160], ["imatinib", "CHEMICAL", 164, 172], ["imatinib", "CHEMICAL", 196, 204], ["imatinib", "CHEMICAL", 164, 172], ["imatinib", "CHEMICAL", 196, 204], ["haematopoietic cells", "CELL", 122, 142], ["cells", "CELL", 155, 160], ["imatinib", "SIMPLE_CHEMICAL", 164, 172], ["imatinib", "SIMPLE_CHEMICAL", 196, 204], ["junction fusion sequence", "DNA", 53, 77], ["transformed haematopoietic cells", "CELL_LINE", 110, 142], ["imatinib mutant", "PROTEIN", 196, 211], ["siRNA molecules", "TREATMENT", 23, 38], ["the junction fusion sequence", "TREATMENT", 49, 77], ["transformed haematopoietic cells", "PROBLEM", 110, 142], ["imatinib", "TREATMENT", 164, 172], ["an imatinib mutant", "PROBLEM", 193, 211], ["siRNA molecules", "OBSERVATION", 23, 38], ["proliferation", "OBSERVATION_MODIFIER", 93, 106], ["transformed haematopoietic cells", "OBSERVATION", 110, 142], ["imatinib mutant", "OBSERVATION", 196, 211]]], ["The ability of siRNAs to silence specific oncogenic variants while sparing the wild-type products of genes has been demonstrated for K-Ras V12 in human pancreatic carcinoma (Brummelkamp et al., 2002) .", [["pancreatic carcinoma", "ANATOMY", 152, 172], ["pancreatic carcinoma", "DISEASE", 152, 172], ["K-Ras V12", "GENE_OR_GENE_PRODUCT", 133, 142], ["human", "ORGANISM", 146, 151], ["pancreatic carcinoma", "CANCER", 152, 172], ["K", "PROTEIN", 133, 134], ["Ras V12", "PROTEIN", 135, 142], ["human", "SPECIES", 146, 151], ["human", "SPECIES", 146, 151], ["silence specific oncogenic variants", "PROBLEM", 25, 60], ["K", "TEST", 133, 134], ["human pancreatic carcinoma", "PROBLEM", 146, 172], ["oncogenic variants", "OBSERVATION", 42, 60], ["pancreatic", "ANATOMY", 152, 162], ["carcinoma", "OBSERVATION", 163, 172]]], ["Similarly, a single point mutation in the tumour suppressor p53 was effectively discriminated using siRNAs (Martinez et al., 2002) , resulting in the targeted destruction of the mutant, but not the wild-type product.", [["tumour", "ANATOMY", 42, 48], ["tumour", "DISEASE", 42, 48], ["tumour", "CANCER", 42, 48], ["p53", "GENE_OR_GENE_PRODUCT", 60, 63], ["tumour suppressor p53", "PROTEIN", 42, 63], ["wild-type product", "PROTEIN", 198, 215], ["a single point mutation", "PROBLEM", 11, 34], ["the tumour suppressor p53", "TREATMENT", 38, 63], ["the targeted destruction of the mutant", "PROBLEM", 146, 184], ["targeted", "OBSERVATION_MODIFIER", 150, 158], ["destruction", "OBSERVATION", 159, 170]]], ["In uterine cancers, specific knockdown of Akt isoforms 2 and 3, but not 1 using siRNA technology, was shown to significantly reduce the resistance of the endometrial KLE cells to cisplatin-induced apoptosis (Gagnon et al., 2004) .CancerReceptors associated with certain mitogenic pathways are known to promote malignancy.", [["uterine cancers", "ANATOMY", 3, 18], ["endometrial KLE cells", "ANATOMY", 154, 175], ["uterine cancers", "DISEASE", 3, 18], ["cisplatin", "CHEMICAL", 179, 188], ["malignancy", "DISEASE", 310, 320], ["cisplatin", "CHEMICAL", 179, 188], ["uterine cancers", "CANCER", 3, 18], ["Akt", "GENE_OR_GENE_PRODUCT", 42, 45], ["3", "GENE_OR_GENE_PRODUCT", 61, 62], ["endometrial KLE cells", "CELL", 154, 175], ["cisplatin", "SIMPLE_CHEMICAL", 179, 188], ["malignancy", "CANCER", 310, 320], ["Akt isoforms 2 and 3", "PROTEIN", 42, 62], ["endometrial KLE cells", "CELL_TYPE", 154, 175], ["uterine cancers", "PROBLEM", 3, 18], ["Akt isoforms", "TEST", 42, 54], ["siRNA technology", "TREATMENT", 80, 96], ["the endometrial KLE cells", "PROBLEM", 150, 175], ["cisplatin", "TREATMENT", 179, 188], ["apoptosis", "PROBLEM", 197, 206], ["certain mitogenic pathways", "PROBLEM", 262, 288], ["malignancy", "PROBLEM", 310, 320], ["uterine", "ANATOMY", 3, 10], ["cancers", "OBSERVATION", 11, 18], ["endometrial", "ANATOMY", 154, 165], ["KLE cells", "OBSERVATION", 166, 175], ["malignancy", "OBSERVATION", 310, 320]]], ["For example, stimulation of the gonadotropin receptor activates the mitogen-activated protein kinase (MAPK) cascade, and this has been shown to enhance the development of a wide range of gynaecological malignancies, including ovarian and breast endometrial carcinomas (Freimann et al., 2004) .", [["gynaecological malignancies", "ANATOMY", 187, 214], ["ovarian", "ANATOMY", 226, 233], ["breast endometrial carcinomas", "ANATOMY", 238, 267], ["gynaecological malignancies", "DISEASE", 187, 214], ["ovarian and breast endometrial carcinomas", "DISEASE", 226, 267], ["gonadotropin receptor", "GENE_OR_GENE_PRODUCT", 32, 53], ["mitogen-activated protein kinase", "GENE_OR_GENE_PRODUCT", 68, 100], ["MAPK", "GENE_OR_GENE_PRODUCT", 102, 106], ["gynaecological malignancies", "CANCER", 187, 214], ["ovarian", "CANCER", 226, 233], ["breast endometrial carcinomas", "CANCER", 238, 267], ["gonadotropin receptor", "PROTEIN", 32, 53], ["mitogen-activated protein kinase", "PROTEIN", 68, 100], ["MAPK", "PROTEIN", 102, 106], ["the gonadotropin receptor", "TEST", 28, 53], ["the mitogen", "TEST", 64, 75], ["gynaecological malignancies", "PROBLEM", 187, 214], ["ovarian and breast endometrial carcinomas", "PROBLEM", 226, 267], ["wide", "OBSERVATION_MODIFIER", 173, 177], ["gynaecological malignancies", "OBSERVATION", 187, 214], ["ovarian", "ANATOMY", 226, 233], ["breast", "ANATOMY", 238, 244], ["endometrial carcinomas", "OBSERVATION", 245, 267]]], ["When the chemokine receptor chemokine (C-X -C motif), receptor 4 (CXCR4) on the breast cancer cell line MDA-MB-231 was specifically targeted by siRNA, the rate of cell expansion slowed dramatically (Lapteva et al., 2004) .", [["breast cancer cell line MDA-MB-231", "ANATOMY", 80, 114], ["cell", "ANATOMY", 163, 167], ["breast cancer", "DISEASE", 80, 93], ["MDA-MB-231", "CHEMICAL", 104, 114], ["C-X -C motif), receptor 4", "GENE_OR_GENE_PRODUCT", 39, 64], ["CXCR4", "GENE_OR_GENE_PRODUCT", 66, 71], ["breast cancer cell line MDA-MB-231", "CELL", 80, 114], ["cell", "CELL", 163, 167], ["chemokine receptor chemokine", "PROTEIN", 9, 37], ["C-X -C motif", "PROTEIN", 39, 51], ["receptor 4", "PROTEIN", 54, 64], ["CXCR4", "PROTEIN", 66, 71], ["breast cancer cell line MDA-MB-231", "CELL_LINE", 80, 114], ["the chemokine receptor chemokine", "TEST", 5, 37], ["C-X -C motif)", "TREATMENT", 39, 52], ["receptor", "TEST", 54, 62], ["CXCR4", "TEST", 66, 71], ["the breast cancer", "TEST", 76, 93], ["MDA-MB", "TEST", 104, 110], ["siRNA", "TEST", 144, 149], ["cell expansion", "PROBLEM", 163, 177], ["breast", "ANATOMY", 80, 86], ["cancer", "OBSERVATION", 87, 93], ["cell expansion", "OBSERVATION", 163, 177]]], ["Furthermore, a 6 h 4 integrin (Lipscomb et al., 2003) and EpCAM (Osta et al., 2004c ) receptors on the same cells were identified by RNA interference as being involved in cellular invasion and metastasis.", [["cells", "ANATOMY", 108, 113], ["cellular", "ANATOMY", 171, 179], ["integrin", "GENE_OR_GENE_PRODUCT", 21, 29], ["EpCAM", "GENE_OR_GENE_PRODUCT", 58, 63], ["cells", "CELL", 108, 113], ["cellular", "CELL", 171, 179], ["integrin", "PROTEIN", 21, 29], ["EpCAM", "PROTEIN", 58, 63], ["Osta et al., 2004c ) receptors", "PROTEIN", 65, 95], ["a 6 h 4 integrin (Lipscomb et al.", "TREATMENT", 13, 46], ["EpCAM (Osta et al.", "TREATMENT", 58, 76], ["cellular invasion", "PROBLEM", 171, 188], ["metastasis", "PROBLEM", 193, 203], ["RNA interference", "OBSERVATION", 133, 149], ["cellular", "OBSERVATION_MODIFIER", 171, 179], ["invasion", "OBSERVATION", 180, 188], ["metastasis", "OBSERVATION", 193, 203]]], ["In prostate cancers, the androgen receptor was shown to be essential in the androgen-induced down-regulation of oncogene Bcell chronic lymphocytic leukemia/lymphoma 2 (Bcl-2) expression using siRNAs directed against several genes encoding proteins involved in the androgen signalling pathway (Huang et al., 2004b) .CancerThe selective regulation of the expression of cancerassociated genes is evolving as another potential therapeutic approach.", [["prostate cancers", "ANATOMY", 3, 19], ["Cancer", "ANATOMY", 315, 321], ["prostate cancers", "DISEASE", 3, 19], ["chronic lymphocytic leukemia/lymphoma", "DISEASE", 127, 164], ["Cancer", "DISEASE", 315, 321], ["androgen", "CHEMICAL", 25, 33], ["androgen", "CHEMICAL", 76, 84], ["androgen", "CHEMICAL", 264, 272], ["prostate cancers", "CANCER", 3, 19], ["androgen receptor", "GENE_OR_GENE_PRODUCT", 25, 42], ["androgen", "SIMPLE_CHEMICAL", 76, 84], ["Bcell chronic lymphocytic leukemia", "CANCER", 121, 155], ["lymphoma 2", "GENE_OR_GENE_PRODUCT", 156, 166], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 168, 173], ["androgen", "GENE_OR_GENE_PRODUCT", 264, 272], ["Cancer", "CANCER", 315, 321], ["androgen receptor", "PROTEIN", 25, 42], ["cancerassociated genes", "DNA", 367, 389], ["Cancer", "SPECIES", 315, 321], ["prostate cancers", "PROBLEM", 3, 19], ["the androgen receptor", "TREATMENT", 21, 42], ["oncogene Bcell chronic lymphocytic leukemia", "PROBLEM", 112, 155], ["lymphoma", "PROBLEM", 156, 164], ["Bcl", "TEST", 168, 171], ["siRNAs", "TREATMENT", 192, 198], ["several genes encoding proteins", "PROBLEM", 216, 247], ["Cancer", "PROBLEM", 315, 321], ["cancerassociated genes", "PROBLEM", 367, 389], ["prostate", "ANATOMY", 3, 11], ["cancers", "OBSERVATION", 12, 19], ["oncogene Bcell", "OBSERVATION", 112, 126], ["chronic", "OBSERVATION_MODIFIER", 127, 134], ["lymphocytic leukemia", "OBSERVATION", 135, 155], ["lymphoma", "OBSERVATION", 156, 164], ["selective", "OBSERVATION_MODIFIER", 325, 334], ["cancerassociated genes", "OBSERVATION", 367, 389]]], ["Clusterin is an antiapoptotic protein commonly expressed in cancer cells that are refractory to conventional chemotherapy.", [["cancer cells", "ANATOMY", 60, 72], ["cancer", "DISEASE", 60, 66], ["Clusterin", "GENE_OR_GENE_PRODUCT", 0, 9], ["cancer cells", "CELL", 60, 72], ["Clusterin", "PROTEIN", 0, 9], ["antiapoptotic protein", "PROTEIN", 16, 37], ["cancer cells", "CELL_TYPE", 60, 72], ["an antiapoptotic protein", "TREATMENT", 13, 37], ["cancer cells", "PROBLEM", 60, 72], ["conventional chemotherapy", "TREATMENT", 96, 121], ["antiapoptotic protein commonly", "OBSERVATION_MODIFIER", 16, 46], ["cancer cells", "OBSERVATION", 60, 72], ["refractory", "OBSERVATION_MODIFIER", 82, 92]]], ["Using A549 cells, July et al. (2004) showed a strong correlation between siRNA-mediated reduction of clusterin protein and the chemosensitivity of the cells in vitro.", [["A549 cells", "ANATOMY", 6, 16], ["cells", "ANATOMY", 151, 156], ["A549 cells", "CELL", 6, 16], ["clusterin", "GENE_OR_GENE_PRODUCT", 101, 110], ["cells", "CELL", 151, 156], ["A549 cells", "CELL_LINE", 6, 16], ["clusterin protein", "PROTEIN", 101, 118], ["siRNA", "TEST", 73, 78], ["clusterin protein", "PROBLEM", 101, 118], ["clusterin protein", "OBSERVATION", 101, 118]]], ["Perhaps, the most well-studied member of this class of antiapoptotic proteins is survivin, whose expression levels have been shown to be directly proportional to tumour grade, recurrence risk, and survival of patients with bladder cancer (Ambrosini et al., 1997) .", [["tumour", "ANATOMY", 162, 168], ["bladder cancer", "ANATOMY", 223, 237], ["tumour", "DISEASE", 162, 168], ["bladder cancer", "DISEASE", 223, 237], ["survivin", "GENE_OR_GENE_PRODUCT", 81, 89], ["tumour", "CANCER", 162, 168], ["patients", "ORGANISM", 209, 217], ["bladder cancer", "CANCER", 223, 237], ["antiapoptotic proteins", "PROTEIN", 55, 77], ["survivin", "PROTEIN", 81, 89], ["patients", "SPECIES", 209, 217], ["antiapoptotic proteins", "TREATMENT", 55, 77], ["recurrence risk", "PROBLEM", 176, 191], ["bladder cancer", "PROBLEM", 223, 237], ["bladder", "ANATOMY", 223, 230], ["cancer", "OBSERVATION", 231, 237]]], ["Ning et al. (2004) demonstrated that survivin siRNAs promoted apoptosis and inhibited the survival of bladder cancer cells.", [["bladder cancer cells", "ANATOMY", 102, 122], ["bladder cancer", "DISEASE", 102, 116], ["survivin", "GENE_OR_GENE_PRODUCT", 37, 45], ["bladder cancer cells", "CELL", 102, 122], ["survivin", "PROTEIN", 37, 45], ["bladder cancer cells", "CELL_TYPE", 102, 122], ["survivin siRNAs", "TREATMENT", 37, 52], ["apoptosis", "PROBLEM", 62, 71], ["bladder cancer cells", "PROBLEM", 102, 122], ["bladder", "ANATOMY", 102, 109], ["cancer cells", "OBSERVATION", 110, 122]]], ["Genes that encode the multidrug-resistance protein (MDR; pumps chemotherapeutic drugs out of tumours; Stege et al., 2004) , telomerase (involved in overcoming the chromosomal shortening that occurs with each cell division; Ma et al., 2004) , and Bcl-2 (makes cells resistant to caspase-mediated apoptosis; Yin et al., 2004) are further examples of genes that are not mutated in cancer but are overexpressed in a variety of cancers and represent attractive targets for silencing.", [["tumours", "ANATOMY", 93, 100], ["chromosomal", "ANATOMY", 163, 174], ["cell", "ANATOMY", 208, 212], ["cells", "ANATOMY", 259, 264], ["cancer", "ANATOMY", 378, 384], ["cancers", "ANATOMY", 423, 430], ["cancer", "DISEASE", 378, 384], ["cancers", "DISEASE", 423, 430], ["multidrug-resistance protein", "GENE_OR_GENE_PRODUCT", 22, 50], ["tumours", "CANCER", 93, 100], ["telomerase", "GENE_OR_GENE_PRODUCT", 124, 134], ["chromosomal", "CELLULAR_COMPONENT", 163, 174], ["cell", "CELL", 208, 212], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 246, 251], ["cells", "CELL", 259, 264], ["caspase", "GENE_OR_GENE_PRODUCT", 278, 285], ["cancer", "CANCER", 378, 384], ["cancers", "CANCER", 423, 430], ["multidrug-resistance protein", "PROTEIN", 22, 50], ["MDR", "PROTEIN", 52, 55], ["telomerase", "PROTEIN", 124, 134], ["Bcl-2", "PROTEIN", 246, 251], ["caspase", "PROTEIN", 278, 285], ["the multidrug-resistance protein (MDR", "TREATMENT", 18, 55], ["pumps chemotherapeutic drugs", "TREATMENT", 57, 85], ["tumours", "PROBLEM", 93, 100], ["the chromosomal shortening", "PROBLEM", 159, 185], ["Ma et al.", "TEST", 223, 232], ["Bcl", "TEST", 246, 249], ["apoptosis", "PROBLEM", 295, 304], ["cancer", "PROBLEM", 378, 384], ["cancers", "PROBLEM", 423, 430], ["Bcl", "ANATOMY", 246, 249], ["cancer", "OBSERVATION", 378, 384], ["cancers", "OBSERVATION", 423, 430]]], ["DNA repair mechanisms are crucial for the maintenance of genomic stability and are emerging as potential therapeutic targets for cancer.", [["cancer", "ANATOMY", 129, 135], ["cancer", "DISEASE", 129, 135], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["cancer", "CANCER", 129, 135], ["DNA repair mechanisms", "TREATMENT", 0, 21], ["cancer", "PROBLEM", 129, 135], ["repair", "OBSERVATION", 4, 10], ["genomic stability", "OBSERVATION", 57, 74], ["cancer", "OBSERVATION", 129, 135]]], ["Chow et al. (2004) used siRNA to identify endo-exonuclease (a protein involved in the recombination repair process of the DNA double-stranded break pathway, which is overexpressed in a variety of cancer cells), as a potential anticancer target.CancerSignalling molecules have been intensively researched as potential therapeutic targets in some cancers.", [["cancer cells", "ANATOMY", 196, 208], ["anticancer", "ANATOMY", 226, 236], ["cancers", "ANATOMY", 345, 352], ["cancer", "DISEASE", 196, 202], ["cancers", "DISEASE", 345, 352], ["endo-exonuclease", "GENE_OR_GENE_PRODUCT", 42, 58], ["DNA", "CELLULAR_COMPONENT", 122, 125], ["cancer cells", "CELL", 196, 208], ["anticancer", "CANCER", 226, 236], ["cancers", "CANCER", 345, 352], ["endo-exonuclease", "PROTEIN", 42, 58], ["cancer cells", "CELL_TYPE", 196, 208], ["CancerSignalling molecules", "PROTEIN", 244, 270], ["siRNA", "TREATMENT", 24, 29], ["endo-exonuclease", "TREATMENT", 42, 58], ["a protein", "TREATMENT", 60, 69], ["the recombination repair process", "TREATMENT", 82, 114], ["the DNA double-stranded break pathway", "TREATMENT", 118, 155], ["cancer cells", "PROBLEM", 196, 208], ["CancerSignalling molecules", "PROBLEM", 244, 270], ["some cancers", "PROBLEM", 340, 352], ["cancer cells", "OBSERVATION", 196, 208], ["cancers", "OBSERVATION", 345, 352]]], ["For instance, B-RAF is a serine/threonine-specific protein kinase that is mutated in\u00a870% of human melanomas, and B-RAF linked extracellular signal regulated protein kinase (ERK) signalling promotes proliferation and is antiapoptotic (Wellbrock et al., 2004) .", [["melanomas", "ANATOMY", 98, 107], ["melanomas", "DISEASE", 98, 107], ["serine", "CHEMICAL", 25, 31], ["threonine", "CHEMICAL", 32, 41], ["B-RAF", "GENE_OR_GENE_PRODUCT", 14, 19], ["serine", "AMINO_ACID", 25, 31], ["threonine", "AMINO_ACID", 32, 41], ["human", "ORGANISM", 92, 97], ["melanomas", "CANCER", 98, 107], ["B-RAF", "GENE_OR_GENE_PRODUCT", 113, 118], ["extracellular signal regulated protein kinase", "GENE_OR_GENE_PRODUCT", 126, 171], ["ERK", "GENE_OR_GENE_PRODUCT", 173, 176], ["B", "PROTEIN", 14, 15], ["RAF", "PROTEIN", 16, 19], ["serine/threonine-specific protein kinase", "PROTEIN", 25, 65], ["RAF", "PROTEIN", 115, 118], ["extracellular signal regulated protein kinase", "PROTEIN", 126, 171], ["ERK", "PROTEIN", 173, 176], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 92, 97], ["a serine/threonine-specific protein kinase", "PROBLEM", 23, 65], ["human melanomas", "PROBLEM", 92, 107], ["B-RAF linked extracellular signal", "TEST", 113, 146], ["protein kinase", "TEST", 157, 171], ["human", "ANATOMY", 92, 97], ["melanomas", "OBSERVATION", 98, 107], ["proliferation", "OBSERVATION_MODIFIER", 198, 211]]], ["Karasarides et al. (2004) showed that B-RAF depletion by siRNA blocked ERK activity, inhibited DNA synthesis, and induced apoptosis in three melanoma cell lines.", [["melanoma cell lines", "ANATOMY", 141, 160], ["melanoma", "DISEASE", 141, 149], ["B-RAF", "GENE_OR_GENE_PRODUCT", 38, 43], ["ERK", "GENE_OR_GENE_PRODUCT", 71, 74], ["DNA", "CELLULAR_COMPONENT", 95, 98], ["melanoma cell lines", "CELL", 141, 160], ["RAF", "PROTEIN", 40, 43], ["ERK", "PROTEIN", 71, 74], ["melanoma cell lines", "CELL_LINE", 141, 160], ["B-RAF depletion", "PROBLEM", 38, 53], ["siRNA blocked ERK activity", "PROBLEM", 57, 83], ["DNA synthesis", "PROBLEM", 95, 108], ["induced apoptosis in three melanoma cell lines", "PROBLEM", 114, 160], ["RAF depletion", "OBSERVATION", 40, 53], ["apoptosis", "OBSERVATION_MODIFIER", 122, 131], ["melanoma cell lines", "OBSERVATION", 141, 160]]], ["Many studies indicate that Rho GTPases are important in malignant transformation and angiogenesis and represent good anticancer targets (Aznar et al., 2004) .", [["anticancer", "ANATOMY", 117, 127], ["malignant transformation", "DISEASE", 56, 80], ["Rho", "GENE_OR_GENE_PRODUCT", 27, 30], ["anticancer", "CANCER", 117, 127], ["Rho GTPases", "PROTEIN", 27, 38], ["Many studies", "TEST", 0, 12], ["Rho GTPases", "PROBLEM", 27, 38], ["malignant transformation", "PROBLEM", 56, 80], ["angiogenesis", "PROBLEM", 85, 97], ["malignant transformation", "OBSERVATION", 56, 80], ["good", "OBSERVATION_MODIFIER", 112, 116], ["anticancer", "OBSERVATION_MODIFIER", 117, 127]]], ["Pille et al. (2005) used anti-RhoA and anti-RhoC siRNAs to block the Rhosignalling pathway and demonstrated that the siRNAs inhibited cell proliferation and invasion more effectively than do conventional blockers of Rho signalling (e.g., HMG-CoA reductase inhibitors), both in vitro and in vivo.CancerReports on in vivo experiments of siRNA in cancer are growing.", [["cell", "ANATOMY", 134, 138], ["cancer", "ANATOMY", 344, 350], ["cancer", "DISEASE", 344, 350], ["HMG-CoA", "CHEMICAL", 238, 245], ["anti-RhoA", "GENE_OR_GENE_PRODUCT", 25, 34], ["anti-RhoC", "GENE_OR_GENE_PRODUCT", 39, 48], ["Rhosignalling", "GENE_OR_GENE_PRODUCT", 69, 82], ["cell", "CELL", 134, 138], ["Rho", "GENE_OR_GENE_PRODUCT", 216, 219], ["HMG-CoA reductase", "GENE_OR_GENE_PRODUCT", 238, 255], ["cancer", "CANCER", 344, 350], ["anti-RhoA", "PROTEIN", 25, 34], ["Rho", "PROTEIN", 216, 219], ["HMG-CoA reductase", "PROTEIN", 238, 255], ["anti-RhoA", "TREATMENT", 25, 34], ["anti-RhoC siRNAs", "TREATMENT", 39, 55], ["the siRNAs inhibited cell proliferation", "PROBLEM", 113, 152], ["invasion", "PROBLEM", 157, 165], ["conventional blockers", "TREATMENT", 191, 212], ["Rho signalling", "PROBLEM", 216, 230], ["HMG-CoA reductase inhibitors", "TREATMENT", 238, 266], ["siRNA in cancer", "PROBLEM", 335, 350], ["cell proliferation", "OBSERVATION", 134, 152], ["siRNA", "OBSERVATION", 335, 340], ["cancer", "OBSERVATION", 344, 350]]], ["When nude mice were implanted with colon adenocarcinoma cells, the survival of these mice was greatly prolonged by pretreating the cells with siRNA against hcatenin .", [["colon adenocarcinoma cells", "ANATOMY", 35, 61], ["cells", "ANATOMY", 131, 136], ["colon adenocarcinoma", "DISEASE", 35, 55], ["hcatenin", "CHEMICAL", 156, 164], ["nude mice", "ORGANISM", 5, 14], ["colon adenocarcinoma cells", "CELL", 35, 61], ["mice", "ORGANISM", 85, 89], ["cells", "CELL", 131, 136], ["hcatenin", "GENE_OR_GENE_PRODUCT", 156, 164], ["colon adenocarcinoma cells", "CELL_TYPE", 35, 61], ["hcatenin", "PROTEIN", 156, 164], ["mice", "SPECIES", 10, 14], ["mice", "SPECIES", 85, 89], ["mice", "SPECIES", 10, 14], ["mice", "SPECIES", 85, 89], ["colon adenocarcinoma cells", "PROBLEM", 35, 61], ["siRNA against hcatenin", "TREATMENT", 142, 164], ["colon", "ANATOMY", 35, 40], ["adenocarcinoma cells", "OBSERVATION", 41, 61]]], ["Similarly, silencing of the oncogene H-Ras led to the inhibition of in vivo tumour growth of human ovarian cancer in mice .Viruses and bacteriaThe availability of the genome sequences of a range of pathogenic viruses (http://www.ncbi.nlm.nih.gov/genomes/ VIRUSES/viruses.html) provides the basis for the development of new antiviral therapies (DeFilippis et al., 2003; Wang et al., 2003) .", [["tumour", "ANATOMY", 76, 82], ["ovarian cancer", "ANATOMY", 99, 113], ["tumour", "DISEASE", 76, 82], ["ovarian cancer", "DISEASE", 99, 113], ["H-Ras", "GENE_OR_GENE_PRODUCT", 37, 42], ["tumour", "CANCER", 76, 82], ["human", "ORGANISM", 93, 98], ["ovarian cancer", "CANCER", 99, 113], ["mice", "ORGANISM", 117, 121], ["oncogene H-Ras", "PROTEIN", 28, 42], ["human", "SPECIES", 93, 98], ["mice", "SPECIES", 117, 121], ["human", "SPECIES", 93, 98], ["mice", "SPECIES", 117, 121], ["the inhibition", "TREATMENT", 50, 64], ["human ovarian cancer", "PROBLEM", 93, 113], ["Viruses", "PROBLEM", 123, 130], ["bacteria", "PROBLEM", 135, 143], ["pathogenic viruses", "PROBLEM", 198, 216], ["new antiviral therapies", "TREATMENT", 319, 342], ["human ovarian cancer", "OBSERVATION", 93, 113], ["bacteria", "OBSERVATION_MODIFIER", 135, 143], ["new", "OBSERVATION_MODIFIER", 319, 322], ["antiviral therapies", "OBSERVATION", 323, 342]]], ["Attractive targets are viral genes that are essential for virus replication and host genes that are essential for virus entry or that play an essential role in the virus life cycle.", [["viral genes", "DNA", 23, 34], ["host genes", "DNA", 80, 90], ["viral genes", "PROBLEM", 23, 34], ["virus replication", "TREATMENT", 58, 75], ["virus entry", "PROBLEM", 114, 125], ["viral genes", "OBSERVATION", 23, 34]]], ["For RNA viruses such as HIV, potentially any region of the viral genome can be targeted by siRNA/ shRNA.", [["HIV", "ORGANISM", 24, 27], ["viral genome", "DNA", 59, 71], ["shRNA", "DNA", 98, 103], ["HIV", "SPECIES", 24, 27], ["HIV", "SPECIES", 24, 27], ["RNA viruses", "PROBLEM", 4, 15], ["HIV", "PROBLEM", 24, 27], ["the viral genome", "PROBLEM", 55, 71], ["siRNA/ shRNA", "PROBLEM", 91, 103], ["viruses", "OBSERVATION", 8, 15], ["viral genome", "OBSERVATION", 59, 71]]], ["Silencing of genes relevant to viral diseases, such as HIV (Dave & Pomerantz, 2004) , hepatitis (Wilson et al., 2003) , and severe acute respiratory syndrome (SARS)associated coronavirus (Zhang et al., 2004a) , has been achieved using RNAi.", [["viral diseases", "DISEASE", 31, 45], ["hepatitis", "DISEASE", 86, 95], ["acute respiratory syndrome", "DISEASE", 131, 157], ["SARS", "DISEASE", 159, 163], ["coronavirus", "DISEASE", 175, 186], ["HIV", "SPECIES", 55, 58], ["HIV", "SPECIES", 55, 58], ["viral diseases", "PROBLEM", 31, 45], ["HIV", "PROBLEM", 55, 58], ["hepatitis", "PROBLEM", 86, 95], ["severe acute respiratory syndrome", "PROBLEM", 124, 157], ["SARS)", "PROBLEM", 159, 164], ["coronavirus", "PROBLEM", 175, 186], ["viral diseases", "OBSERVATION", 31, 45], ["hepatitis", "ANATOMY", 86, 95], ["severe", "OBSERVATION_MODIFIER", 124, 130], ["acute", "OBSERVATION_MODIFIER", 131, 136], ["respiratory syndrome", "OBSERVATION", 137, 157]]], ["In the case of HIV, silencing of the primary HIV receptor chemokine (C -C motif) receptor 5 (CCR5) by siRNA resulted in the prevention of viral entry into human peripheral blood lymphocytes (Qin et al., 2003) and primary haematopoietic stem cells .", [["peripheral blood lymphocytes", "ANATOMY", 161, 189], ["primary haematopoietic stem cells", "ANATOMY", 213, 246], ["HIV", "ORGANISM", 15, 18], ["C -C motif) receptor 5", "GENE_OR_GENE_PRODUCT", 69, 91], ["CCR5", "GENE_OR_GENE_PRODUCT", 93, 97], ["human", "ORGANISM", 155, 160], ["peripheral blood lymphocytes", "CELL", 161, 189], ["haematopoietic stem cells", "CELL", 221, 246], ["primary HIV receptor chemokine (C -C motif) receptor 5", "PROTEIN", 37, 91], ["CCR5", "PROTEIN", 93, 97], ["human peripheral blood lymphocytes", "CELL_TYPE", 155, 189], ["primary haematopoietic stem cells", "CELL_TYPE", 213, 246], ["HIV", "SPECIES", 15, 18], ["human", "SPECIES", 155, 160], ["HIV", "SPECIES", 15, 18], ["HIV", "SPECIES", 45, 48], ["human", "SPECIES", 155, 160], ["HIV", "PROBLEM", 15, 18], ["the primary HIV receptor chemokine (C -C motif) receptor", "TREATMENT", 33, 89], ["blood lymphocytes", "TEST", 172, 189], ["primary haematopoietic stem cells", "PROBLEM", 213, 246], ["blood lymphocytes", "ANATOMY", 172, 189], ["haematopoietic stem cells", "OBSERVATION", 221, 246]]], ["In hepatitis C, siRNA silencing led to a 98% reduction in detectable virus in infected cells (Randall et al., 2003; Randall & Rice, 2004) .", [["cells", "ANATOMY", 87, 92], ["hepatitis C", "DISEASE", 3, 14], ["hepatitis C", "ORGANISM", 3, 14], ["cells", "CELL", 87, 92], ["infected cells", "CELL_TYPE", 78, 92], ["hepatitis C", "PROBLEM", 3, 14], ["siRNA silencing", "PROBLEM", 16, 31], ["a 98% reduction", "TREATMENT", 39, 54], ["detectable virus in infected cells", "PROBLEM", 58, 92], ["hepatitis", "OBSERVATION", 3, 12], ["siRNA silencing", "OBSERVATION", 16, 31], ["detectable", "OBSERVATION_MODIFIER", 58, 68], ["virus", "OBSERVATION", 69, 74], ["infected cells", "OBSERVATION", 78, 92]]], ["Using siRNA targeted to the surface antigen region of the hepatitis B virus (HBV), Giladi et al. (2003) showed that the viral mRNA, viral antigens, and viral genomic DNA were significantly reduced in vitro and in vivo.", [["surface", "ANATOMY", 28, 35], ["hepatitis B", "DISEASE", 58, 69], ["hepatitis B virus", "ORGANISM", 58, 75], ["HBV", "ORGANISM", 77, 80], ["DNA", "CELLULAR_COMPONENT", 166, 169], ["surface antigen region", "PROTEIN", 28, 50], ["viral mRNA", "RNA", 120, 130], ["viral antigens", "PROTEIN", 132, 146], ["viral genomic DNA", "DNA", 152, 169], ["hepatitis B virus", "SPECIES", 58, 75], ["hepatitis B virus", "SPECIES", 58, 75], ["HBV", "SPECIES", 77, 80], ["siRNA", "TREATMENT", 6, 11], ["the hepatitis B virus", "PROBLEM", 54, 75], ["Giladi et al.", "TEST", 83, 96], ["the viral mRNA", "TEST", 116, 130], ["viral antigens", "PROBLEM", 132, 146], ["viral genomic DNA", "PROBLEM", 152, 169], ["hepatitis", "OBSERVATION", 58, 67], ["viral mRNA", "OBSERVATION", 120, 130], ["viral antigens", "OBSERVATION", 132, 146], ["viral genomic DNA", "OBSERVATION", 152, 169]]], ["Similarly, shRNAs have been used to inhibit the expression of hepatitis B virus surface antigen in HepG2 cells and decrease the levels of secreted antigen .", [["HepG2 cells", "ANATOMY", 99, 110], ["hepatitis B", "DISEASE", 62, 73], ["hepatitis B virus", "ORGANISM", 62, 79], ["surface antigen", "GENE_OR_GENE_PRODUCT", 80, 95], ["HepG2 cells", "CELL", 99, 110], ["secreted antigen", "GENE_OR_GENE_PRODUCT", 138, 154], ["shRNAs", "DNA", 11, 17], ["hepatitis B virus surface antigen", "PROTEIN", 62, 95], ["HepG2 cells", "CELL_LINE", 99, 110], ["secreted antigen", "PROTEIN", 138, 154], ["hepatitis B virus", "SPECIES", 62, 79], ["hepatitis B virus", "SPECIES", 62, 79], ["shRNAs", "PROBLEM", 11, 17], ["hepatitis B virus surface antigen", "TEST", 62, 95], ["HepG2 cells", "TEST", 99, 110], ["the levels of secreted antigen", "PROBLEM", 124, 154], ["shRNAs", "OBSERVATION", 11, 17], ["hepatitis", "OBSERVATION", 62, 71], ["decrease", "OBSERVATION_MODIFIER", 115, 123]]], ["In the case of SARS, it has recently been shown that SARS-associated coronavirus replication can be efficiently inhibited using siRNAs against two SARS viral polymerases .", [["SARS", "DISEASE", 15, 19], ["SARS", "DISEASE", 53, 57], ["coronavirus", "ORGANISM", 69, 80], ["SARS viral polymerases", "PROTEIN", 147, 169], ["SARS", "PROBLEM", 15, 19], ["SARS", "PROBLEM", 53, 57], ["coronavirus replication", "PROBLEM", 69, 92], ["siRNAs", "TREATMENT", 128, 134], ["two SARS viral polymerases", "PROBLEM", 143, 169], ["SARS", "OBSERVATION", 15, 19], ["coronavirus", "OBSERVATION", 69, 80]]], ["Similarly, Zhang et al. (2003) used the cytotoxicity of Vero cells as a surrogate marker of SARS-virus infection to show that siRNA transfection could effectively inhibit coronavirus replication.Viruses and bacteriaThe targeting of other infectious viruses using RNAi is also being pursued.", [["Vero cells", "ANATOMY", 56, 66], ["SARS-virus infection", "DISEASE", 92, 112], ["Vero cells", "CELL", 56, 66], ["SARS-virus", "ORGANISM", 92, 102], ["coronavirus", "ORGANISM", 171, 182], ["Vero cells", "CELL_LINE", 56, 66], ["coronavirus", "SPECIES", 171, 182], ["SARS-virus", "SPECIES", 92, 102], ["coronavirus", "SPECIES", 171, 182], ["the cytotoxicity of Vero cells", "TREATMENT", 36, 66], ["SARS", "PROBLEM", 92, 96], ["virus infection", "PROBLEM", 97, 112], ["siRNA transfection", "TREATMENT", 126, 144], ["coronavirus replication", "PROBLEM", 171, 194], ["Viruses", "PROBLEM", 195, 202], ["bacteria", "PROBLEM", 207, 215], ["other infectious viruses", "PROBLEM", 232, 256], ["RNAi", "TREATMENT", 263, 267], ["Vero cells", "OBSERVATION", 56, 66], ["bacteria", "OBSERVATION_MODIFIER", 207, 215], ["infectious", "OBSERVATION_MODIFIER", 238, 248], ["viruses", "OBSERVATION", 249, 256]]], ["For instance, it is possible to induce apoptosis in primary patient tumour samples by targeting the E6 gene of human papilloma virus (Butz et al., 2003) .", [["primary patient tumour samples", "ANATOMY", 52, 82], ["tumour", "DISEASE", 68, 74], ["human papilloma virus", "DISEASE", 111, 132], ["patient", "ORGANISM", 60, 67], ["tumour samples", "CANCER", 68, 82], ["E6", "GENE_OR_GENE_PRODUCT", 100, 102], ["human papilloma virus", "ORGANISM", 111, 132], ["E6 gene", "DNA", 100, 107], ["patient", "SPECIES", 60, 67], ["human", "SPECIES", 111, 116], ["papilloma virus", "SPECIES", 117, 132], ["human papilloma virus", "SPECIES", 111, 132], ["apoptosis in primary patient tumour samples", "PROBLEM", 39, 82], ["human papilloma virus", "PROBLEM", 111, 132], ["papilloma virus", "OBSERVATION", 117, 132]]], ["Plasmid-driven siRNA specific to West Nile Virus was effective in suppressing viral transcripts and infectious virion production in cell lines (McCown et al., 2003) .", [["cell lines", "ANATOMY", 132, 142], ["West Nile Virus", "ORGANISM", 33, 48], ["cell lines", "CELL", 132, 142], ["viral transcripts", "RNA", 78, 95], ["cell lines", "CELL_LINE", 132, 142], ["West Nile Virus", "SPECIES", 33, 48], ["Plasmid-driven siRNA", "TREATMENT", 0, 20], ["West Nile Virus", "TREATMENT", 33, 48], ["suppressing viral transcripts", "TREATMENT", 66, 95], ["infectious virion production", "PROBLEM", 100, 128], ["viral transcripts", "OBSERVATION", 78, 95], ["infectious", "OBSERVATION_MODIFIER", 100, 110], ["cell lines", "OBSERVATION", 132, 142]]], ["In addition, siRNAs specific for the conserved regions of the influenza A virus genome can protect cell lines and embryonated chicken eggs against infection (Ge et al., 2004a) .", [["cell lines", "ANATOMY", 99, 109], ["eggs", "ANATOMY", 134, 138], ["infection", "DISEASE", 147, 156], ["influenza A virus", "ORGANISM", 62, 79], ["cell lines", "CELL", 99, 109], ["chicken", "ORGANISM", 126, 133], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 134, 138], ["influenza A virus genome", "DNA", 62, 86], ["cell lines", "CELL_LINE", 99, 109], ["influenza A virus", "SPECIES", 62, 79], ["chicken", "SPECIES", 126, 133], ["influenza A virus", "SPECIES", 62, 79], ["chicken", "SPECIES", 126, 133], ["siRNAs", "TREATMENT", 13, 19], ["the influenza A virus genome", "PROBLEM", 58, 86], ["cell lines", "TREATMENT", 99, 109], ["embryonated chicken eggs", "TREATMENT", 114, 138], ["infection", "PROBLEM", 147, 156], ["influenza", "OBSERVATION", 62, 71], ["cell lines", "OBSERVATION", 99, 109]]], ["Respiratory syncytial virus (RSV) is ubiquitous in the environment and is the common cause of bronchiolitisassociated hospitalization of children and immunocompromised adults (McBride, 1999) .", [["Respiratory syncytial virus", "DISEASE", 0, 27], ["Respiratory syncytial virus", "ORGANISM", 0, 27], ["RSV", "ORGANISM", 29, 32], ["children", "ORGANISM", 137, 145], ["Respiratory syncytial virus", "SPECIES", 0, 27], ["children", "SPECIES", 137, 145], ["Respiratory syncytial virus", "SPECIES", 0, 27], ["RSV", "SPECIES", 29, 32], ["Respiratory syncytial virus", "PROBLEM", 0, 27], ["syncytial virus", "OBSERVATION", 12, 27]]], ["Monick et al. (2004) showed that RSV infection activates ERK via epidermal growth factor receptor (EGFR), leading to pronounced inflammation and prolonged survival of infected cells.", [["cells", "ANATOMY", 176, 181], ["RSV infection", "DISEASE", 33, 46], ["inflammation", "DISEASE", 128, 140], ["RSV", "ORGANISM", 33, 36], ["ERK", "GENE_OR_GENE_PRODUCT", 57, 60], ["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 65, 97], ["EGFR", "GENE_OR_GENE_PRODUCT", 99, 103], ["cells", "CELL", 176, 181], ["ERK", "PROTEIN", 57, 60], ["epidermal growth factor receptor", "PROTEIN", 65, 97], ["EGFR", "PROTEIN", 99, 103], ["infected cells", "CELL_TYPE", 167, 181], ["RSV", "SPECIES", 33, 36], ["RSV infection", "PROBLEM", 33, 46], ["epidermal growth factor receptor", "PROBLEM", 65, 97], ["EGFR", "TEST", 99, 103], ["pronounced inflammation", "PROBLEM", 117, 140], ["infected cells", "PROBLEM", 167, 181], ["RSV", "ANATOMY", 33, 36], ["infection", "OBSERVATION", 37, 46], ["pronounced", "OBSERVATION_MODIFIER", 117, 127], ["inflammation", "OBSERVATION", 128, 140], ["infected cells", "OBSERVATION", 167, 181]]], ["The inflammation was resolved, and apoptosis was induced in both infected immortalized (A549) and primary lung epithelial cells by targeting EGFR using siRNA.", [["A549", "ANATOMY", 88, 92], ["primary lung epithelial cells", "ANATOMY", 98, 127], ["inflammation", "DISEASE", 4, 16], ["A549", "CELL", 88, 92], ["lung epithelial cells", "CELL", 106, 127], ["EGFR", "GENE_OR_GENE_PRODUCT", 141, 145], ["A549", "CELL_LINE", 88, 92], ["primary lung epithelial cells", "CELL_TYPE", 98, 127], ["EGFR", "PROTEIN", 141, 145], ["The inflammation", "PROBLEM", 0, 16], ["apoptosis", "PROBLEM", 35, 44], ["primary lung epithelial cells", "PROBLEM", 98, 127], ["siRNA", "PROBLEM", 152, 157], ["inflammation", "OBSERVATION", 4, 16], ["resolved", "OBSERVATION_MODIFIER", 21, 29], ["lung", "ANATOMY", 106, 110], ["epithelial cells", "OBSERVATION", 111, 127]]], ["In another study, Rudd et al. (2005) showed that toll-like receptor 3 (TLR3) mediates inflammatory cytokine and chemokine production in RSV-infected epithelial cells using siRNAs targeting tolllike receptor 3 (TLR3).", [["epithelial cells", "ANATOMY", 149, 165], ["toll-like receptor 3", "GENE_OR_GENE_PRODUCT", 49, 69], ["TLR3", "GENE_OR_GENE_PRODUCT", 71, 75], ["RSV", "ORGANISM", 136, 139], ["epithelial cells", "CELL", 149, 165], ["tolllike receptor 3", "GENE_OR_GENE_PRODUCT", 189, 208], ["TLR3", "GENE_OR_GENE_PRODUCT", 210, 214], ["toll-like receptor 3", "PROTEIN", 49, 69], ["TLR3", "PROTEIN", 71, 75], ["inflammatory cytokine", "PROTEIN", 86, 107], ["chemokine", "PROTEIN", 112, 121], ["RSV-infected epithelial cells", "CELL_TYPE", 136, 165], ["tolllike receptor 3", "PROTEIN", 189, 208], ["TLR3", "PROTEIN", 210, 214], ["RSV", "SPECIES", 136, 139], ["another study", "TEST", 3, 16], ["inflammatory cytokine", "PROBLEM", 86, 107], ["chemokine production", "TEST", 112, 132], ["RSV", "PROBLEM", 136, 139], ["infected epithelial cells", "PROBLEM", 140, 165], ["siRNAs targeting tolllike receptor", "TREATMENT", 172, 206], ["inflammatory", "OBSERVATION_MODIFIER", 86, 98], ["infected epithelial cells", "OBSERVATION", 140, 165]]], ["As a complement to the experiments in vitro, Zhang et al. (2005) showed that mice treated intranasally with siRNA nanoparticles targeting the viral NS1 gene before or after infection with RSV showed substantially decreased virus titers in the lung and decreased inflammation and airway reactivity compared with the controls.Viruses and bacteriaIn contrast to viruses, bacteria are not generally amenable to silencing by siRNA because they mainly replicate outside of host cells and lack the necessary machinery (Lieberman et al., 2003) .", [["lung", "ANATOMY", 243, 247], ["airway", "ANATOMY", 279, 285], ["cells", "ANATOMY", 472, 477], ["infection", "DISEASE", 173, 182], ["inflammation", "DISEASE", 262, 274], ["mice", "ORGANISM", 77, 81], ["NS1", "GENE_OR_GENE_PRODUCT", 148, 151], ["RSV", "ORGANISM", 188, 191], ["lung", "ORGAN", 243, 247], ["airway", "MULTI-TISSUE_STRUCTURE", 279, 285], ["host cells", "CELL", 467, 477], ["viral NS1 gene", "DNA", 142, 156], ["host cells", "CELL_TYPE", 467, 477], ["mice", "SPECIES", 77, 81], ["mice", "SPECIES", 77, 81], ["RSV", "SPECIES", 188, 191], ["siRNA nanoparticles", "TREATMENT", 108, 127], ["the viral NS1 gene", "TREATMENT", 138, 156], ["infection", "PROBLEM", 173, 182], ["RSV", "PROBLEM", 188, 191], ["substantially decreased virus titers in the lung", "PROBLEM", 199, 247], ["decreased inflammation", "PROBLEM", 252, 274], ["airway reactivity", "PROBLEM", 279, 296], ["Viruses", "PROBLEM", 324, 331], ["bacteriaIn contrast", "TREATMENT", 336, 355], ["viruses", "PROBLEM", 359, 366], ["bacteria", "PROBLEM", 368, 376], ["decreased virus titers", "OBSERVATION", 213, 235], ["lung", "ANATOMY", 243, 247], ["decreased", "OBSERVATION_MODIFIER", 252, 261], ["inflammation", "OBSERVATION", 262, 274], ["airway reactivity", "OBSERVATION", 279, 296]]], ["However, it might still be possible to reduce morbidity and mortality from life-threatening bacterial infections by silencing host genes involved in aspects of the immune response that lead to adverse consequences, or host genes involved in mediating bacterial invasion.", [["bacterial infections", "DISEASE", 92, 112], ["host genes", "DNA", 218, 228], ["morbidity", "PROBLEM", 46, 55], ["life-threatening bacterial infections", "PROBLEM", 75, 112], ["adverse consequences", "PROBLEM", 193, 213], ["mediating bacterial invasion", "PROBLEM", 241, 269], ["bacterial", "OBSERVATION_MODIFIER", 92, 101], ["infections", "OBSERVATION", 102, 112], ["bacterial", "OBSERVATION_MODIFIER", 251, 260], ["invasion", "OBSERVATION", 261, 269]]], ["For instance, reducing the expression of proinflammatory cytokines such as tumour necrosis factor a (TNFa) lessened septic shock in mice treated with lipopolysaccharide (LPS) without jeopardizing the development of protective immunity (Sorensen et al., 2003) .", [["tumour necrosis", "DISEASE", 75, 90], ["septic shock", "DISEASE", 116, 128], ["lipopolysaccharide", "CHEMICAL", 150, 168], ["LPS", "CHEMICAL", 170, 173], ["tumour necrosis factor a", "GENE_OR_GENE_PRODUCT", 75, 99], ["TNFa", "GENE_OR_GENE_PRODUCT", 101, 105], ["mice", "ORGANISM", 132, 136], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 150, 168], ["LPS", "SIMPLE_CHEMICAL", 170, 173], ["proinflammatory cytokines", "PROTEIN", 41, 66], ["tumour necrosis factor", "PROTEIN", 75, 97], ["mice", "SPECIES", 132, 136], ["mice", "SPECIES", 132, 136], ["proinflammatory cytokines", "PROBLEM", 41, 66], ["tumour necrosis factor", "PROBLEM", 75, 97], ["a (TNFa)", "TREATMENT", 98, 106], ["septic shock", "PROBLEM", 116, 128], ["lipopolysaccharide (LPS", "TREATMENT", 150, 173], ["proinflammatory cytokines", "OBSERVATION", 41, 66], ["tumour necrosis", "OBSERVATION", 75, 90], ["septic shock", "OBSERVATION", 116, 128]]], ["Knockdown of caveolin-2 in murine lung epithelial cells inhibited Pseudomonas aeruginosa (the major pulmonary pathogen in cystic fibrosis patients) invasion by a lipid raft-dependent mechanism (Zaas et al., 2005) .ParasitesDespite the rapid expansion of medical technologies in recent years, Malaria still claims an estimated 2.7 million deaths per year, with 90% of the casualties occurring in sub-Saharan Africa (Vernick & Waters, 2004) .", [["lung epithelial cells", "ANATOMY", 34, 55], ["pulmonary", "ANATOMY", 100, 109], ["cystic", "ANATOMY", 122, 128], ["raft", "ANATOMY", 168, 172], ["fibrosis", "DISEASE", 129, 137], ["Malaria", "DISEASE", 292, 299], ["deaths", "DISEASE", 338, 344], ["casualties", "DISEASE", 371, 381], ["caveolin-2", "GENE_OR_GENE_PRODUCT", 13, 23], ["murine", "ORGANISM", 27, 33], ["lung epithelial cells", "CELL", 34, 55], ["Pseudomonas aeruginosa", "ORGANISM", 66, 88], ["pulmonary", "ORGAN", 100, 109], ["patients", "ORGANISM", 138, 146], ["caveolin-2", "PROTEIN", 13, 23], ["murine lung epithelial cells", "CELL_TYPE", 27, 55], ["murine", "SPECIES", 27, 33], ["Pseudomonas aeruginosa", "SPECIES", 66, 88], ["patients", "SPECIES", 138, 146], ["Pseudomonas aeruginosa", "SPECIES", 66, 88], ["caveolin", "TEST", 13, 21], ["murine lung epithelial cells", "TEST", 27, 55], ["Pseudomonas aeruginosa", "PROBLEM", 66, 88], ["the major pulmonary pathogen in cystic fibrosis", "PROBLEM", 90, 137], ["a lipid raft", "TREATMENT", 160, 172], ["Parasites", "PROBLEM", 214, 223], ["Malaria", "PROBLEM", 292, 299], ["caveolin", "ANATOMY", 13, 21], ["lung", "ANATOMY", 34, 38], ["epithelial cells", "OBSERVATION", 39, 55], ["Pseudomonas aeruginosa", "OBSERVATION", 66, 88], ["major", "OBSERVATION_MODIFIER", 94, 99], ["pulmonary", "ANATOMY", 100, 109], ["pathogen", "OBSERVATION_MODIFIER", 110, 118], ["cystic", "OBSERVATION_MODIFIER", 122, 128], ["fibrosis", "OBSERVATION", 129, 137], ["rapid", "OBSERVATION_MODIFIER", 235, 240], ["expansion", "OBSERVATION_MODIFIER", 241, 250]]], ["During the latter part of the 20th century, there was an alarming increase in the number of cases of Malaria reported in the Indian subcontinent, Southeast Asia, and South America (Malaney et al., 2004) .", [["Malaria", "DISEASE", 101, 108], ["Malaria", "PROBLEM", 101, 108], ["alarming", "OBSERVATION_MODIFIER", 57, 65], ["increase", "OBSERVATION_MODIFIER", 66, 74], ["Malaria", "OBSERVATION", 101, 108]]], ["Chloroquine remains the gold standard treatment for Malaria today.", [["Chloroquine", "CHEMICAL", 0, 11], ["Malaria", "DISEASE", 52, 59], ["Chloroquine", "CHEMICAL", 0, 11], ["Chloroquine", "SIMPLE_CHEMICAL", 0, 11], ["Chloroquine", "TREATMENT", 0, 11], ["the gold standard treatment", "TREATMENT", 20, 47], ["Malaria", "PROBLEM", 52, 59]]], ["However, chloroquine resistance is a growing concern (Verdrager, 1995) .", [["chloroquine", "CHEMICAL", 9, 20], ["chloroquine", "CHEMICAL", 9, 20], ["chloroquine", "SIMPLE_CHEMICAL", 9, 20], ["chloroquine resistance", "PROBLEM", 9, 31], ["chloroquine resistance", "OBSERVATION", 9, 31]]], ["The causative agent of the disease, Plasmodium falciparum, is a member of the intracellular protozoan family Apicomplexa (Kumar et al., 2002) .", [["intracellular", "ANATOMY", 78, 91], ["Plasmodium falciparum", "DISEASE", 36, 57], ["Plasmodium falciparum", "ORGANISM", 36, 57], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 78, 91], ["Plasmodium falciparum", "SPECIES", 36, 57], ["Plasmodium falciparum", "SPECIES", 36, 57], ["the disease", "PROBLEM", 23, 34], ["Plasmodium falciparum", "PROBLEM", 36, 57], ["disease", "OBSERVATION", 27, 34]]], ["Kumar et al. (2002) silenced a PP1 serine/ threonine protein phosphatase in the parasite and showed that the enzyme plays an essential role in its life cycle, therefore offering a potential target for drug development.", [["threonine", "CHEMICAL", 43, 52], ["serine", "CHEMICAL", 35, 41], ["threonine", "CHEMICAL", 43, 52], ["PP1", "GENE_OR_GENE_PRODUCT", 31, 34], ["threonine", "AMINO_ACID", 43, 52], ["PP1 serine/ threonine protein phosphatase", "PROTEIN", 31, 72], ["a PP1 serine", "TREATMENT", 29, 41], ["threonine protein phosphatase", "TEST", 43, 72], ["the enzyme", "TEST", 105, 115]]], ["The downside to this approach is that PP1 is highly conserved throughout evolution, and toxic side effects can be expected unless specific variants of the protein are identified.", [["PP1", "GENE_OR_GENE_PRODUCT", 38, 41], ["PP1", "PROTEIN", 38, 41], ["PP1", "PROBLEM", 38, 41], ["toxic side effects", "PROBLEM", 88, 106], ["specific variants of the protein", "PROBLEM", 130, 162], ["PP1", "OBSERVATION", 38, 41], ["highly", "OBSERVATION_MODIFIER", 45, 51], ["conserved", "OBSERVATION_MODIFIER", 52, 61], ["toxic", "OBSERVATION_MODIFIER", 88, 93]]], ["The finding that the machinery for RNAi exists in Anopheles gambiae (the principal malaria vector in Africa; Hoa et al., 2003) has allowed insights into the effects of mosquito genes on Plasmodium development (Osta et al., 2004a) .", [["malaria", "DISEASE", 83, 90], ["Anopheles gambiae", "ORGANISM", 50, 67], ["mosquito", "ORGANISM", 168, 176], ["Plasmodium", "ORGANISM", 186, 196], ["mosquito genes", "DNA", 168, 182], ["Anopheles gambiae", "SPECIES", 50, 67], ["Anopheles gambiae", "SPECIES", 50, 67]]], ["In addition, it has opened up the possibility of developing transgenic insect vectors that have innate resistance to the development and growth of P. falciparum (Osta et al., 2004b) .ParasitesAnother protozoan parasite, Entamoeba histolytica, causes human amoebiasis (Vayssie et al., 2004 )-the second leading cause of death worldwide due to protozoan infection.", [["P. falciparum", "DISEASE", 147, 160], ["protozoan parasite", "DISEASE", 200, 218], ["Entamoeba histolytica", "DISEASE", 220, 241], ["amoebiasis", "DISEASE", 256, 266], ["death", "DISEASE", 319, 324], ["protozoan infection", "DISEASE", 342, 361], ["P. falciparum", "ORGANISM", 147, 160], ["Entamoeba histolytica", "ORGANISM", 220, 241], ["human", "ORGANISM", 250, 255], ["P. falciparum", "SPECIES", 147, 160], ["Entamoeba histolytica", "SPECIES", 220, 241], ["human", "SPECIES", 250, 255], ["P. falciparum", "SPECIES", 147, 160], ["Entamoeba histolytica", "SPECIES", 220, 241], ["human", "SPECIES", 250, 255], ["developing transgenic insect vectors", "PROBLEM", 49, 85], ["P. falciparum", "PROBLEM", 147, 160], ["Parasites", "PROBLEM", 183, 192], ["Entamoeba histolytica", "PROBLEM", 220, 241], ["human amoebiasis", "PROBLEM", 250, 266], ["death", "PROBLEM", 319, 324], ["protozoan infection", "PROBLEM", 342, 361], ["transgenic insect vectors", "OBSERVATION", 60, 85], ["growth", "OBSERVATION_MODIFIER", 137, 143], ["protozoan", "OBSERVATION_MODIFIER", 200, 209], ["parasite", "OBSERVATION_MODIFIER", 210, 218], ["Entamoeba histolytica", "OBSERVATION", 220, 241], ["protozoan", "OBSERVATION_MODIFIER", 342, 351], ["infection", "OBSERVATION", 352, 361]]], ["Once inside its host, the parasite invades the intestinal mucosa, causing dysentery, and travels through the circulatory system to the liver, where it causes the development of abscesses (Petri, 2002) .", [["intestinal mucosa", "ANATOMY", 47, 64], ["circulatory system", "ANATOMY", 109, 127], ["liver", "ANATOMY", 135, 140], ["abscesses", "ANATOMY", 177, 186], ["dysentery", "DISEASE", 74, 83], ["abscesses", "DISEASE", 177, 186], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 47, 64], ["liver", "ORGAN", 135, 140], ["abscesses", "PATHOLOGICAL_FORMATION", 177, 186], ["dysentery", "PROBLEM", 74, 83], ["abscesses", "PROBLEM", 177, 186], ["intestinal mucosa", "ANATOMY", 47, 64], ["dysentery", "OBSERVATION", 74, 83], ["circulatory system", "ANATOMY", 109, 127], ["liver", "ANATOMY", 135, 140], ["abscesses", "OBSERVATION", 177, 186]]], ["Using RNAi knockdown, Vayssie et al. (2004) demonstrated that gtubulin is essential for microtubule nucleation and cycling of the parasite.", [["microtubule", "ANATOMY", 88, 99], ["gtubulin", "CHEMICAL", 62, 70], ["gtubulin", "GENE_OR_GENE_PRODUCT", 62, 70], ["microtubule", "CELLULAR_COMPONENT", 88, 99], ["gtubulin", "PROTEIN", 62, 70], ["microtubule", "PROTEIN", 88, 99], ["microtubule nucleation", "PROBLEM", 88, 110], ["microtubule nucleation", "OBSERVATION", 88, 110]]], ["Importantly, the primary amino acid sequence of the protein is homologous (46%) but not identical to its human homolog.", [["amino acid", "CHEMICAL", 25, 35], ["amino acid", "CHEMICAL", 25, 35], ["amino acid", "AMINO_ACID", 25, 35], ["human", "ORGANISM", 105, 110], ["primary amino acid sequence", "PROTEIN", 17, 44], ["human homolog", "PROTEIN", 105, 118], ["human", "SPECIES", 105, 110], ["human", "SPECIES", 105, 110], ["the primary amino acid sequence", "TEST", 13, 44], ["the protein", "TEST", 48, 59]]], ["Therefore, specific siRNA may be developed to destroy the parasite's g-tubulin while leaving the host's counterpart untouched.Respiratory diseasesThe discovery and development of inhaled antisense oligonucleotides (Ball et al., 2003) suggest that the delivery of siRNA molecules to the lung might be a viable approach to the treatment of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis.Respiratory diseasesCOPD is a global health problem and is the fourth leading cause of death in the United States alone (Murphy, 2000) .", [["Respiratory", "ANATOMY", 126, 137], ["lung", "ANATOMY", 286, 290], ["respiratory", "ANATOMY", 338, 349], ["pulmonary", "ANATOMY", 395, 404], ["cystic", "ANATOMY", 425, 431], ["Respiratory diseases", "DISEASE", 126, 146], ["respiratory diseases", "DISEASE", 338, 358], ["asthma", "DISEASE", 367, 373], ["chronic obstructive pulmonary disease", "DISEASE", 375, 412], ["COPD", "DISEASE", 414, 418], ["cystic fibrosis", "DISEASE", 425, 440], ["Respiratory diseasesCOPD", "DISEASE", 441, 465], ["death", "DISEASE", 528, 533], ["g-tubulin", "GENE_OR_GENE_PRODUCT", 69, 78], ["lung", "ORGAN", 286, 290], ["pulmonary", "ORGAN", 395, 404], ["g-tubulin", "PROTEIN", 69, 78], ["specific siRNA", "TREATMENT", 11, 25], ["Respiratory diseases", "PROBLEM", 126, 146], ["inhaled antisense oligonucleotides", "TREATMENT", 179, 213], ["the delivery of siRNA molecules", "TREATMENT", 247, 278], ["respiratory diseases", "PROBLEM", 338, 358], ["asthma", "PROBLEM", 367, 373], ["chronic obstructive pulmonary disease (COPD)", "PROBLEM", 375, 419], ["cystic fibrosis", "PROBLEM", 425, 440], ["Respiratory diseasesCOPD", "PROBLEM", 441, 465], ["a global health problem", "PROBLEM", 469, 492], ["death", "PROBLEM", 528, 533], ["g-tubulin", "OBSERVATION", 69, 78], ["diseases", "OBSERVATION", 138, 146], ["inhaled", "OBSERVATION_MODIFIER", 179, 186], ["antisense oligonucleotides", "OBSERVATION", 187, 213], ["lung", "ANATOMY", 286, 290], ["respiratory diseases", "OBSERVATION", 338, 358], ["asthma", "OBSERVATION", 367, 373], ["chronic", "OBSERVATION_MODIFIER", 375, 382], ["obstructive", "OBSERVATION_MODIFIER", 383, 394], ["pulmonary", "ANATOMY", 395, 404], ["disease", "OBSERVATION", 405, 412], ["COPD", "OBSERVATION", 414, 418], ["cystic", "OBSERVATION_MODIFIER", 425, 431], ["fibrosis", "OBSERVATION", 432, 440], ["diseasesCOPD", "OBSERVATION", 453, 465], ["global", "OBSERVATION_MODIFIER", 471, 477]]], ["Goblet cell hyperplasia and mucus hypersecretion are prominent features of COPD, especially during exacerbations (Pistelli et al., 2003) .", [["Goblet cell", "ANATOMY", 0, 11], ["mucus", "ANATOMY", 28, 33], ["Goblet cell hyperplasia", "DISEASE", 0, 23], ["mucus hypersecretion", "DISEASE", 28, 48], ["COPD", "DISEASE", 75, 79], ["Goblet cell", "CELL", 0, 11], ["mucus", "ORGANISM_SUBSTANCE", 28, 33], ["Goblet cell hyperplasia", "PROBLEM", 0, 23], ["mucus hypersecretion", "PROBLEM", 28, 48], ["COPD", "PROBLEM", 75, 79], ["cell hyperplasia", "OBSERVATION", 7, 23], ["mucus hypersecretion", "OBSERVATION", 28, 48], ["prominent", "OBSERVATION_MODIFIER", 53, 62], ["COPD", "OBSERVATION", 75, 79]]], ["Shao et al. (2004) showed that by specifically knocking down transforming growth factor (TGF)-a production via siRNA in NCI-H292 human airway epithelial cells, the expression of epidermal growth factor receptor (EGFR) was significantly reduced, leading to diminished mucus production.", [["NCI-H292", "ANATOMY", 120, 128], ["airway epithelial cells", "ANATOMY", 135, 158], ["mucus", "ANATOMY", 267, 272], ["transforming growth factor (TGF)-a", "GENE_OR_GENE_PRODUCT", 61, 95], ["NCI-H292 human airway epithelial cells", "CELL", 120, 158], ["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 178, 210], ["EGFR", "GENE_OR_GENE_PRODUCT", 212, 216], ["mucus", "ORGANISM_SUBSTANCE", 267, 272], ["TGF", "PROTEIN", 89, 92], ["NCI-H292 human airway epithelial cells", "CELL_LINE", 120, 158], ["epidermal growth factor receptor", "PROTEIN", 178, 210], ["EGFR", "PROTEIN", 212, 216], ["human", "SPECIES", 129, 134], ["human", "SPECIES", 129, 134], ["knocking down transforming growth factor", "PROBLEM", 47, 87], ["TGF", "TEST", 89, 92], ["epidermal growth factor receptor", "PROBLEM", 178, 210], ["diminished mucus production", "PROBLEM", 256, 283], ["airway", "ANATOMY", 135, 141], ["epithelial cells", "OBSERVATION", 142, 158], ["diminished", "OBSERVATION_MODIFIER", 256, 266], ["mucus production", "OBSERVATION", 267, 283]]], ["Another clinical manifestation of asthma and COPD is chronic inflammation and injury of both the airways and the parenchymal structures of the lung, in which TGF-h is thought to play a key role (Rennard, 1999; Sacco et al., 2004) .", [["airways", "ANATOMY", 97, 104], ["parenchymal structures", "ANATOMY", 113, 135], ["lung", "ANATOMY", 143, 147], ["asthma", "DISEASE", 34, 40], ["COPD", "DISEASE", 45, 49], ["inflammation", "DISEASE", 61, 73], ["airways", "MULTI-TISSUE_STRUCTURE", 97, 104], ["parenchymal structures", "TISSUE", 113, 135], ["lung", "ORGAN", 143, 147], ["TGF-h", "GENE_OR_GENE_PRODUCT", 158, 163], ["TGF", "PROTEIN", 158, 161], ["asthma", "PROBLEM", 34, 40], ["COPD", "PROBLEM", 45, 49], ["chronic inflammation", "PROBLEM", 53, 73], ["injury of both the airways and the parenchymal structures of the lung", "PROBLEM", 78, 147], ["asthma", "OBSERVATION", 34, 40], ["COPD", "OBSERVATION", 45, 49], ["chronic", "OBSERVATION_MODIFIER", 53, 60], ["inflammation", "OBSERVATION", 61, 73], ["injury", "OBSERVATION", 78, 84], ["both", "ANATOMY_MODIFIER", 88, 92], ["airways", "ANATOMY", 97, 104], ["parenchymal", "ANATOMY_MODIFIER", 113, 124], ["lung", "ANATOMY", 143, 147]]], ["TGF-h mediates a diverse range of cellular processes, including cell proliferation and differentiation, wound healing, and angiogenesis (Blobe et al., 2000) .", [["cellular", "ANATOMY", 34, 42], ["cell", "ANATOMY", 64, 68], ["wound", "ANATOMY", 104, 109], ["TGF-h", "GENE_OR_GENE_PRODUCT", 0, 5], ["cellular", "CELL", 34, 42], ["cell", "CELL", 64, 68], ["wound", "PATHOLOGICAL_FORMATION", 104, 109], ["TGF", "PROTEIN", 0, 3], ["TGF", "TEST", 0, 3], ["cellular processes", "PROBLEM", 34, 52], ["cell proliferation", "PROBLEM", 64, 82], ["wound healing", "PROBLEM", 104, 117], ["angiogenesis", "PROBLEM", 123, 135], ["diverse range", "OBSERVATION_MODIFIER", 17, 30], ["cellular processes", "OBSERVATION", 34, 52], ["cell proliferation", "OBSERVATION", 64, 82], ["differentiation", "OBSERVATION_MODIFIER", 87, 102], ["wound", "OBSERVATION_MODIFIER", 104, 109], ["healing", "OBSERVATION_MODIFIER", 110, 117]]], ["In a murine lung fibrosis model (Gurujeyalakshmi & Giri, 1995) , interferon (IFN)-g downregulated TGF-h expression and improved fibrosis.", [["lung", "ANATOMY", 12, 16], ["lung fibrosis", "DISEASE", 12, 25], ["fibrosis", "DISEASE", 128, 136], ["murine", "ORGANISM", 5, 11], ["lung", "ORGAN", 12, 16], ["interferon (IFN)-g", "GENE_OR_GENE_PRODUCT", 65, 83], ["TGF-h", "GENE_OR_GENE_PRODUCT", 98, 103], ["interferon", "PROTEIN", 65, 75], ["IFN", "PROTEIN", 77, 80], ["TGF", "PROTEIN", 98, 101], ["murine", "SPECIES", 5, 11], ["a murine lung fibrosis model", "PROBLEM", 3, 31], ["interferon (IFN)", "TREATMENT", 65, 81], ["improved fibrosis", "PROBLEM", 119, 136], ["lung", "ANATOMY", 12, 16], ["fibrosis", "OBSERVATION", 17, 25], ["improved", "OBSERVATION_MODIFIER", 119, 127], ["fibrosis", "OBSERVATION", 128, 136]]], ["Wen et al. (2004) further identified that TGF-h suppression was mediated via Smad 7 proteins, as targeted knockdown of Smad 7 by siRNA reversed the suppression.", [["TGF", "GENE_OR_GENE_PRODUCT", 42, 45], ["Smad 7", "GENE_OR_GENE_PRODUCT", 77, 83], ["Smad 7", "GENE_OR_GENE_PRODUCT", 119, 125], ["TGF", "PROTEIN", 42, 45], ["Smad 7 proteins", "PROTEIN", 77, 92], ["Smad 7", "PROTEIN", 119, 125], ["TGF-h suppression", "TREATMENT", 42, 59]]], ["Jeffery et al. (2005) used Smad 1 siRNA to show that the antiproliferative and prodifferentiation effects of bone morphogenetic protein 4 (BMP4) on lung fibroblasts were Smad1 dependent.", [["lung fibroblasts", "ANATOMY", 148, 164], ["Smad 1", "GENE_OR_GENE_PRODUCT", 27, 33], ["bone morphogenetic protein 4", "GENE_OR_GENE_PRODUCT", 109, 137], ["BMP4", "GENE_OR_GENE_PRODUCT", 139, 143], ["lung fibroblasts", "CELL", 148, 164], ["Smad1", "GENE_OR_GENE_PRODUCT", 170, 175], ["Smad 1", "PROTEIN", 27, 33], ["bone morphogenetic protein 4", "PROTEIN", 109, 137], ["BMP4", "PROTEIN", 139, 143], ["lung fibroblasts", "CELL_TYPE", 148, 164], ["Smad1", "PROTEIN", 170, 175], ["Smad 1 siRNA", "TREATMENT", 27, 39], ["the antiproliferative", "PROBLEM", 53, 74], ["bone morphogenetic protein", "TREATMENT", 109, 135], ["lung fibroblasts", "PROBLEM", 148, 164], ["Smad1 dependent", "PROBLEM", 170, 185], ["bone", "ANATOMY", 109, 113], ["lung", "ANATOMY", 148, 152], ["fibroblasts", "OBSERVATION", 153, 164], ["Smad1 dependent", "OBSERVATION", 170, 185]]], ["Fibroblast proliferation, differentiation, and migration contribute to the characteristic pulmonary vascular remodeling seen in primary pulmonary hypertension (PPH).Respiratory diseasesThe recruitment of neutrophils to the lung is central to host defense against invading pathogens.", [["Fibroblast", "ANATOMY", 0, 10], ["pulmonary vascular", "ANATOMY", 90, 108], ["pulmonary", "ANATOMY", 136, 145], ["Respiratory", "ANATOMY", 165, 176], ["neutrophils", "ANATOMY", 204, 215], ["lung", "ANATOMY", 223, 227], ["primary pulmonary hypertension", "DISEASE", 128, 158], ["PPH", "DISEASE", 160, 163], ["Respiratory diseases", "DISEASE", 165, 185], ["Fibroblast", "CELL", 0, 10], ["pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 90, 108], ["pulmonary", "ORGAN", 136, 145], ["neutrophils", "CELL", 204, 215], ["lung", "ORGAN", 223, 227], ["neutrophils", "CELL_TYPE", 204, 215], ["Fibroblast proliferation", "PROBLEM", 0, 24], ["the characteristic pulmonary vascular remodeling", "PROBLEM", 71, 119], ["primary pulmonary hypertension", "PROBLEM", 128, 158], ["PPH", "PROBLEM", 160, 163], ["Respiratory diseases", "PROBLEM", 165, 185], ["invading pathogens", "PROBLEM", 263, 281], ["proliferation", "OBSERVATION", 11, 24], ["pulmonary", "ANATOMY_MODIFIER", 90, 99], ["vascular", "ANATOMY", 100, 108], ["remodeling", "OBSERVATION", 109, 119], ["primary", "OBSERVATION_MODIFIER", 128, 135], ["pulmonary", "ANATOMY", 136, 145], ["hypertension", "OBSERVATION", 146, 158], ["PPH", "OBSERVATION_MODIFIER", 160, 163], ["diseases", "OBSERVATION", 177, 185], ["recruitment", "OBSERVATION_MODIFIER", 189, 200], ["lung", "ANATOMY", 223, 227]]], ["However, in trauma patients exposed to a secondary infectious/septic challenge, neutrophil targeting and sequestration can result in acute lung injury (ALI) and contribute to the high morbidity/mortality seen in this population.", [["neutrophil", "ANATOMY", 80, 90], ["lung", "ANATOMY", 139, 143], ["trauma", "DISEASE", 12, 18], ["acute lung injury", "DISEASE", 133, 150], ["ALI", "DISEASE", 152, 155], ["patients", "ORGANISM", 19, 27], ["neutrophil", "CELL", 80, 90], ["lung", "ORGAN", 139, 143], ["patients", "SPECIES", 19, 27], ["a secondary infectious/septic challenge", "PROBLEM", 39, 78], ["neutrophil targeting and sequestration", "PROBLEM", 80, 118], ["acute lung injury", "PROBLEM", 133, 150], ["the high morbidity/mortality", "PROBLEM", 175, 203], ["secondary", "OBSERVATION_MODIFIER", 41, 50], ["infectious", "OBSERVATION", 51, 61], ["septic", "OBSERVATION", 62, 68], ["acute", "OBSERVATION_MODIFIER", 133, 138], ["lung", "ANATOMY", 139, 143], ["injury", "OBSERVATION", 144, 150], ["high", "OBSERVATION_MODIFIER", 179, 183], ["morbidity", "OBSERVATION", 184, 193]]], ["ALI is a progressive syndrome in which an exaggerated inflammatory response is central to causing lung injury.", [["lung", "ANATOMY", 98, 102], ["ALI", "DISEASE", 0, 3], ["lung injury", "DISEASE", 98, 109], ["lung", "ORGAN", 98, 102], ["ALI", "PROBLEM", 0, 3], ["a progressive syndrome", "PROBLEM", 7, 29], ["an exaggerated inflammatory response", "PROBLEM", 39, 75], ["lung injury", "PROBLEM", 98, 109], ["progressive", "OBSERVATION_MODIFIER", 9, 20], ["syndrome", "OBSERVATION", 21, 29], ["exaggerated", "OBSERVATION_MODIFIER", 42, 53], ["inflammatory response", "OBSERVATION", 54, 75], ["central", "OBSERVATION_MODIFIER", 79, 86], ["lung", "ANATOMY", 98, 102], ["injury", "OBSERVATION", 103, 109]]], ["Lomas-Neira et al. (in press) used a mouse model of haemorrhagic shock to analyse the effects of postshock/sepsis intratracheal instillation of siRNA targeting keratinocyte-derived chemokine (KC) and macrophage-inflammatory protein-2 (MIP-2) on the development of ALI.", [["intratracheal", "ANATOMY", 114, 127], ["keratinocyte", "ANATOMY", 160, 172], ["haemorrhagic shock", "DISEASE", 52, 70], ["sepsis", "DISEASE", 107, 113], ["ALI", "DISEASE", 264, 267], ["mouse", "ORGANISM", 37, 42], ["keratinocyte-derived chemokine", "GENE_OR_GENE_PRODUCT", 160, 190], ["KC", "GENE_OR_GENE_PRODUCT", 192, 194], ["macrophage-inflammatory protein-2", "GENE_OR_GENE_PRODUCT", 200, 233], ["MIP-2", "GENE_OR_GENE_PRODUCT", 235, 240], ["keratinocyte-derived chemokine", "PROTEIN", 160, 190], ["KC", "PROTEIN", 192, 194], ["macrophage-inflammatory protein-2 (MIP-2", "PROTEIN", 200, 240], ["mouse", "SPECIES", 37, 42], ["mouse", "SPECIES", 37, 42], ["Lomas", "TREATMENT", 0, 5], ["haemorrhagic shock", "PROBLEM", 52, 70], ["postshock/sepsis intratracheal instillation", "TREATMENT", 97, 140], ["siRNA targeting keratinocyte", "TREATMENT", 144, 172], ["macrophage", "TEST", 200, 210], ["inflammatory protein", "TEST", 211, 231], ["MIP", "TEST", 235, 238], ["ALI", "PROBLEM", 264, 267], ["sepsis", "OBSERVATION", 107, 113], ["inflammatory", "OBSERVATION_MODIFIER", 211, 223], ["ALI", "OBSERVATION", 264, 267]]], ["The results showed that the local production of MIP-2 was a regulator of neutrophil influx.", [["neutrophil", "ANATOMY", 73, 83], ["MIP-2", "GENE_OR_GENE_PRODUCT", 48, 53], ["neutrophil", "CELL", 73, 83], ["MIP", "PROTEIN", 48, 51], ["MIP", "TEST", 48, 51], ["neutrophil influx", "PROBLEM", 73, 90], ["neutrophil influx", "OBSERVATION", 73, 90]]], ["Increased endothelial cell (EC) permeability is central to the pathophysiology of ALI.", [["endothelial cell", "ANATOMY", 10, 26], ["EC", "ANATOMY", 28, 30], ["ALI", "DISEASE", 82, 85], ["endothelial cell", "CELL", 10, 26], ["EC", "CELL", 28, 30], ["EC", "CELL_TYPE", 28, 30], ["Increased endothelial cell (EC) permeability", "PROBLEM", 0, 44], ["ALI", "PROBLEM", 82, 85], ["endothelial cell", "OBSERVATION", 10, 26], ["ALI", "ANATOMY", 82, 85]]], ["By silencing sphingosine 1-phosphate (S1P) expression using siRNA, Finigan et al. (2005) showed that activated protein C mediates EC permeability via the transactivation of S1P1, the potent barrier-enhancing receptor for S1P.Respiratory diseasesThe airway epithelium provides a barrier against the external and internal milieu in the lung and is responsive to various environmental factors, as well as being an active participant in inflammatory and immune responses.", [["EC", "ANATOMY", 130, 132], ["Respiratory", "ANATOMY", 225, 236], ["airway epithelium", "ANATOMY", 249, 266], ["lung", "ANATOMY", 334, 338], ["sphingosine 1-phosphate", "CHEMICAL", 13, 36], ["S1P", "CHEMICAL", 38, 41], ["S1P", "CHEMICAL", 221, 224], ["Respiratory diseases", "DISEASE", 225, 245], ["sphingosine 1-phosphate", "CHEMICAL", 13, 36], ["S1P", "CHEMICAL", 38, 41], ["S1P", "CHEMICAL", 221, 224], ["sphingosine 1-phosphate", "GENE_OR_GENE_PRODUCT", 13, 36], ["S1P", "GENE_OR_GENE_PRODUCT", 38, 41], ["protein C", "GENE_OR_GENE_PRODUCT", 111, 120], ["EC", "CELL", 130, 132], ["S1P1", "GENE_OR_GENE_PRODUCT", 173, 177], ["S1P", "GENE_OR_GENE_PRODUCT", 221, 224], ["airway epithelium", "TISSUE", 249, 266], ["lung", "ORGAN", 334, 338], ["protein C", "PROTEIN", 111, 120], ["EC", "CELL_TYPE", 130, 132], ["S1P1", "PROTEIN", 173, 177], ["S1P", "PROTEIN", 221, 224], ["silencing sphingosine 1-phosphate (S1P) expression using siRNA", "TREATMENT", 3, 65], ["activated protein C mediates", "PROBLEM", 101, 129], ["EC permeability", "TEST", 130, 145], ["the transactivation of S1P1", "TREATMENT", 150, 177], ["the potent barrier-enhancing receptor", "TREATMENT", 179, 216], ["Respiratory diseases", "PROBLEM", 225, 245], ["a barrier", "TREATMENT", 276, 285], ["diseases", "OBSERVATION", 237, 245], ["airway", "ANATOMY", 249, 255], ["epithelium", "ANATOMY_MODIFIER", 256, 266], ["internal milieu", "ANATOMY", 311, 326], ["lung", "ANATOMY", 334, 338], ["responsive", "OBSERVATION_MODIFIER", 346, 356], ["active", "OBSERVATION_MODIFIER", 411, 417], ["inflammatory", "OBSERVATION_MODIFIER", 433, 445]]], ["Epithelial cells respond to cytokines, chemokines, hormones, growth factors, and inflammatory mediators, and it has been postulated that they play a crucial role in airway diseases such as asthma (Cookson, 2004) .", [["Epithelial cells", "ANATOMY", 0, 16], ["airway", "ANATOMY", 165, 171], ["airway diseases", "DISEASE", 165, 180], ["asthma", "DISEASE", 189, 195], ["Epithelial cells", "CELL", 0, 16], ["airway", "MULTI-TISSUE_STRUCTURE", 165, 171], ["Epithelial cells", "CELL_TYPE", 0, 16], ["cytokines", "PROTEIN", 28, 37], ["chemokines", "PROTEIN", 39, 49], ["growth factors", "PROTEIN", 61, 75], ["inflammatory mediators", "PROTEIN", 81, 103], ["Epithelial cells", "PROBLEM", 0, 16], ["cytokines", "TREATMENT", 28, 37], ["growth factors", "PROBLEM", 61, 75], ["inflammatory mediators", "PROBLEM", 81, 103], ["airway diseases", "PROBLEM", 165, 180], ["asthma", "PROBLEM", 189, 195], ["inflammatory", "OBSERVATION_MODIFIER", 81, 93], ["airway", "ANATOMY", 165, 171], ["diseases", "OBSERVATION", 172, 180], ["asthma", "OBSERVATION", 189, 195]]], ["However, the intracellular signalling pathways involved in the regulation of epithelial cells are poorly understood.", [["intracellular", "ANATOMY", 13, 26], ["epithelial cells", "ANATOMY", 77, 93], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 13, 26], ["epithelial cells", "CELL", 77, 93], ["epithelial cells", "CELL_TYPE", 77, 93], ["the intracellular signalling pathways", "PROBLEM", 9, 46], ["epithelial cells", "OBSERVATION", 77, 93]]], ["Using siRNA targeting Syk tyrosine kinase, Ulanova et al. (2005) showed that Syk (which is regarded as an attractive antiinflammatory target) participates in h 1 -integrin signalling and inflammatory responses in airway epithelial cells.Respiratory diseasesCell-specific targeting of siRNA is an important issue to consider when considering therapy.", [["airway epithelial cells", "ANATOMY", 213, 236], ["Respiratory", "ANATOMY", 237, 248], ["Cell", "ANATOMY", 257, 261], ["tyrosine", "CHEMICAL", 26, 34], ["Respiratory diseases", "DISEASE", 237, 257], ["tyrosine", "CHEMICAL", 26, 34], ["Syk", "GENE_OR_GENE_PRODUCT", 22, 25], ["Syk", "GENE_OR_GENE_PRODUCT", 77, 80], ["1 -integrin", "GENE_OR_GENE_PRODUCT", 160, 171], ["airway epithelial cells", "CELL", 213, 236], ["Cell", "CELL", 257, 261], ["Syk tyrosine kinase", "PROTEIN", 22, 41], ["Syk", "PROTEIN", 77, 80], ["integrin", "PROTEIN", 163, 171], ["airway epithelial cells", "CELL_TYPE", 213, 236], ["siRNA targeting Syk tyrosine kinase", "TREATMENT", 6, 41], ["an attractive antiinflammatory target", "TREATMENT", 103, 140], ["integrin signalling", "PROBLEM", 163, 182], ["inflammatory responses in airway epithelial cells", "PROBLEM", 187, 236], ["Respiratory diseases", "PROBLEM", 237, 257], ["siRNA", "PROBLEM", 284, 289], ["therapy", "TREATMENT", 341, 348], ["inflammatory", "OBSERVATION_MODIFIER", 187, 199], ["airway", "ANATOMY", 213, 219], ["epithelial cells", "OBSERVATION", 220, 236], ["diseases", "OBSERVATION", 249, 257], ["siRNA", "OBSERVATION", 284, 289]]], ["With regards to the lung, Gou et al. (2004) were able to get RNAi silencing specifically in rat lung alveolar epithelial type II cells using adenoviral vectors containing various shRNAs under the control of the surfactant protein C promoter, both in vitro and in vivo.siRNA molecules as therapeutics: from cells to manGiven the ability of RNAi to silence disease-associated genes, including allelic variants (Dykxhoorn et al., 2003) , in tissue culture and animal models, it is not surprising that there has been a lot of interest in developing RNAi-based reagents for clinical applications (Wall & Shi, 2003) .", [["lung", "ANATOMY", 20, 24], ["lung alveolar epithelial type II cells", "ANATOMY", 96, 134], ["cells", "ANATOMY", 306, 311], ["tissue culture", "ANATOMY", 438, 452], ["lung", "ORGAN", 20, 24], ["rat", "ORGANISM", 92, 95], ["lung alveolar epithelial type II cells", "CELL", 96, 134], ["adenoviral", "ORGANISM", 141, 151], ["surfactant protein C", "GENE_OR_GENE_PRODUCT", 211, 231], ["cells", "CELL", 306, 311], ["tissue culture", "CELL", 438, 452], ["rat lung alveolar epithelial type II cells", "CELL_TYPE", 92, 134], ["shRNAs", "DNA", 179, 185], ["surfactant protein C promoter", "DNA", 211, 240], ["vivo.siRNA molecules", "PROTEIN", 263, 283], ["disease-associated genes", "DNA", 355, 379], ["rat", "SPECIES", 92, 95], ["rat", "SPECIES", 92, 95], ["RNAi silencing", "PROBLEM", 61, 75], ["adenoviral vectors", "TREATMENT", 141, 159], ["various shRNAs", "TREATMENT", 171, 185], ["the surfactant protein C promoter", "TREATMENT", 207, 240], ["silence disease", "PROBLEM", 347, 362], ["allelic variants", "PROBLEM", 391, 407], ["tissue culture", "TEST", 438, 452], ["RNAi-based reagents", "TREATMENT", 545, 564], ["lung", "ANATOMY", 20, 24], ["lung", "ANATOMY", 96, 100], ["alveolar", "ANATOMY_MODIFIER", 101, 109], ["epithelial", "ANATOMY_MODIFIER", 110, 120], ["tissue", "ANATOMY", 438, 444]]], ["Currently, there are a dozen or so biotechnology companies developing clinical applications of siRNA in various human diseases (Howard, 2003; Table 1 ).", [["human", "ORGANISM", 112, 117], ["human", "SPECIES", 112, 117], ["human", "SPECIES", 112, 117], ["siRNA in various human diseases", "PROBLEM", 95, 126], ["siRNA", "OBSERVATION", 95, 100], ["various human", "OBSERVATION_MODIFIER", 104, 117]]], ["In addition to the ease of synthesis and low production costs (compared with protein or antibody therapies), data indicate that siRNA has favourable pharmacokinetic properties and can be delivered to a wide range of organs (Braasch et al., 2004) .", [["organs", "ANATOMY", 216, 222], ["organs", "ORGAN", 216, 222], ["synthesis", "PROBLEM", 27, 36], ["low production costs", "PROBLEM", 41, 61], ["antibody therapies", "TREATMENT", 88, 106], ["siRNA", "PROBLEM", 128, 133], ["low production", "OBSERVATION_MODIFIER", 41, 55], ["siRNA", "OBSERVATION", 128, 133]]], ["However, blood stability, delivery, poor intracellular uptake, and nonspecific immune stimulation still present significant challenges for the development of RNAi reagents for clinical use.StabilityAlthough siRNA molecules appear to be more resistant to nuclease degradation than antisense molecules (Bertrand et al., 2002) , some serum nucleases can degrade siRNAs (Paroo & Corey, 2004; Dykxhoorn & Lieberman, 2005) .", [["blood", "ANATOMY", 9, 14], ["intracellular", "ANATOMY", 41, 54], ["serum", "ANATOMY", 331, 336], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 41, 54], ["serum", "ORGANISM_SUBSTANCE", 331, 336], ["nuclease", "PROTEIN", 254, 262], ["serum nucleases", "PROTEIN", 331, 346], ["delivery", "TREATMENT", 26, 34], ["poor intracellular uptake", "PROBLEM", 36, 61], ["nonspecific immune stimulation", "TREATMENT", 67, 97], ["RNAi reagents", "TREATMENT", 158, 171], ["StabilityAlthough siRNA molecules", "PROBLEM", 189, 222], ["nuclease degradation than antisense molecules", "PROBLEM", 254, 299], ["some serum nucleases", "PROBLEM", 326, 346], ["stability", "OBSERVATION_MODIFIER", 15, 24], ["intracellular uptake", "OBSERVATION", 41, 61]]], ["As a result, a number of groups have investigated the use of chemical modifications that improve stability and protect against nuclease degradation (Fougerolles et al., 2005) .", [["nuclease", "PROTEIN", 127, 135], ["chemical modifications", "TREATMENT", 61, 83], ["nuclease degradation", "PROBLEM", 127, 147]]], ["Although phosphothioate modification has been important for the success of antisense applications in vivo (Crooke, 2004) , studies have shown that toxicity and loss of silencing activity can be a problem with phosphothioate siRNAs (Braasch et al., 2003; Harborth et al., 2003) .", [["phosphothioate", "CHEMICAL", 9, 23], ["toxicity", "DISEASE", 147, 155], ["phosphothioate", "CHEMICAL", 209, 223], ["phosphothioate", "CHEMICAL", 9, 23], ["phosphothioate", "CHEMICAL", 209, 223], ["phosphothioate", "SIMPLE_CHEMICAL", 9, 23], ["phosphothioate", "SIMPLE_CHEMICAL", 209, 223], ["phosphothioate modification", "TREATMENT", 9, 36], ["antisense applications", "TREATMENT", 75, 97], ["toxicity", "PROBLEM", 147, 155], ["loss of silencing activity", "PROBLEM", 160, 186], ["phosphothioate siRNAs", "TREATMENT", 209, 230]]], ["As a result, several groups have investigated the use of alternative backbone and nucleotide modifications to address these problems.", [["nucleotide", "CHEMICAL", 82, 92], ["nucleotide", "CHEMICAL", 82, 92], ["alternative backbone", "TREATMENT", 57, 77], ["nucleotide modifications", "TREATMENT", 82, 106], ["these problems", "PROBLEM", 118, 132]]], ["Hall et al. (2004) showed that boranophosphate siRNAs were more effective at silencing than phosphothioate siRNAs and were 10 times more nuclease resistant than are unmodified siRNAs.", [["boranophosphate", "CHEMICAL", 31, 46], ["phosphothioate", "CHEMICAL", 92, 106], ["boranophosphate", "CHEMICAL", 31, 46], ["phosphothioate", "CHEMICAL", 92, 106], ["boranophosphate", "SIMPLE_CHEMICAL", 31, 46], ["phosphothioate", "SIMPLE_CHEMICAL", 92, 106], ["phosphothioate siRNAs", "RNA", 92, 113], ["boranophosphate siRNAs", "PROBLEM", 31, 53], ["phosphothioate siRNAs", "TREATMENT", 92, 113], ["unmodified siRNAs", "OBSERVATION", 165, 182]]], ["In addition, boranophosphate siRNAs were more potent than unmodified siRNAs and appeared to act through the standard RNAi pathway.", [["boranophosphate", "CHEMICAL", 13, 28], ["boranophosphate", "CHEMICAL", 13, 28], ["boranophosphate", "SIMPLE_CHEMICAL", 13, 28], ["boranophosphate siRNAs", "TREATMENT", 13, 35], ["more potent", "OBSERVATION_MODIFIER", 41, 52]]], ["Elmen et al. (2005) modified siRNAs with the synthetic RNA-like high-affinity nucleotide analogue, locked nucleic acid (LNA), and showed that the incorporation of a modest number of LNA modifications significantly enhanced the serum half-life of siRNAs and stabilized the duplex structure while not affecting gene silencing.", [["serum", "ANATOMY", 227, 232], ["nucleotide", "CHEMICAL", 78, 88], ["nucleic acid", "CHEMICAL", 106, 118], ["LNA", "CHEMICAL", 120, 123], ["LNA", "CHEMICAL", 182, 185], ["nucleotide", "CHEMICAL", 78, 88], ["nucleic acid", "SIMPLE_CHEMICAL", 106, 118], ["LNA", "SIMPLE_CHEMICAL", 120, 123], ["LNA", "SIMPLE_CHEMICAL", 182, 185], ["serum", "ORGANISM_SUBSTANCE", 227, 232], ["modified siRNAs", "TREATMENT", 20, 35], ["the synthetic RNA", "TEST", 41, 58], ["locked nucleic acid (LNA", "TEST", 99, 123], ["LNA modifications", "PROBLEM", 182, 199], ["siRNAs", "PROBLEM", 246, 252], ["the duplex structure", "PROBLEM", 268, 288], ["modest", "OBSERVATION_MODIFIER", 165, 171], ["LNA modifications", "OBSERVATION", 182, 199]]], ["Similarly, Allerson et al. (2005) showed that siRNAs containing 2V-O-methyl and 2V-fluoro nucleotides not only displayed enhanced stability but also showed increased potency.", [["2V-O-methyl", "CHEMICAL", 64, 75], ["2V-fluoro nucleotides", "CHEMICAL", 80, 101], ["2V-O-methyl and 2V-fluoro nucleotides", "CHEMICAL", 64, 101], ["2V-O-methyl", "SIMPLE_CHEMICAL", 64, 75], ["2V-fluoro nucleotides", "SIMPLE_CHEMICAL", 80, 101], ["siRNAs", "TEST", 46, 52], ["methyl and 2V-fluoro nucleotides", "TREATMENT", 69, 101], ["increased potency", "PROBLEM", 156, 173], ["increased", "OBSERVATION_MODIFIER", 156, 165], ["potency", "OBSERVATION_MODIFIER", 166, 173]]], ["Experiments indicate that gene silencing by 2V-modified siRNAs in vivo is not impaired (Layzer et al., 2004) .StabilityAs an alternative to backbone modifications, other groups have improved the stability of siRNAs and improved their delivery in vivo by complexing them with polyethyleneimine (PEI; Urban-Klein et al., 2005), atelocollagen (Minakuchi et al., 2004) , or cholesterol (Soutschek et al., 2004) .", [["polyethyleneimine", "CHEMICAL", 275, 292], ["PEI", "CHEMICAL", 294, 297], ["cholesterol", "CHEMICAL", 370, 381], ["polyethyleneimine", "CHEMICAL", 275, 292], ["PEI", "CHEMICAL", 294, 297], ["cholesterol", "CHEMICAL", 370, 381], ["polyethyleneimine", "SIMPLE_CHEMICAL", 275, 292], ["PEI", "SIMPLE_CHEMICAL", 294, 297], ["atelocollagen", "SIMPLE_CHEMICAL", 326, 339], ["cholesterol", "SIMPLE_CHEMICAL", 370, 381], ["2V", "PROTEIN", 44, 46], ["gene silencing", "PROBLEM", 26, 40], ["2V-modified siRNAs", "TREATMENT", 44, 62], ["backbone modifications", "TREATMENT", 140, 162], ["siRNAs", "PROBLEM", 208, 214], ["polyethyleneimine (PEI", "TREATMENT", 275, 297]]], ["In another approach, biodegradable poly (d,llactide-co-glycolide) copolymer microspheres were shown to give sustained release of siRNA molecules at the site of administration in mice even after 7 days postadministration (Khan et al., 2004) .DeliveryA number of different approaches have been developed for the in vivo delivery of siRNA (Fig. 4) .", [["poly (d,llactide-co-glycolide", "CHEMICAL", 35, 64], ["poly (d,llactide-co-glycolide)", "CHEMICAL", 35, 65], ["poly (d,llactide-co-glycolide) copolymer microspheres", "SIMPLE_CHEMICAL", 35, 88], ["mice", "ORGANISM", 178, 182], ["mice", "SPECIES", 178, 182], ["mice", "SPECIES", 178, 182], ["biodegradable poly (d,llactide-co-glycolide) copolymer microspheres", "TREATMENT", 21, 88], ["siRNA molecules", "PROBLEM", 129, 144], ["Delivery", "TREATMENT", 241, 249], ["the in vivo delivery of siRNA", "TREATMENT", 306, 335], ["siRNA molecules", "OBSERVATION", 129, 144]]], ["Among the approaches tried in rodents, rapid infusion by hydrodynamic injection of siRNA achieves the best delivery, albeit to a limited set of vascularized tissues (Lewis & Wolff, 2005) .", [["tissues", "ANATOMY", 157, 164], ["tissues", "TISSUE", 157, 164], ["rapid infusion", "TREATMENT", 39, 53], ["hydrodynamic injection of siRNA", "TREATMENT", 57, 88], ["vascularized tissues", "ANATOMY", 144, 164]]], ["The primary recipient tissue is the liver, where successful transgene delivery and expression in up to 40% of hepatocytes can be obtained (Liu et al., 1999) .", [["primary recipient tissue", "ANATOMY", 4, 28], ["liver", "ANATOMY", 36, 41], ["hepatocytes", "ANATOMY", 110, 121], ["recipient tissue", "TISSUE", 12, 28], ["liver", "ORGAN", 36, 41], ["hepatocytes", "CELL", 110, 121], ["hepatocytes", "CELL_TYPE", 110, 121], ["successful transgene delivery", "TREATMENT", 49, 78], ["recipient tissue", "OBSERVATION", 12, 28], ["liver", "ANATOMY", 36, 41], ["successful", "OBSERVATION_MODIFIER", 49, 59], ["transgene", "OBSERVATION", 60, 69]]], ["Several groups have used this technique to successfully introduce siRNA-or shRNA-expressing constructs into mice, achieving efficient delivery and subsequent silencing of target genes (McCaffrey et al., 2002; Giladi et al., 2003; Zender et al., 2003; Hamar et al., 2004; Xu et al., 2005) .", [["mice", "ORGANISM", 108, 112], ["siRNA-or shRNA-expressing constructs", "DNA", 66, 102], ["target genes", "DNA", 171, 183], ["mice", "SPECIES", 108, 112], ["mice", "SPECIES", 108, 112], ["this technique", "TREATMENT", 25, 39], ["siRNA", "TREATMENT", 66, 71]]], ["A key constraint to this method is that delivery tends to be restricted to highly vascularized tissues, such as the liver, spleen, or kidneys.", [["tissues", "ANATOMY", 95, 102], ["liver", "ANATOMY", 116, 121], ["spleen", "ANATOMY", 123, 129], ["kidneys", "ANATOMY", 134, 141], ["tissues", "TISSUE", 95, 102], ["liver", "ORGAN", 116, 121], ["spleen", "ORGAN", 123, 129], ["kidneys", "ORGAN", 134, 141], ["delivery", "TREATMENT", 40, 48], ["vascularized", "OBSERVATION", 82, 94], ["liver", "ANATOMY", 116, 121], ["spleen", "ANATOMY", 123, 129], ["kidneys", "ANATOMY", 134, 141]]], ["In addition, this technique is currently not a viable method for delivery in human clinical studies.DeliveryIn an effort to develop methods for targeted, tissuespecific delivery, lipid-based strategies for in vivo applications have been devised (Sioud & Sorensen, 2004) .", [["human", "ORGANISM", 77, 82], ["lipid", "SIMPLE_CHEMICAL", 179, 184], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 77, 82], ["delivery", "TREATMENT", 65, 73], ["human clinical studies", "TEST", 77, 99], ["methods", "TEST", 132, 139], ["tissuespecific delivery", "TREATMENT", 154, 177], ["lipid-based strategies", "TREATMENT", 179, 201]]], ["While lipid-based formulations have been used extensively for cell culture experiments, the attributes for optimal uptake in cell culture are different from those in vivo.", [["cell", "ANATOMY", 62, 66], ["cell culture", "ANATOMY", 125, 137], ["lipid", "SIMPLE_CHEMICAL", 6, 11], ["cell", "CELL", 62, 66], ["cell", "CELL", 125, 129], ["lipid-based formulations", "TREATMENT", 6, 30], ["cell culture experiments", "TEST", 62, 86], ["optimal uptake in cell culture", "PROBLEM", 107, 137]]], ["The principal issue is that the cationic nature of the lipids used in cell culture leads to aggregation when used in animals and results in rapid serum clearance and lung accumulation.", [["cell culture", "ANATOMY", 70, 82], ["serum", "ANATOMY", 146, 151], ["lung", "ANATOMY", 166, 170], ["lipids", "SIMPLE_CHEMICAL", 55, 61], ["cell", "CELL", 70, 74], ["serum", "ORGANISM_SUBSTANCE", 146, 151], ["lung", "ORGAN", 166, 170], ["cell culture", "CELL_LINE", 70, 82], ["the lipids", "TREATMENT", 51, 61], ["cell culture", "TEST", 70, 82], ["rapid serum clearance", "TEST", 140, 161], ["lung accumulation", "PROBLEM", 166, 183], ["lung", "ANATOMY", 166, 170], ["accumulation", "OBSERVATION", 171, 183]]], ["Despite this, there are an increasing number of reports citing success with lipid-mediated delivery of siRNAs in vivo (Ge et al., 2004b; Hassani et al., 2004; Zhang et al., 2004b) .", [["lipid", "SIMPLE_CHEMICAL", 76, 81], ["lipid-mediated delivery of siRNAs", "TREATMENT", 76, 109], ["increasing", "OBSERVATION_MODIFIER", 27, 37], ["number", "OBSERVATION_MODIFIER", 38, 44]]], ["In a subcutaneous mouse tumour model, intraperitoneal administration of siRNAs complexed with PEI led to the delivery of intact siRNAs into tumours (Urban-Klein et al., 2005) .", [["tumour", "ANATOMY", 24, 30], ["intraperitoneal", "ANATOMY", 38, 53], ["tumours", "ANATOMY", 140, 147], ["tumour", "DISEASE", 24, 30], ["PEI", "CHEMICAL", 94, 97], ["PEI", "CHEMICAL", 94, 97], ["mouse", "ORGANISM", 18, 23], ["tumour", "CANCER", 24, 30], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 38, 53], ["PEI", "SIMPLE_CHEMICAL", 94, 97], ["tumours", "CANCER", 140, 147], ["mouse", "SPECIES", 18, 23], ["mouse", "SPECIES", 18, 23], ["a subcutaneous mouse tumour model", "TREATMENT", 3, 36], ["intraperitoneal administration of siRNAs", "TREATMENT", 38, 78], ["PEI", "TREATMENT", 94, 97], ["intact siRNAs into tumours", "PROBLEM", 121, 147], ["subcutaneous mouse", "ANATOMY", 5, 23], ["tumour", "OBSERVATION", 24, 30], ["intraperitoneal", "ANATOMY", 38, 53], ["intact siRNAs", "OBSERVATION", 121, 134]]], ["Schiffelers et al. (2004) constructed self-assembling nanoparticles with siRNA and PEI PEGylated with an Arg-Gly-Asp peptide ligand attached to the distal end of the polyethylene glycol (PEG) as a means to target tumour neovasculature-expressing integrins.", [["tumour neovasculature", "ANATOMY", 213, 234], ["PEI", "CHEMICAL", 83, 86], ["Arg-Gly-Asp", "CHEMICAL", 105, 116], ["polyethylene glycol", "CHEMICAL", 166, 185], ["PEG", "CHEMICAL", 187, 190], ["PEI", "CHEMICAL", 83, 86], ["Arg-Gly-Asp peptide", "CHEMICAL", 105, 124], ["polyethylene glycol", "CHEMICAL", 166, 185], ["PEG", "CHEMICAL", 187, 190], ["PEI PEGylated", "SIMPLE_CHEMICAL", 83, 96], ["polyethylene glycol", "SIMPLE_CHEMICAL", 166, 185], ["PEG", "SIMPLE_CHEMICAL", 187, 190], ["tumour neovasculature", "CANCER", 213, 234], ["integrins", "GENE_OR_GENE_PRODUCT", 246, 255], ["integrins", "PROTEIN", 246, 255], ["siRNA", "TREATMENT", 73, 78], ["PEI PEGylated", "TREATMENT", 83, 96], ["an Arg-Gly-Asp peptide ligand", "TREATMENT", 102, 131], ["the polyethylene glycol (PEG", "TREATMENT", 162, 190], ["target tumour neovasculature", "PROBLEM", 206, 234], ["distal", "ANATOMY_MODIFIER", 148, 154], ["polyethylene glycol", "OBSERVATION", 166, 185], ["tumour", "OBSERVATION", 213, 219]]], ["Intravenous administration into tumour-bearing mice resulted in selective tumour uptake, siRNA sequence-specific inhibition of protein expression within the tumour, and inhibition of both tumour angiogenesis and growth rate.", [["Intravenous", "ANATOMY", 0, 11], ["tumour", "ANATOMY", 32, 38], ["tumour", "ANATOMY", 74, 80], ["tumour", "ANATOMY", 157, 163], ["tumour", "ANATOMY", 188, 194], ["tumour", "DISEASE", 32, 38], ["tumour", "DISEASE", 74, 80], ["tumour", "DISEASE", 157, 163], ["tumour", "DISEASE", 188, 194], ["Intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 11], ["tumour", "CANCER", 32, 38], ["mice", "ORGANISM", 47, 51], ["tumour", "CANCER", 74, 80], ["tumour", "CANCER", 157, 163], ["tumour", "CANCER", 188, 194], ["mice", "SPECIES", 47, 51], ["mice", "SPECIES", 47, 51], ["Intravenous administration", "TREATMENT", 0, 26], ["tumour-bearing mice", "TREATMENT", 32, 51], ["selective tumour uptake", "PROBLEM", 64, 87], ["siRNA sequence", "TEST", 89, 103], ["protein expression within the tumour", "PROBLEM", 127, 163], ["both tumour angiogenesis", "PROBLEM", 183, 207], ["growth rate", "TEST", 212, 223], ["selective", "OBSERVATION_MODIFIER", 64, 73], ["tumour uptake", "OBSERVATION", 74, 87], ["protein expression", "OBSERVATION", 127, 145], ["tumour", "OBSERVATION", 157, 163], ["both", "OBSERVATION_MODIFIER", 183, 187], ["tumour angiogenesis", "OBSERVATION", 188, 207], ["growth", "OBSERVATION_MODIFIER", 212, 218]]], ["The results show that siRNA can be targeted at two levels: tumour tissue-selective delivery via the nanoparticle ligand and gene pathway selectivity via the siRNA oligonucleotide.", [["tumour tissue", "ANATOMY", 59, 72], ["tumour", "DISEASE", 59, 65], ["tumour tissue", "TISSUE", 59, 72], ["siRNA", "PROBLEM", 22, 27], ["tumour tissue", "PROBLEM", 59, 72], ["selective delivery", "TREATMENT", 73, 91], ["the nanoparticle ligand", "TREATMENT", 96, 119], ["the siRNA oligonucleotide", "TREATMENT", 153, 178], ["siRNA", "OBSERVATION", 22, 27], ["tumour tissue", "OBSERVATION", 59, 72], ["siRNA oligonucleotide", "OBSERVATION", 157, 178]]], ["To improve the delivery of siRNA into human liver cells without transfection agents, Lorenz et al. (2004) synthesized lipophilic siRNAs conjugated with derivatives of cholesterol, lithocholic acid, or lauric acid.", [["liver cells", "ANATOMY", 44, 55], ["cholesterol", "CHEMICAL", 167, 178], ["lithocholic acid", "CHEMICAL", 180, 196], ["lauric acid", "CHEMICAL", 201, 212], ["cholesterol", "CHEMICAL", 167, 178], ["lithocholic acid", "CHEMICAL", 180, 196], ["lauric acid", "CHEMICAL", 201, 212], ["human", "ORGANISM", 38, 43], ["liver cells", "CELL", 44, 55], ["cholesterol", "SIMPLE_CHEMICAL", 167, 178], ["lithocholic acid", "SIMPLE_CHEMICAL", 180, 196], ["lauric acid", "SIMPLE_CHEMICAL", 201, 212], ["human liver cells", "CELL_TYPE", 38, 55], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 38, 43], ["the delivery of siRNA into human liver cells", "TREATMENT", 11, 55], ["transfection agents", "TREATMENT", 64, 83], ["Lorenz et al. (2004) synthesized lipophilic siRNAs", "TREATMENT", 85, 135], ["derivatives of cholesterol", "TREATMENT", 152, 178], ["lithocholic acid", "TREATMENT", 180, 196], ["lauric acid", "TREATMENT", 201, 212], ["liver", "ANATOMY", 44, 49]]], ["The lipid moieties were covalently linked to the 5V-ends of the RNAs using phosphoramidite chemistry and were shown to down-regulate the expression of a LacZ expression construct.", [["phosphoramidite", "CHEMICAL", 75, 90], ["phosphoramidite", "CHEMICAL", 75, 90], ["lipid moieties", "SIMPLE_CHEMICAL", 4, 18], ["LacZ", "GENE_OR_GENE_PRODUCT", 153, 157], ["5V-ends", "DNA", 49, 56], ["RNAs", "RNA", 64, 68], ["LacZ expression construct", "DNA", 153, 178], ["phosphoramidite chemistry", "TEST", 75, 100], ["a LacZ expression construct", "TREATMENT", 151, 178]]], ["By conjugating cholesterol to the 3V-end of the sense strand of siRNA by means of a pyrrolidine linker, Soutschek et al. (2004) markedly improved the pharmacological properties of siRNA molecules.", [["cholesterol", "CHEMICAL", 15, 26], ["pyrrolidine", "CHEMICAL", 84, 95], ["cholesterol", "CHEMICAL", 15, 26], ["pyrrolidine", "CHEMICAL", 84, 95], ["cholesterol", "SIMPLE_CHEMICAL", 15, 26], ["pyrrolidine", "SIMPLE_CHEMICAL", 84, 95], ["3V-end", "DNA", 34, 40], ["a pyrrolidine linker", "TREATMENT", 82, 102], ["siRNA molecules", "PROBLEM", 180, 195], ["siRNA molecules", "OBSERVATION", 180, 195]]], ["Besides being more resistant to nuclease degradation, the cholesterol attachment stabilized the siRNA molecules in the blood by increasing binding to human serum albumin and increased uptake of siRNA molecules by the liver.", [["blood", "ANATOMY", 119, 124], ["serum", "ANATOMY", 156, 161], ["liver", "ANATOMY", 217, 222], ["cholesterol", "CHEMICAL", 58, 69], ["cholesterol", "CHEMICAL", 58, 69], ["cholesterol", "SIMPLE_CHEMICAL", 58, 69], ["blood", "ORGANISM_SUBSTANCE", 119, 124], ["human", "ORGANISM", 150, 155], ["serum", "ORGANISM_SUBSTANCE", 156, 161], ["albumin", "GENE_OR_GENE_PRODUCT", 162, 169], ["liver", "ORGAN", 217, 222], ["nuclease", "PROTEIN", 32, 40], ["siRNA molecules", "PROTEIN", 96, 111], ["human serum albumin", "PROTEIN", 150, 169], ["siRNA molecules", "PROTEIN", 194, 209], ["human", "SPECIES", 150, 155], ["human", "SPECIES", 150, 155], ["nuclease degradation", "TREATMENT", 32, 52], ["the cholesterol attachment", "TEST", 54, 80], ["the siRNA molecules", "PROBLEM", 92, 111], ["the blood", "TEST", 115, 124], ["increasing binding", "PROBLEM", 128, 146], ["human serum albumin", "TEST", 150, 169], ["increased uptake of siRNA molecules", "PROBLEM", 174, 209], ["more resistant", "OBSERVATION_MODIFIER", 14, 28], ["siRNA molecules", "OBSERVATION", 96, 111], ["increased", "OBSERVATION_MODIFIER", 174, 183], ["uptake of", "OBSERVATION", 184, 193], ["siRNA molecules", "OBSERVATION", 194, 209], ["liver", "ANATOMY", 217, 222]]], ["Massaro et al. (2004) showed that siRNA could be effectively delivered to pulmonary alveoli in mice using pulmonary surfactant (a lipoprotein that lines the alveoli) as the delivery vehicle.", [["pulmonary alveoli", "ANATOMY", 74, 91], ["pulmonary", "ANATOMY", 106, 115], ["alveoli", "ANATOMY", 157, 164], ["pulmonary alveoli", "MULTI-TISSUE_STRUCTURE", 74, 91], ["mice", "ORGANISM", 95, 99], ["pulmonary", "ORGAN", 106, 115], ["alveoli", "MULTI-TISSUE_STRUCTURE", 157, 164], ["mice", "SPECIES", 95, 99], ["mice", "SPECIES", 95, 99], ["siRNA", "PROBLEM", 34, 39], ["pulmonary surfactant", "TREATMENT", 106, 126], ["a lipoprotein", "TREATMENT", 128, 141], ["siRNA", "OBSERVATION", 34, 39], ["pulmonary", "ANATOMY", 74, 83], ["alveoli", "ANATOMY_MODIFIER", 84, 91], ["pulmonary", "ANATOMY", 106, 115], ["surfactant", "OBSERVATION", 116, 126], ["alveoli", "ANATOMY", 157, 164]]], ["Intravascular delivery of siRNA molecules is attractive because of its inherent simplicity and has been used to deliver siRNA in mice.", [["Intravascular", "ANATOMY", 0, 13], ["Intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 13], ["mice", "ORGANISM", 129, 133], ["mice", "SPECIES", 129, 133], ["mice", "SPECIES", 129, 133], ["Intravascular delivery of siRNA molecules", "TREATMENT", 0, 41], ["siRNA molecules", "OBSERVATION", 26, 41]]], ["In an attempt to protect mice from fulminant hepatitis using siRNAs against Fas receptors, Song et al. (2003) administered Fas siRNA by intravenous injection into mice over a 24-hr period.", [["intravenous", "ANATOMY", 136, 147], ["fulminant hepatitis", "DISEASE", 35, 54], ["mice", "ORGANISM", 25, 29], ["Fas receptors", "GENE_OR_GENE_PRODUCT", 76, 89], ["Fas", "GENE_OR_GENE_PRODUCT", 123, 126], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 136, 147], ["mice", "ORGANISM", 163, 167], ["Fas receptors", "PROTEIN", 76, 89], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 163, 167], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 163, 167], ["fulminant hepatitis", "PROBLEM", 35, 54], ["siRNAs against Fas receptors", "TREATMENT", 61, 89], ["Fas siRNA", "TREATMENT", 123, 132], ["fulminant", "OBSERVATION_MODIFIER", 35, 44], ["hepatitis", "OBSERVATION", 45, 54]]], ["The effects persisted for 10 days and protected mice against experimentally induced liver fibrosis.", [["liver", "ANATOMY", 84, 89], ["liver fibrosis", "DISEASE", 84, 98], ["mice", "ORGANISM", 48, 52], ["liver", "ORGAN", 84, 89], ["mice", "SPECIES", 48, 52], ["mice", "SPECIES", 48, 52], ["experimentally induced liver fibrosis", "PROBLEM", 61, 98], ["liver", "ANATOMY", 84, 89], ["fibrosis", "OBSERVATION", 90, 98]]], ["Hagstrom et al. (2004) injected naked siRNA into a distal vein of a limb transiently isolated by tourniquet or blood pressure cuff and were able to show an efficient and repeatable delivery of nucleic acids to muscle cells (myofibers) throughout the limb muscles of mammals.", [["distal vein", "ANATOMY", 51, 62], ["limb", "ANATOMY", 68, 72], ["blood", "ANATOMY", 111, 116], ["muscle cells", "ANATOMY", 210, 222], ["myofibers", "ANATOMY", 224, 233], ["limb muscles", "ANATOMY", 250, 262], ["nucleic acids", "CHEMICAL", 193, 206], ["distal vein", "MULTI-TISSUE_STRUCTURE", 51, 62], ["limb", "ORGANISM_SUBDIVISION", 68, 72], ["blood", "ORGANISM_SUBSTANCE", 111, 116], ["muscle cells", "CELL", 210, 222], ["myofibers", "TISSUE", 224, 233], ["limb muscles", "ORGANISM_SUBDIVISION", 250, 262], ["muscle cells", "CELL_TYPE", 210, 222], ["myofibers", "CELL_TYPE", 224, 233], ["blood pressure cuff", "TEST", 111, 130], ["nucleic acids", "TREATMENT", 193, 206], ["distal", "ANATOMY_MODIFIER", 51, 57], ["vein", "ANATOMY", 58, 62], ["limb", "ANATOMY_MODIFIER", 68, 72], ["limb muscles", "ANATOMY", 250, 262]]], ["The rapid injection of a sufficient volume enabled the extravasation of siRNA into myofibers.", [["myofibers", "ANATOMY", 83, 92], ["myofibers", "CELL", 83, 92], ["myofibers", "CELL_TYPE", 83, 92], ["The rapid injection", "TREATMENT", 0, 19], ["the extravasation of siRNA into myofibers", "TREATMENT", 51, 92], ["rapid", "OBSERVATION_MODIFIER", 4, 9], ["extravasation", "OBSERVATION", 55, 68]]], ["High levels of transgene expression in skeletal muscle were achieved in both small and large animals with apparently minimal toxicity.DeliveryOther approaches for the delivery of siRNAs in vivo have been described.", [["skeletal muscle", "ANATOMY", 39, 54], ["toxicity", "DISEASE", 125, 133], ["skeletal muscle", "ORGAN", 39, 54], ["transgene expression in skeletal muscle", "PROBLEM", 15, 54], ["apparently minimal toxicity", "PROBLEM", 106, 133], ["DeliveryOther approaches", "TREATMENT", 134, 158], ["the delivery of siRNAs", "TREATMENT", 163, 185], ["transgene expression", "OBSERVATION", 15, 35], ["skeletal muscle", "ANATOMY", 39, 54], ["small", "OBSERVATION_MODIFIER", 77, 82], ["minimal", "OBSERVATION_MODIFIER", 117, 124], ["toxicity", "OBSERVATION", 125, 133], ["siRNAs", "OBSERVATION", 179, 185]]], ["Local delivery of siRNAs into the eye has been used to show that siRNAs targeting the vascular endothelial growth factor (VEGF) pathway could be therapeutically beneficial in neovascularization-related eye diseases (Kim et al., 2004) .", [["eye", "ANATOMY", 34, 37], ["eye", "ANATOMY", 202, 205], ["neovascularization", "DISEASE", 175, 193], ["eye diseases", "DISEASE", 202, 214], ["eye", "ORGAN", 34, 37], ["vascular endothelial growth factor", "GENE_OR_GENE_PRODUCT", 86, 120], ["VEGF", "GENE_OR_GENE_PRODUCT", 122, 126], ["eye", "ORGAN", 202, 205], ["vascular endothelial growth factor", "PROTEIN", 86, 120], ["VEGF", "PROTEIN", 122, 126], ["Local delivery of siRNAs", "TREATMENT", 0, 24], ["the vascular endothelial growth factor (VEGF) pathway", "PROBLEM", 82, 135], ["neovascularization", "PROBLEM", 175, 193], ["eye diseases", "PROBLEM", 202, 214], ["siRNAs", "OBSERVATION", 18, 24], ["eye", "ANATOMY", 34, 37], ["vascular endothelial", "ANATOMY", 86, 106], ["neovascularization", "OBSERVATION", 175, 193], ["eye", "ANATOMY", 202, 205]]], ["Electroporation has been used to deliver siRNAs into the kidney (Takabatake et al., in press), brain (Akaneya et al., 2005) , eyes (Matsuda & Cepko, 2004) , muscles (Golzio et al., 2005) , and skin (Zhang et al., 2002) of rodents.", [["kidney", "ANATOMY", 57, 63], ["brain", "ANATOMY", 95, 100], ["eyes", "ANATOMY", 126, 130], ["muscles", "ANATOMY", 157, 164], ["skin", "ANATOMY", 193, 197], ["kidney", "ORGAN", 57, 63], ["brain", "ORGAN", 95, 100], ["eyes", "ORGAN", 126, 130], ["muscles", "ORGAN", 157, 164], ["skin", "ORGAN", 193, 197], ["rodents", "ORGANISM", 222, 229], ["Electroporation", "TREATMENT", 0, 15], ["kidney", "ANATOMY", 57, 63], ["brain", "ANATOMY", 95, 100], ["eyes", "ANATOMY", 126, 130], ["muscles", "ANATOMY", 157, 164], ["skin", "ANATOMY", 193, 197]]], ["Topical gels have also been used to deliver siRNAs to cells and could open the way for dermatological applications, as well as the treatment of cervical cancer (Jiang et al., 2004) .", [["cells", "ANATOMY", 54, 59], ["cervical cancer", "ANATOMY", 144, 159], ["cervical cancer", "DISEASE", 144, 159], ["cells", "CELL", 54, 59], ["cervical cancer", "CANCER", 144, 159], ["Topical gels", "TREATMENT", 0, 12], ["siRNAs to cells", "TREATMENT", 44, 59], ["dermatological applications", "TREATMENT", 87, 114], ["cervical cancer", "PROBLEM", 144, 159], ["cervical", "ANATOMY", 144, 152], ["cancer", "OBSERVATION", 153, 159]]], ["Intradermal administration of nucleic acids via gene gun has been used to deliver siRNA in vivo to enhance cancer vaccine potency (Kim et al., 2005) .", [["Intradermal", "ANATOMY", 0, 11], ["cancer", "ANATOMY", 107, 113], ["nucleic acids", "CHEMICAL", 30, 43], ["cancer", "DISEASE", 107, 113], ["nucleic acids", "SIMPLE_CHEMICAL", 30, 43], ["cancer", "CANCER", 107, 113], ["nucleic acids via gene gun", "TREATMENT", 30, 56], ["siRNA", "TREATMENT", 82, 87]]], ["Ultrasound (Taniyama et al., 2002) could be also be potentially used to deliver siRNA, although there are no reports of this currently.", [["Ultrasound", "TEST", 0, 10], ["siRNA", "TREATMENT", 80, 85]]], ["For clinical applications, gentle methods for the delivery of siRNA molecules similar to those that have been developed for antisense molecules (inhaled, cream formulation, and oral; Crooke, 2004) would be preferable.", [["oral", "ANATOMY", 177, 181], ["oral", "ORGANISM_SUBDIVISION", 177, 181], ["clinical applications", "TREATMENT", 4, 25], ["gentle methods", "TREATMENT", 27, 41], ["the delivery of siRNA molecules", "TREATMENT", 46, 77], ["antisense molecules (inhaled, cream formulation", "TREATMENT", 124, 171]]], ["Several groups have investigated the use of direct injection of viral vectors for the in vivo delivery of siRNA.", [["direct injection of viral vectors", "TREATMENT", 44, 77], ["the in vivo delivery of siRNA", "TREATMENT", 82, 111], ["siRNA", "OBSERVATION", 106, 111]]], ["An AAV shRNA vector injected directly into the midbrain neurons of adult mice resulted in the silencing of the tyrosine hydroxylase gene near the site of injection for several weeks (Hommel et al., 2003) .", [["midbrain neurons", "ANATOMY", 47, 63], ["tyrosine", "CHEMICAL", 111, 119], ["tyrosine", "CHEMICAL", 111, 119], ["AAV", "ORGANISM", 3, 6], ["midbrain neurons", "CELL", 47, 63], ["mice", "ORGANISM", 73, 77], ["tyrosine hydroxylase", "GENE_OR_GENE_PRODUCT", 111, 131], ["AAV shRNA vector", "DNA", 3, 19], ["midbrain neurons", "CELL_TYPE", 47, 63], ["tyrosine hydroxylase gene", "DNA", 111, 136], ["mice", "SPECIES", 73, 77], ["mice", "SPECIES", 73, 77], ["An AAV shRNA vector", "TREATMENT", 0, 19], ["the tyrosine hydroxylase gene", "TREATMENT", 107, 136], ["AAV shRNA", "OBSERVATION", 3, 12], ["midbrain", "ANATOMY", 47, 55], ["tyrosine hydroxylase", "OBSERVATION", 111, 131]]], ["This resulted in behavioural changes, including a motor performance deficit and reduced response to a psychostimulant.", [["behavioural changes", "PROBLEM", 17, 36], ["a motor performance deficit", "PROBLEM", 48, 75], ["a psychostimulant", "TREATMENT", 100, 117], ["behavioural changes", "OBSERVATION", 17, 36]]], ["Intracerebellar injection of an AAV vector expressing shRNAs directed against a mutant variant of ataxin-1 profoundly improved motor coordination, restored cerebellar morphology, and resolved characteristic ataxin-1 inclusions in Purkinje cells in a mouse model of the neurodegenerative disorder spinocerebellar ataxia .", [["Intracerebellar", "ANATOMY", 0, 15], ["cerebellar", "ANATOMY", 156, 166], ["Purkinje cells", "ANATOMY", 230, 244], ["spinocerebellar", "ANATOMY", 296, 311], ["neurodegenerative disorder", "DISEASE", 269, 295], ["spinocerebellar ataxia", "DISEASE", 296, 318], ["AAV", "ORGANISM", 32, 35], ["shRNAs", "GENE_OR_GENE_PRODUCT", 54, 60], ["ataxin-1", "GENE_OR_GENE_PRODUCT", 98, 106], ["cerebellar", "ORGAN", 156, 166], ["ataxin-1", "GENE_OR_GENE_PRODUCT", 207, 215], ["Purkinje cells", "CELL", 230, 244], ["mouse", "ORGANISM", 250, 255], ["shRNAs", "DNA", 54, 60], ["ataxin-1", "PROTEIN", 98, 106], ["ataxin", "PROTEIN", 207, 213], ["Purkinje cells", "CELL_TYPE", 230, 244], ["mouse", "SPECIES", 250, 255], ["AAV", "SPECIES", 32, 35], ["mouse", "SPECIES", 250, 255], ["Intracerebellar injection", "TREATMENT", 0, 25], ["an AAV vector expressing shRNAs", "TREATMENT", 29, 60], ["characteristic ataxin", "PROBLEM", 192, 213], ["1 inclusions in Purkinje cells", "PROBLEM", 214, 244], ["the neurodegenerative disorder spinocerebellar ataxia", "PROBLEM", 265, 318], ["cerebellar", "ANATOMY", 156, 166], ["Purkinje cells", "OBSERVATION", 230, 244], ["neurodegenerative disorder", "OBSERVATION", 269, 295], ["spinocerebellar ataxia", "OBSERVATION", 296, 318]]], ["As an alternative to injection, Banerjea et al. (2003) used an ex vivo approach to generate HIV-1-resistant lymphocytes and macrophages.", [["lymphocytes", "ANATOMY", 108, 119], ["macrophages", "ANATOMY", 124, 135], ["HIV-1", "ORGANISM", 92, 97], ["lymphocytes", "CELL", 108, 119], ["macrophages", "CELL", 124, 135], ["HIV-1-resistant lymphocytes", "CELL_LINE", 92, 119], ["macrophages", "CELL_TYPE", 124, 135], ["HIV-1", "SPECIES", 92, 97], ["HIV-1", "SPECIES", 92, 97], ["an ex vivo approach", "TREATMENT", 60, 79], ["HIV", "TEST", 92, 95], ["macrophages", "PROBLEM", 124, 135], ["lymphocytes", "ANATOMY", 108, 119], ["macrophages", "ANATOMY", 124, 135]]], ["Using a lentiviral vector, an anti-rev siRNA construct was introduced into CD34(+) hematopoietic progenitor cells.", [["CD34(+) hematopoietic progenitor cells", "ANATOMY", 75, 113], ["lentiviral", "ORGANISM", 8, 18], ["anti-rev", "GENE_OR_GENE_PRODUCT", 30, 38], ["CD34", "GENE_OR_GENE_PRODUCT", 75, 79], ["anti-rev siRNA construct", "DNA", 30, 54], ["CD34(+) hematopoietic progenitor cells", "CELL_TYPE", 75, 113], ["a lentiviral vector", "TREATMENT", 6, 25], ["an anti-rev siRNA construct", "TREATMENT", 27, 54], ["hematopoietic progenitor cells", "PROBLEM", 83, 113], ["hematopoietic progenitor cells", "OBSERVATION", 83, 113]]], ["The siRNA-transduced progenitor cells were allowed to mature into macrophages in vitro and T-cells in vivo in severe combined immunodeficiency (SCID) mice transplanted with human thymus and fetal liver grafts.", [["progenitor cells", "ANATOMY", 21, 37], ["macrophages", "ANATOMY", 66, 77], ["T-cells", "ANATOMY", 91, 98], ["thymus", "ANATOMY", 179, 185], ["fetal liver grafts", "ANATOMY", 190, 208], ["severe combined immunodeficiency", "DISEASE", 110, 142], ["SCID", "DISEASE", 144, 148], ["progenitor cells", "CELL", 21, 37], ["macrophages", "CELL", 66, 77], ["T-cells", "CELL", 91, 98], ["mice", "ORGANISM", 150, 154], ["human", "ORGANISM", 173, 178], ["thymus", "ORGAN", 179, 185], ["fetal liver grafts", "TISSUE", 190, 208], ["siRNA-transduced progenitor cells", "CELL_LINE", 4, 37], ["macrophages", "CELL_TYPE", 66, 77], ["T-cells", "CELL_TYPE", 91, 98], ["mice", "SPECIES", 150, 154], ["human", "SPECIES", 173, 178], ["mice", "SPECIES", 150, 154], ["human", "SPECIES", 173, 178], ["The siRNA-transduced progenitor cells", "TREATMENT", 0, 37], ["severe combined immunodeficiency (SCID) mice transplanted", "TREATMENT", 110, 167], ["human thymus", "TREATMENT", 173, 185], ["fetal liver grafts", "TREATMENT", 190, 208], ["siRNA", "ANATOMY", 4, 9], ["progenitor cells", "OBSERVATION", 21, 37], ["severe", "OBSERVATION_MODIFIER", 110, 116], ["thymus", "ANATOMY", 179, 185], ["fetal", "ANATOMY_MODIFIER", 190, 195], ["liver", "ANATOMY", 196, 201], ["grafts", "OBSERVATION", 202, 208]]], ["Phenotypically normal T-cells and macrophages displaying characteristic surface markers were obtained.", [["T-cells", "ANATOMY", 22, 29], ["macrophages", "ANATOMY", 34, 45], ["surface", "ANATOMY", 72, 79], ["T-cells", "CELL", 22, 29], ["macrophages", "CELL", 34, 45], ["normal T-cells", "CELL_TYPE", 15, 29], ["macrophages", "CELL_TYPE", 34, 45], ["normal", "OBSERVATION", 15, 21], ["macrophages", "ANATOMY", 34, 45], ["surface markers", "OBSERVATION", 72, 87]]], ["In vitro HIV-1 challenge of the siRNA-expressing macrophages and Tcells with macrophage-tropic and T-cell-tropic HIV-1, respectively, showed marked viral resistance.", [["macrophages", "ANATOMY", 49, 60], ["Tcells", "ANATOMY", 65, 71], ["T-cell", "ANATOMY", 99, 105], ["HIV-1", "ORGANISM", 9, 14], ["macrophages", "CELL", 49, 60], ["Tcells", "CELL", 65, 71], ["macrophage", "CELL", 77, 87], ["T-cell-tropic HIV-1", "ORGANISM", 99, 118], ["expressing macrophages", "CELL_TYPE", 38, 60], ["Tcells", "CELL_TYPE", 65, 71], ["HIV-1", "SPECIES", 9, 14], ["HIV-1", "SPECIES", 113, 118], ["HIV-1", "SPECIES", 9, 14], ["HIV-1", "SPECIES", 113, 118], ["the siRNA", "TEST", 28, 37], ["Tcells", "TEST", 65, 71], ["macrophage", "TEST", 77, 87], ["tropic HIV", "TEST", 106, 116], ["marked viral resistance", "PROBLEM", 141, 164], ["siRNA", "ANATOMY", 32, 37], ["marked", "OBSERVATION_MODIFIER", 141, 147], ["viral resistance", "OBSERVATION", 148, 164]]], ["Despite these successes, reports of viral-mediated insertional mutagenesis in patients receiving retrovirus-mediated gene therapy for treatment of X-linked severe combined immunodeficiency (X-SCID; Hacein-Bey- Abina et al., 2003; Marshall, 2003) have raised concerns over the safety of using viral vectors for therapy.Off-target and nonspecific effectsA careful selection of sequences is needed to maximise gene silencing and minimise off-target and nonspecific effects.", [["X-linked severe combined immunodeficiency (X-SCID", "DISEASE", 147, 196], ["patients", "ORGANISM", 78, 86], ["retrovirus", "ORGANISM", 97, 107], ["patients", "SPECIES", 78, 86], ["viral-mediated insertional mutagenesis", "TREATMENT", 36, 74], ["retrovirus-mediated gene therapy", "TREATMENT", 97, 129], ["treatment", "TREATMENT", 134, 143], ["X-linked severe combined immunodeficiency", "PROBLEM", 147, 188], ["viral vectors", "TREATMENT", 292, 305], ["therapy", "TREATMENT", 310, 317], ["nonspecific effects", "PROBLEM", 333, 352], ["A careful selection of sequences", "TEST", 352, 384], ["severe", "OBSERVATION_MODIFIER", 156, 162], ["nonspecific effects", "OBSERVATION_MODIFIER", 333, 352]]], ["Although initially thought to have laser-like specificity, the off-target effects of siRNA have become evident (Jackson et al., 2003; Couzin, 2004; Jackson & Linsley, 2004; Scacheri et al., 2004 ).", [["laser-like specificity", "PROBLEM", 35, 57], ["siRNA", "TREATMENT", 85, 90]]], ["An siRNA duplex may target more than 1 mRNA molecule because of sequence homologies.", [["1 mRNA molecule", "RNA", 37, 52], ["An siRNA duplex", "TEST", 0, 15], ["sequence homologies", "TEST", 64, 83], ["siRNA", "OBSERVATION", 3, 8]]], ["It is now widely observed that most siRNAs can tolerate 1 mismatch to the mRNA target and at the same time retain good silencing capacity (Yu et al., 2002; Pusch et al., 2003; Vickers et al., 2003) .", [["mRNA target", "RNA", 74, 85]]], ["In some cases, siRNAs can tolerate several mismatches (Saxena et al., 2003) or even tolerate mismatches while acting as a single-stranded antisense siRNA (Holen et al., 2003) .", [["a single-stranded antisense siRNA", "TREATMENT", 120, 153]]], ["In addition, some domains of the siRNAs tolerate more mismatches than others do (Schwarz et al., 2003) .", [["siRNAs", "OBSERVATION", 33, 39]]], ["Saxena et al. (2003) also demonstrated tolerance for G/U wobble pairing between the RNA oligo and the target RNA.", [["G/U", "GENE_OR_GENE_PRODUCT", 53, 56], ["RNA oligo", "RNA", 84, 93], ["target RNA", "RNA", 102, 112], ["G/U wobble pairing", "TREATMENT", 53, 71], ["the RNA oligo", "TREATMENT", 80, 93]]], ["To further investigate the effect of mismatches of siRNAs on off-target activity, Snove and Holen (2004) analysed 359 published siRNA sequences and found that around 75% could potentially elicit nonspecific effects.", [["siRNA sequences", "DNA", 128, 143], ["mismatches of siRNAs", "TREATMENT", 37, 57], ["published siRNA sequences", "TEST", 118, 143], ["siRNAs", "OBSERVATION", 51, 57]]], ["Microarray technology has been used to examine off-target effects, but results have been contradictory, with some studies finding a high specificity of siRNA effects (Chi et al., 2003; Semizarov et al., 2004) , but others not (Jackson et al., 2003; Persengiev et al., 2004) .", [["Microarray technology", "TEST", 0, 21], ["some studies", "TEST", 109, 121], ["siRNA effects", "PROBLEM", 152, 165]]], ["Another consideration is that some off-target activities might actually represent genuine physiological knock-on effects of specific target knock-down in certain biochemical pathways/cascades.", [["genuine physiological knock", "PROBLEM", 82, 109]]], ["Therefore, such activity should be interpreted carefully in the context of the biological system in question, and the results of RNAi studies should be confirmed using complementary approaches or the use of multiple siRNA duplexes.Off-target and nonspecific effectsRecent data suggest that siRNAs and shRNAs can induce subsets of genes involved in the interferon response in mammalian cells.", [["cells", "ANATOMY", 385, 390], ["shRNAs", "GENE_OR_GENE_PRODUCT", 301, 307], ["mammalian cells", "CELL", 375, 390], ["shRNAs", "DNA", 301, 307], ["interferon", "PROTEIN", 352, 362], ["mammalian cells", "CELL_TYPE", 375, 390], ["RNAi studies", "TEST", 129, 141], ["multiple siRNA duplexes", "TREATMENT", 207, 230], ["nonspecific effects", "PROBLEM", 246, 265], ["Recent data", "TEST", 265, 276], ["siRNAs and shRNAs", "PROBLEM", 290, 307], ["the interferon response in mammalian cells", "TREATMENT", 348, 390], ["multiple", "OBSERVATION_MODIFIER", 207, 215], ["siRNA duplexes", "OBSERVATION", 216, 230], ["nonspecific effects", "OBSERVATION_MODIFIER", 246, 265], ["siRNAs", "OBSERVATION", 290, 296], ["mammalian cells", "OBSERVATION", 375, 390]]], ["Sledz et al. (2003) showed that 21-bp siRNAs activate the Jak -Stat pathway and induce a global up-regulation of IFN-stimulated genes, mediated by the dsRNA-dependent protein kinase PKR.", [["Jak", "GENE_OR_GENE_PRODUCT", 58, 61], ["Stat", "GENE_OR_GENE_PRODUCT", 63, 67], ["IFN-stimulated genes", "GENE_OR_GENE_PRODUCT", 113, 133], ["dsRNA-dependent protein kinase PKR", "GENE_OR_GENE_PRODUCT", 151, 185], ["21-bp siRNAs", "DNA", 32, 44], ["Jak", "PROTEIN", 58, 61], ["Stat", "PROTEIN", 63, 67], ["IFN-stimulated genes", "DNA", 113, 133], ["dsRNA-dependent protein kinase", "PROTEIN", 151, 181], ["PKR", "PROTEIN", 182, 185], ["bp siRNAs", "TREATMENT", 35, 44], ["a global up-regulation of IFN", "PROBLEM", 87, 116], ["the dsRNA", "TEST", 147, 156], ["dependent protein kinase PKR", "PROBLEM", 157, 185]]], ["However, their findings also confirmed that siRNA-induced knockdown is independent of the IFN system.", [["IFN", "GENE_OR_GENE_PRODUCT", 90, 93], ["IFN", "PROTEIN", 90, 93], ["siRNA-induced knockdown", "PROBLEM", 44, 67], ["siRNA", "OBSERVATION", 44, 49], ["knockdown", "OBSERVATION", 58, 67]]], ["Another report (Bridge et al., 2003) linked the activation of interferon to the expression vectors carrying shRNA hairpins, while siRNA alone did not elicit such response.", [["interferon", "GENE_OR_GENE_PRODUCT", 62, 72], ["interferon", "PROTEIN", 62, 72], ["expression vectors", "DNA", 80, 98], ["shRNA hairpins", "DNA", 108, 122], ["interferon", "TREATMENT", 62, 72], ["the expression vectors", "TREATMENT", 76, 98], ["shRNA hairpins", "TREATMENT", 108, 122]]], ["In a complementary study, Heidel et al. (2004) showed that it was possible to administer naked synthetic DNA to mice and down-regulate an endogenous or exogenous target without inducing the IFN response.", [["DNA", "CELLULAR_COMPONENT", 105, 108], ["mice", "ORGANISM", 112, 116], ["IFN", "GENE_OR_GENE_PRODUCT", 190, 193], ["IFN", "PROTEIN", 190, 193], ["mice", "SPECIES", 112, 116], ["mice", "SPECIES", 112, 116], ["a complementary study", "TEST", 3, 24], ["naked synthetic DNA", "TREATMENT", 89, 108]]], ["In addition to the IFN response, it has been reported that si/shRNAs initiated immune activation in macrophages and dendritic cells through toll-like receptor 3 (toll receptors recognize exogenous nucleic acids; Kariko et al., 2004) .", [["macrophages", "ANATOMY", 100, 111], ["dendritic cells", "ANATOMY", 116, 131], ["nucleic acids", "CHEMICAL", 197, 210], ["shRNAs", "GENE_OR_GENE_PRODUCT", 62, 68], ["macrophages", "CELL", 100, 111], ["dendritic cells", "CELL", 116, 131], ["toll-like receptor 3", "GENE_OR_GENE_PRODUCT", 140, 160], ["toll receptors", "GENE_OR_GENE_PRODUCT", 162, 176], ["IFN", "PROTEIN", 19, 22], ["shRNAs", "DNA", 62, 68], ["macrophages", "CELL_TYPE", 100, 111], ["dendritic cells", "CELL_TYPE", 116, 131], ["toll-like receptor 3", "PROTEIN", 140, 160], ["toll receptors", "PROTEIN", 162, 176], ["si/shRNAs", "TREATMENT", 59, 68], ["immune activation in macrophages", "TREATMENT", 79, 111], ["dendritic cells", "PROBLEM", 116, 131], ["dendritic cells", "OBSERVATION", 116, 131]]], ["Currently, it is unclear how often si/shRNAs trigger such effects in cells and what conditions favour these responses.", [["cells", "ANATOMY", 69, 74], ["shRNAs", "GENE_OR_GENE_PRODUCT", 38, 44], ["cells", "CELL", 69, 74], ["shRNAs", "DNA", 38, 44], ["such effects in cells", "PROBLEM", 53, 74]]], ["Immunosuppression, selection of different administration routes, and dose of the vectors, using tissue-specific promoters and vector modification, are being investigated .Off-target and nonspecific effectsAlthough RNAi in plants is associated with de novo RNA-directed DNA methylation (RdDM; Hamilton et al., 2002) , experiments suggest that this may not be the case in mammalian cells (Park et al., 2004) , although effects on other epigenetic modifications such as histone modification have yet to be assessed.Conclusions and future prospectsIn a relatively short time, RNAi has rapidly progressed to become a key experimental tool for the analysis of gene function and target validation in mammalian systems, both in vitro and in vivo.", [["tissue", "ANATOMY", 96, 102], ["cells", "ANATOMY", 380, 385], ["tissue", "TISSUE", 96, 102], ["DNA", "CELLULAR_COMPONENT", 269, 272], ["mammalian cells", "CELL", 370, 385], ["histone", "GENE_OR_GENE_PRODUCT", 467, 474], ["promoters", "DNA", 112, 121], ["mammalian cells", "CELL_TYPE", 370, 385], ["histone", "PROTEIN", 467, 474], ["Immunosuppression", "TREATMENT", 0, 17], ["different administration routes", "TREATMENT", 32, 63], ["the vectors", "TREATMENT", 77, 88], ["tissue-specific promoters", "TREATMENT", 96, 121], ["vector modification", "TREATMENT", 126, 145], ["nonspecific effects", "PROBLEM", 186, 205], ["de novo RNA", "PROBLEM", 248, 259], ["other epigenetic modifications", "TREATMENT", 428, 458], ["histone modification", "TREATMENT", 467, 487], ["gene function", "PROBLEM", 654, 667], ["nonspecific effects", "OBSERVATION_MODIFIER", 186, 205]]], ["However, we hope that we have been sufficiently thorough in our coverage to give readers an insight into the many uses to which this important technology is being put, as well as highlight current limitations and the potential of RNAi as a therapeutic strategy.", [["RNAi", "TREATMENT", 230, 234], ["a therapeutic strategy", "TREATMENT", 238, 260]]], ["The effectiveness of RNAi reagents will improve, as more is gleaned about the biology of RNAi in mammalian systems, and improvements in the stability, delivery, and reduction of off-target and nonspecific effects are made.", [["RNAi reagents", "TREATMENT", 21, 34], ["delivery", "TREATMENT", 151, 159], ["stability", "OBSERVATION_MODIFIER", 140, 149], ["nonspecific", "OBSERVATION_MODIFIER", 193, 204]]], ["Although still a fledgling area, clinical applications for RNAi will build on the lessons learned from clinical use of antisense molecules.", [["antisense molecules", "PROTEIN", 119, 138], ["a fledgling area", "PROBLEM", 15, 31], ["RNAi", "TREATMENT", 59, 63], ["antisense molecules", "TREATMENT", 119, 138]]], ["The delivery (viral or otherwise) and target specificity of siRNA will be the keys to unlock this transition.", [["The delivery", "TREATMENT", 0, 12], ["siRNA", "TREATMENT", 60, 65]]], ["RNAi-based gene therapy has great potential in cancer and infectious disease, as well as in genetic diseases that are due to a dominant genetic effect (e.g., Huntington's chorea and amyotrophic lateral sclerosis).", [["cancer", "ANATOMY", 47, 53], ["cancer", "DISEASE", 47, 53], ["infectious disease", "DISEASE", 58, 76], ["Huntington's chorea", "DISEASE", 158, 177], ["amyotrophic lateral sclerosis", "DISEASE", 182, 211], ["cancer", "CANCER", 47, 53], ["amyotrophic lateral sclerosis", "CANCER", 182, 211], ["RNAi", "TREATMENT", 0, 4], ["based gene therapy", "TREATMENT", 5, 23], ["infectious disease", "PROBLEM", 58, 76], ["genetic diseases", "PROBLEM", 92, 108], ["a dominant genetic effect", "PROBLEM", 125, 150], ["Huntington's chorea", "PROBLEM", 158, 177], ["amyotrophic lateral sclerosis)", "PROBLEM", 182, 212], ["cancer", "OBSERVATION", 47, 53], ["infectious", "OBSERVATION", 58, 68], ["amyotrophic", "OBSERVATION_MODIFIER", 182, 193], ["lateral", "OBSERVATION_MODIFIER", 194, 201], ["sclerosis", "OBSERVATION", 202, 211]]], ["The use of inducible RNAi systems will be particularly attractive in the clinical setting, where the ability to reverse siRNA treatment by simply withdrawing the inducing agent would allow treatment to be terminated as appropriate.", [["inducible RNAi systems", "PROBLEM", 11, 33], ["reverse siRNA treatment", "TREATMENT", 112, 135], ["the inducing agent", "TREATMENT", 158, 176], ["treatment", "TREATMENT", 189, 198]]]], "PMC3016762": [["Emergence of SARS-Associated Coronavirus in HumansAvailable evidence suggests that SARS emerged in Guangdong Province, in southern China.", [["SARS", "DISEASE", 13, 17], ["SARS", "DISEASE", 83, 87], ["SARS", "PROBLEM", 13, 17], ["Coronavirus", "PROBLEM", 29, 40], ["SARS", "PROBLEM", 83, 87], ["SARS", "OBSERVATION", 13, 17], ["Coronavirus", "OBSERVATION", 29, 40]]], ["Did the causative agent evolve in an animal species and jump to humans (or perhaps first to other animal species), or did the virus evolve within humans?", [["humans", "ORGANISM", 64, 70], ["humans", "ORGANISM", 146, 152], ["humans", "SPECIES", 64, 70], ["humans", "SPECIES", 146, 152], ["humans", "SPECIES", 64, 70], ["humans", "SPECIES", 146, 152], ["an animal species", "PROBLEM", 34, 51], ["the virus", "PROBLEM", 122, 131], ["animal species", "OBSERVATION", 37, 51]]], ["The genetic sequence of the virus has been obtained in several laboratories, and phylogenetic analyses have shown that it is unlike other coronaviruses of animal and human origin.", [["human", "ORGANISM", 166, 171], ["human", "SPECIES", 166, 171], ["human", "SPECIES", 166, 171], ["the virus", "PROBLEM", 24, 33], ["phylogenetic analyses", "TEST", 81, 102], ["coronaviruses", "OBSERVATION", 138, 151]]], ["Indeed, the virus has been tentatively placed in a new fourth genetic group (2,3).Emergence of SARS-Associated Coronavirus in HumansWhy is it so important to answer the question of how SARS emerged?", [["SARS", "DISEASE", 95, 99], ["SARS", "DISEASE", 185, 189], ["the virus", "PROBLEM", 8, 17], ["SARS", "PROBLEM", 95, 99], ["Coronavirus", "PROBLEM", 111, 122], ["virus", "OBSERVATION", 12, 17], ["new", "OBSERVATION_MODIFIER", 51, 54], ["Coronavirus", "OBSERVATION", 111, 122]]], ["Most recently recognized novel emergent viruses have been zoonotic, usually with a reservoir in wildlife (4,5).", [["viruses", "OBSERVATION", 40, 47]]], ["Thus, SARS coronavirus, if zoonotic, may provide the basis for modeling and predicting the appearance of other potential zoonotic human pathogens.", [["SARS coronavirus", "DISEASE", 6, 22], ["SARS coronavirus", "ORGANISM", 6, 22], ["human", "ORGANISM", 130, 135], ["human", "SPECIES", 130, 135], ["SARS coronavirus", "SPECIES", 6, 22], ["human", "SPECIES", 130, 135], ["SARS coronavirus", "PROBLEM", 6, 22], ["zoonotic", "PROBLEM", 27, 35], ["other potential zoonotic human pathogens", "PROBLEM", 105, 145], ["zoonotic human pathogens", "OBSERVATION", 121, 145]]], ["More importantly, the information may be crucial for control of SARS.", [["SARS", "DISEASE", 64, 68], ["SARS", "PROBLEM", 64, 68]]], ["If this disease is to be curtailed or eliminated by strict public health measures, blocking further animal-to-human transmission will be critical.", [["human", "ORGANISM", 110, 115], ["human", "SPECIES", 110, 115], ["human", "SPECIES", 110, 115], ["this disease", "PROBLEM", 3, 15]]], ["Only about half of the cases in Guangdong are attributed to contact with a SARS patient.", [["SARS", "DISEASE", 75, 79], ["Guangdong", "ORGANISM", 32, 41], ["patient", "ORGANISM", 80, 87], ["patient", "SPECIES", 80, 87]]], ["Transmission from an unknown, but persisting animal reservoir might explain this finding; however, a nonspecific case definition (i.e., many \u201ccases\u201d might not actually be SARS) and limitations in contact-tracing capacity are other potential explanations.Emergence of SARS-Associated Coronavirus in HumansFinding a potential animal source is, however, a daunting task.", [["SARS", "DISEASE", 171, 175], ["SARS", "DISEASE", 267, 271], ["a nonspecific case definition", "PROBLEM", 99, 128], ["SARS", "PROBLEM", 171, 175], ["SARS", "PROBLEM", 267, 271], ["Coronavirus", "PROBLEM", 283, 294], ["SARS", "OBSERVATION", 267, 271], ["Coronavirus", "OBSERVATION", 283, 294]]], ["The opportunity for contact, not only with farmed animals but also with a variety of otherwise rare or uncommon wild animals, is enormous.", [["enormous", "OBSERVATION_MODIFIER", 129, 137]]], ["More than one third of early cases, with dates of onset before February 1, 2003, were in food handlers (persons who handle, kill, and sell food animals, or those who prepare and serve food) (Guangdong Province Center for Disease Control and Prevention, unpub. data,).Emergence of SARS-Associated Coronavirus in HumansHypothesis-generating epidemiologic studies should be carried out immediately in China, focusing on early cases of SARS and cases in persons without known contact with infected persons.", [["SARS", "DISEASE", 280, 284], ["SARS", "DISEASE", 432, 436], ["persons", "ORGANISM", 450, 457], ["persons", "ORGANISM", 494, 501], ["persons", "SPECIES", 104, 111], ["persons", "SPECIES", 450, 457], ["persons", "SPECIES", 494, 501], ["Disease Control", "TREATMENT", 221, 236], ["SARS", "PROBLEM", 280, 284], ["Coronavirus", "PROBLEM", 296, 307], ["epidemiologic studies", "TEST", 339, 360], ["SARS", "PROBLEM", 432, 436], ["SARS", "OBSERVATION", 280, 284], ["Coronavirus", "OBSERVATION", 296, 307]]], ["These studies should also collect information from appropriately selected controls (i.e., matched by categories such as community and age), regarding exposures to animals of any kind in any setting (including food preparation, dietary habits, pets, and a variety of other activities and behaviors in the community).Emergence of SARS-Associated Coronavirus in HumansPlausible hypotheses generated by epidemiologic studies should be briskly followed by intensive, focused, laboratory studies where relevant, including surveys of specific animal populations to identify SARS-associated coronaviruses (by culture and polymerase chain reaction [PCR]) or to measure specific antibodies.", [["SARS", "DISEASE", 328, 332], ["SARS", "DISEASE", 567, 571], ["coronaviruses", "ORGANISM", 583, 596], ["specific antibodies", "PROTEIN", 660, 679], ["These studies", "TEST", 0, 13], ["SARS", "PROBLEM", 328, 332], ["Coronavirus", "PROBLEM", 344, 355], ["epidemiologic studies", "TEST", 399, 420], ["laboratory studies", "TEST", 471, 489], ["SARS", "PROBLEM", 567, 571], ["coronaviruses", "PROBLEM", 583, 596], ["culture", "TEST", 601, 608], ["polymerase chain reaction", "PROBLEM", 613, 638], ["PCR", "TEST", 640, 643], ["SARS", "OBSERVATION", 328, 332], ["Coronavirus", "OBSERVATION", 344, 355]]], ["Some virologic surveys have already been conducted among prevalent animal populations, including those known to harbor other coronaviruses or other viruses transmissible to humans or wild animals, handled and sold in the markets; a variety of animals have been reported to harbor SARS-associated coronavirus.", [["SARS", "DISEASE", 280, 284], ["coronavirus", "DISEASE", 296, 307], ["coronaviruses", "ORGANISM", 125, 138], ["humans", "ORGANISM", 173, 179], ["animals", "ORGANISM", 243, 250], ["coronavirus", "ORGANISM", 296, 307], ["humans", "SPECIES", 173, 179], ["humans", "SPECIES", 173, 179], ["coronavirus", "PROBLEM", 296, 307], ["viruses", "OBSERVATION", 148, 155]]], ["However, whether these animals are transmitting virus or are recipients of virus transmission is not yet clear.", [["transmitting virus", "PROBLEM", 35, 53], ["virus transmission", "PROBLEM", 75, 93]]], ["Solutions will lie with identifying epidemiologic links, which should guide targeted animal studies.", [["targeted animal studies", "TEST", 76, 99]]], ["Molecular epidemiologic and genetic studies can then be helpful in evaluating viruses isolated from animals and from humans.Natural History of the EpidemicSince the earliest known cases were in Guangdong Province, China has had more time than any other location to observe disease incidence over time.", [["humans", "ORGANISM", 117, 123], ["humans", "SPECIES", 117, 123], ["humans", "SPECIES", 117, 123], ["genetic studies", "TEST", 28, 43], ["viruses", "PROBLEM", 78, 85]]], ["Evidence from Guangdong Provincial Centers for Disease Control suggests that the disease incidence peaked in mid-February, and declined weekly through May.", [["Disease Control", "TREATMENT", 47, 62], ["the disease incidence", "PROBLEM", 77, 98]]], ["What were the reasons for the decline?", [["the decline", "PROBLEM", 26, 37]]], ["Introduction of stringent infection-control measures in hospital settings undoubtedly resulted in reduced incidence in healthcare settings but would not likely have accounted for reductions in community transmission.", [["infection", "DISEASE", 26, 35], ["stringent infection", "PROBLEM", 16, 35], ["stringent", "OBSERVATION_MODIFIER", 16, 25], ["infection", "OBSERVATION", 26, 35], ["reduced", "OBSERVATION_MODIFIER", 98, 105]]], ["Efforts have been made to reduce the interval between onset of illness and hospitalization (minimizing the potential for community transmission).", [["illness", "DISEASE", 63, 70], ["illness", "PROBLEM", 63, 70]]], ["This effort likely had substantial impact in reducing disease incidence, as shown elsewhere (6).Natural History of the EpidemicThe initial hypothesis was that the virus attenuated after multiple generations of transmission; this hypothesis now seems unlikely.", [["reducing disease incidence", "PROBLEM", 45, 71], ["the virus", "PROBLEM", 159, 168], ["this hypothesis", "PROBLEM", 224, 239], ["substantial", "OBSERVATION_MODIFIER", 23, 34], ["impact", "OBSERVATION_MODIFIER", 35, 41], ["reducing", "OBSERVATION_MODIFIER", 45, 53], ["disease", "OBSERVATION", 54, 61], ["seems unlikely", "UNCERTAINTY", 244, 258]]], ["Were there a limited number of susceptible people within the population to begin with?", [["people", "ORGANISM", 43, 49], ["people", "SPECIES", 43, 49]]], ["Such a concept is possible if there had been earlier spread of a less virulent coronavirus, providing some immunity to a proportion of the population.", [["coronavirus", "DISEASE", 79, 90], ["coronavirus", "ORGANISM", 79, 90], ["a less virulent coronavirus", "PROBLEM", 63, 90]]], ["This scenario would require a good deal of asymptomatic or mildly symptomatic disease.", [["asymptomatic or mildly symptomatic disease", "PROBLEM", 43, 85], ["mildly", "OBSERVATION_MODIFIER", 59, 65], ["symptomatic", "OBSERVATION_MODIFIER", 66, 77], ["disease", "OBSERVATION", 78, 85]]], ["At this stage, no reason exists to exclude the possibility of a much wider spectrum of disease than is currently appreciated, since the spectrum of illness has not been fully evaluated.Natural History of the EpidemicAnother possibility is that a second agent might be required, in addition to coronavirus, to produce severe illness; if this is the case, the epidemiology (like seasonality) of the second agent (perhaps a less recently emerged pathogen for which there is already fairly widespread immunity), rather than coronavirus, may actually be responsible for the decline of the incidence of SARS in Guangdong.Natural History of the EpidemicExtensive seroprevalence studies will be helpful for sorting through these possibilities.", [["illness", "DISEASE", 148, 155], ["coronavirus", "DISEASE", 293, 304], ["SARS", "DISEASE", 597, 601], ["coronavirus", "ORGANISM", 293, 304], ["disease", "PROBLEM", 87, 94], ["illness", "PROBLEM", 148, 155], ["a second agent", "TREATMENT", 244, 258], ["coronavirus", "PROBLEM", 293, 304], ["severe illness", "PROBLEM", 317, 331], ["pathogen", "PROBLEM", 443, 451], ["coronavirus", "PROBLEM", 520, 531], ["SARS", "PROBLEM", 597, 601], ["the EpidemicExtensive seroprevalence studies", "TEST", 634, 678], ["no reason", "UNCERTAINTY", 15, 24], ["disease", "OBSERVATION", 87, 94], ["illness", "OBSERVATION", 148, 155], ["severe", "OBSERVATION_MODIFIER", 317, 323], ["illness", "OBSERVATION", 324, 331]]], ["Analyzing stored serum samples, collected before the onset of this outbreak, could be of immense value in evaluating the possibility of preexisting immunity.", [["serum samples", "ANATOMY", 17, 30], ["serum samples", "ORGANISM_SUBSTANCE", 17, 30], ["Analyzing stored serum samples", "TEST", 0, 30], ["this outbreak", "PROBLEM", 62, 75]]], ["Some researchers have found human metapneumoviruses (7) and species of Chlamydia in patients with SARS, but the importance of these findings is unclear.", [["Chlamydia", "DISEASE", 71, 80], ["SARS", "DISEASE", 98, 102], ["human", "ORGANISM", 28, 33], ["Chlamydia", "ORGANISM", 71, 80], ["patients", "ORGANISM", 84, 92], ["human", "SPECIES", 28, 33], ["patients", "SPECIES", 84, 92], ["human", "SPECIES", 28, 33], ["human metapneumoviruses", "PROBLEM", 28, 51], ["Chlamydia", "PROBLEM", 71, 80], ["SARS", "PROBLEM", 98, 102], ["Chlamydia", "OBSERVATION", 71, 80]]], ["Systematic evaluation of specimens available from all cases, severe cases, and healthy controls in China regarding the presence of antibodies to coronavirus, as well as hypothesized co-infecting agents, should be done.", [["specimens", "ANATOMY", 25, 34], ["coronavirus", "DISEASE", 145, 156], ["specimens", "CANCER", 25, 34], ["coronavirus", "ORGANISM", 145, 156], ["antibodies", "PROTEIN", 131, 141], ["Systematic evaluation of specimens", "TEST", 0, 34], ["severe cases", "PROBLEM", 61, 73], ["antibodies", "PROBLEM", 131, 141], ["coronavirus", "PROBLEM", 145, 156], ["hypothesized co-infecting agents", "TREATMENT", 169, 201]]], ["Important clues may come from seroprevalence and other epidemiologic studies in children.", [["children", "ORGANISM", 80, 88], ["children", "SPECIES", 80, 88]]], ["As in other affected countries, children were disproportionately less affected by SARS than adults.", [["SARS", "DISEASE", 82, 86], ["children", "ORGANISM", 32, 40], ["children", "SPECIES", 32, 40]]], ["Carefully working through the bases for reduced incidence and severity may uncover cross-protecting infectious or immunizing agents or crucial host factors for protection.\u201cSuper-Spreaders\u201dWhen documenting the source of person-to-person transmission of SARS has been possible, a substantial proportion of cases have emanated from single persons, so-called super-spreaders (l).", [["SARS", "DISEASE", 252, 256], ["person", "SPECIES", 219, 225], ["person", "SPECIES", 229, 235], ["persons", "SPECIES", 336, 343], ["reduced incidence", "PROBLEM", 40, 57], ["severity", "PROBLEM", 62, 70], ["immunizing agents", "TREATMENT", 114, 131], ["SARS", "PROBLEM", 252, 256]]], ["While contact tracing is undoubtedly incomplete, most infected patients have transmitted illness to few other people.", [["illness", "DISEASE", 89, 96], ["patients", "ORGANISM", 63, 71], ["people", "ORGANISM", 110, 116], ["patients", "SPECIES", 63, 71], ["people", "SPECIES", 110, 116], ["contact tracing", "TEST", 6, 21]]], ["Understanding the differentiating characteristics of persons who transmit, especially patients who are able to transmit to several other people, often after minimal contact, may provide important clues for public health strategies focused on preventing transmission.", [["persons", "ORGANISM", 53, 60], ["patients", "ORGANISM", 86, 94], ["people", "ORGANISM", 137, 143], ["persons", "SPECIES", 53, 60], ["patients", "SPECIES", 86, 94], ["people", "SPECIES", 137, 143], ["public health strategies", "TREATMENT", 206, 230]]], ["The country could participate in multinational studies to define the characteristics of super-spreaders and their role in the epidemiology of SARS.", [["SARS", "DISEASE", 142, 146], ["multinational studies", "TEST", 33, 54]]], ["Of particular interest is the virus load of super-spreaders, compared with those of other infected persons.\u201cSuper-Spreaders\u201dLittle is known about the importance of fecal-oral transmission or about the length of time that virus shedding occurs in the gastrointestinal tract.", [["oral", "ANATOMY", 170, 174], ["gastrointestinal tract", "ANATOMY", 250, 272], ["fecal", "ORGANISM_SUBDIVISION", 164, 169], ["oral", "ORGANISM_SUBDIVISION", 170, 174], ["gastrointestinal tract", "ORGAN", 250, 272], ["persons", "SPECIES", 99, 106], ["fecal-oral transmission", "TREATMENT", 164, 187], ["virus shedding", "PROBLEM", 221, 235], ["infected", "OBSERVATION", 90, 98], ["virus", "OBSERVATION", 221, 226], ["gastrointestinal tract", "ANATOMY", 250, 272]]], ["Virus shedding in feces has major implications for control strategies and for the possibility of continued carriage and shedding by clinically recovered patients.", [["feces", "ANATOMY", 18, 23], ["Virus", "ORGANISM", 0, 5], ["feces", "ORGANISM_SUBSTANCE", 18, 23], ["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 153, 161], ["Virus shedding in feces", "PROBLEM", 0, 23], ["control strategies", "TREATMENT", 51, 69], ["continued carriage", "PROBLEM", 97, 115]]], ["China has the opportunity to explore the role of fecal spread in the transmission of SARS.Evolution of the VirusThe causative agent is a coronavirus (8\u201310), and the entire genome of several strains has been fully sequenced by many laboratories globally (2,3,11).", [["fecal", "ANATOMY", 49, 54], ["SARS", "DISEASE", 85, 89], ["coronavirus", "DISEASE", 137, 148], ["fecal", "ORGANISM_SUBSTANCE", 49, 54], ["Virus", "ORGANISM", 107, 112], ["fecal spread", "PROBLEM", 49, 61], ["the Virus", "PROBLEM", 103, 112], ["a coronavirus", "PROBLEM", 135, 148], ["several strains", "PROBLEM", 182, 197], ["fecal", "ANATOMY", 49, 54], ["spread", "OBSERVATION", 55, 61], ["Virus", "OBSERVATION", 107, 112], ["several", "OBSERVATION_MODIFIER", 182, 189], ["strains", "OBSERVATION", 190, 197]]], ["Tests have been developed to detect coronavirus genetic sequences by PCR.", [["coronavirus", "ORGANISM", 36, 47], ["coronavirus genetic sequences", "DNA", 36, 65], ["Tests", "TEST", 0, 5], ["coronavirus genetic sequences", "PROBLEM", 36, 65], ["PCR", "TEST", 69, 72]]], ["In addition, tests to detect SARS-associated coronavirus antibodies have been developed, but the sensitivity and specificity of these tests are low, especially early in the illness when public health and clinical needs are greatest.", [["SARS", "DISEASE", 29, 33], ["coronavirus", "ORGANISM", 45, 56], ["SARS-associated coronavirus antibodies", "PROTEIN", 29, 67], ["coronavirus", "SPECIES", 45, 56], ["tests", "TEST", 13, 18], ["SARS", "PROBLEM", 29, 33], ["coronavirus antibodies", "PROBLEM", 45, 67], ["the sensitivity", "TEST", 93, 108], ["these tests", "TEST", 128, 139]]], ["A good test for SARS would be important not only for diagnosis and management but also for investigating the origin of the disease and for defining its epidemiology.Evolution of the VirusIf the causative agent can be isolated from stored specimens from the earliest group of patients (from November 2002 to January 2003), how their genetic sequences compare with those from viruses isolated later from various parts of China and elsewhere, and from animals from Guangdong and Guanxi Provinces, would be useful to know.", [["specimens", "ANATOMY", 238, 247], ["SARS", "DISEASE", 16, 20], ["VirusIf", "GENE_OR_GENE_PRODUCT", 182, 189], ["patients", "ORGANISM", 275, 283], ["VirusIf", "DNA", 182, 189], ["patients", "SPECIES", 275, 283], ["SARS", "PROBLEM", 16, 20], ["management", "TREATMENT", 67, 77], ["the disease", "PROBLEM", 119, 130], ["the VirusIf the causative agent", "PROBLEM", 178, 209], ["viruses", "PROBLEM", 374, 381], ["disease", "OBSERVATION", 123, 130]]], ["They may affect transmissibility and virulence; they may provide (or frustrate) therapeutic targets for new drugs; and they may pose challenges for development of diagnostic tests and vaccines.", [["virulence", "PROBLEM", 37, 46], ["new drugs", "TREATMENT", 104, 113], ["diagnostic tests", "TEST", 163, 179], ["vaccines", "TREATMENT", 184, 192]]], ["Specimens from Chinese patients provide the longest observation window with which mutational tendencies can be evaluated.Evolution of the VirusAn analysis of 14 full-length sequences suggests that two genetic lineages might have arisen from Guangdong.", [["Specimens", "ANATOMY", 0, 9], ["patients", "ORGANISM", 23, 31], ["VirusAn", "DNA", 138, 145], ["14 full-length sequences", "DNA", 158, 182], ["patients", "SPECIES", 23, 31], ["Specimens", "TEST", 0, 9], ["the VirusAn analysis", "TEST", 134, 154], ["two genetic lineages", "PROBLEM", 197, 217]]], ["One lineage is represented by the chain of transmission associated with the physician from Guangzhou who traveled to Hong Kong, Special Administrative Region, in February.", [["lineage", "OBSERVATION_MODIFIER", 4, 11]]], ["The other lineage is associated with isolates from Hong Kong, Guangzhou, and Beijing (11).", [["lineage", "OBSERVATION_MODIFIER", 10, 17], ["isolates", "OBSERVATION_MODIFIER", 37, 45]]], ["If two genetic lineages arose in Guangdong, were there two separate transmission events from an animal host to humans, or did the lineage diverge within humans?", [["humans", "ORGANISM", 111, 117], ["humans", "ORGANISM", 153, 159], ["humans", "SPECIES", 111, 117], ["humans", "SPECIES", 153, 159], ["humans", "SPECIES", 111, 117], ["humans", "SPECIES", 153, 159]]], ["Specimens from early cases in Guangdong may be helpful in addressing this question.Outcomes of InfectionEpidemiologic, immunologic, and microbiologic factors associated with severe outcome are not fully defined.", [["Specimens", "ANATOMY", 0, 9], ["Specimens", "TEST", 0, 9], ["InfectionEpidemiologic, immunologic, and microbiologic factors", "PROBLEM", 95, 157], ["severe outcome", "PROBLEM", 174, 188], ["severe", "OBSERVATION_MODIFIER", 174, 180], ["outcome", "OBSERVATION", 181, 188]]], ["As with other respiratory diseases, age-related coexisting conditions reduce the capacity to compensate to conditions associated with severe disease.", [["respiratory diseases", "DISEASE", 14, 34], ["other respiratory diseases", "PROBLEM", 8, 34], ["coexisting conditions", "PROBLEM", 48, 69], ["the capacity", "PROBLEM", 77, 89], ["severe disease", "PROBLEM", 134, 148], ["respiratory diseases", "OBSERVATION", 14, 34], ["severe", "OBSERVATION_MODIFIER", 134, 140], ["disease", "OBSERVATION", 141, 148]]], ["Understanding other specific factors that result in poor outcome will have value for optimizing therapeutic approaches.Outcomes of InfectionExperienced clinicians disagree about the value of early treatment with ribavirin and high-dose corticosteroids, and some are reticent to ventilate patients because of high risk for transmission to healthcare workers associated with intubation.", [["ribavirin", "CHEMICAL", 212, 221], ["ribavirin", "CHEMICAL", 212, 221], ["corticosteroids", "CHEMICAL", 236, 251], ["ribavirin", "SIMPLE_CHEMICAL", 212, 221], ["patients", "ORGANISM", 288, 296], ["patients", "SPECIES", 288, 296], ["optimizing therapeutic approaches", "TREATMENT", 85, 118], ["Infection", "PROBLEM", 131, 140], ["early treatment", "TREATMENT", 191, 206], ["ribavirin", "TREATMENT", 212, 221], ["high-dose corticosteroids", "TREATMENT", 226, 251], ["intubation", "TREATMENT", 373, 383], ["Infection", "OBSERVATION", 131, 140]]], ["More data are needed to help define the most effective treatment strategy, particularly for areas with limited resources.Outcomes of InfectionExtraordinary clinical expertise exists among health professionals in Guangdong Province.", [["treatment strategy", "TREATMENT", 55, 73], ["Infection", "PROBLEM", 133, 142], ["Infection", "OBSERVATION", 133, 142]]], ["They have substantial experience with a variety of antivirals, antibiotics, alternative (herbal) medicines, and corticosteroids, and with using assisted ventilation in the treatment of patients with SARS (12).", [["SARS", "DISEASE", 199, 203], ["corticosteroids", "SIMPLE_CHEMICAL", 112, 127], ["patients", "ORGANISM", 185, 193], ["patients", "SPECIES", 185, 193], ["antivirals", "TREATMENT", 51, 61], ["antibiotics", "TREATMENT", 63, 74], ["alternative (herbal) medicines", "TREATMENT", 76, 106], ["corticosteroids", "TREATMENT", 112, 127], ["assisted ventilation", "TREATMENT", 144, 164], ["the treatment", "TREATMENT", 168, 181], ["SARS", "PROBLEM", 199, 203]]], ["While randomized clinical trials have not been conducted, careful compilations of existing case series data would be helpful in evaluating the potential effectiveness of various management regimens.Outcomes of InfectionThe store of clinical data, accumulated from treating hundreds of SARS cases, needs to be put to good use.", [["SARS", "DISEASE", 285, 289], ["existing case series data", "TEST", 82, 107], ["various management regimens", "TREATMENT", 170, 197], ["Infection", "PROBLEM", 210, 219], ["clinical data", "TEST", 232, 245], ["SARS cases", "PROBLEM", 285, 295], ["Infection", "OBSERVATION", 210, 219]]], ["One priority is to investigate clinical, epidemiologic, and laboratory predictors of poor outcome.", [["poor outcome", "PROBLEM", 85, 97]]], ["Do patients exposed to high viral doses (for which a short incubation period may be a surrogate) or to a co-infecting pathogen have poorer outcomes?", [["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["high viral doses", "TREATMENT", 23, 39], ["a short incubation period", "TREATMENT", 51, 76], ["a co-infecting pathogen", "PROBLEM", 103, 126]]], ["What is the impact of multiple exposures to SARS-associated coronavirus, like that which occurred among healthcare workers early in the epidemic?", [["SARS", "DISEASE", 44, 48], ["coronavirus", "DISEASE", 60, 71], ["coronavirus", "ORGANISM", 60, 71], ["SARS", "PROBLEM", 44, 48], ["coronavirus", "PROBLEM", 60, 71], ["coronavirus", "OBSERVATION", 60, 71]]], ["Do patients infected early in the transmission cycle perform more poorly than those infected during subsequent cycles of transmission?Learning from the SARS EpidemicSeldom have intersections between politics, economic development, and public health been more graphically demonstrated.", [["SARS", "DISEASE", 152, 156], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["infected", "OBSERVATION", 12, 20]]], ["While awaiting the development of effective prophylactic and therapeutic options, many countries have had to muster substantial political will for quick and transparent steps to declare the presence of a lethal pathogen within their borders; conduct surveillance and report the results; use contact tracing, quarantine, and border control measures when needed; and apply stringent infection control measures in healthcare settings.", [["infection", "DISEASE", 381, 390], ["effective prophylactic and therapeutic options", "TREATMENT", 34, 80], ["quick and transparent steps", "TREATMENT", 147, 174], ["a lethal pathogen", "PROBLEM", 202, 219], ["conduct surveillance", "TEST", 242, 262], ["contact tracing", "TEST", 291, 306], ["quarantine", "TREATMENT", 308, 318], ["border control measures", "TREATMENT", 324, 347], ["stringent infection control measures", "TREATMENT", 371, 407], ["infection", "OBSERVATION", 381, 390]]], ["Providing the general public with timely and candid information about the magnitude of the problem, the known risks, and how persons can protect themselves has also been necessary.", [["persons", "ORGANISM", 125, 132], ["persons", "SPECIES", 125, 132]]], ["As has been shown in China, delaying implementation can result in disastrous public health consequences extending beyond its borders, in addition to damage to the economy and national image.Learning from the SARS EpidemicThe work outlined here involves descriptive and epidemiologic inquiry, fundamental to establishing an understanding of this new pathogen and disease.", [["SARS", "DISEASE", 208, 212], ["this new pathogen", "PROBLEM", 340, 357], ["disease", "PROBLEM", 362, 369]]], ["The SARS pandemic has shown that virulent pathogens are beholden to no political philosophy or edict.", [["SARS", "DISEASE", 4, 8], ["The SARS pandemic", "PROBLEM", 0, 17], ["virulent pathogens", "PROBLEM", 33, 51], ["edict", "PROBLEM", 95, 100], ["virulent", "OBSERVATION_MODIFIER", 33, 41], ["pathogens", "OBSERVATION", 42, 51]]], ["Only careful and rapid application of knowledge and reason through a variety of public health measures has been effective in minimizing the spread and severity of the SARS epidemic.", [["SARS", "DISEASE", 167, 171], ["public health measures", "TREATMENT", 80, 102], ["the SARS epidemic", "PROBLEM", 163, 180]]], ["More information and data generated from studies of the epidemic in China are needed immediately to save lives and to prevent fear and disease, both in China itself and elsewhere in the world.Learning from the SARS EpidemicSARS became a public health emergency for China, where investment in health services has been given low priority for many years.", [["SARS", "DISEASE", 210, 214], ["disease", "PROBLEM", 135, 142], ["disease", "OBSERVATION", 135, 142]]], ["Many are larger than most countries in Europe.", [["larger", "OBSERVATION_MODIFIER", 9, 15], ["than most", "OBSERVATION_MODIFIER", 16, 25]]], ["Given the potential for reemergence of SARS in the future, if sustained control measures are not in place in China, the possibility of controlling the global threat posed by the disease until new technology (i.e., an effective vaccine) is available may be slight.", [["SARS", "DISEASE", 39, 43], ["SARS", "PROBLEM", 39, 43], ["sustained control measures", "TREATMENT", 62, 88], ["the disease", "PROBLEM", 174, 185], ["an effective vaccine", "TREATMENT", 214, 234]]], ["Key strategies include effective disease surveillance and reporting with early detection and isolation; hospital infection control during triage and treatment of cases; and transparent, open public communication about risk and disease magnitude.Learning from the SARS EpidemicChina has recently begun to vigorously address the need for better surveillance, accurate reporting, and forthright public communication.", [["infection", "DISEASE", 113, 122], ["SARS", "DISEASE", 263, 267], ["effective disease surveillance", "PROBLEM", 23, 53], ["early detection", "TEST", 73, 88], ["isolation", "TREATMENT", 93, 102], ["hospital infection control", "TREATMENT", 104, 130], ["treatment of cases", "TREATMENT", 149, 167], ["disease magnitude", "PROBLEM", 227, 244], ["effective", "OBSERVATION_MODIFIER", 23, 32], ["disease", "OBSERVATION", 33, 40]]], ["Substantial epidemiologic, clinical, virologic, and immunologic expertise and interest are available within China to address the fundamental questions.", [["Substantial epidemiologic, clinical, virologic", "PROBLEM", 0, 46]]], ["Support from the government will be needed to carry out valid, transparent studies, and for permission to report the findings, regardless of the conclusions.", [["transparent studies", "TEST", 63, 82]]], ["SARS provides a jarring reminder of the preparedness that is needed to respond to emerging and existing disease threats; it highlights the need to reinvest in health in China, and strengthen public health programs, including surveillance systems and response capacity.Learning from the SARS EpidemicWhile disease incidence has abated in China and in other locations globally, the disease may still represent an important threat in the future.", [["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 286, 290], ["existing disease threats", "PROBLEM", 95, 119], ["surveillance systems", "TEST", 225, 245], ["response capacity", "TEST", 250, 267], ["the SARS EpidemicWhile disease incidence", "PROBLEM", 282, 322], ["the disease", "PROBLEM", 376, 387], ["disease", "OBSERVATION", 380, 387]]], ["Many of the solutions to solve the multifaceted puzzle of SARS and to prevent future epidemics must come from China.", [["SARS", "DISEASE", 58, 62], ["the solutions", "TREATMENT", 8, 21], ["SARS", "PROBLEM", 58, 62], ["future epidemics", "PROBLEM", 78, 94]]], ["Without solutions from that country, the degree of difficulty for sustained control of the problem globally is raised still higher.", [["solutions", "TREATMENT", 8, 17], ["higher", "OBSERVATION_MODIFIER", 124, 130]]]], "b0d0591bedf6e0758feb55bafc4cf155947c1fdb": [["diminishing the burden on healthcare systems, while also providing the best possible care for patients, most regions and nations have enforced exceptional public health measures together with unprecedented social and economic interventions (IMF, 2020) .", [["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["burden", "OBSERVATION_MODIFIER", 16, 22]]], ["Community-based measures include actions taken by national and/or regional governments, and companies to protect vulnerable groups, employees and the overall population.", [["Community-based measures", "TREATMENT", 0, 24]]], ["Consequently, almost all avoidable outdoor human activities have ceased worldwide in some way or another.", [["human", "ORGANISM", 43, 48], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 43, 48]]], ["Lockdown measures affect different supply chains, leading to a reduction of economic growth or a foreseeable economic recession.", [["different supply chains", "PROBLEM", 25, 48], ["economic growth", "PROBLEM", 76, 91], ["a foreseeable economic recession", "PROBLEM", 95, 127], ["supply chains", "OBSERVATION", 35, 48], ["economic", "OBSERVATION_MODIFIER", 76, 84], ["growth", "OBSERVATION_MODIFIER", 85, 91], ["foreseeable", "OBSERVATION_MODIFIER", 97, 108], ["economic recession", "OBSERVATION", 109, 127]]], ["Food supply chains (FSC), referring to the processes describing how food from a farm ends up on our tables, are not exempt from these disruptions.", [["chains", "OBSERVATION_MODIFIER", 12, 18]]], ["In fact, since the beginning of the pandemic, COVID-19 has created huge shifts in terms of food access, food security and food loss and waste (FLW) (ReFED, 2020) .", [["COVID-19", "CHEMICAL", 46, 54], ["COVID", "TEST", 46, 51], ["huge", "OBSERVATION_MODIFIER", 67, 71]]], ["Accordingly, the exceptional nature of food production and consumption habits due to COVID-19 may have influence on the generation of FLW along the supply chain (Jribi et al, 2020) and on other aspects of sustainability (Song et al.2019 ).", [["COVID-19", "CHEMICAL", 85, 93], ["FLW", "CHEMICAL", 134, 137], ["COVID-19", "CHEMICAL", 85, 93], ["FLW", "SIMPLE_CHEMICAL", 134, 137], ["COVID", "TEST", 85, 90], ["FLW", "TREATMENT", 134, 137]]], ["Considering the previously described scenarios, the conclusions and strategies depend on a large number of variables that should be subject to assessment.", [["assessment", "TEST", 143, 153], ["large", "OBSERVATION_MODIFIER", 91, 96]]], ["Likewise, changes in eating habits, as a consequence of lifestyle disruptions and psychological stress due to lockdowns, may produce an important hotspot that could sway the generation and distribution patterns of FLW along the supply chain.", [["FLW", "SIMPLE_CHEMICAL", 214, 217], ["lifestyle disruptions", "PROBLEM", 56, 77], ["psychological stress", "PROBLEM", 82, 102]]], ["The reports show, in general terms, that household consumption has increased significantly across all food categories.", [["increased", "OBSERVATION_MODIFIER", 67, 76]]], ["Obviously, these behavioral patterns imply not only changes in food supply chains and in the generation of FLW, but also repercussions in the dietary pattern, which may be detrimental to the health and also other environmental attributes offered by the Spanish Mediterranean diet (Batlle-Bayer et al. 2019a), triggering obesity, sleep disruptions or impacts on the immune system (Muscogiuri et al.,2020) .", [["immune system", "ANATOMY", 365, 378], ["obesity", "DISEASE", 320, 327], ["sleep disruptions", "DISEASE", 329, 346], ["FLW", "GENE_OR_GENE_PRODUCT", 107, 110], ["triggering obesity", "PROBLEM", 309, 327], ["sleep disruptions", "PROBLEM", 329, 346], ["obesity", "OBSERVATION", 320, 327]]], ["After years of awareness, FLW has gradually become a mainstream concern (V\u00e1zquez-Rowe et al, 2019).", [["FLW", "CHEMICAL", 26, 29]]], ["The Food and Agriculture Organization of the United Nations (FAO) considers a distinction between food loss (i.e. a decrease of quantity or quality in edible food mass, intended for human consumption, that occur in the primary stages of the supply chainproduction, postharvest and processing stages) and food waste (i.e. food losses occurring at the end of the food chainretail and final consumption -related to retailers' and consumers' behaviour) (FAO, 2011) .", [["food loss", "DISEASE", 98, 107], ["human", "ORGANISM", 182, 187], ["human", "SPECIES", 182, 187], ["human", "SPECIES", 182, 187], ["food loss", "PROBLEM", 98, 107], ["edible food mass", "PROBLEM", 151, 167], ["food loss", "OBSERVATION", 98, 107], ["decrease", "OBSERVATION_MODIFIER", 116, 124], ["mass", "OBSERVATION", 163, 167]]], ["Albeit, usually both terms are considered together as FLW when quantifying them for further analysis (Corrado and Sala, 2018; Wunderlich and Martinez, 2018) .", [["further analysis", "TEST", 84, 100]]]], "c37645123550f636b43cc53e693023ff3c7558a9": [["In the 1890s, pioneering studies from the laboratory of Robert Koch demonstrated that administration of sheep antiserum against diphtheria toxin to a girl dying from diphtheria led to her rapid recovery within hours, and ultimate survival 1 .", [["diphtheria toxin", "CHEMICAL", 128, 144], ["diphtheria", "DISEASE", 166, 176], ["sheep", "ORGANISM", 104, 109], ["antiserum", "ORGANISM_SUBSTANCE", 110, 119], ["diphtheria toxin", "ORGANISM", 128, 144], ["girl", "ORGANISM", 150, 154], ["diphtheria toxin", "PROTEIN", 128, 144], ["sheep", "SPECIES", 104, 109], ["girl", "SPECIES", 150, 154], ["sheep", "SPECIES", 104, 109], ["pioneering studies", "TEST", 14, 32], ["sheep antiserum", "TREATMENT", 104, 119], ["diphtheria toxin", "PROBLEM", 128, 144], ["diphtheria", "PROBLEM", 166, 176]]], ["As early as 1907, sera from individuals recovering from rubeola (measles) was used to prevent infection from this highly contagious virus 2 .", [["sera", "ANATOMY", 18, 22], ["rubeola", "CHEMICAL", 56, 63], ["infection", "DISEASE", 94, 103], ["sera", "ORGANISM_SUBSTANCE", 18, 22], ["rubeola (measles)", "TREATMENT", 56, 73], ["infection", "PROBLEM", 94, 103], ["this highly contagious virus", "PROBLEM", 109, 137], ["infection", "OBSERVATION", 94, 103]]], ["Since then, the strategy of administering sera from survivors of various viral epidemics for the treatment of acute cytopathic viral disease has been widely practiced ( Table 1) .", [["sera", "ANATOMY", 42, 46], ["cytopathic viral disease", "DISEASE", 116, 140], ["sera", "ORGANISM_SUBSTANCE", 42, 46], ["administering sera", "TREATMENT", 28, 46], ["various viral epidemics", "PROBLEM", 65, 88], ["acute cytopathic viral disease", "PROBLEM", 110, 140], ["acute", "OBSERVATION_MODIFIER", 110, 115], ["cytopathic", "OBSERVATION_MODIFIER", 116, 126], ["viral disease", "OBSERVATION", 127, 140]]], ["During the 1940s, improvements in the quality of fractionated human immunoglobulin led to the widespread use of intramuscular injections of pooled human immunoglobulin to prevent and treat viral infections, such as rubella and hepatitis A, with better protection and less severe reactions than sera.", [["intramuscular", "ANATOMY", 112, 125], ["sera", "ANATOMY", 294, 298], ["viral infections", "DISEASE", 189, 205], ["rubella and hepatitis A", "DISEASE", 215, 238], ["human", "ORGANISM", 62, 67], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 68, 82], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 112, 125], ["human", "ORGANISM", 147, 152], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 153, 167], ["sera", "ORGANISM_SUBSTANCE", 294, 298], ["fractionated human immunoglobulin", "PROTEIN", 49, 82], ["human immunoglobulin", "PROTEIN", 147, 167], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 147, 152], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 147, 152], ["hepatitis A", "SPECIES", 227, 238], ["fractionated human immunoglobulin", "TREATMENT", 49, 82], ["intramuscular injections", "TREATMENT", 112, 136], ["pooled human immunoglobulin", "TREATMENT", 140, 167], ["viral infections", "PROBLEM", 189, 205], ["rubella", "PROBLEM", 215, 222], ["hepatitis A", "PROBLEM", 227, 238], ["less severe reactions than sera", "PROBLEM", 267, 298], ["hepatitis", "OBSERVATION", 227, 236], ["less severe", "OBSERVATION_MODIFIER", 267, 278]]], ["By the early 1980s, several immunoglobulin G (IgG) preparations were licensed for intravenous use to prevent and treat viral diseases, permitting as much as 10-to 20-fold increases in the amounts of immunoglobulin administered 3 .", [["intravenous", "ANATOMY", 82, 93], ["viral diseases", "DISEASE", 119, 133], ["immunoglobulin G", "GENE_OR_GENE_PRODUCT", 28, 44], ["IgG", "GENE_OR_GENE_PRODUCT", 46, 49], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 82, 93], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 199, 213], ["immunoglobulin G", "PROTEIN", 28, 44], ["IgG", "PROTEIN", 46, 49], ["immunoglobulin", "PROTEIN", 199, 213], ["several immunoglobulin G (IgG) preparations", "TREATMENT", 20, 63], ["intravenous use", "TREATMENT", 82, 97], ["viral diseases", "PROBLEM", 119, 133], ["immunoglobulin administered", "TREATMENT", 199, 226], ["viral diseases", "OBSERVATION", 119, 133]]], ["Many of these products are still on the market today and include generic pooled human IgG for prevention of measles and hepatitis A, as well as hyperimmune human IgG preparations against cytomegalovirus (CMV), respiratory syncytial virus (RSV), hepatitis B virus (HBV), hepatitis C virus (HCV), rabies, vaccinia, varicella-zoster virus (VZV) and West Nile virus (WNV) (Box 1 and Table 2 ).", [["measles and hepatitis A", "DISEASE", 108, 131], ["cytomegalovirus (CMV), respiratory syncytial virus (RSV), hepatitis B virus (HBV), hepatitis C virus (HCV), rabies, vaccinia", "DISEASE", 187, 311], ["varicella-zoster virus (VZV) and West Nile virus", "DISEASE", 313, 361], ["human", "ORGANISM", 80, 85], ["IgG", "GENE_OR_GENE_PRODUCT", 86, 89], ["measles", "ORGANISM", 108, 115], ["hepatitis A", "ORGANISM", 120, 131], ["hyperimmune", "ORGANISM", 144, 155], ["human", "ORGANISM", 156, 161], ["IgG", "ORGANISM", 162, 165], ["cytomegalovirus", "ORGANISM", 187, 202], ["CMV", "ORGANISM", 204, 207], ["respiratory syncytial virus", "ORGANISM", 210, 237], ["RSV", "ORGANISM", 239, 242], ["hepatitis B virus", "ORGANISM", 245, 262], ["HBV", "ORGANISM", 264, 267], ["hepatitis C virus", "ORGANISM", 270, 287], ["HCV", "ORGANISM", 289, 292], ["rabies", "ORGANISM", 295, 301], ["vaccinia,", "ORGANISM", 303, 312], ["varicella-zoster virus", "ORGANISM", 313, 335], ["VZV", "ORGANISM", 337, 340], ["West Nile virus", "ORGANISM", 346, 361], ["WNV", "ORGANISM", 363, 366], ["human IgG", "PROTEIN", 80, 89], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 156, 161], ["respiratory syncytial virus", "SPECIES", 210, 237], ["hepatitis B virus", "SPECIES", 245, 262], ["hepatitis C virus", "SPECIES", 270, 287], ["varicella-zoster virus", "SPECIES", 313, 335], ["West Nile virus", "SPECIES", 346, 361], ["human", "SPECIES", 80, 85], ["measles", "SPECIES", 108, 115], ["hepatitis A", "SPECIES", 120, 131], ["human", "SPECIES", 156, 161], ["CMV", "SPECIES", 204, 207], ["respiratory syncytial virus", "SPECIES", 210, 237], ["RSV", "SPECIES", 239, 242], ["hepatitis B virus", "SPECIES", 245, 262], ["HBV", "SPECIES", 264, 267], ["hepatitis C virus", "SPECIES", 270, 287], ["HCV", "SPECIES", 289, 292], ["rabies", "SPECIES", 295, 301], ["varicella-zoster virus", "SPECIES", 313, 335], ["VZV", "SPECIES", 337, 340], ["West Nile virus", "SPECIES", 346, 361], ["WNV", "SPECIES", 363, 366], ["generic pooled human IgG", "TREATMENT", 65, 89], ["measles", "PROBLEM", 108, 115], ["hepatitis A", "PROBLEM", 120, 131], ["hyperimmune human IgG preparations", "TREATMENT", 144, 178], ["cytomegalovirus (CMV)", "PROBLEM", 187, 208], ["respiratory syncytial virus (RSV)", "PROBLEM", 210, 243], ["hepatitis B virus", "PROBLEM", 245, 262], ["HBV", "PROBLEM", 264, 267], ["hepatitis C virus (HCV)", "PROBLEM", 270, 293], ["rabies", "PROBLEM", 295, 301], ["vaccinia", "PROBLEM", 303, 311], ["varicella", "PROBLEM", 313, 322], ["zoster virus", "PROBLEM", 323, 335], ["VZV", "PROBLEM", 337, 340], ["West Nile virus", "PROBLEM", 346, 361], ["products", "OBSERVATION", 14, 22], ["respiratory", "ANATOMY", 210, 221], ["syncytial virus", "OBSERVATION", 222, 237], ["varicella", "ANATOMY", 313, 322], ["zoster virus", "OBSERVATION", 323, 335]]]], "PMC7302726": [["IntroductionThe COVID-19 pandemic is not over yet and its consequences will be seen for a long time across the world.", [["The COVID", "TREATMENT", 12, 21]]], ["Apart from new scenarios that we will face in the next weeks, the pandemic has already deeply impacted the life of billion peoples around the world, leaving dramatic changes and sequelae in almost all the aspects of the social life.", [["new scenarios", "PROBLEM", 11, 24], ["new", "OBSERVATION_MODIFIER", 11, 14], ["scenarios", "OBSERVATION", 15, 24], ["dramatic", "OBSERVATION_MODIFIER", 157, 165]]], ["The medical community has been probably one of the most impacted sectors, especially because the tremendous efforts physicians and caregivers were required to afford to contain the spreading of the pandemic.", [["the pandemic", "PROBLEM", 194, 206]]], ["Among this, also the Neurosurgical Community has been involved into the management of the pandemic, being asked to continue ensuring appropriate neurosurgical care also to COVID-19 patients.", [["patients", "ORGANISM", 181, 189], ["patients", "SPECIES", 181, 189], ["appropriate neurosurgical care", "TREATMENT", 133, 163]]], ["On the other hand, practice has consistently changed during the SARS-CoV-2 pandemic and neurosurgery also had to adapt, coming in the help of the national health systems, especially in the most affected countries like Italy, to manage COVID-19 patients outside the neurosurgical clinics [3, 6, 7, 9, 14, 19].", [["SARS", "DISEASE", 64, 68], ["pandemic", "DISEASE", 75, 83], ["patients", "ORGANISM", 244, 252], ["patients", "SPECIES", 244, 252]]], ["Obviously, in such a dramatic scenario, also neurosurgical education and training have been influenced by the pandemic.", [["neurosurgical education", "TREATMENT", 45, 68], ["training", "TREATMENT", 73, 81]]], ["Conversely, reporting the point of view of residents who experienced the real and concrete changes of the neurosurgical education and training due to the pandemic in most affected countries could be extremely useful.", [["the neurosurgical education", "TREATMENT", 102, 129], ["training", "TREATMENT", 134, 142]]], ["The questions were focused on the experience of neurosurgical residents in the last 2 months (from March to May 2020) and analyzed different clinical and educational aspects, including time spent in clinic in routine neurosurgical practice, time spent outside the neurosurgical clinic for the management of COVID-19 patients, availability of personal protective equipment (PPE), COVID-19 screening, and finally educational and scientific activities.", [["COVID", "DISEASE", 307, 312], ["patients", "ORGANISM", 316, 324], ["patients", "SPECIES", 316, 324], ["personal protective equipment", "TREATMENT", 342, 371], ["COVID", "TREATMENT", 379, 384]]], ["Data were elaborated using Google Forms software online and responses were analyzed considering the overall survey participants in a first step; thereafter, a further subgroup analysis has been performed distinguishing between junior (PGY-1 and 2) vs. senior (PGY-3, 4, and 5) residents.ResultsOn May 11, 2020, the survey was closed after 192 responses out of the 331 Italian neurosurgical residents were received.", [["participants", "SPECIES", 115, 127], ["a further subgroup analysis", "TEST", 157, 184]]], ["Residents from all the 5 post-graduate years (PGY) were homogenously represented: 41 PGY-1 (21.4%), 43 PGY-2 (22.4%), 31 PGY-3(16.1%), 40 PGY-4 (20.8%), 37 PGY-5 (19.3%) (Fig. 1).ResultsThe first observed result was that no Residency Programs has been stopped in Italy, unlike the medical student\u2019s internship, which has been stopped to preserve student health and to limit the number of people present in the neurosurgical departments.ResultsResident\u2019s time spent in neurosurgical departments was reduced in 139 cases (72.4%), unchanged in 40 cases (20.8%), and increased only in 13 cases (6.8%).", [["people", "ORGANISM", 388, 394], ["people", "SPECIES", 388, 394], ["PGY", "TEST", 103, 106], ["PGY", "TEST", 121, 124], ["PGY", "TEST", 138, 141], ["PGY", "TEST", 156, 159], ["Fig", "TEST", 171, 174], ["unchanged", "OBSERVATION_MODIFIER", 528, 537], ["increased", "OBSERVATION_MODIFIER", 563, 572]]], ["This \u201cwork-time\u201d reduction was imposed by the educational providers in 63.5% of cases, to avoid unnecessary exposure of residents to COVID-19 patients (Fig. 2).", [["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 142, 150]]], ["The majority of responders (135, 70.4%) were not directly involved in the treatment of \u201cCOVID-19\u201d patients (inside or outside neurosurgical department); the other 57 managed \u201cCOVID-19\u201d patients under supervision (42, 21.9%) or alone (15, 7.8%).", [["patients", "ORGANISM", 98, 106], ["patients", "ORGANISM", 185, 193], ["patients", "SPECIES", 98, 106], ["patients", "SPECIES", 185, 193]]], ["The majority of responders (72.9%) answered that they did not receive any theoretical preparation on the use of PPE, and the 55.2% said that the given PPEs were not adequate to their duties, at least at the beginning of the pandemic.", [["PPE", "TREATMENT", 112, 115], ["PPEs", "TEST", 151, 155]]], ["Residents involved in the direct management of \u201cCOVID-19\u201d patients, both inside and outside the neurosurgical departments, reported to have received good support from supervisors most of the time (65.9%).", [["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66]]], ["The overall reported screening rate for SARS-CoV-2 between residents was 35.9%; Sixteen (8.3%) were tested in March and 53 (27.6%) in April/May, while 123 (64.1%) did not perform any screening test.", [["SARS", "DISEASE", 40, 44], ["SARS-CoV", "SPECIES", 40, 48], ["screening rate", "TEST", 21, 35], ["SARS", "TEST", 40, 44], ["CoV", "TEST", 45, 48], ["any screening test", "TEST", 179, 197]]], ["Thanks probably also to the reduction of the working time, 83.9% of residents did not refer any symptoms of the COVID-19 infection.", [["infection", "DISEASE", 121, 130], ["any symptoms", "PROBLEM", 92, 104], ["the COVID-19 infection", "PROBLEM", 108, 130], ["infection", "OBSERVATION", 121, 130]]], ["Almost all of the interviewed reduced their surgical activity (78.6% perform less operation and 16.1% did not perform any operation at all); only 3 participants reported their surgical activity was increased, while 7 reported an unchanged surgical activity (Fig. 3).", [["participants", "SPECIES", 148, 160], ["any operation", "TREATMENT", 118, 131], ["unchanged", "OBSERVATION_MODIFIER", 229, 238], ["surgical activity", "OBSERVATION", 239, 256]]], ["In cases of neurosurgical procedures performed on \u201cCOVID-19\u201d patients, participants responded their engagement was unchanged compared to usual in 59.1% of cases, reduced in 39.1%, and augmented in 1.8%.", [["patients", "ORGANISM", 61, 69], ["participants", "ORGANISM", 71, 83], ["patients", "SPECIES", 61, 69], ["participants", "SPECIES", 71, 83], ["neurosurgical procedures", "TEST", 12, 36]]], ["Finally, participants homogenously reported an increase of the educational and scientific activities, as well as of time spent for studying.", [["participants", "SPECIES", 9, 21], ["increase", "OBSERVATION_MODIFIER", 47, 55]]], ["The production of scientific papers or research projects was increased in 55.7% of cases and also the theoretic educational activity had an increase for 64.6% of responders (Fig. 4).", [["research projects", "TREATMENT", 39, 56], ["increased", "OBSERVATION_MODIFIER", 61, 70]]], ["That was mainly due to the spread and increased availability and visibility of neurosurgical seminars and webinars performed though different web-based commercial platforms, and strongly promoted by the educational providers.", [["the spread", "PROBLEM", 23, 33], ["neurosurgical seminars", "TEST", 79, 101], ["webinars", "TREATMENT", 106, 114]]], ["The subgroup analysis of responses according to the PGY showed that no major differences were reported by senior vs. junior residents in almost all the survey questions.", [["PGY", "DNA", 52, 55], ["the PGY", "TEST", 48, 55]]], ["In particular, among 78.6% (151 out of 192 responders) of participants who reported a reduced surgical activity, senior resident represented the 80.1% (121 out of 151).", [["participants", "ORGANISM", 58, 70], ["participants", "SPECIES", 58, 70], ["a reduced surgical activity", "PROBLEM", 84, 111]]], ["Similarly, senior residents reported a more evident increase of their scientific activity as well as of time spent for studying compared with the junior ones.", [["increase", "OBSERVATION_MODIFIER", 52, 60]]], ["In particular, senior residents accounted for the 73% (78 out of 107) and the 69% (95 out of 138) of participants who reported respectively an increase of scientific activity and time spent for studying during the last 2 months.DiscussionAlso, many areas of the modern society, including neurosurgical care, have been dramatically impacted and changed by the COVID-19 pandemic; also, the fundamental sector of neurosurgical training and education suffered from deep changes and limitations.", [["participants", "ORGANISM", 101, 113], ["participants", "SPECIES", 101, 113], ["neurosurgical care", "TREATMENT", 288, 306], ["neurosurgical training", "TREATMENT", 410, 432], ["increase", "OBSERVATION_MODIFIER", 143, 151], ["deep changes", "OBSERVATION", 461, 473]]], ["Despite experts\u2019 and educational providers\u2019 point of view on the topic being already reported [10\u201312], the most appropriate way to assess how neurosurgical education and training has changed in the last 2 months still remains to hear from opinions of directly involved people, neurosurgical residents.DiscussionIn Italy, that has been for long time the most affected country in the world (before being sadly overpassed by Spain and, lastly, the USA), neurosurgical residents felt on their own the impact of the COVID-19 pandemic.DiscussionFirst of all, our survey demonstrated that neurosurgical educational providers promptly reacted to the pandemic: the first result was that no Residency Programs were stopped but there was a tendency to reduce the working time of neurosurgical residents to avoid unnecessary exposure to the COVID-19.", [["COVID-19", "CHEMICAL", 829, 837], ["people", "ORGANISM", 269, 275], ["COVID-19", "DNA", 829, 837], ["people", "SPECIES", 269, 275], ["the COVID", "TEST", 507, 516], ["Residency Programs", "TREATMENT", 681, 699], ["neurosurgical residents", "TREATMENT", 768, 791], ["the COVID", "TEST", 825, 834]]], ["In any case, when needed, some residents were asked to help the National Health System in the management of COVID-19 patients, even outside Neurosurgical Departments.", [["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125]]], ["Residents answered responsibly to their duty and supported healthcare providers in the management of COVID-19 patients, waiving to their neurosurgical practice, education, and training (at least during their clinical working time).DiscussionSince the spread of the virus was very different along the Italian peninsula, elective neurosurgical activity decreased in all Italian regions and collectively, we recorded a reduction of the residents\u2019 working time at neurosurgical departments in the majority of responses (63.5%).", [["COVID", "DISEASE", 101, 106], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["the virus", "PROBLEM", 261, 270], ["elective neurosurgical activity", "TREATMENT", 319, 350], ["peninsula", "ANATOMY_MODIFIER", 308, 317], ["activity", "OBSERVATION_MODIFIER", 342, 350], ["decreased", "OBSERVATION_MODIFIER", 351, 360]]], ["That, of course, mainly impacted surgical practice, especially because at the same time also the activity in the Operating Room (OR) was limited to emergent and oncologic cases in many hospitals of the country.DiscussionSadly, the sudden onset of the COVID-19 outbreak in Italy combined with the complex and chaotic international trading of PPE reduced the availability of PPE for all healthcare providers including neurosurgical residents, especially during the first weeks from the beginning of the emergency; that is witnessed by the response to the survey in which 55.2% of responders said that available PPEs were not adequate to their duties.DiscussionThe reduced time spent at neurosurgical departments and for surgical practice was translated in an increase of educational and scientific activities, as well as of time spent for individual study.", [["the COVID", "PROBLEM", 247, 256], ["available PPEs", "PROBLEM", 599, 613], ["surgical practice", "TREATMENT", 718, 735], ["individual study", "TEST", 837, 853], ["impacted", "OBSERVATION_MODIFIER", 24, 32], ["surgical", "OBSERVATION", 33, 41]]], ["Educational providers revealed to pay a great attention to this topic and tried to promptly compensate the reduced practice in the OR with an increase of the offer for online activities like seminars, webinars, and frontal lessons.", [["frontal", "ANATOMY", 215, 222]]], ["That resulted in a homogenous positive feedback from survey participants, who reported an increase of the web-based educational activity (64.6%), even through the participation to a nation-wide network of neurosurgical residency programs providing frontal lessons, expert opinions, and discussions on neurosurgical hot topics (reported by the 86.5% of survey participants).", [["participants", "SPECIES", 60, 72], ["participants", "SPECIES", 359, 371], ["neurosurgical residency programs", "TREATMENT", 205, 237], ["increase", "OBSERVATION_MODIFIER", 90, 98]]], ["Similarly, the increased time availability outside neurosurgical departments resulted in an increased scientific activity of residents (55.7% of responders), as well as a longer time spent to individual study as compared the pre-COVID-19 era (71.9% of participants).DiscussionInterestingly, we observed a different responses\u2019 trend among senior vs. junior residents regarding changes in surgical, scientific, and study activities.", [["participants", "SPECIES", 252, 264], ["individual study", "TEST", 192, 208], ["the pre-COVID", "TEST", 221, 234], ["increased", "OBSERVATION_MODIFIER", 15, 24], ["increased", "OBSERVATION_MODIFIER", 92, 101]]], ["Senior residents were more affected by the global reduction of neurosurgical activity as compared with PGY-1 and 2 residents, probably because they are usually more involved in direct surgical training than their younger colleagues.", [["direct surgical training", "TREATMENT", 177, 201], ["reduction", "OBSERVATION_MODIFIER", 50, 59]]], ["Conversely, their reduced time spent in the OR was compensated with an increase of time spent for study and especially for writing research projects, scientific drafts, and papers.", [["study", "TEST", 98, 103]]], ["As they should have already maturated good scientific attitudes and skills in comparison with junior residents, they have been able to exploit the reduced time spent in surgical training for a deeper commitment to scientific and study activities.DiscussionDespite these few differences between senior and junior residents, all participant\u2019s responses collectively highlight the fact that, apart the dramatic impact of the pandemic resulting, in some cases, in their direct involvement in the clinical management of COVID-19 patients outside neurosurgical departments and the reduction of their neurosurgical practice, the pandemic caused also the enhancement of the web-based neurosurgical education.", [["COVID", "DISEASE", 515, 520], ["patients", "ORGANISM", 524, 532], ["participant", "SPECIES", 327, 338], ["patients", "SPECIES", 524, 532], ["surgical training", "TREATMENT", 169, 186], ["their neurosurgical practice", "TREATMENT", 588, 616], ["neurosurgical education", "TREATMENT", 676, 699], ["few", "OBSERVATION_MODIFIER", 270, 273]]], ["Online neurosurgical education on national and/or international basis has been already strongly advocated prior to the COVID-19 outbreak as a formidable tool to increase neurosurgical knowledge and improve patient care, as well as to reduce the worldwide gap in neurosurgical education [5].", [["patient", "ORGANISM", 206, 213], ["patient", "SPECIES", 206, 213]]], ["In Italy, neurosurgical educational providers were incredibly able to re-organize their teaching model in few weeks, creating new opportunities for online neurosurgical education on a local basis but also at a nation-wide level, thanks also to the contribution and support of the Italian Society of Neurosurgery (SINch) that already had a good web-visibility prior to the COVID-19 outbreak.", [["online neurosurgical education", "TREATMENT", 148, 178], ["the COVID", "TEST", 368, 377]]], ["We are sure that such a new online nation-wide network for neurosurgical education will continue to offer new learning opportunities even after the end of the COVID-19 crisis, thus further enriching the educational opportunities for Italian neurosurgical residents.DiscussionWhile there may not yet be other similar studies of neurosurgery resident experience during COVID-19 with which to compare the results of this study, it is possible to compare findings from our study with those from other studies regarding different Residency Programs.", [["neurosurgical education", "TREATMENT", 59, 82], ["this study", "TEST", 413, 423], ["our study", "TEST", 465, 474], ["other studies", "TEST", 491, 504]]], ["Marasco et al. described findings from a survey distributed among young Italian gastroenterologists: they reported a reduced activity of gastroenterology units that was restricted to emergency visits and endoscopy, with reductions of activities of up to 90%.", [["endoscopy", "TEST", 204, 213]]], ["Moreover, 84.5% of participants felt that the COVID-19 outbreak impacted on their training, due to unavailability of mentors (52.6%) and interruption of trainee\u2019s involvement (66.4%) [13].", [["participants", "ORGANISM", 19, 31], ["participants", "SPECIES", 19, 31]]], ["These findings are similar to our results, especially for the global reduction of the clinical/surgical activity.", [["global", "OBSERVATION_MODIFIER", 62, 68], ["reduction", "OBSERVATION_MODIFIER", 69, 78], ["surgical activity", "OBSERVATION", 95, 112]]], ["Conversely, the organization of new web-based educational networks represents the most important novelty for neurosurgical training introduced after the COVID-19 outbreak.DiscussionAnother useful comparison can be done with the organizational model of the orthopedic residency program reported by Schwartz et al., who proposed to divide residents into two teams, the \u201cactive-duty inpatient\u201d and \u201cremotely-working,\u201d which remained completely isolated from each other to decrease their exposure to the virus [15, 16].", [["neurosurgical training", "TREATMENT", 109, 131], ["the COVID", "TEST", 149, 158]]], ["This method seems to be really effective to maintain residents\u2019 surgical practice and training, as well as to guarantee appropriate surgical care to patients.", [["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["surgical practice", "TREATMENT", 64, 81]]], ["Nevertheless, in countries where such a model cannot be easily and quickly implemented, the Italian neurosurgical model based on the global reduction of the residency surgical training and its compensation with improved scientific and online educational activities seems a good compromise to protect residents from contagion while ensuring their theoretical education.DiscussionOur study has some limits.", [["the residency surgical training", "TREATMENT", 153, 184], ["DiscussionOur study", "TEST", 368, 387]]], ["First, it is not an epidemiologic study and does not allow drawing conclusions about the actual prevalence and incidence of the variables investigated.", [["an epidemiologic study", "TEST", 17, 39]]], ["The typical process for development of a psychometric instrument involves searching the literature to see what is currently available and in use, focus groups and interviews to decide on topics, the development of individual questions, and then testing and validation of the instrument prior to distribution.", [["a psychometric instrument", "PROBLEM", 39, 64], ["testing", "TEST", 245, 252]]], ["In the case of the present study, such a process cannot be performed because of the necessity to develop the survey and distribute it as quickly as possible, given the overall pandemic situation.", [["the present study", "TEST", 15, 32]]], ["Notwithstanding, this is the first survey conducted on the impact of COVID-19 on the neurosurgical residents about their training and education, and we believe that the data from this study can help to understand the impact of this pandemic in these specific fields.ConclusionsThe spread of COVID-19 has put new obstacles to neurosurgical training, especially in most affected countries.", [["COVID-19", "CHEMICAL", 291, 299], ["COVID-19", "CHEMICAL", 291, 299], ["this study", "TEST", 179, 189], ["COVID", "TEST", 291, 296], ["neurosurgical training", "TREATMENT", 325, 347], ["spread", "OBSERVATION_MODIFIER", 281, 287], ["new", "OBSERVATION_MODIFIER", 308, 311]]], ["Italian educational models and teaching methods have been forced to change in few weeks, demonstrating a really effective response to the pandemic outbreak through the use of modern web-based tools.", [["teaching methods", "TREATMENT", 31, 47]]], ["Despite Italian neurosurgical residents facing a transient reduction of their surgical training, they had the possibility to compensate this lack with increased opportunities for theoretical education, thanks also to the creation of educational networks at a local and nation-wide level.", [["their surgical training", "TREATMENT", 72, 95], ["theoretical education", "TREATMENT", 179, 200]]]], "bcde15209d8d14135e73cdf3f208401dd6ded3be": [["BiowarfareOne of the major biomedical concerns is the continued emergence of new infectious agents that cause disease in the human population.", [["BiowarfareOne", "CHEMICAL", 0, 13], ["human", "ORGANISM", 125, 130], ["human", "SPECIES", 125, 130], ["human", "SPECIES", 125, 130], ["new infectious agents", "TREATMENT", 77, 98], ["disease in the human population", "PROBLEM", 110, 141], ["new", "OBSERVATION_MODIFIER", 77, 80], ["infectious", "OBSERVATION", 81, 91]]], ["Recent years have provided a number of examples including HIV, West Nile Virus, SARS, and increasing frequency of antibiotic-resistant bacterial isolates.", [["HIV, West Nile Virus", "DISEASE", 58, 78], ["SARS", "DISEASE", 80, 84], ["HIV", "ORGANISM", 58, 61], ["West Nile Virus", "ORGANISM", 63, 78], ["HIV", "SPECIES", 58, 61], ["HIV", "SPECIES", 58, 61], ["West Nile Virus", "SPECIES", 63, 78], ["HIV", "PROBLEM", 58, 61], ["West Nile Virus", "PROBLEM", 63, 78], ["SARS", "PROBLEM", 80, 84], ["antibiotic", "TREATMENT", 114, 124], ["resistant bacterial isolates", "PROBLEM", 125, 153], ["bacterial isolates", "OBSERVATION", 135, 153]]], ["Although nature has been responsible for these problems, of equally great concern is the possibility that infectious agents will be introduced into our environment by a deliberate act of bioterrorism or biowarfare.BiowarfareBiowarfare concerns used to be limited to battlefield interactions between armed combatants.", [["these problems", "PROBLEM", 41, 55], ["infectious agents", "TREATMENT", 106, 123], ["infectious", "OBSERVATION", 106, 116]]], ["However, with ready access to modern molecular biology and microbiological procedures, it is relatively easy for a person to obtain, grow, and disperse a biowarfare agent for the express purpose of causing morbidity and mortality in a target population.", [["person", "SPECIES", 115, 121], ["microbiological procedures", "TEST", 59, 85], ["a biowarfare agent", "TREATMENT", 152, 170], ["morbidity", "PROBLEM", 206, 215]]], ["While chemicals and toxins are bona fide threats, infectious pathogens represent the biggest problem for several reasons.", [["infectious pathogens", "PROBLEM", 50, 70], ["infectious", "OBSERVATION_MODIFIER", 50, 60], ["biggest", "OBSERVATION_MODIFIER", 85, 92]]], ["First, there is a wide diversity of pathogenic agents (bacteria, viruses, fungi, etc.) that are capable of causing a variety of diseases.", [["pathogenic agents", "TREATMENT", 36, 53], ["bacteria", "PROBLEM", 55, 63], ["viruses", "PROBLEM", 65, 72], ["fungi", "PROBLEM", 74, 79], ["a variety of diseases", "PROBLEM", 115, 136], ["wide", "OBSERVATION_MODIFIER", 18, 22], ["diversity", "OBSERVATION_MODIFIER", 23, 32], ["pathogenic agents", "OBSERVATION", 36, 53], ["variety", "OBSERVATION_MODIFIER", 117, 124], ["diseases", "OBSERVATION", 128, 136]]], ["Second, unlike chemicals or toxins, microorganisms have the ability to replicate and survive in the environment.", [["toxins", "PROBLEM", 28, 34], ["microorganisms", "PROBLEM", 36, 50]]], ["And third, in some cases microorganisms have the ability to spread from individual to individual.", [["some cases microorganisms", "PROBLEM", 14, 39]]], ["Once a weapon like this is deployed, it cannot be recalled or controlled, nor can it distinguish between friend and foe.Category A, B, C biopathogensA list of viral or bacterial pathogens, rated according to their predicted risk to national security, was compiled by the Centers for Disease Control and Prevention (Table 1) .", [["B", "GENE_OR_GENE_PRODUCT", 132, 133], ["viral or bacterial pathogens", "PROBLEM", 159, 187], ["Disease Control", "TREATMENT", 283, 298], ["bacterial pathogens", "OBSERVATION", 168, 187]]], ["Category A agents pose the most serious threat because they can easily be disseminated or spread from person to person, can result in high mortality rates, may cause public panic, and would require special action for public health preparedness.", [["panic", "DISEASE", 173, 178], ["person", "SPECIES", 102, 108], ["person", "SPECIES", 112, 118], ["Category A agents", "TREATMENT", 0, 17], ["public panic", "PROBLEM", 166, 178], ["public health preparedness", "TREATMENT", 217, 243]]], ["Those pathogens in Category B are second in priority for their moderate ease of dissemination and their moderate morbidity and low mortality rates.", [["dissemination", "PROBLEM", 80, 93], ["their moderate morbidity", "PROBLEM", 98, 122], ["low mortality rates", "PROBLEM", 127, 146], ["moderate", "OBSERVATION_MODIFIER", 63, 71], ["dissemination", "OBSERVATION", 80, 93], ["moderate", "OBSERVATION_MODIFIER", 104, 112], ["morbidity", "OBSERVATION", 113, 122]]], ["In addition, CDC's diagnostic capacity and disease surveillance capability for these agents is currently inadequate and would require vast improvements.", [["CDC's diagnostic capacity", "TEST", 13, 38], ["disease surveillance capability", "PROBLEM", 43, 74], ["these agents", "TREATMENT", 79, 91]]], ["Agents comprising Category C include those that could be easily engineered for mass dissemination in the future because of their availability and their potential to be easily produced and disseminated.Category A, B, C biopathogensOf the pathogens listed in Table 1 , those that cause smallpox, anthrax, and plague are particularly dangerous because they are easily spread from person to person via a respiratory route.", [["respiratory", "ANATOMY", 400, 411], ["smallpox", "DISEASE", 284, 292], ["anthrax", "DISEASE", 294, 301], ["plague", "DISEASE", 307, 313], ["person", "SPECIES", 377, 383], ["person", "SPECIES", 387, 393], ["mass dissemination", "PROBLEM", 79, 97], ["the pathogens", "PROBLEM", 233, 246], ["smallpox", "PROBLEM", 284, 292], ["anthrax", "PROBLEM", 294, 301], ["mass", "OBSERVATION", 79, 83], ["disseminated", "OBSERVATION", 188, 200], ["smallpox", "OBSERVATION", 284, 292]]], ["An accidental, planned, or natural outbreak of one of these agents with respiratory mode of transmission, combined with frequent worldwide travel prevalent in today's society could lead to disastrous consequences.", [["these agents", "TREATMENT", 54, 66], ["disastrous consequences", "PROBLEM", 189, 212]]], ["The potential for this to occur was evident during the recent SARS outbreak.", [["SARS", "DISEASE", 62, 66], ["the recent SARS outbreak", "PROBLEM", 51, 75]]], ["Had the coronavirus responsible for causing SARS been more virulent, or more easily transmitted, the outcome of last year's outbreak could have been devastating.Category A, B, C biopathogensIn addition to the introduction of natural pathogens into the human population by bioterrorists, the capability exists for pathogens to be purposefully engineered to become even more infectious.", [["coronavirus", "DISEASE", 8, 19], ["SARS", "DISEASE", 44, 48], ["coronavirus", "ORGANISM", 8, 19], ["human", "ORGANISM", 252, 257], ["human", "SPECIES", 252, 257], ["human", "SPECIES", 252, 257], ["the coronavirus", "PROBLEM", 4, 19], ["SARS", "PROBLEM", 44, 48], ["virulent", "PROBLEM", 59, 67], ["C biopathogens", "PROBLEM", 176, 190], ["natural pathogens", "TREATMENT", 225, 242], ["pathogens", "PROBLEM", 313, 322], ["coronavirus", "OBSERVATION", 8, 19], ["devastating", "OBSERVATION_MODIFIER", 149, 160], ["infectious", "OBSERVATION", 373, 383]]], ["In these experiments an immune-suppressing gene was spliced into a mousepox virus, creating a virus that caused significant mortality, even in immunized mice.Components of biowarfare defenseIn order to effectively protect the population against infectious biowarfare threats, a number of measures need to be deployed: Detection (or surveillance), development of methods for monitoring our environmental space and detecting when an unusual or unexpected infectious agent arrives; Diagnostics, rapid methods for determining what type of pathogen has arrived, be it a toxin, bacteria or virus, and perhaps to profile its genome for drug resistance; Treatment, development of drugs or therapeutics to treat individuals exposed or about to be exposed (first-responders or military personnel) to non-traditional pathogenic agents; Decontamination, neutralization and/or removal from the environment where it was introduced or shed by infected individuals; Epidemiology, to identify all of the individuals who were or are at risk, and finally; Prophylaxis, the development and deployment of effective and safe vaccines to either break an epidemic or prevent primary infections (Fig. 1 ).", [["primary infections", "DISEASE", 1151, 1169], ["mousepox virus", "ORGANISM", 67, 81], ["mice", "ORGANISM", 153, 157], ["immune-suppressing gene", "DNA", 24, 47], ["mice", "SPECIES", 153, 157], ["mousepox virus", "SPECIES", 67, 81], ["mice", "SPECIES", 153, 157], ["an immune-suppressing gene", "TREATMENT", 21, 47], ["a mousepox virus", "PROBLEM", 65, 81], ["a virus", "PROBLEM", 92, 99], ["monitoring our environmental space", "TEST", 374, 408], ["pathogen", "PROBLEM", 535, 543], ["a toxin", "PROBLEM", 563, 570], ["bacteria", "PROBLEM", 572, 580], ["virus", "PROBLEM", 584, 589], ["drug resistance", "TREATMENT", 629, 644], ["Treatment", "TREATMENT", 646, 655], ["drugs", "TREATMENT", 672, 677], ["therapeutics", "TREATMENT", 681, 693], ["non-traditional pathogenic agents", "TREATMENT", 790, 823], ["Decontamination", "TREATMENT", 825, 840], ["neutralization", "TREATMENT", 842, 856], ["removal", "TREATMENT", 864, 871], ["Prophylaxis", "TREATMENT", 1037, 1048], ["effective and safe vaccines", "TREATMENT", 1084, 1111], ["primary infections", "PROBLEM", 1151, 1169], ["significant", "OBSERVATION_MODIFIER", 112, 123], ["mortality", "OBSERVATION", 124, 133]]], ["While all of these measures are important in the overall biodefense scheme, the development of a new generation of vaccines is the focus of the subsequent discussion.Five generations of vaccinesVaccines are widely considered to be one of the miracles of modern medicine.", [["Vaccines", "ORGANISM", 194, 202], ["vaccines", "TREATMENT", 115, 123], ["vaccinesVaccines", "TREATMENT", 186, 202], ["modern medicine", "TREATMENT", 254, 269], ["new", "OBSERVATION_MODIFIER", 97, 100]]], ["Their widespread implementation has greatly reduced the disease burden from once common diseases such as pertussis and measles, and in the case of smallpox, completely eliminated the disease from the human population.", [["pertussis", "DISEASE", 105, 114], ["measles", "DISEASE", 119, 126], ["smallpox", "DISEASE", 147, 155], ["human", "ORGANISM", 200, 205], ["human", "SPECIES", 200, 205], ["human", "SPECIES", 200, 205], ["the disease burden", "PROBLEM", 52, 70], ["common diseases", "PROBLEM", 81, 96], ["pertussis", "PROBLEM", 105, 114], ["measles", "PROBLEM", 119, 126], ["smallpox", "PROBLEM", 147, 155], ["the disease", "PROBLEM", 179, 190], ["widespread", "OBSERVATION_MODIFIER", 6, 16], ["greatly", "OBSERVATION_MODIFIER", 36, 43], ["reduced", "OBSERVATION_MODIFIER", 44, 51], ["disease", "OBSERVATION", 56, 63], ["disease", "OBSERVATION", 183, 190]]], ["Historically, there have been four generations of vaccines.", [["vaccines", "TREATMENT", 50, 58]]], ["For example, with regard to viral vaccines, the first generation is represented by live viruses, such as vaccinia virus or rabies virus, that were grown in animals, harvested, and then chemically inactivated (in the case of rabies virus).", [["vaccinia virus", "ORGANISM", 105, 119], ["rabies virus", "ORGANISM", 123, 135], ["rabies virus", "ORGANISM", 224, 236], ["vaccinia virus or rabies virus", "SPECIES", 105, 135], ["rabies virus", "SPECIES", 224, 236], ["vaccinia virus", "SPECIES", 105, 119], ["rabies virus", "SPECIES", 123, 135], ["rabies virus", "SPECIES", 224, 236], ["viral vaccines", "TREATMENT", 28, 42], ["live viruses", "PROBLEM", 83, 95], ["vaccinia virus", "PROBLEM", 105, 119], ["rabies virus", "PROBLEM", 123, 135], ["rabies virus", "PROBLEM", 224, 236], ["viral vaccines", "OBSERVATION", 28, 42]]], ["The second generation of vaccines was grown on embryonated chicken eggs, as typified by the traditional influenza vaccine.", [["eggs", "ANATOMY", 67, 71], ["chicken", "ORGANISM", 59, 66], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 67, 71], ["chicken", "SPECIES", 59, 66], ["chicken", "SPECIES", 59, 66], ["vaccines", "TREATMENT", 25, 33], ["embryonated chicken eggs", "TREATMENT", 47, 71], ["the traditional influenza vaccine", "TREATMENT", 88, 121]]], ["The advent of cell culture technology heralded the third generation of vaccines, such as measles or mumps that were grown in tissue culture cells.", [["cell", "ANATOMY", 14, 18], ["tissue culture cells", "ANATOMY", 125, 145], ["measles or mumps", "DISEASE", 89, 105], ["cell", "CELL", 14, 18], ["measles", "ORGANISM", 89, 96], ["mumps", "ORGANISM", 100, 105], ["tissue culture cells", "CELL", 125, 145], ["tissue culture cells", "CELL_LINE", 125, 145], ["cell culture technology", "TEST", 14, 37], ["vaccines", "TREATMENT", 71, 79], ["measles", "PROBLEM", 89, 96], ["mumps", "PROBLEM", 100, 105], ["tissue culture cells", "TEST", 125, 145]]], ["The fourth generation of vaccines is currently the state-of-the-art, as typified by the Hepatitis B vaccine, in which a component of a virus is cloned, over-expressed, and purified from a recombinant microorganism and then delivered as a subunit vaccine in combination with an adjuvant.", [["Hepatitis B", "DISEASE", 88, 99], ["Hepatitis B vaccine", "ORGANISM", 88, 107], ["Hepatitis B", "SPECIES", 88, 99], ["vaccines", "TREATMENT", 25, 33], ["the Hepatitis B vaccine", "TREATMENT", 84, 107], ["a virus", "PROBLEM", 133, 140], ["a recombinant microorganism", "PROBLEM", 186, 213], ["a subunit vaccine", "TREATMENT", 236, 253], ["an adjuvant", "TREATMENT", 274, 285], ["virus", "OBSERVATION", 135, 140]]], ["There are some unique challenges associated with developing vaccines against biowarfare agents which make traditional vaccine development approaches difficult.", [["developing vaccines", "TREATMENT", 49, 68], ["biowarfare agents", "TREATMENT", 77, 94], ["traditional vaccine", "TREATMENT", 106, 125]]], ["In many cases there is a paucity of research data available about the replication and virulence mechanisms of exotic pathogens.", [["the replication", "TREATMENT", 66, 81], ["exotic pathogens", "PROBLEM", 110, 126], ["exotic pathogens", "OBSERVATION", 110, 126]]], ["Likewise, in some cases such as smallpox, there are no appropriate animal models in which to conduct challenge experiments.", [["smallpox", "DISEASE", 32, 40], ["no", "UNCERTAINTY", 52, 54]]], ["Moreover, since many of the disease agents of interest cause death they cannot be tested in humans directly.Five generations of vaccinesVaccine development for biowarfare agents represents a conundrum.", [["death", "DISEASE", 61, 66], ["humans", "ORGANISM", 92, 98], ["humans", "SPECIES", 92, 98], ["humans", "SPECIES", 92, 98], ["death", "PROBLEM", 61, 66], ["vaccines", "TREATMENT", 128, 136], ["Vaccine", "TREATMENT", 136, 143], ["biowarfare agents", "TREATMENT", 160, 177]]], ["On one hand, the diseases in question have high associated morbidity and mortality, yet on the other hand, the likelihood of encountering these pathogens is extremely low.", [["the diseases", "PROBLEM", 13, 25], ["high associated morbidity", "PROBLEM", 43, 68], ["these pathogens", "PROBLEM", 138, 153], ["diseases", "OBSERVATION", 17, 25], ["morbidity", "OBSERVATION", 59, 68], ["pathogens", "OBSERVATION", 144, 153]]], ["Since all vaccines have some side effects associated with them, one needs to carefully consider the risk-to-benefit ratio for these types of products.", [["all vaccines", "TREATMENT", 6, 18]]], ["In order for a vaccine against a biowarfare agent to be widely implemented, it will have to be shown to be effective in an animal model and extremely safe.", [["a vaccine", "TREATMENT", 13, 22], ["a biowarfare agent", "TREATMENT", 31, 49]]], ["It is unlikely that traditional vaccine approaches will meet these requirements.", [["traditional vaccine approaches", "TREATMENT", 20, 50], ["unlikely", "UNCERTAINTY", 6, 14]]], ["Therefore, fifth generation vaccine delivery technologies will need to be employed.", [["fifth generation vaccine delivery technologies", "TREATMENT", 11, 57]]], ["While there are a number of new vaccine delivery technologies in development that show promise, including DNA vaccines [2, 3] , transdermal patches [4, 5] , and recombinant plants [6] , the use of commensal bacteria as an antigen delivery platform holds particular promise for this utility.General conceptCommensal bacteria are those that are found in the natural flora of living organisms.", [["DNA", "CELLULAR_COMPONENT", 106, 109], ["transdermal patches", "SIMPLE_CHEMICAL", 128, 147], ["new vaccine delivery technologies", "TREATMENT", 28, 61], ["DNA vaccines", "TREATMENT", 106, 118], ["transdermal patches", "TREATMENT", 128, 147], ["commensal bacteria", "PROBLEM", 197, 215], ["an antigen delivery platform", "TREATMENT", 219, 247], ["General conceptCommensal bacteria", "PROBLEM", 290, 323], ["conceptCommensal", "OBSERVATION_MODIFIER", 298, 314], ["bacteria", "OBSERVATION", 315, 323]]], ["These bacteria reside mainly within mucosal sites such as the mouth, the nose, the lungs, and the gastrointestinal and urogenital tracts.", [["mucosal sites", "ANATOMY", 36, 49], ["mouth", "ANATOMY", 62, 67], ["nose", "ANATOMY", 73, 77], ["lungs", "ANATOMY", 83, 88], ["gastrointestinal", "ANATOMY", 98, 114], ["urogenital tracts", "ANATOMY", 119, 136], ["mucosal sites", "MULTI-TISSUE_STRUCTURE", 36, 49], ["mouth", "ORGANISM_SUBDIVISION", 62, 67], ["nose", "ORGAN", 73, 77], ["lungs", "ORGAN", 83, 88], ["gastrointestinal", "ORGAN", 98, 114], ["urogenital tracts", "MULTI-TISSUE_STRUCTURE", 119, 136], ["These bacteria", "PROBLEM", 0, 14], ["the mouth, the nose, the lungs, and the gastrointestinal and urogenital tracts", "PROBLEM", 58, 136], ["bacteria", "OBSERVATION", 6, 14], ["mucosal sites", "OBSERVATION", 36, 49], ["mouth", "ANATOMY", 62, 67], ["nose", "ANATOMY", 73, 77], ["lungs", "ANATOMY", 83, 88], ["gastrointestinal", "ANATOMY", 98, 114], ["urogenital tracts", "ANATOMY", 119, 136]]], ["Although normally tolerant of commensal organisms, mucosal surfaces present physical barriers to invading pathogens.", [["mucosal surfaces", "ANATOMY", 51, 67], ["mucosal surfaces", "PATHOLOGICAL_FORMATION", 51, 67], ["commensal organisms", "PROBLEM", 30, 49], ["invading pathogens", "PROBLEM", 97, 115], ["tolerant", "OBSERVATION_MODIFIER", 18, 26]]], ["Antigen delivery directly to mucosal sites via non-pathogenic commensal bacterial vectors could provide a significant advantage over some of the more traditional vaccines in that live bacteria are capable of stimulating sustained systemic as well as local immune responses [8] .", [["mucosal sites", "ANATOMY", 29, 42], ["mucosal sites", "MULTI-TISSUE_STRUCTURE", 29, 42], ["Antigen delivery", "TREATMENT", 0, 16], ["mucosal sites", "TREATMENT", 29, 42], ["non-pathogenic commensal bacterial vectors", "TREATMENT", 47, 89], ["traditional vaccines", "TREATMENT", 150, 170]]], ["In addition, commensal bacteria are able to colonize the niche invaded by the pathogen and stimulate an immune response at their portal of entry to prevent infection.", [["infection", "DISEASE", 156, 165], ["commensal bacteria", "PROBLEM", 13, 31], ["the pathogen", "PROBLEM", 74, 86], ["infection", "PROBLEM", 156, 165], ["commensal", "OBSERVATION_MODIFIER", 13, 22], ["bacteria", "OBSERVATION", 23, 31], ["infection", "OBSERVATION", 156, 165]]], ["This ability, combined with the facts that bacteria are easily administered (i.e. topically), are cost efficient, and are well-tolerated [9] , makes live commensal bacteria attractive vehicles for subunit vaccine delivery.", [["bacteria", "PROBLEM", 43, 51], ["subunit vaccine delivery", "TREATMENT", 197, 221]]], ["One such promising commensal bacterium is Streptococcus gordonii, a normal inhabitant of the human oral cavity.General conceptThe secreted protein expression (SPEX) or the bacterial commensal vector (BCV) systems are novel protein expression vector systems that use S. gordonii to produce and export proteins (Fig. 2) .", [["oral cavity", "ANATOMY", 99, 110], ["Streptococcus gordonii", "ORGANISM", 42, 64], ["human", "ORGANISM", 93, 98], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 99, 110], ["SPEX", "GENE_OR_GENE_PRODUCT", 159, 163], ["S. gordonii", "ORGANISM", 266, 277], ["SPEX", "PROTEIN", 159, 163], ["Streptococcus gordonii", "SPECIES", 42, 64], ["human", "SPECIES", 93, 98], ["S. gordonii", "SPECIES", 266, 277], ["Streptococcus gordonii", "SPECIES", 42, 64], ["human", "SPECIES", 93, 98], ["BCV", "SPECIES", 200, 203], ["S. gordonii", "SPECIES", 266, 277], ["commensal bacterium", "PROBLEM", 19, 38], ["Streptococcus gordonii", "PROBLEM", 42, 64], ["the bacterial commensal vector (BCV) systems", "PROBLEM", 168, 212], ["novel protein expression vector systems", "PROBLEM", 217, 256], ["commensal", "OBSERVATION_MODIFIER", 19, 28], ["bacterium", "OBSERVATION", 29, 38], ["Streptococcus gordonii", "OBSERVATION", 42, 64], ["normal", "OBSERVATION_MODIFIER", 68, 74], ["inhabitant", "OBSERVATION_MODIFIER", 75, 85], ["oral cavity", "ANATOMY", 99, 110], ["protein expression", "OBSERVATION", 139, 157]]], ["These systems use the conserved pathway that all Gram-positive bacteria utilize to export and anchor proteins on the cell surface [10] .", [["cell surface", "ANATOMY", 117, 129], ["Gram-", "GENE_OR_GENE_PRODUCT", 49, 54], ["cell surface", "CELLULAR_COMPONENT", 117, 129], ["anchor proteins", "PROTEIN", 94, 109], ["all Gram-positive bacteria", "PROBLEM", 45, 71]]], ["The foreign proteins are directed to the cell surface of the Gram-positive host by using portions of the M protein, a surface protein of S. pyogenes, as a fusion partner.", [["cell surface", "ANATOMY", 41, 53], ["surface", "ANATOMY", 118, 125], ["cell surface", "CELLULAR_COMPONENT", 41, 53], ["Gram-", "GENE_OR_GENE_PRODUCT", 61, 66], ["M protein", "GENE_OR_GENE_PRODUCT", 105, 114], ["S. pyogenes", "ORGANISM", 137, 148], ["foreign proteins", "PROTEIN", 4, 20], ["M protein", "PROTEIN", 105, 114], ["surface protein", "PROTEIN", 118, 133], ["S. pyogenes", "SPECIES", 137, 148], ["S. pyogenes", "SPECIES", 137, 148], ["The foreign proteins", "TREATMENT", 0, 20], ["the M protein", "TEST", 101, 114], ["S. pyogenes", "PROBLEM", 137, 148], ["foreign proteins", "OBSERVATION", 4, 20], ["cell", "OBSERVATION_MODIFIER", 41, 45], ["surface", "OBSERVATION_MODIFIER", 46, 53], ["positive host", "OBSERVATION", 66, 79]]], ["The C-terminal end of the M protein consists of a conserved immunogenic C-repeat region (CRR), a hydrophilic region, the highly conserved enzymatic cleavage site (Pro/Gly), and hydrophobic amino acids that act to anchor the M protein to the cell surface (Fig. 3A) .", [["cell surface", "ANATOMY", 241, 253], ["amino acids", "CHEMICAL", 189, 200], ["Gly", "CHEMICAL", 167, 170], ["amino acids", "CHEMICAL", 189, 200], ["amino acids", "AMINO_ACID", 189, 200], ["cell surface", "CELLULAR_COMPONENT", 241, 253], ["C-terminal end", "PROTEIN", 4, 18], ["M protein", "PROTEIN", 26, 35], ["immunogenic C-repeat region", "DNA", 60, 87], ["CRR", "PROTEIN", 89, 92], ["enzymatic cleavage site", "PROTEIN", 138, 161], ["M protein", "PROTEIN", 224, 233], ["the M protein", "TEST", 22, 35], ["a hydrophilic region", "PROBLEM", 95, 115], ["Pro/Gly)", "TREATMENT", 163, 171], ["hydrophobic amino acids", "TREATMENT", 177, 200], ["hydrophilic", "OBSERVATION_MODIFIER", 97, 108], ["enzymatic cleavage", "OBSERVATION", 138, 156]]], ["If secreted proteins are needed a stop codon is introduced at the carboxy terminus of the foreign protein.", [["carboxy", "CHEMICAL", 66, 73], ["secreted proteins", "PROTEIN", 3, 20], ["stop codon", "DNA", 34, 44], ["carboxy terminus", "PROTEIN", 66, 82], ["foreign protein", "PROTEIN", 90, 105], ["secreted proteins", "PROBLEM", 3, 20], ["a stop codon", "TREATMENT", 32, 44], ["foreign protein", "OBSERVATION", 90, 105]]], ["Without the membrane-anchoring regions to retain the protein on the surface of S. gordonii, the fusion protein is translocated through the cell membrane of the Gram-positive host cell, and secreted directly into the culture medium (Fig. 3B ).", [["membrane", "ANATOMY", 12, 20], ["surface", "ANATOMY", 68, 75], ["cell membrane", "ANATOMY", 139, 152], ["cell", "ANATOMY", 179, 183], ["membrane", "CELLULAR_COMPONENT", 12, 20], ["surface", "CELLULAR_COMPONENT", 68, 75], ["S. gordonii", "ORGANISM", 79, 90], ["cell membrane", "CELLULAR_COMPONENT", 139, 152], ["Gram-", "GENE_OR_GENE_PRODUCT", 160, 165], ["cell", "CELL", 179, 183], ["membrane-anchoring regions", "PROTEIN", 12, 38], ["fusion protein", "PROTEIN", 96, 110], ["Gram-positive host cell", "CELL_TYPE", 160, 183], ["S. gordonii", "SPECIES", 79, 90], ["S. gordonii", "SPECIES", 79, 90], ["the fusion protein", "TEST", 92, 110], ["the culture medium", "TEST", 212, 230], ["gordonii", "OBSERVATION", 82, 90], ["fusion protein", "OBSERVATION", 96, 110], ["cell membrane", "OBSERVATION", 139, 152], ["positive host cell", "OBSERVATION", 165, 183]]], ["This is called the SPEX vector system (for secreted protein expression).Recombinant constructionAfter a candidate antigen has been identified, it is a relatively easy task to create the commensal BCV recombinant for its expression.", [["BCV", "ORGANISM", 196, 199], ["commensal BCV recombinant", "PROTEIN", 186, 211], ["BCV", "SPECIES", 196, 199]]], ["Restriction sites are incorporated into primers homologous to the DNA sequence of interest, and the gene is synthesized by PCR.", [["DNA", "CELLULAR_COMPONENT", 66, 69], ["DNA sequence", "DNA", 66, 78], ["Restriction sites", "PROBLEM", 0, 17]]], ["The DNA fragment is cloned into plasmid pSMB104.", [["plasmid", "ANATOMY", 32, 39], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["pSMB104", "GENE_OR_GENE_PRODUCT", 40, 47], ["DNA fragment", "DNA", 4, 16], ["plasmid pSMB104", "DNA", 32, 47], ["The DNA fragment", "PROBLEM", 0, 16], ["DNA fragment", "OBSERVATION", 4, 16]]], ["Because this plasmid cannot replicate in the Gram-positive host, it must integrate into the chromosome of the naturally competent S. gordonii in order to impart erythromycin resistance.", [["plasmid", "ANATOMY", 13, 20], ["chromosome", "ANATOMY", 92, 102], ["erythromycin", "CHEMICAL", 161, 173], ["erythromycin", "CHEMICAL", 161, 173], ["Gram-", "GENE_OR_GENE_PRODUCT", 45, 50], ["chromosome", "CELLULAR_COMPONENT", 92, 102], ["S. gordonii", "ORGANISM", 130, 141], ["erythromycin", "SIMPLE_CHEMICAL", 161, 173], ["S. gordonii", "SPECIES", 130, 141], ["S. gordonii", "SPECIES", 130, 141], ["erythromycin resistance", "TREATMENT", 161, 184], ["erythromycin resistance", "OBSERVATION", 161, 184]]], ["Integration into the correct chromosomal location is confirmed by PCR, and expression of the encoded antigen is tested by Western blot using the appropriate antisera.", [["chromosomal", "ANATOMY", 29, 40], ["chromosomal", "CELLULAR_COMPONENT", 29, 40], ["PCR", "TEST", 66, 69], ["the encoded antigen", "PROBLEM", 89, 108], ["chromosomal location", "OBSERVATION", 29, 49]]], ["Because the encoded antigen exists as an M-protein fusion, if no specific antiserum is available for the antigen, expression of the heterologous protein can be tested by reactivity with an anti-M protein monoclonal antibody [11] .Recombinant constructionA number of different promoter elements and insertion sites that enable the expression of multiple foreign inserts from the same recombinant have been identified in S. gordonii [12] .", [["antiserum", "ORGANISM_SUBSTANCE", 74, 83], ["S. gordonii", "ORGANISM", 419, 430], ["heterologous protein", "PROTEIN", 132, 152], ["M protein monoclonal antibody", "PROTEIN", 194, 223], ["promoter elements", "DNA", 276, 293], ["insertion sites", "DNA", 298, 313], ["S. gordonii", "SPECIES", 419, 430], ["S. gordonii", "SPECIES", 419, 430], ["an M-protein fusion", "TREATMENT", 38, 57], ["specific antiserum", "TEST", 65, 83], ["the antigen", "TEST", 101, 112], ["the heterologous protein", "PROBLEM", 128, 152], ["an anti-M protein monoclonal antibody", "TEST", 186, 223], ["different promoter elements", "TREATMENT", 266, 293], ["insertion sites", "TREATMENT", 298, 313], ["multiple foreign inserts", "TREATMENT", 344, 368], ["different", "OBSERVATION_MODIFIER", 266, 275], ["promoter elements", "OBSERVATION", 276, 293], ["multiple", "OBSERVATION_MODIFIER", 344, 352], ["foreign inserts", "OBSERVATION", 353, 368]]], ["This could potentially allow for the simultaneous presentation of two or more antigens on a single bacterium.", [["antigens", "PROTEIN", 78, 86], ["a single bacterium", "PROBLEM", 90, 108]]], ["In addition, insertion sites containing inducible promoters have been characterized, thereby allowing the controlled expression of the heterologous gene [13] .", [["insertion sites", "DNA", 13, 28], ["inducible promoters", "DNA", 40, 59], ["heterologous gene [13]", "DNA", 135, 157], ["insertion sites containing inducible promoters", "TREATMENT", 13, 59], ["inducible promoters", "OBSERVATION", 40, 59]]], ["Finally, it is possible to express the antigen from the chromosome or from a plasmid.", [["chromosome", "ANATOMY", 56, 66], ["plasmid", "ANATOMY", 77, 84], ["chromosome", "CELLULAR_COMPONENT", 56, 66], ["plasmid", "DNA", 77, 84], ["a plasmid", "TREATMENT", 75, 84]]], ["The plasmid-based system can easily be adapted for expression in other Grampositive species such as Lactococcus lactis.", [["Lactococcus lactis", "ORGANISM", 100, 118], ["plasmid", "DNA", 4, 11], ["Lactococcus lactis", "SPECIES", 100, 118], ["Lactococcus lactis", "SPECIES", 100, 118], ["The plasmid-based system", "TREATMENT", 0, 24], ["expression in other Grampositive species", "PROBLEM", 51, 91], ["Lactococcus lactis", "TREATMENT", 100, 118]]], ["For example, we have successfully expressed portions of the S. pyogenes M6 protein on the surface of L. lactis from a plasmid (Hruby, unpublished).Antigen expressionProteins from virus, bacteria, protozoans, animals, and humans have been successfully expressed using S. gordonii. heterologous proteins expressed by the BCV/SPEX system that have been shown to be reactive with the appropriate antisera.", [["surface", "ANATOMY", 90, 97], ["plasmid", "ANATOMY", 118, 125], ["S. pyogenes M6", "ORGANISM", 60, 74], ["surface", "CELLULAR_COMPONENT", 90, 97], ["L. lactis", "ORGANISM", 101, 110], ["humans", "ORGANISM", 221, 227], ["S. gordonii", "ORGANISM", 267, 278], ["BCV", "GENE_OR_GENE_PRODUCT", 319, 322], ["SPEX", "GENE_OR_GENE_PRODUCT", 323, 327], ["S. pyogenes M6 protein", "PROTEIN", 60, 82], ["plasmid", "DNA", 118, 125], ["Antigen expressionProteins", "PROTEIN", 147, 173], ["heterologous proteins", "PROTEIN", 280, 301], ["SPEX", "PROTEIN", 323, 327], ["S. pyogenes", "SPECIES", 60, 71], ["L. lactis", "SPECIES", 101, 110], ["humans", "SPECIES", 221, 227], ["S. gordonii", "SPECIES", 267, 278], ["S. pyogenes M6", "SPECIES", 60, 74], ["L. lactis", "SPECIES", 101, 110], ["humans", "SPECIES", 221, 227], ["S. gordonii", "SPECIES", 267, 278], ["Antigen expressionProteins", "TEST", 147, 173], ["virus", "PROBLEM", 179, 184], ["bacteria", "PROBLEM", 186, 194], ["protozoans", "PROBLEM", 196, 206], ["heterologous proteins", "PROBLEM", 280, 301], ["the BCV/SPEX system", "TEST", 315, 334], ["BCV", "ANATOMY", 319, 322], ["reactive", "OBSERVATION_MODIFIER", 362, 370]]], ["While this is an impressive list there are some limitations to the use of bacteria for the expression of eukaryotic proteins.", [["eukaryotic proteins", "PROTEIN", 105, 124], ["bacteria", "PROBLEM", 74, 82], ["eukaryotic proteins", "PROBLEM", 105, 124], ["impressive", "OBSERVATION_MODIFIER", 17, 27], ["eukaryotic proteins", "OBSERVATION", 105, 124]]], ["Bacteria are not able to perform the post-translational processing, i.e. disulfide bonds, glycosylation, myristoylation, etc., important for the structure and function of many eukaryotic proteins.", [["disulfide", "CHEMICAL", 73, 82], ["Bacteria", "CELL", 0, 8], ["eukaryotic proteins", "PROTEIN", 176, 195], ["Bacteria", "PROBLEM", 0, 8], ["disulfide bonds", "TREATMENT", 73, 88], ["glycosylation, myristoylation", "TREATMENT", 90, 119], ["many eukaryotic proteins", "PROBLEM", 171, 195], ["eukaryotic proteins", "OBSERVATION", 176, 195]]], ["Hence, antibodies with specificities that include recognition of the modified proteins will not be generated in response to the BCV bacterial expression vector and alternative modes of antigen delivery would need to be explored.Animal immunizationS. gordonii can readily colonize mice, rats, and monkeys as well as humans.", [["BCV", "ORGANISM", 128, 131], ["gordonii", "ORGANISM", 250, 258], ["mice", "ORGANISM", 280, 284], ["rats", "ORGANISM", 286, 290], ["monkeys", "ORGANISM", 296, 303], ["humans", "ORGANISM", 315, 321], ["antibodies", "PROTEIN", 7, 17], ["modified proteins", "PROTEIN", 69, 86], ["gordonii", "SPECIES", 250, 258], ["mice", "SPECIES", 280, 284], ["rats", "SPECIES", 286, 290], ["monkeys", "SPECIES", 296, 303], ["humans", "SPECIES", 315, 321], ["BCV", "SPECIES", 128, 131], ["gordonii", "SPECIES", 250, 258], ["mice", "SPECIES", 280, 284], ["humans", "SPECIES", 315, 321], ["the modified proteins", "TREATMENT", 65, 86], ["the BCV bacterial expression vector", "TREATMENT", 124, 159], ["alternative modes of antigen delivery", "TREATMENT", 164, 201], ["Animal immunizationS", "TREATMENT", 228, 248], ["gordonii", "PROBLEM", 250, 258]]], ["Hence, the ability of recombinant BCV to induce an immune response can be examined in several animal models.", [["BCV", "ORGANISM", 34, 37], ["BCV", "SPECIES", 34, 37], ["recombinant BCV", "TREATMENT", 22, 37]]], ["The first demonstration that S. gordonii could successfully induce a mucosal and systemic immune response to foreign antigens was presented in experiments performed by Medaglini et al. [14] .", [["mucosal", "ANATOMY", 69, 76], ["S. gordonii", "ORGANISM", 29, 40], ["mucosal", "PATHOLOGICAL_FORMATION", 69, 76], ["foreign antigens", "PROTEIN", 109, 125], ["S. gordonii", "SPECIES", 29, 40], ["S. gordonii", "SPECIES", 29, 40], ["S. gordonii", "PROBLEM", 29, 40], ["foreign antigens", "PROBLEM", 109, 125], ["mucosal", "ANATOMY", 69, 76]]], ["Expression of the hornet venom allergen Ag5.2 as a fusion protein to the anchor region of the M6 protein of S. pyogenes induced a significant increase in Ag5.2-specific salivary and lung IgA as well as an increase in systemic IgG in mice.Animal immunizationSeveral additional studies have shown that a variety of antigens expressed on the surface of S. gordonii are immunogenic when delivered to mice or monkeys by either the systemic or mucosal routes [15] [16] [17] [18] [19] [20] [21] [22] .", [["salivary", "ANATOMY", 169, 177], ["lung", "ANATOMY", 182, 186], ["surface", "ANATOMY", 339, 346], ["mucosal", "ANATOMY", 438, 445], ["Ag5.2", "CHEMICAL", 40, 45], ["hornet venom", "GENE_OR_GENE_PRODUCT", 18, 30], ["Ag5.2", "GENE_OR_GENE_PRODUCT", 40, 45], ["M6", "GENE_OR_GENE_PRODUCT", 94, 96], ["S. pyogenes", "ORGANISM", 108, 119], ["Ag5.2", "SIMPLE_CHEMICAL", 154, 159], ["salivary", "ORGAN", 169, 177], ["lung", "ORGAN", 182, 186], ["IgA", "GENE_OR_GENE_PRODUCT", 187, 190], ["IgG", "GENE_OR_GENE_PRODUCT", 226, 229], ["mice", "ORGANISM", 233, 237], ["surface", "CELLULAR_COMPONENT", 339, 346], ["S. gordonii", "ORGANISM", 350, 361], ["mice", "ORGANISM", 396, 400], ["monkeys", "ORGANISM", 404, 411], ["[15] [16] [17] [18] [19] [20] [21] [22]", "SIMPLE_CHEMICAL", 453, 492], ["hornet venom allergen Ag5.2", "PROTEIN", 18, 45], ["fusion protein", "PROTEIN", 51, 65], ["anchor region", "PROTEIN", 73, 86], ["M6 protein", "PROTEIN", 94, 104], ["Ag5.2", "PROTEIN", 154, 159], ["lung IgA", "PROTEIN", 182, 190], ["systemic IgG", "PROTEIN", 217, 229], ["antigens", "PROTEIN", 313, 321], ["S. pyogenes", "SPECIES", 108, 119], ["mice", "SPECIES", 233, 237], ["S. gordonii", "SPECIES", 350, 361], ["mice", "SPECIES", 396, 400], ["monkeys", "SPECIES", 404, 411], ["S. pyogenes", "SPECIES", 108, 119], ["mice", "SPECIES", 233, 237], ["S. gordonii", "SPECIES", 350, 361], ["mice", "SPECIES", 396, 400], ["the hornet venom allergen", "TREATMENT", 14, 39], ["a fusion protein", "TREATMENT", 49, 65], ["S. pyogenes", "PROBLEM", 108, 119], ["a significant increase", "PROBLEM", 128, 150], ["Ag5.2", "TEST", 154, 159], ["systemic IgG in mice", "TREATMENT", 217, 237], ["Animal immunization", "TREATMENT", 238, 257], ["Several additional studies", "TEST", 257, 283], ["pyogenes", "OBSERVATION", 111, 119], ["significant", "OBSERVATION_MODIFIER", 130, 141], ["increase", "OBSERVATION_MODIFIER", 142, 150], ["lung", "ANATOMY", 182, 186], ["IgA", "OBSERVATION", 187, 190], ["increase", "OBSERVATION_MODIFIER", 205, 213], ["systemic", "OBSERVATION_MODIFIER", 217, 225], ["IgG", "OBSERVATION", 226, 229]]], ["Immunization of rabbits with live or heatkilled S. gordonii expressing domains of the Porphyromonas gingivalis fimbrillin protein or the Bordetella S1 pertussis toxin induced antibodies specific for the encoded antigens [18, 23] .", [["rabbits", "ORGANISM", 16, 23], ["S. gordonii", "ORGANISM", 48, 59], ["Porphyromonas gingivalis", "ORGANISM", 86, 110], ["fimbrillin", "GENE_OR_GENE_PRODUCT", 111, 121], ["Bordetella S1 pertussis", "ORGANISM", 137, 160], ["toxin", "ORGANISM", 161, 166], ["Porphyromonas gingivalis fimbrillin protein", "PROTEIN", 86, 129], ["Bordetella S1 pertussis toxin", "PROTEIN", 137, 166], ["antibodies", "PROTEIN", 175, 185], ["encoded antigens", "PROTEIN", 203, 219], ["rabbits", "SPECIES", 16, 23], ["S. gordonii", "SPECIES", 48, 59], ["Porphyromonas gingivalis", "SPECIES", 86, 110], ["Bordetella S1 pertussis toxin", "SPECIES", 137, 166], ["rabbits", "SPECIES", 16, 23], ["S. gordonii", "SPECIES", 48, 59], ["Porphyromonas gingivalis", "SPECIES", 86, 110], ["Bordetella S1 pertussis", "SPECIES", 137, 160], ["Immunization of rabbits", "TREATMENT", 0, 23], ["the Porphyromonas gingivalis fimbrillin protein", "PROBLEM", 82, 129], ["the Bordetella S1 pertussis toxin induced antibodies", "TEST", 133, 185], ["the encoded antigens", "TEST", 199, 219]]], ["In addition to inducing potent humoral immune responses, recombinant S. gordonii can be internalized by human and mouse dendritic cells and its encoded antigens presented by MHC Class II molecules [24] as well as MHC class I molecules [25] .", [["dendritic cells", "ANATOMY", 120, 135], ["S. gordonii", "ORGANISM", 69, 80], ["human", "ORGANISM", 104, 109], ["mouse", "ORGANISM", 114, 119], ["dendritic cells", "CELL", 120, 135], ["human and mouse dendritic cells", "CELL_TYPE", 104, 135], ["MHC Class II molecules", "PROTEIN", 174, 196], ["MHC class I molecules", "PROTEIN", 213, 234], ["S. gordonii", "SPECIES", 69, 80], ["human", "SPECIES", 104, 109], ["mouse", "SPECIES", 114, 119], ["S. gordonii", "SPECIES", 69, 80], ["human", "SPECIES", 104, 109], ["mouse", "SPECIES", 114, 119], ["potent humoral immune responses", "TREATMENT", 24, 55], ["recombinant S. gordonii", "PROBLEM", 57, 80], ["dendritic cells", "OBSERVATION", 120, 135]]], ["Most importantly, the potential for recombinant S. gordonii to be developed as a safe vaccine vector was supported by the finding that immunization of mice with S. gordonii expressing tetanus toxin fragment C (TTFC) induced protection from a lethal challenge with 50 LD 50 of tetanus toxin [26] .", [["TTFC", "CHEMICAL", 210, 214], ["LD 50 of tetanus toxin", "CHEMICAL", 267, 289], ["S. gordonii", "ORGANISM", 48, 59], ["mice", "ORGANISM", 151, 155], ["S. gordonii", "ORGANISM", 161, 172], ["tetanus toxin", "ORGANISM", 184, 197], ["fragment C", "SIMPLE_CHEMICAL", 198, 208], ["tetanus toxin fragment C", "PROTEIN", 184, 208], ["S. gordonii", "SPECIES", 48, 59], ["mice", "SPECIES", 151, 155], ["S. gordonii", "SPECIES", 161, 172], ["S. gordonii", "SPECIES", 48, 59], ["mice", "SPECIES", 151, 155], ["S. gordonii", "SPECIES", 161, 172], ["recombinant S. gordonii", "PROBLEM", 36, 59], ["a safe vaccine vector", "TREATMENT", 79, 100], ["immunization of mice", "TREATMENT", 135, 155], ["S. gordonii", "PROBLEM", 161, 172], ["tetanus toxin fragment C", "PROBLEM", 184, 208], ["a lethal challenge", "TREATMENT", 240, 258], ["tetanus toxin", "TREATMENT", 276, 289]]], ["Moreover, S. gordonii recombinants expressing FimA, the major subunit protein of P. gingivalis fimbriae, induced strong serum IgG and salivary IgA antibody responses, and protected against subsequent P. gingivalis-induced alveolar bone loss in germ free rats [27] .Human clinical trialsTwo Phase I human clinical trials (total 150 subjects) were conducted at the Center for Vaccine Development, University of Maryland, School of Medicine, Baltimore, MD, to determine the time to eradication (spontaneous and antibiotic-induced) of a strain of S. gordonii that was experimentally implanted into the nose and mouth of healthy volunteers.", [["serum", "ANATOMY", 120, 125], ["alveolar bone", "ANATOMY", 222, 235], ["germ", "ANATOMY", 244, 248], ["nose", "ANATOMY", 598, 602], ["mouth", "ANATOMY", 607, 612], ["alveolar bone loss", "DISEASE", 222, 240], ["S. gordonii", "ORGANISM", 10, 21], ["FimA", "GENE_OR_GENE_PRODUCT", 46, 50], ["P. gingivalis fimbriae", "GENE_OR_GENE_PRODUCT", 81, 103], ["serum", "ORGANISM_SUBSTANCE", 120, 125], ["IgG", "GENE_OR_GENE_PRODUCT", 126, 129], ["salivary", "ORGANISM_SUBSTANCE", 134, 142], ["IgA", "GENE_OR_GENE_PRODUCT", 143, 146], ["P. gingivalis", "ORGANISM", 200, 213], ["alveolar bone", "MULTI-TISSUE_STRUCTURE", 222, 235], ["germ", "ORGANISM_SUBSTANCE", 244, 248], ["rats", "ORGANISM", 254, 258], ["Human", "ORGANISM", 265, 270], ["human", "ORGANISM", 298, 303], ["S. gordonii", "ORGANISM", 543, 554], ["nose", "ORGANISM_SUBDIVISION", 598, 602], ["mouth", "ORGANISM_SUBDIVISION", 607, 612], ["volunteers", "ORGANISM", 624, 634], ["FimA", "PROTEIN", 46, 50], ["major subunit protein", "PROTEIN", 56, 77], ["P. gingivalis fimbriae", "PROTEIN", 81, 103], ["serum IgG", "PROTEIN", 120, 129], ["salivary IgA antibody", "PROTEIN", 134, 155], ["S. gordonii", "SPECIES", 10, 21], ["P. gingivalis", "SPECIES", 81, 94], ["P. gingivalis", "SPECIES", 200, 213], ["rats", "SPECIES", 254, 258], ["Human", "SPECIES", 265, 270], ["human", "SPECIES", 298, 303], ["S. gordonii", "SPECIES", 543, 554], ["S. gordonii", "SPECIES", 10, 21], ["P. gingivalis", "SPECIES", 81, 94], ["P. gingivalis", "SPECIES", 200, 213], ["human", "SPECIES", 298, 303], ["S. gordonii", "SPECIES", 543, 554], ["P. gingivalis fimbriae", "PROBLEM", 81, 103], ["serum IgG", "TEST", 120, 129], ["salivary IgA antibody responses", "TEST", 134, 165], ["P. gingivalis", "PROBLEM", 200, 213], ["alveolar bone loss", "PROBLEM", 222, 240], ["antibiotic", "TREATMENT", 508, 518], ["a strain of S. gordonii", "PROBLEM", 531, 554], ["alveolar", "ANATOMY_MODIFIER", 222, 230], ["bone", "ANATOMY", 231, 235], ["loss", "OBSERVATION", 236, 240], ["nose", "ANATOMY", 598, 602], ["mouth", "ANATOMY", 607, 612]]], ["These studies showed that antibiotic treatment cleared the implanted strain from subjects 3.", [["These studies", "TEST", 0, 13], ["antibiotic treatment", "TREATMENT", 26, 46]]], ["An example: BCV/smallpox vaccineSmallpox as a BW pathogenSmallpox was the most destructive disease in recorded history having killed, crippled, or disfigured nearly 1/10 of all humankind.", [["BCV", "ORGANISM", 12, 15], ["smallpox", "ORGANISM", 16, 24], ["vaccineSmallpox", "ORGANISM", 25, 40], ["BCV/smallpox vaccineSmallpox", "SPECIES", 12, 40], ["BCV/smallpox vaccineSmallpox", "TREATMENT", 12, 40], ["a BW pathogenSmallpox", "TREATMENT", 44, 65], ["the most destructive disease", "PROBLEM", 70, 98], ["BCV", "ANATOMY", 12, 15], ["destructive", "OBSERVATION_MODIFIER", 79, 90]]], ["In the 20th century alone, more than 300 million people succumbed to the disease.", [["people", "ORGANISM", 49, 55], ["people", "SPECIES", 49, 55], ["the disease", "PROBLEM", 69, 80], ["disease", "OBSERVATION", 73, 80]]], ["Variola virus, the causative agent of smallpox, is extremely infectious.", [["Variola", "CHEMICAL", 0, 7], ["smallpox", "DISEASE", 38, 46], ["Variola virus", "ORGANISM", 0, 13], ["Variola virus", "SPECIES", 0, 13], ["Variola virus", "SPECIES", 0, 13], ["Variola virus", "PROBLEM", 0, 13], ["smallpox", "PROBLEM", 38, 46], ["extremely infectious", "PROBLEM", 51, 71], ["virus", "OBSERVATION", 8, 13], ["extremely", "OBSERVATION_MODIFIER", 51, 60], ["infectious", "OBSERVATION", 61, 71]]], ["It is usually acquired by inhalation of aerosol droplets spread by infected individuals.", [["aerosol droplets", "TREATMENT", 40, 56]]], ["Variola major, a highly virulent form of smallpox, can cause death rates as high as 30%.", [["Variola", "CHEMICAL", 0, 7], ["smallpox", "DISEASE", 41, 49], ["death", "DISEASE", 61, 66], ["smallpox", "TREATMENT", 41, 49], ["death rates", "TEST", 61, 72], ["highly", "OBSERVATION_MODIFIER", 17, 23], ["virulent", "OBSERVATION_MODIFIER", 24, 32], ["smallpox", "OBSERVATION", 41, 49]]], ["The disease has a number of features that make it an bidealQ agent of bioterrorism (Table 3) .", [["The disease", "PROBLEM", 0, 11], ["disease", "OBSERVATION", 4, 11]]], ["Although smallpox is of paramount concern, one should not neglect other potential orthopoxvirus pathogens.", [["smallpox", "DISEASE", 9, 17], ["potential orthopoxvirus pathogens", "PROBLEM", 72, 105], ["orthopoxvirus", "OBSERVATION", 82, 95]]], ["For example, there have been several recent incursions of monkeypox virus into the human population.", [["monkeypox virus", "ORGANISM", 58, 73], ["human", "ORGANISM", 83, 88], ["human", "SPECIES", 83, 88], ["monkeypox virus", "SPECIES", 58, 73], ["human", "SPECIES", 83, 88], ["monkeypox virus", "PROBLEM", 58, 73], ["several", "OBSERVATION_MODIFIER", 29, 36], ["monkeypox virus", "OBSERVATION", 58, 73]]], ["Such an event transpired in the Midwest in the summer of 2003 when prairie dogs sold as pets became infected with the monkeypox virus through contact with Gambian giant rats and other rodents.", [["dogs", "ORGANISM", 75, 79], ["monkeypox virus", "ORGANISM", 118, 133], ["rats", "ORGANISM", 169, 173], ["dogs", "SPECIES", 75, 79], ["rats", "SPECIES", 169, 173], ["monkeypox virus", "SPECIES", 118, 133], ["the monkeypox virus", "PROBLEM", 114, 133]]], ["Over 70 people became ill during this outbreak [28] .", [["people", "ORGANISM", 8, 14], ["people", "SPECIES", 8, 14]]], ["Another more chilling scenario is the possibility that a laboratory strain of vaccinia virus or cowpox virus could be genetically engineered to produce a toxin to convert it into a potent pathogen [29] .", [["vaccinia virus", "ORGANISM", 78, 92], ["cowpox virus", "ORGANISM", 96, 108], ["vaccinia virus or cowpox virus", "SPECIES", 78, 108], ["vaccinia virus", "SPECIES", 78, 92], ["cowpox virus", "SPECIES", 96, 108], ["Another more chilling scenario", "PROBLEM", 0, 30], ["a laboratory strain", "PROBLEM", 55, 74], ["vaccinia virus", "PROBLEM", 78, 92], ["cowpox virus", "PROBLEM", 96, 108], ["a toxin", "PROBLEM", 152, 159], ["a potent pathogen", "PROBLEM", 179, 196]]], ["Fortunately, orthopoxviruses are highly related at the DNA level (e.g. 90% between variola and vaccinia) making it likely that any vaccine developed would stimulate immunity to this entire group of viruses [30] .Existing vaccine/problemsSmallpox was eliminated from the US in the 1960s and subsequently, routine prophylactic immunization was discontinued.", [["orthopoxviruses", "GENE_OR_GENE_PRODUCT", 13, 28], ["DNA", "CELLULAR_COMPONENT", 55, 58], ["vaccinia", "ORGANISM", 95, 103], ["orthopoxviruses", "PROBLEM", 13, 28], ["the DNA level", "TEST", 51, 64], ["variola", "PROBLEM", 83, 90], ["vaccinia", "PROBLEM", 95, 103], ["any vaccine", "PROBLEM", 127, 138], ["Existing vaccine/problems", "TREATMENT", 212, 237], ["Smallpox", "TREATMENT", 237, 245], ["the US", "TEST", 266, 272], ["routine prophylactic immunization", "TREATMENT", 304, 337], ["orthopoxviruses", "OBSERVATION", 13, 28]]], ["As a result, we now have a population that is highly susceptible to orthopoxvirus infection.", [["infection", "DISEASE", 82, 91], ["orthopoxvirus", "CANCER", 68, 81], ["orthopoxvirus infection", "PROBLEM", 68, 91], ["highly susceptible to", "UNCERTAINTY", 46, 67], ["orthopoxvirus", "OBSERVATION_MODIFIER", 68, 81], ["infection", "OBSERVATION", 82, 91]]], ["However, mass immunization of the populace is not advisable as a response to the potential threat of bioterrorism because of the risk of serious complications from vaccination with the currently available vaccine.", [["mass immunization", "TREATMENT", 9, 26], ["bioterrorism", "PROBLEM", 101, 113], ["serious complications", "PROBLEM", 137, 158], ["vaccination", "TREATMENT", 164, 175], ["the currently available vaccine", "TREATMENT", 181, 212], ["mass", "OBSERVATION", 9, 13]]], ["These potentially fatal complications include postvaccinial encephalitis, myopericarditis, progressive vaccinia, fetal vaccinia, and eczema vaccinatum (in addition to several other less serious complications).", [["fetal", "ANATOMY", 113, 118], ["encephalitis", "DISEASE", 60, 72], ["myopericarditis", "DISEASE", 74, 89], ["vaccinia", "DISEASE", 103, 111], ["fetal vaccinia", "DISEASE", 113, 127], ["eczema vaccinatum", "DISEASE", 133, 150], ["vaccinia", "ORGANISM", 103, 111], ["fetal vaccinia", "ORGANISM", 113, 127], ["eczema vaccinatum", "ORGANISM", 133, 150], ["eczema vaccinatum", "SPECIES", 133, 150], ["fatal complications", "PROBLEM", 18, 37], ["postvaccinial encephalitis", "PROBLEM", 46, 72], ["myopericarditis", "PROBLEM", 74, 89], ["progressive vaccinia", "PROBLEM", 91, 111], ["fetal vaccinia", "PROBLEM", 113, 127], ["eczema vaccinatum", "PROBLEM", 133, 150], ["several other less serious complications", "PROBLEM", 167, 207], ["fatal", "OBSERVATION_MODIFIER", 18, 23], ["complications", "OBSERVATION", 24, 37], ["postvaccinial", "OBSERVATION_MODIFIER", 46, 59], ["encephalitis", "OBSERVATION", 60, 72], ["myopericarditis", "OBSERVATION", 74, 89], ["progressive", "OBSERVATION_MODIFIER", 91, 102], ["vaccinia", "OBSERVATION", 103, 111], ["fetal vaccinia", "OBSERVATION", 113, 127]]], ["The need for a new, safe smallpox vaccine is significant.Existing vaccine/problemsA great deal of recent research has focused on the development of attenuated live vaccinia virus, mainly for use as recombinant vaccine delivery systems.", [["vaccinia virus", "ORGANISM", 164, 178], ["vaccinia virus", "SPECIES", 164, 178], ["a new, safe smallpox vaccine", "TREATMENT", 13, 41], ["Existing vaccine/problems", "TREATMENT", 57, 82], ["attenuated live vaccinia virus", "PROBLEM", 148, 178], ["recombinant vaccine delivery systems", "TREATMENT", 198, 234], ["significant", "OBSERVATION_MODIFIER", 45, 56], ["great", "OBSERVATION_MODIFIER", 84, 89], ["vaccinia virus", "OBSERVATION", 164, 178]]], ["One such virus is the modified vaccinia virus Ankara (MVA).", [["vaccinia virus Ankara", "ORGANISM", 31, 52], ["vaccinia virus", "SPECIES", 31, 45], ["One such virus", "PROBLEM", 0, 14], ["virus", "OBSERVATION", 9, 14]]], ["Several studies show promising results as to the ability of MVA and other attenuated vaccinia to induce both humoral and cell-mediated immune responses against vaccinia and heterologous antigens [31] [32] [33] [34] [35] [36] [37] .", [["cell", "ANATOMY", 121, 125], ["MVA", "CHEMICAL", 60, 63], ["MVA", "ORGANISM", 60, 63], ["vaccinia", "ORGANISM", 85, 93], ["cell", "CELL", 121, 125], ["vaccinia", "ORGANISM", 160, 168], ["[31] [32] [33] [34] [35] [36] [37]", "SIMPLE_CHEMICAL", 195, 229], ["vaccinia", "SPECIES", 85, 93], ["vaccinia", "SPECIES", 160, 168], ["Several studies", "TEST", 0, 15], ["MVA", "PROBLEM", 60, 63], ["other attenuated vaccinia", "PROBLEM", 68, 93], ["vaccinia", "PROBLEM", 160, 168], ["heterologous antigens", "TEST", 173, 194]]], ["It should be noted that although the MVA genome has deletions in many of the known poxvirus immunomodulatory genes, it still retains the ability to express a large number of viral gene products of unknown biological activity.", [["MVA genome", "DNA", 37, 47], ["poxvirus immunomodulatory genes", "DNA", 83, 114], ["viral gene products", "PROTEIN", 174, 193], ["deletions", "PROBLEM", 52, 61], ["viral gene products", "TREATMENT", 174, 193], ["poxvirus", "OBSERVATION_MODIFIER", 83, 91], ["immunomodulatory genes", "OBSERVATION", 92, 114], ["large", "OBSERVATION_MODIFIER", 158, 163], ["viral gene products", "OBSERVATION", 174, 193], ["biological activity", "OBSERVATION", 205, 224]]], ["Furthermore, MVA recombinants are being widely developed as therapeutic vaccines against cancers.", [["cancers", "ANATOMY", 89, 96], ["cancers", "DISEASE", 89, 96], ["MVA recombinants", "ORGANISM", 13, 29], ["cancers", "CANCER", 89, 96], ["MVA", "SPECIES", 13, 16], ["MVA recombinants", "PROBLEM", 13, 29], ["therapeutic vaccines", "TREATMENT", 60, 80], ["cancers", "PROBLEM", 89, 96]]], ["Widespread vaccination of the populace could induce immunity against the MVA virus itself and thus limit its usability as an anti-cancer vector.", [["MVA virus", "ORGANISM", 73, 82], ["MVA virus", "SPECIES", 73, 82], ["the MVA virus itself", "PROBLEM", 69, 89], ["an anti-cancer vector", "TREATMENT", 122, 143]]], ["Therefore, these attenuated vaccinia strains may not be as useful as hoped as a smallpox vaccine for the general population.Candidate antigensUnlike many other viruses, VV produces many virion forms, all of which appear to be infectious.", [["vaccinia", "ORGANISM", 28, 36], ["VV", "ORGANISM", 169, 171], ["antigens", "PROTEIN", 134, 142], ["VV", "SPECIES", 169, 171], ["these attenuated vaccinia strains", "PROBLEM", 11, 44], ["a smallpox vaccine", "TREATMENT", 78, 96], ["the general population", "TREATMENT", 101, 123], ["many other viruses", "PROBLEM", 149, 167], ["many virion forms", "PROBLEM", 181, 198], ["infectious", "PROBLEM", 226, 236], ["viruses", "OBSERVATION", 160, 167], ["many", "OBSERVATION_MODIFIER", 181, 185], ["virion forms", "OBSERVATION", 186, 198], ["appear to be", "UNCERTAINTY", 213, 225], ["infectious", "OBSERVATION", 226, 236]]], ["The molecular details of poxvirus assembly and differentiation are thought to be as follows: After (or concurrent with) viral DNA replication, progeny DNA molecules, viral enzymes, and structural proteins coalesce to form pre-virion particles [38] .", [["poxvirus", "ORGANISM", 25, 33], ["DNA", "CELLULAR_COMPONENT", 126, 129], ["DNA", "CELLULAR_COMPONENT", 151, 154], ["progeny DNA molecules", "PROTEIN", 143, 164], ["viral enzymes", "PROTEIN", 166, 179], ["structural proteins", "PROTEIN", 185, 204], ["viral DNA replication", "TREATMENT", 120, 141], ["progeny DNA molecules", "TEST", 143, 164], ["viral enzymes", "TEST", 166, 179], ["structural proteins coalesce", "PROBLEM", 185, 213], ["poxvirus", "OBSERVATION", 25, 33]]], ["These particles acquire two membranes by budding through the intermediate compartment (between the endoplas- [39] .", [["membranes", "ANATOMY", 28, 37], ["intermediate compartment", "ANATOMY", 61, 85], ["membranes", "CELLULAR_COMPONENT", 28, 37], ["two membranes", "OBSERVATION_MODIFIER", 24, 37]]], ["The EV can either remain associated with the cell as a cell-associated enveloped virus, (CEV) or can be released into the external medium as extracellular enveloped virus (EEV) [40] .", [["cell", "ANATOMY", 45, 49], ["cell", "ANATOMY", 55, 59], ["cell", "CELL", 45, 49], ["cell", "CELL", 55, 59], ["enveloped virus", "ORGANISM", 71, 86], ["extracellular enveloped virus", "ORGANISM", 141, 170], ["the cell", "PROBLEM", 41, 49], ["a cell", "PROBLEM", 53, 59], ["enveloped virus", "PROBLEM", 71, 86], ["enveloped", "OBSERVATION_MODIFIER", 71, 80], ["virus", "OBSERVATION", 81, 86]]], ["When developing a strategy for designing a vaccine against smallpox, it is important to consider the different forms of this family of poxvirus.", [["smallpox", "DISEASE", 59, 67], ["poxvirus", "ORGANISM", 135, 143], ["smallpox", "SPECIES", 59, 67], ["a vaccine", "TREATMENT", 41, 50], ["smallpox", "PROBLEM", 59, 67], ["poxvirus", "PROBLEM", 135, 143]]], ["The EEV form of the virus is important for the long range dissemination of the virus within the host while the IMV form is thought to be important for transmitting infection between hosts [40, 41] .", [["infection", "DISEASE", 164, 173], ["the virus", "PROBLEM", 16, 25], ["the virus", "PROBLEM", 75, 84], ["transmitting infection", "PROBLEM", 151, 173], ["virus", "OBSERVATION", 20, 25], ["thought to be", "UNCERTAINTY", 123, 136], ["infection", "OBSERVATION", 164, 173]]], ["Thus, a suitable smallpox vaccine must be effective against both forms of this virus.", [["a suitable smallpox vaccine", "TREATMENT", 6, 33], ["this virus", "PROBLEM", 74, 84]]], ["For this reason, several VV proteins that were chosen as BCV vaccine candidate proteins are associated with the IMV form of the virus while others are associated only with the EEV forms.", [["VV", "ORGANISM", 25, 27], ["BCV", "ORGANISM", 57, 60], ["VV proteins", "PROTEIN", 25, 36], ["BCV vaccine candidate proteins", "PROTEIN", 57, 87], ["VV", "SPECIES", 25, 27], ["BCV", "SPECIES", 57, 60], ["several VV proteins", "TREATMENT", 17, 36], ["BCV vaccine candidate proteins", "TREATMENT", 57, 87], ["the virus", "PROBLEM", 124, 133], ["virus", "OBSERVATION", 128, 133]]], ["Other criteria required for the candidate subunit VV proteins were one or more of the following: (1) Does the candidate elicit humoral or cell-mediated immune responses? (2) Have the antibodies specific for the proteins been shown to be protective in animal models? (3) Can the parenterally delivered purified VV protein elicit protection? and (4) Does the induction of a cell-mediated response by delivery of these genes in a DNA vaccine confer at least partial protection?", [["cell", "ANATOMY", 138, 142], ["cell", "ANATOMY", 372, 376], ["cell", "CELL", 138, 142], ["VV", "ORGANISM", 310, 312], ["cell", "CELL", 372, 376], ["DNA", "CELLULAR_COMPONENT", 427, 430], ["candidate subunit VV proteins", "PROTEIN", 32, 61], ["antibodies", "PROTEIN", 183, 193], ["VV protein", "PROTEIN", 310, 320], ["VV", "SPECIES", 310, 312], ["subunit VV proteins", "TREATMENT", 42, 61], ["the antibodies", "TEST", 179, 193], ["the proteins", "PROBLEM", 207, 219], ["purified VV protein elicit protection", "TREATMENT", 301, 338], ["a cell-mediated response", "TREATMENT", 370, 394], ["a DNA vaccine", "TREATMENT", 425, 438]]], ["Based on these criteria several vaccinia proteins were chosen as promising candidates for the commensal smallpox vaccine.", [["vaccinia", "ORGANISM", 32, 40], ["vaccinia proteins", "PROTEIN", 32, 49], ["several vaccinia proteins", "TREATMENT", 24, 49], ["the commensal smallpox vaccine", "TREATMENT", 90, 120]]], ["Some of these proteins and their characteristics are listed in Table 4 .BCV/VV recombinantsDNA encoding the VV Copenhagen proteins A27L, L1R, F13L, D8L, A33R, and A4L was cloned into the S. gordonii chromosome as described above.", [["chromosome", "ANATOMY", 199, 209], ["BCV/VV recombinantsDNA", "ORGANISM", 72, 94], ["VV Copenhagen", "ORGANISM", 108, 121], ["A27L", "GENE_OR_GENE_PRODUCT", 131, 135], ["L1R", "GENE_OR_GENE_PRODUCT", 137, 140], ["F13L", "GENE_OR_GENE_PRODUCT", 142, 146], ["D8L", "GENE_OR_GENE_PRODUCT", 148, 151], ["A33R", "GENE_OR_GENE_PRODUCT", 153, 157], ["A4L", "GENE_OR_GENE_PRODUCT", 163, 166], ["S. gordonii", "ORGANISM", 187, 198], ["chromosome", "CELLULAR_COMPONENT", 199, 209], ["BCV/VV recombinantsDNA", "DNA", 72, 94], ["VV Copenhagen proteins", "PROTEIN", 108, 130], ["A27L", "PROTEIN", 131, 135], ["L1R", "PROTEIN", 137, 140], ["F13L", "PROTEIN", 142, 146], ["D8L", "PROTEIN", 148, 151], ["A33R", "PROTEIN", 153, 157], ["A4L", "PROTEIN", 163, 166], ["S. gordonii", "SPECIES", 187, 198], ["VV", "SPECIES", 76, 78], ["VV", "SPECIES", 108, 110], ["S. gordonii", "SPECIES", 187, 198], ["BCV", "TEST", 72, 75], ["D8L", "TREATMENT", 148, 151], ["A33R", "TREATMENT", 153, 157], ["A4L", "TREATMENT", 163, 166], ["proteins", "OBSERVATION", 14, 22], ["VV", "ANATOMY", 76, 78], ["gordonii chromosome", "OBSERVATION", 190, 209]]], ["Expression of these proteins from S. gordonii was tested by streak blot Western analysis using antibodies specific for the M protein portion of the fusion protein [11] .", [["S. gordonii", "ORGANISM", 34, 45], ["antibodies", "PROTEIN", 95, 105], ["M protein portion", "PROTEIN", 123, 140], ["fusion protein", "PROTEIN", 148, 162], ["S. gordonii", "SPECIES", 34, 45], ["S. gordonii", "SPECIES", 34, 45], ["these proteins", "PROBLEM", 14, 28], ["S. gordonii", "PROBLEM", 34, 45], ["streak blot Western analysis", "TEST", 60, 88], ["antibodies", "TEST", 95, 105], ["the fusion protein", "TEST", 144, 162]]], ["Streak blot analysis tests for the surface expression of the heterologous proteins as whole bacteria are transferred to the nitrocellulose membrane.", [["surface", "ANATOMY", 35, 42], ["membrane", "ANATOMY", 139, 147], ["nitrocellulose", "CHEMICAL", 124, 138], ["surface", "CELLULAR_COMPONENT", 35, 42], ["membrane", "CELLULAR_COMPONENT", 139, 147], ["heterologous proteins", "PROTEIN", 61, 82], ["Streak blot analysis tests", "TEST", 0, 26], ["the heterologous proteins", "PROBLEM", 57, 82], ["whole bacteria", "PROBLEM", 86, 100], ["the nitrocellulose membrane", "TREATMENT", 120, 147]]], ["The VV A27L, F13L, and A4L fusion proteins were expressed at high levels (Fig. 4) ; however, expression of D8L, L1R, and A33R was very low (not shown).", [["VV", "ORGANISM", 4, 6], ["A27L", "GENE_OR_GENE_PRODUCT", 7, 11], ["F13L", "GENE_OR_GENE_PRODUCT", 13, 17], ["A4L", "GENE_OR_GENE_PRODUCT", 23, 26], ["D8L", "GENE_OR_GENE_PRODUCT", 107, 110], ["L1R", "GENE_OR_GENE_PRODUCT", 112, 115], ["A33R", "GENE_OR_GENE_PRODUCT", 121, 125], ["VV A27L, F13L, and A4L fusion proteins", "PROTEIN", 4, 42], ["D8L", "PROTEIN", 107, 110], ["L1R", "PROTEIN", 112, 115], ["A33R", "PROTEIN", 121, 125], ["VV", "SPECIES", 4, 6], ["The VV A27L", "TEST", 0, 11], ["F13L", "TEST", 13, 17], ["A4L fusion proteins", "PROBLEM", 23, 42]]], ["These three proteins contain large hydrophobic regions that could interfere with the processing and anchoring mechanism, or secretion through the membrane of S. gordonii.", [["membrane", "ANATOMY", 146, 154], ["membrane", "CELLULAR_COMPONENT", 146, 154], ["S. gordonii", "ORGANISM", 158, 169], ["hydrophobic regions", "PROTEIN", 35, 54], ["S. gordonii", "SPECIES", 158, 169], ["S. gordonii", "SPECIES", 158, 169], ["large hydrophobic regions", "PROBLEM", 29, 54], ["large", "OBSERVATION_MODIFIER", 29, 34], ["hydrophobic regions", "OBSERVATION", 35, 54], ["gordonii", "OBSERVATION", 161, 169]]], ["When these hydrophobic regions were deleted, S. gordonii was able to efficiently express the truncated proteins.", [["S. gordonii", "ORGANISM", 45, 56], ["hydrophobic regions", "PROTEIN", 11, 30], ["truncated proteins", "PROTEIN", 93, 111], ["S. gordonii", "SPECIES", 45, 56], ["S. gordonii", "SPECIES", 45, 56], ["S. gordonii", "PROBLEM", 45, 56], ["the truncated proteins", "PROBLEM", 89, 111]]], ["Fig. 4 indicates that immunoreactive VV proteins can be expressed by S. gordonii.", [["VV", "GENE_OR_GENE_PRODUCT", 37, 39], ["S. gordonii", "ORGANISM", 69, 80], ["immunoreactive VV proteins", "PROTEIN", 22, 48], ["S. gordonii", "SPECIES", 69, 80], ["VV", "SPECIES", 37, 39], ["S. gordonii", "SPECIES", 69, 80], ["immunoreactive VV proteins", "PROBLEM", 22, 48]]], ["Preliminary experiments using the BCVDA27L VV recombinants indicate that BALB/c mice inoculated either subcutaneously or intranasally had significant levels of A27Lspecific serum IgG as well as salivary IgG and IgA antibodies.", [["subcutaneously", "ANATOMY", 103, 117], ["serum", "ANATOMY", 173, 178], ["BCVDA27L VV recombinants", "ORGANISM", 34, 58], ["BALB/c mice", "ORGANISM", 73, 84], ["serum", "ORGANISM_SUBSTANCE", 173, 178], ["IgG", "ORGANISM_SUBSTANCE", 179, 182], ["salivary IgG", "GENE_OR_GENE_PRODUCT", 194, 206], ["IgA antibodies", "GENE_OR_GENE_PRODUCT", 211, 225], ["A27Lspecific serum IgG", "PROTEIN", 160, 182], ["salivary IgG", "PROTEIN", 194, 206], ["IgA antibodies", "PROTEIN", 211, 225], ["mice", "SPECIES", 80, 84], ["VV", "SPECIES", 43, 45], ["mice", "SPECIES", 80, 84], ["the BCVDA27L VV recombinants", "TREATMENT", 30, 58], ["BALB/c mice", "TREATMENT", 73, 84], ["A27Lspecific serum IgG", "TEST", 160, 182], ["salivary IgG", "TEST", 194, 206], ["IgA antibodies", "TEST", 211, 225]]], ["In addition, neutralizing antibodies (antibodies capable of inhibiting vaccinia virus-infection of tissue culture cells) were present in the serum of vaccinated animals.", [["tissue culture cells", "ANATOMY", 99, 119], ["serum", "ANATOMY", 141, 146], ["infection", "DISEASE", 86, 95], ["vaccinia virus", "ORGANISM", 71, 85], ["tissue culture cells", "CELL", 99, 119], ["serum", "ORGANISM_SUBSTANCE", 141, 146], ["neutralizing antibodies", "PROTEIN", 13, 36], ["antibodies", "PROTEIN", 38, 48], ["vaccinia virus", "SPECIES", 71, 85], ["vaccinia virus", "SPECIES", 71, 85], ["neutralizing antibodies", "TEST", 13, 36], ["antibodies", "TEST", 38, 48], ["inhibiting vaccinia virus", "PROBLEM", 60, 85], ["infection of tissue culture cells", "PROBLEM", 86, 119], ["neutralizing antibodies", "OBSERVATION", 13, 36]]], ["Additional studies using other BCV/VV recombinants are in progress and will include challenge studies to assess whether the recombinants are capable of inducing protective immunity against vaccinia virus infection.Animal immunizationThe BALB/c mouse model for vaccinia virus challenge is an excellent system in which to study vaccines for their potential to prevent smallpox.", [["vaccinia virus infection", "DISEASE", 189, 213], ["smallpox", "DISEASE", 366, 374], ["BCV/VV recombinants", "ORGANISM", 31, 50], ["vaccinia virus", "ORGANISM", 189, 203], ["BALB/c mouse", "ORGANISM", 237, 249], ["vaccinia virus", "ORGANISM", 260, 274], ["vaccinia virus", "SPECIES", 189, 203], ["mouse", "SPECIES", 244, 249], ["VV", "SPECIES", 35, 37], ["vaccinia virus", "SPECIES", 189, 203], ["mouse", "SPECIES", 244, 249], ["vaccinia virus", "SPECIES", 260, 274], ["Additional studies", "TEST", 0, 18], ["other BCV/VV recombinants", "TREATMENT", 25, 50], ["challenge studies", "TEST", 84, 101], ["vaccinia virus infection", "PROBLEM", 189, 213], ["Animal immunization", "TREATMENT", 214, 233], ["The BALB/c mouse model", "TREATMENT", 233, 255], ["vaccinia virus challenge", "TREATMENT", 260, 284], ["study vaccines", "TREATMENT", 320, 334], ["smallpox", "PROBLEM", 366, 374], ["smallpox", "OBSERVATION", 366, 374]]], ["However, because of the high degree of homology among the orthopoxvirus, several additional animal models using other orthopoxvirus can also provide important information.", [["the high degree of homology among the orthopoxvirus", "PROBLEM", 20, 71], ["other orthopoxvirus", "TREATMENT", 112, 131]]], ["Smallpox is a respiratory pathogen acquired by aerosolized virus.", [["respiratory pathogen", "DISEASE", 14, 34], ["a respiratory pathogen", "PROBLEM", 12, 34], ["aerosolized virus", "PROBLEM", 47, 64], ["respiratory pathogen", "OBSERVATION", 14, 34], ["aerosolized virus", "OBSERVATION", 47, 64]]], ["Cowpox virus can efficiently infect BALB/c mice by aerosol administration and, as such, can be used to evaluate the efficacy of smallpox vaccines in preventing lethal respiratory infections.", [["respiratory", "ANATOMY", 167, 178], ["respiratory infections", "DISEASE", 167, 189], ["Cowpox virus", "ORGANISM", 0, 12], ["BALB/c mice", "ORGANISM", 36, 47], ["mice", "SPECIES", 43, 47], ["Cowpox virus", "SPECIES", 0, 12], ["mice", "SPECIES", 43, 47], ["Cowpox virus", "PROBLEM", 0, 12], ["aerosol administration", "TREATMENT", 51, 73], ["smallpox vaccines", "TREATMENT", 128, 145], ["lethal respiratory infections", "PROBLEM", 160, 189], ["respiratory", "ANATOMY", 167, 178], ["infections", "OBSERVATION", 179, 189]]], ["Perhaps the most rigorous model for testing candidate smallpox vaccines is the monkeypox model used in Rhesus macaques.", [["monkeypox", "ORGANISM", 79, 88], ["Rhesus macaques", "ORGANISM", 103, 118], ["Rhesus macaques", "SPECIES", 103, 118], ["Rhesus macaques", "SPECIES", 103, 118], ["smallpox vaccines", "TREATMENT", 54, 71], ["the monkeypox model", "TREATMENT", 75, 94]]], ["Monkeypox is an orthopoxvirus that infects monkeys and sometimes humans and is over 85% homologous to the variola major genome [42] .", [["Monkeypox", "CHEMICAL", 0, 9], ["Monkeypox", "GENE_OR_GENE_PRODUCT", 0, 9], ["monkeys", "ORGANISM", 43, 50], ["humans", "ORGANISM", 65, 71], ["variola major genome", "DNA", 106, 126], ["monkeys", "SPECIES", 43, 50], ["humans", "SPECIES", 65, 71], ["humans", "SPECIES", 65, 71], ["an orthopoxvirus", "TREATMENT", 13, 29]]], ["This model has also been used to evaluate the efficacy of vaccines against smallpox.Challenges facing BW vaccine developmentRegardless of the technology employed, commercial development of vaccines against potential biowarfare pathogens will be a challenge for a number of reasons.", [["smallpox", "DISEASE", 75, 83], ["vaccines", "TREATMENT", 58, 66], ["smallpox", "PROBLEM", 75, 83], ["vaccines", "TREATMENT", 189, 197], ["potential biowarfare pathogens", "PROBLEM", 206, 236]]], ["Given the political nature of the funding process, it is not known how long, or to what level funding will be available.", [["funding", "OBSERVATION", 34, 41]]], ["Third, there is the paucity of BSL-3 and BSL-4 laboratories available to use for the animal challenge experiments, as well as the experts to conduct the experiments.", [["BSL-3", "GENE_OR_GENE_PRODUCT", 31, 36], ["BSL", "TEST", 31, 34], ["BSL", "TEST", 41, 44], ["the animal challenge experiments", "TREATMENT", 81, 113], ["paucity", "OBSERVATION_MODIFIER", 20, 27]]], ["Fourth, there are the unanswered regulatory questions of what will be required in order to license a vaccine for human use.", [["human", "ORGANISM", 113, 118], ["human", "SPECIES", 113, 118], ["human", "SPECIES", 113, 118]]], ["Who will be the consumer and how will they pay for the costs of the vaccine and its development?", [["the vaccine", "TREATMENT", 64, 75]]], ["Recombinant clones expressing the indicated full-length or deleted VV proteins, or the S. pyogenes M protein alone, were streaked onto a bacterial plate, lifted onto a nitrocellulose membrane and probed with monospecific antisera to the M protein to verify surface expression of fusion protein.", [["clones", "ANATOMY", 12, 18], ["membrane", "ANATOMY", 183, 191], ["surface", "ANATOMY", 257, 264], ["nitrocellulose", "CHEMICAL", 168, 182], ["S. pyogenes", "ORGANISM", 87, 98], ["membrane", "CELLULAR_COMPONENT", 183, 191], ["surface", "CELLULAR_COMPONENT", 257, 264], ["VV proteins", "PROTEIN", 67, 78], ["S. pyogenes M protein", "PROTEIN", 87, 108], ["M protein", "PROTEIN", 237, 246], ["fusion protein", "PROTEIN", 279, 293], ["S. pyogenes", "SPECIES", 87, 98], ["VV", "SPECIES", 67, 69], ["S. pyogenes", "SPECIES", 87, 98], ["Recombinant clones", "PROBLEM", 0, 18], ["deleted VV proteins", "PROBLEM", 59, 78], ["a bacterial plate", "TREATMENT", 135, 152], ["a nitrocellulose membrane", "TREATMENT", 166, 191], ["monospecific antisera", "TREATMENT", 208, 229], ["the M protein", "TREATMENT", 233, 246], ["fusion protein", "PROBLEM", 279, 293], ["bacterial plate", "OBSERVATION", 137, 152], ["fusion protein", "OBSERVATION", 279, 293]]]], "PMC7153435": [["Box 3\u2002The Flint Water Crisis ::: IntroductionThis event is considered a disaster, still unfolding, initiated from a political decision to save money, and ending up with acute and chronic illnesses and deaths to residents of a Michigan city, as well as high system remediation and health-related costs to the taxpayer.", [["deaths", "DISEASE", 201, 207], ["acute and chronic illnesses", "PROBLEM", 169, 196], ["high system remediation", "TREATMENT", 252, 275], ["chronic", "OBSERVATION_MODIFIER", 179, 186], ["illnesses", "OBSERVATION", 187, 196]]], ["This was to be an interim measure until a new pipeline from Lake Huron was constructed in 2016 to serve the region.", [["Lake Huron", "TREATMENT", 60, 70]]], ["Soon after the switch, residents begin to complain about the water\u2019s color, taste and odor, and to report rashes and concerns about bacteria.", [["rashes", "DISEASE", 106, 112], ["odor", "PROBLEM", 86, 90], ["rashes", "PROBLEM", 106, 112], ["bacteria", "PROBLEM", 132, 140]]], ["In August and September 2014 city officials issued boil-water advisories after coliform bacteria were detected in tap water.", [["coliform bacteria", "PROBLEM", 79, 96]]], ["On January 4, 2015, the city announced that Flint\u2019s water contained a high level of trihalomethanes, a byproduct from increased disinfection by the city.", [["trihalomethanes", "CHEMICAL", 84, 99], ["trihalomethanes", "CHEMICAL", 84, 99], ["trihalomethanes", "SIMPLE_CHEMICAL", 84, 99], ["increased disinfection", "PROBLEM", 118, 140], ["increased", "OBSERVATION_MODIFIER", 118, 127], ["disinfection", "OBSERVATION", 128, 140]]], ["In January 2015, Detroit\u2019s water system offered to reconnect to Flint, waiving a $4 million connection fee but the offer was declined by the emergency manager.", [["a $4 million connection fee", "TREATMENT", 79, 106]]], ["The EPA does not require action until levels reach 15 parts per billion, but science indicates that there is no safe level for lead in potable water.", [["EPA", "CHEMICAL", 4, 7], ["EPA", "CHEMICAL", 4, 7], ["EPA", "SIMPLE_CHEMICAL", 4, 7]]], ["Officials from EPA and MDEQ discussed the lead level in the sample, and EPA found that the State was testing the water in a way that could profoundly understate the lead levels.", [["EPA", "CHEMICAL", 72, 75]]], ["On March 3, 2015, a second testing detected 397 ppb of lead in Flint drinking water.", [["a second testing", "TEST", 18, 34]]], ["In May, tests revealed high lead levels in two more homes in Flint.", [["tests", "TEST", 8, 13], ["high lead levels", "PROBLEM", 23, 39], ["high lead", "OBSERVATION", 23, 32]]], ["However, in September, Flint was asked to stop using the Flint water supply or consider corrosion control for it, because it was causing lead to leach from the water pipes and children had high levels in their blood.", [["blood", "ANATOMY", 210, 215], ["children", "ORGANISM", 176, 184], ["blood", "ORGANISM_SUBSTANCE", 210, 215], ["children", "SPECIES", 176, 184], ["the Flint water supply", "TREATMENT", 53, 75], ["corrosion control", "TREATMENT", 88, 105], ["the water pipes", "TREATMENT", 156, 171], ["high levels in their blood", "PROBLEM", 189, 215]]], ["Nevertheless, on October 1, the Governor of Michigan ordered the distribution of filters, the testing of water in schools, and the expansion of water and blood testing after a briefing on the lead problems with the MDEQ and federal officials.", [["blood", "ANATOMY", 154, 159], ["blood", "ORGANISM_SUBSTANCE", 154, 159], ["blood testing", "TEST", 154, 167]]], ["On October 19, the Director of MDEQ reported that his staff had used inappropriate federal protocol for corrosion control, and soon after, the Governor announced that an independent advisory task force would review water use and testing in Flint.", [["inappropriate federal protocol", "TREATMENT", 69, 99], ["corrosion control", "TREATMENT", 104, 121]]], ["On December 9 Flint added additional corrosion controls, and soon after an emergency was declared.", [["additional corrosion controls", "TREATMENT", 26, 55]]], ["On January 16, 2016, the Governor asked the National Guard to distribute bottled water and filters in Flint, and President Obama declared a state of emergency in the city and surrounding county, allowing the Federal Emergency Management Agency to provide up to $5 million in aid.Box 3\u2002The Flint Water Crisis ::: IntroductionThree days earlier the crisis expanded to include Legionnaires\u2019 disease, because of a spike in cases, including ten deaths, after the city started using river water.", [["Legionnaires\u2019 disease", "DISEASE", 374, 395], ["deaths", "DISEASE", 440, 446], ["the crisis", "PROBLEM", 343, 353], ["Legionnaires\u2019 disease", "PROBLEM", 374, 395], ["a spike in cases", "PROBLEM", 408, 424]]], ["On January 21, the Michigan Department of Health and Human Services stated it did not have enough information to conclude that the increase in cases was related to the ongoing Flint water crisis, although the. head of Michigan\u2019s Communicable Disease Division had said three months earlier that the number of Legionella cases at that time \u201clikely represents the tip of the iceberg.\u201d", [["head", "ANATOMY", 210, 214], ["Legionella", "DISEASE", 308, 318], ["Human", "ORGANISM", 53, 58], ["head", "ORGANISM_SUBDIVISION", 210, 214], ["Human", "SPECIES", 53, 58], ["the ongoing Flint water crisis", "PROBLEM", 164, 194], ["Legionella cases", "PROBLEM", 308, 324], ["water crisis", "OBSERVATION", 182, 194], ["Legionella", "OBSERVATION", 308, 318], ["likely represents", "UNCERTAINTY", 339, 356], ["tip", "OBSERVATION_MODIFIER", 361, 364], ["iceberg", "OBSERVATION", 372, 379]]], ["A Flint hospital official was surprised that Michigan and local health agencies did not inform the public about the Legionnaires\u2019 outbreak in Genesee County in 2014\u201315 until January 13; the hospital earlier had spent more than $300,000 on a water treatment system and bought bottled water for patients.", [["Legionnaires\u2019 outbreak", "DISEASE", 116, 138], ["patients", "ORGANISM", 293, 301], ["patients", "SPECIES", 293, 301], ["a water treatment system", "TREATMENT", 239, 263]]], ["The source of Legionella is not known but it was likely in the Flint River, and possibly extensive flushing of Flint\u2019s colored water, which had undesirable odors and tastes, by residents may have caused chlorine residual in the pipes to be washed away, leaving the pipes susceptible to growth of the Legionella; in addition, aerosols from the extensive flushing from turned-on faucets might have led to close contact between the residents and the pathogen.", [["chlorine", "CHEMICAL", 203, 211], ["Legionella", "DISEASE", 300, 310], ["chlorine", "CHEMICAL", 203, 211], ["chlorine", "SIMPLE_CHEMICAL", 203, 211], ["Legionella", "PROBLEM", 14, 24], ["extensive flushing of Flint\u2019s colored water", "PROBLEM", 89, 132], ["chlorine residual in the pipes", "PROBLEM", 203, 233], ["the Legionella", "PROBLEM", 296, 310], ["aerosols", "TREATMENT", 325, 333], ["the extensive flushing", "TREATMENT", 339, 361], ["faucets", "TREATMENT", 377, 384], ["the pathogen", "PROBLEM", 443, 455], ["Legionella", "OBSERVATION", 14, 24], ["possibly", "UNCERTAINTY", 80, 88], ["extensive", "OBSERVATION_MODIFIER", 89, 98], ["flushing", "OBSERVATION_MODIFIER", 99, 107], ["chlorine residual", "OBSERVATION", 203, 220], ["Legionella", "OBSERVATION", 300, 310], ["extensive", "OBSERVATION_MODIFIER", 343, 352], ["flushing", "OBSERVATION", 353, 361]]], ["The investigation of the cause of the illnesses continues with criminal charges laid against Michigan departmental employees.Box 3\u2002The Flint Water Crisis ::: IntroductionOften when an outbreak is first suspected, the source is not clear, i.e., food, water, animal contact.", [["the illnesses", "PROBLEM", 34, 47], ["IntroductionOften", "TREATMENT", 158, 175]]], ["Investigators have to keep an open mind until laboratory and/or epidemiologic evidence links cases to the primary source.Box 3\u2002The Flint Water Crisis ::: IntroductionAlthough we frequently think of waterborne illness originating from a microbiological agent, we should be aware that water may also be contaminated by pesticides, fertilizers, and other chemicals which may enter through industrial discharge, agriculture runoff, or deliberate contamination.Box 3\u2002The Flint Water Crisis ::: IntroductionWaterborne illness acquired from microorganisms may be classified as:Toxin-mediated infections caused by bacteria that produce enterotoxins or emetic toxins that affect water, glucose, and electrolyte transfer during their colonization and growth in the intestinal tract;Infections caused when microorganisms invade and multiply in the intestinal mucosa, eyes, ears, or respiratory tract, or contact the skin;Intoxications caused by ingestion of water containing poisonous chemicals or toxins produced by other microorganisms", [["intestinal tract", "ANATOMY", 755, 771], ["intestinal mucosa", "ANATOMY", 837, 854], ["eyes", "ANATOMY", 856, 860], ["ears", "ANATOMY", 862, 866], ["respiratory tract", "ANATOMY", 871, 888], ["skin", "ANATOMY", 905, 909], ["waterborne illness", "DISEASE", 198, 216], ["Waterborne illness", "DISEASE", 501, 519], ["infections", "DISEASE", 585, 595], ["glucose", "CHEMICAL", 677, 684], ["Infections", "DISEASE", 772, 782], ["glucose", "CHEMICAL", 677, 684], ["Toxin", "GENE_OR_GENE_PRODUCT", 570, 575], ["water", "SIMPLE_CHEMICAL", 670, 675], ["glucose", "SIMPLE_CHEMICAL", 677, 684], ["electrolyte", "SIMPLE_CHEMICAL", 690, 701], ["intestinal tract", "ORGANISM_SUBDIVISION", 755, 771], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 837, 854], ["eyes", "ORGAN", 856, 860], ["ears", "ORGAN", 862, 866], ["respiratory tract", "ORGANISM_SUBDIVISION", 871, 888], ["skin", "ORGAN", 905, 909], ["waterborne illness", "PROBLEM", 198, 216], ["a microbiological agent", "TREATMENT", 234, 257], ["fertilizers", "TREATMENT", 329, 340], ["agriculture runoff", "TREATMENT", 408, 426], ["deliberate contamination", "PROBLEM", 431, 455], ["IntroductionWaterborne illness", "PROBLEM", 489, 519], ["microorganisms", "PROBLEM", 534, 548], ["Toxin-mediated infections", "PROBLEM", 570, 595], ["bacteria", "PROBLEM", 606, 614], ["enterotoxins", "PROBLEM", 628, 640], ["emetic toxins", "PROBLEM", 644, 657], ["glucose", "TEST", 677, 684], ["electrolyte transfer", "TREATMENT", 690, 710], ["their colonization", "PROBLEM", 718, 736], ["growth in the intestinal tract", "PROBLEM", 741, 771], ["Infections", "PROBLEM", 772, 782], ["microorganisms invade", "PROBLEM", 795, 816], ["eyes, ears, or respiratory tract", "PROBLEM", 856, 888], ["Intoxications", "PROBLEM", 910, 923], ["toxins", "PROBLEM", 987, 993], ["intestinal tract", "ANATOMY", 755, 771], ["intestinal mucosa", "ANATOMY", 837, 854], ["eyes", "ANATOMY", 856, 860], ["ears", "ANATOMY", 862, 866], ["respiratory tract", "ANATOMY", 871, 888], ["skin", "ANATOMY", 905, 909]]]], "PMC7199914": [["IntroductionThis forum article reviews the multifaceted relationship of clozapine and inflammation and its impact on the clinical care of patients.", [["clozapine", "CHEMICAL", 72, 81], ["inflammation", "DISEASE", 86, 98], ["clozapine", "CHEMICAL", 72, 81], ["clozapine", "SIMPLE_CHEMICAL", 72, 81], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["clozapine", "TREATMENT", 72, 81], ["inflammation", "PROBLEM", 86, 98], ["inflammation", "OBSERVATION", 86, 98]]], ["After briefly reviewing clozapine metabolism, four major topics are discussed: (1) inflammation can increase clozapine levels; (2) clozapine can cause inflammation, particularly during titration; (3) clozapine may increase the risk of infection; and (4) more specifically, clozapine may be particularly strongly associated with the risk of pneumonia.IntroductionThis data provides a consistent pattern, but the studies are limited by their observational nature.", [["clozapine", "CHEMICAL", 24, 33], ["inflammation", "DISEASE", 83, 95], ["clozapine", "CHEMICAL", 109, 118], ["clozapine", "CHEMICAL", 131, 140], ["inflammation", "DISEASE", 151, 163], ["clozapine", "CHEMICAL", 200, 209], ["infection", "DISEASE", 235, 244], ["clozapine", "CHEMICAL", 273, 282], ["pneumonia", "DISEASE", 340, 349], ["clozapine", "CHEMICAL", 24, 33], ["clozapine", "CHEMICAL", 109, 118], ["clozapine", "CHEMICAL", 131, 140], ["clozapine", "CHEMICAL", 200, 209], ["clozapine", "CHEMICAL", 273, 282], ["clozapine", "SIMPLE_CHEMICAL", 24, 33], ["clozapine", "SIMPLE_CHEMICAL", 109, 118], ["clozapine", "SIMPLE_CHEMICAL", 131, 140], ["clozapine", "SIMPLE_CHEMICAL", 200, 209], ["clozapine", "SIMPLE_CHEMICAL", 273, 282], ["clozapine metabolism", "TREATMENT", 24, 44], ["inflammation", "PROBLEM", 83, 95], ["clozapine levels", "TREATMENT", 109, 125], ["clozapine", "TREATMENT", 131, 140], ["inflammation", "PROBLEM", 151, 163], ["clozapine", "TREATMENT", 200, 209], ["infection", "PROBLEM", 235, 244], ["clozapine", "TREATMENT", 273, 282], ["pneumonia", "PROBLEM", 340, 349], ["the studies", "TEST", 407, 418], ["inflammation", "OBSERVATION", 151, 163], ["infection", "OBSERVATION", 235, 244], ["pneumonia", "OBSERVATION", 340, 349]]], ["Obviously for ethical reasons, it is not possible to randomise clozapine patients to infections versus placebo.IntroductionThere is no data on COVID-19 in clozapine patients, but based on what we know about clozapine pharmacology, we can hypothesise that clozapine, possibly by impairing immunological mechanisms, may increase the risk of pneumonia in infected patients.", [["clozapine", "CHEMICAL", 63, 72], ["infections", "DISEASE", 85, 95], ["clozapine", "CHEMICAL", 155, 164], ["clozapine", "CHEMICAL", 207, 216], ["clozapine", "CHEMICAL", 255, 264], ["pneumonia", "DISEASE", 339, 348], ["clozapine", "CHEMICAL", 63, 72], ["COVID-19", "CHEMICAL", 143, 151], ["clozapine", "CHEMICAL", 155, 164], ["clozapine", "CHEMICAL", 207, 216], ["clozapine", "CHEMICAL", 255, 264], ["patients", "ORGANISM", 73, 81], ["clozapine", "SIMPLE_CHEMICAL", 155, 164], ["patients", "ORGANISM", 165, 173], ["clozapine", "SIMPLE_CHEMICAL", 207, 216], ["clozapine", "SIMPLE_CHEMICAL", 255, 264], ["patients", "ORGANISM", 361, 369], ["patients", "SPECIES", 73, 81], ["patients", "SPECIES", 165, 173], ["patients", "SPECIES", 361, 369], ["clozapine", "TREATMENT", 63, 72], ["infections", "PROBLEM", 85, 95], ["placebo", "TREATMENT", 103, 110], ["COVID", "TEST", 143, 148], ["clozapine", "TREATMENT", 155, 164], ["clozapine pharmacology", "TREATMENT", 207, 229], ["clozapine", "TREATMENT", 255, 264], ["pneumonia", "PROBLEM", 339, 348], ["not possible", "UNCERTAINTY", 37, 49], ["no", "UNCERTAINTY", 132, 134], ["pneumonia", "OBSERVATION", 339, 348], ["infected", "OBSERVATION_MODIFIER", 352, 360]]], ["More importantly, once fever and/or pneumonia develops, the clozapine dose should be cut in half to decrease the risk of clozapine intoxication.", [["fever", "DISEASE", 23, 28], ["pneumonia", "DISEASE", 36, 45], ["clozapine", "CHEMICAL", 60, 69], ["clozapine", "CHEMICAL", 121, 130], ["clozapine", "CHEMICAL", 60, 69], ["clozapine", "CHEMICAL", 121, 130], ["clozapine", "SIMPLE_CHEMICAL", 60, 69], ["clozapine", "SIMPLE_CHEMICAL", 121, 130], ["fever", "PROBLEM", 23, 28], ["pneumonia", "PROBLEM", 36, 45], ["the clozapine dose", "TREATMENT", 56, 74], ["clozapine intoxication", "PROBLEM", 121, 143], ["pneumonia", "OBSERVATION", 36, 45], ["clozapine intoxication", "OBSERVATION", 121, 143]]], ["If there is any doubt that in spite of halving the dose there are still signs of clozapine intoxication, completely stopping clozapine may be indicated.", [["clozapine", "CHEMICAL", 81, 90], ["clozapine", "CHEMICAL", 125, 134], ["clozapine", "CHEMICAL", 81, 90], ["clozapine", "CHEMICAL", 125, 134], ["clozapine", "SIMPLE_CHEMICAL", 81, 90], ["clozapine", "SIMPLE_CHEMICAL", 125, 134], ["clozapine intoxication", "PROBLEM", 81, 103], ["clozapine", "TREATMENT", 125, 134]]], ["Once the signs of inflammation and fever have disappeared, the clozapine dose can be increased to the prior dosage level.Clozapine metabolismIn 1989 before pharmacokinetic studies were required, the United States (US) Food and Drug Administration (FDA) approved clozapine with very limited information on clozapine metabolism.", [["inflammation", "DISEASE", 18, 30], ["fever", "DISEASE", 35, 40], ["clozapine", "CHEMICAL", 63, 72], ["Clozapine", "CHEMICAL", 121, 130], ["clozapine", "CHEMICAL", 262, 271], ["clozapine", "CHEMICAL", 305, 314], ["clozapine", "CHEMICAL", 63, 72], ["Clozapine", "CHEMICAL", 121, 130], ["clozapine", "CHEMICAL", 262, 271], ["clozapine", "CHEMICAL", 305, 314], ["clozapine", "SIMPLE_CHEMICAL", 63, 72], ["clozapine", "SIMPLE_CHEMICAL", 262, 271], ["clozapine", "SIMPLE_CHEMICAL", 305, 314], ["inflammation", "PROBLEM", 18, 30], ["fever", "PROBLEM", 35, 40], ["the clozapine dose", "TREATMENT", 59, 77], ["Clozapine metabolismIn", "TREATMENT", 121, 143], ["pharmacokinetic studies", "TEST", 156, 179], ["Drug Administration (FDA)", "TREATMENT", 227, 252], ["clozapine", "TREATMENT", 262, 271], ["clozapine metabolism", "TREATMENT", 305, 325], ["inflammation", "OBSERVATION", 18, 30], ["fever", "OBSERVATION", 35, 40]]], ["In 1994, Bertilsson et al1 described CYP1A2 as its major metabolic pathway.", [["CYP1A2", "GENE_OR_GENE_PRODUCT", 37, 43], ["CYP1A2", "PROTEIN", 37, 43]]], ["CYP1A2 pharmacology is highly relevant in clozapine dosing.", [["clozapine", "CHEMICAL", 42, 51], ["clozapine", "CHEMICAL", 42, 51], ["CYP1A2", "GENE_OR_GENE_PRODUCT", 0, 6], ["clozapine", "SIMPLE_CHEMICAL", 42, 51], ["CYP1A2", "PROTEIN", 0, 6], ["CYP1A2 pharmacology", "TEST", 0, 19], ["clozapine dosing", "TREATMENT", 42, 58]]], ["Norclozapine is the main metabolite of clozapine and appears to be mainly eliminated by the kidney, since its conjugated metabolites are present in the urine and the serum free norclozapine is excreted by an unknown renal transporter that can be inhibited by gemfibrozil.", [["kidney", "ANATOMY", 92, 98], ["urine", "ANATOMY", 152, 157], ["serum", "ANATOMY", 166, 171], ["renal", "ANATOMY", 216, 221], ["Norclozapine", "CHEMICAL", 0, 12], ["clozapine", "CHEMICAL", 39, 48], ["norclozapine", "CHEMICAL", 177, 189], ["gemfibrozil", "CHEMICAL", 259, 270], ["Norclozapine", "CHEMICAL", 0, 12], ["clozapine", "CHEMICAL", 39, 48], ["norclozapine", "CHEMICAL", 177, 189], ["gemfibrozil", "CHEMICAL", 259, 270], ["Norclozapine", "SIMPLE_CHEMICAL", 0, 12], ["clozapine", "SIMPLE_CHEMICAL", 39, 48], ["kidney", "ORGAN", 92, 98], ["urine", "ORGANISM_SUBSTANCE", 152, 157], ["serum", "ORGANISM_SUBSTANCE", 166, 171], ["norclozapine", "SIMPLE_CHEMICAL", 177, 189], ["renal", "ORGAN", 216, 221], ["gemfibrozil", "SIMPLE_CHEMICAL", 259, 270], ["renal transporter", "PROTEIN", 216, 233], ["Norclozapine", "TREATMENT", 0, 12], ["clozapine", "TREATMENT", 39, 48], ["the urine", "TEST", 148, 157], ["the serum free norclozapine", "TEST", 162, 189], ["gemfibrozil", "TREATMENT", 259, 270], ["appears to be", "UNCERTAINTY", 53, 66], ["kidney", "ANATOMY", 92, 98]]], ["With geriatric age, clozapine clearance from the body decreases; this is probably explained by the decrease in renal function and subsequent decrease in renal clearance of norclozapine and other metabolites eliminated in the urine.Clozapine metabolismTobacco smoke has polycyclic aromatic hydrocarbons which bind to the aryl hydrocarbon receptor and induce CYP1A2 expression, increasing the levels of CYP1A2, which is mainly expressed in the liver.", [["body", "ANATOMY", 49, 53], ["renal", "ANATOMY", 111, 116], ["renal", "ANATOMY", 153, 158], ["urine", "ANATOMY", 225, 230], ["liver", "ANATOMY", 442, 447], ["clozapine", "CHEMICAL", 20, 29], ["norclozapine", "CHEMICAL", 172, 184], ["Clozapine", "CHEMICAL", 231, 240], ["polycyclic aromatic hydrocarbons", "CHEMICAL", 269, 301], ["clozapine", "CHEMICAL", 20, 29], ["norclozapine", "CHEMICAL", 172, 184], ["Clozapine", "CHEMICAL", 231, 240], ["polycyclic aromatic hydrocarbons", "CHEMICAL", 269, 301], ["aryl hydrocarbon", "CHEMICAL", 320, 336], ["clozapine", "SIMPLE_CHEMICAL", 20, 29], ["body", "ORGANISM_SUBDIVISION", 49, 53], ["renal", "ORGAN", 111, 116], ["renal", "ORGAN", 153, 158], ["norclozapine", "SIMPLE_CHEMICAL", 172, 184], ["urine", "ORGANISM_SUBSTANCE", 225, 230], ["Clozapine", "SIMPLE_CHEMICAL", 231, 240], ["polycyclic aromatic hydrocarbons", "SIMPLE_CHEMICAL", 269, 301], ["aryl hydrocarbon receptor", "GENE_OR_GENE_PRODUCT", 320, 345], ["CYP1A2", "GENE_OR_GENE_PRODUCT", 357, 363], ["CYP1A2", "GENE_OR_GENE_PRODUCT", 401, 407], ["liver", "ORGAN", 442, 447], ["aryl hydrocarbon receptor", "PROTEIN", 320, 345], ["CYP1A2", "PROTEIN", 357, 363], ["CYP1A2", "PROTEIN", 401, 407], ["clozapine clearance", "TREATMENT", 20, 39], ["the decrease in renal function", "PROBLEM", 95, 125], ["renal clearance of norclozapine", "TREATMENT", 153, 184], ["other metabolites", "PROBLEM", 189, 206], ["the urine", "TEST", 221, 230], ["Clozapine metabolismTobacco smoke", "TREATMENT", 231, 264], ["polycyclic aromatic hydrocarbons", "TREATMENT", 269, 301], ["the aryl hydrocarbon receptor", "TREATMENT", 316, 345], ["CYP1A2 expression", "TEST", 357, 374], ["probably explained", "UNCERTAINTY", 73, 91], ["decrease", "OBSERVATION_MODIFIER", 99, 107], ["renal", "ANATOMY", 111, 116], ["function", "OBSERVATION", 117, 125], ["decrease", "OBSERVATION_MODIFIER", 141, 149], ["renal", "ANATOMY", 153, 158], ["clearance", "OBSERVATION", 159, 168], ["polycyclic", "OBSERVATION", 269, 279], ["aromatic hydrocarbons", "OBSERVATION", 280, 301], ["CYP1A2 expression", "OBSERVATION", 357, 374], ["increasing", "OBSERVATION_MODIFIER", 376, 386], ["CYP1A2", "ANATOMY", 401, 407], ["liver", "ANATOMY", 442, 447]]], ["Therefore, smokers tend to have serum concentration values that are approximately 0.80 that of non-smokers when using the same clozapine dose.2 Conversely, oestrogens have inhibitory effects on CYP1A2 activity.", [["serum", "ANATOMY", 32, 37], ["clozapine", "CHEMICAL", 127, 136], ["oestrogens", "CHEMICAL", 156, 166], ["clozapine", "CHEMICAL", 127, 136], ["oestrogens", "CHEMICAL", 156, 166], ["smokers", "ORGANISM", 11, 18], ["serum", "ORGANISM_SUBSTANCE", 32, 37], ["clozapine", "SIMPLE_CHEMICAL", 127, 136], ["oestrogens", "SIMPLE_CHEMICAL", 156, 166], ["CYP1A2", "GENE_OR_GENE_PRODUCT", 194, 200], ["CYP1A2", "PROTEIN", 194, 200], ["serum concentration values", "TEST", 32, 58], ["the same clozapine dose", "TREATMENT", 118, 141], ["CYP1A2 activity", "TREATMENT", 194, 209]]], ["Male patients, then, tend to have serum concentration values that are approximately 0.86 that of females when using the same clozapine dose.2 Co-medication with inducers such as carbamazepine, phenytoin or rifampicin increase clozapine metabolism and decrease clozapine levels.", [["serum", "ANATOMY", 34, 39], ["clozapine", "CHEMICAL", 125, 134], ["carbamazepine", "CHEMICAL", 178, 191], ["phenytoin", "CHEMICAL", 193, 202], ["rifampicin", "CHEMICAL", 206, 216], ["clozapine", "CHEMICAL", 226, 235], ["clozapine", "CHEMICAL", 260, 269], ["clozapine", "CHEMICAL", 125, 134], ["carbamazepine", "CHEMICAL", 178, 191], ["phenytoin", "CHEMICAL", 193, 202], ["rifampicin", "CHEMICAL", 206, 216], ["clozapine", "CHEMICAL", 226, 235], ["clozapine", "CHEMICAL", 260, 269], ["patients", "ORGANISM", 5, 13], ["serum", "ORGANISM_SUBSTANCE", 34, 39], ["clozapine", "SIMPLE_CHEMICAL", 125, 134], ["carbamazepine", "SIMPLE_CHEMICAL", 178, 191], ["phenytoin", "SIMPLE_CHEMICAL", 193, 202], ["rifampicin", "SIMPLE_CHEMICAL", 206, 216], ["clozapine", "SIMPLE_CHEMICAL", 226, 235], ["clozapine", "SIMPLE_CHEMICAL", 260, 269], ["patients", "SPECIES", 5, 13], ["serum concentration values", "TEST", 34, 60], ["the same clozapine dose", "TREATMENT", 116, 139], ["inducers", "TREATMENT", 161, 169], ["carbamazepine", "TREATMENT", 178, 191], ["phenytoin", "TREATMENT", 193, 202], ["rifampicin", "TREATMENT", 206, 216], ["clozapine metabolism", "TREATMENT", 226, 246], ["clozapine levels", "TEST", 260, 276]]], ["The most important inhibitors of clozapine metabolism are ciprofloxacin, oral contraceptives, fluvoxamine and caffeine in high doses.", [["oral", "ANATOMY", 73, 77], ["clozapine", "CHEMICAL", 33, 42], ["ciprofloxacin", "CHEMICAL", 58, 71], ["oral contraceptives", "CHEMICAL", 73, 92], ["fluvoxamine", "CHEMICAL", 94, 105], ["caffeine", "CHEMICAL", 110, 118], ["clozapine", "CHEMICAL", 33, 42], ["ciprofloxacin", "CHEMICAL", 58, 71], ["fluvoxamine", "CHEMICAL", 94, 105], ["caffeine", "CHEMICAL", 110, 118], ["clozapine", "SIMPLE_CHEMICAL", 33, 42], ["ciprofloxacin", "SIMPLE_CHEMICAL", 58, 71], ["oral", "ORGANISM_SUBDIVISION", 73, 77], ["fluvoxamine", "SIMPLE_CHEMICAL", 94, 105], ["caffeine", "SIMPLE_CHEMICAL", 110, 118], ["clozapine metabolism", "TREATMENT", 33, 53], ["ciprofloxacin", "TREATMENT", 58, 71], ["oral contraceptives", "TREATMENT", 73, 92], ["fluvoxamine", "TREATMENT", 94, 105], ["caffeine", "TREATMENT", 110, 118]]], ["Valproic acid can be an inducer and/or an inhibitor of clozapine metabolism; this varies from patient to patient and over time.", [["Valproic acid", "CHEMICAL", 0, 13], ["clozapine", "CHEMICAL", 55, 64], ["Valproic acid", "CHEMICAL", 0, 13], ["clozapine", "CHEMICAL", 55, 64], ["Valproic acid", "SIMPLE_CHEMICAL", 0, 13], ["clozapine", "SIMPLE_CHEMICAL", 55, 64], ["patient", "ORGANISM", 94, 101], ["patient", "ORGANISM", 105, 112], ["patient", "SPECIES", 94, 101], ["patient", "SPECIES", 105, 112], ["Valproic acid", "TREATMENT", 0, 13], ["an inducer", "TREATMENT", 21, 31], ["an inhibitor of clozapine metabolism", "TREATMENT", 39, 75]]], ["During clozapine titration, clinicians should be more concerned about the potential of valproic acid to act as an inhibitor.Clozapine metabolismClozapine is prone to cause side effects, called adverse drug reactions (ADRs) by pharmacologists.", [["clozapine", "CHEMICAL", 7, 16], ["valproic acid", "CHEMICAL", 87, 100], ["Clozapine", "CHEMICAL", 124, 133], ["metabolismClozapine", "CHEMICAL", 134, 153], ["adverse drug reactions", "DISEASE", 193, 215], ["ADRs", "DISEASE", 217, 221], ["clozapine", "CHEMICAL", 7, 16], ["valproic acid", "CHEMICAL", 87, 100], ["Clozapine", "CHEMICAL", 124, 133], ["metabolismClozapine", "CHEMICAL", 134, 153], ["clozapine", "SIMPLE_CHEMICAL", 7, 16], ["valproic acid", "SIMPLE_CHEMICAL", 87, 100], ["Clozapine", "SIMPLE_CHEMICAL", 124, 133], ["metabolismClozapine", "SIMPLE_CHEMICAL", 134, 153], ["clozapine titration", "TREATMENT", 7, 26], ["valproic acid", "TREATMENT", 87, 100], ["an inhibitor", "TREATMENT", 111, 123], ["Clozapine metabolismClozapine", "TREATMENT", 124, 153], ["side effects", "PROBLEM", 172, 184]]], ["Some of these clozapine ADRs, such as sedation, hypersalivation, constipation and seizures, are dose-related.", [["clozapine", "CHEMICAL", 14, 23], ["ADRs", "DISEASE", 24, 28], ["hypersalivation", "DISEASE", 48, 63], ["constipation", "DISEASE", 65, 77], ["seizures", "DISEASE", 82, 90], ["clozapine", "CHEMICAL", 14, 23], ["clozapine", "SIMPLE_CHEMICAL", 14, 23], ["these clozapine ADRs", "TREATMENT", 8, 28], ["sedation", "TREATMENT", 38, 46], ["hypersalivation", "PROBLEM", 48, 63], ["constipation", "PROBLEM", 65, 77], ["seizures", "PROBLEM", 82, 90], ["clozapine ADRs", "OBSERVATION", 14, 28]]], ["It is probably more accurate to describe them as serum concentration-related.", [["serum", "ANATOMY", 49, 54], ["serum", "ORGANISM_SUBSTANCE", 49, 54], ["serum concentration", "TEST", 49, 68], ["probably", "UNCERTAINTY", 6, 14], ["more accurate", "OBSERVATION_MODIFIER", 15, 28]]], ["An expert guideline recommends for efficacy in schizophrenia trough steady-state clozapine concentrations of 350\u2013600 ng/mL.3 This indicates a narrow therapeutic index.", [["schizophrenia", "DISEASE", 47, 60], ["clozapine", "CHEMICAL", 81, 90], ["clozapine", "CHEMICAL", 81, 90], ["clozapine", "SIMPLE_CHEMICAL", 81, 90], ["schizophrenia trough steady", "PROBLEM", 47, 74], ["clozapine concentrations", "TREATMENT", 81, 105], ["a narrow therapeutic index", "PROBLEM", 140, 166], ["narrow", "OBSERVATION_MODIFIER", 142, 148], ["therapeutic", "OBSERVATION_MODIFIER", 149, 160], ["index", "OBSERVATION", 161, 166]]], ["The serum concentration of norclozapine does not contribute to antipsychotic efficacy since norclozapine has no antipsychotic activity.", [["serum", "ANATOMY", 4, 9], ["norclozapine", "CHEMICAL", 27, 39], ["norclozapine", "CHEMICAL", 92, 104], ["norclozapine", "CHEMICAL", 27, 39], ["norclozapine", "CHEMICAL", 92, 104], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["norclozapine", "SIMPLE_CHEMICAL", 27, 39], ["norclozapine", "SIMPLE_CHEMICAL", 92, 104], ["The serum concentration", "TEST", 0, 23], ["norclozapine", "TREATMENT", 27, 39], ["antipsychotic efficacy", "PROBLEM", 63, 85], ["norclozapine", "TREATMENT", 92, 104], ["no", "UNCERTAINTY", 109, 111], ["antipsychotic activity", "OBSERVATION", 112, 134]]], ["On the other hand, it is possible that serum norclozapine concentration may contribute to most or all clozapine ADRs.Clozapine metabolismIf clinicians have access to clozapine levels, they should use them to maintain each clozapine patient on the lowest dose possible that provides stable trough steady-state clozapine levels within the therapeutic range.", [["serum", "ANATOMY", 39, 44], ["norclozapine", "CHEMICAL", 45, 57], ["clozapine", "CHEMICAL", 102, 111], ["ADRs", "DISEASE", 112, 116], ["Clozapine", "CHEMICAL", 117, 126], ["clozapine", "CHEMICAL", 166, 175], ["clozapine", "CHEMICAL", 222, 231], ["clozapine", "CHEMICAL", 309, 318], ["norclozapine", "CHEMICAL", 45, 57], ["clozapine", "CHEMICAL", 102, 111], ["Clozapine", "CHEMICAL", 117, 126], ["clozapine", "CHEMICAL", 166, 175], ["clozapine", "CHEMICAL", 222, 231], ["clozapine", "CHEMICAL", 309, 318], ["serum", "ORGANISM_SUBSTANCE", 39, 44], ["norclozapine", "SIMPLE_CHEMICAL", 45, 57], ["clozapine", "SIMPLE_CHEMICAL", 102, 111], ["Clozapine", "SIMPLE_CHEMICAL", 117, 126], ["clozapine", "SIMPLE_CHEMICAL", 166, 175], ["patient", "ORGANISM", 232, 239], ["clozapine", "SIMPLE_CHEMICAL", 309, 318], ["patient", "SPECIES", 232, 239], ["serum norclozapine concentration", "TREATMENT", 39, 71], ["all clozapine ADRs", "TREATMENT", 98, 116], ["Clozapine metabolismIf", "TREATMENT", 117, 139], ["clozapine levels", "TEST", 166, 182], ["clozapine", "TREATMENT", 222, 231], ["clozapine levels", "TEST", 309, 325]]], ["Assuming that the patient practices good medical adherence and is reliable, we recommend establishing a clozapine dose that provides stable serum concentrations between 350 and 400 ng/mL, to allow some room for normal fluctuations in the clinical environment.", [["serum", "ANATOMY", 140, 145], ["clozapine", "CHEMICAL", 104, 113], ["clozapine", "CHEMICAL", 104, 113], ["patient", "ORGANISM", 18, 25], ["clozapine", "SIMPLE_CHEMICAL", 104, 113], ["serum", "ORGANISM_SUBSTANCE", 140, 145], ["patient", "SPECIES", 18, 25], ["a clozapine dose", "TREATMENT", 102, 118]]], ["To increase compliance and reduce daily ADRs, a single administration at night can be used.Clozapine metabolismClozapine dosing is not only influenced by geriatric age, smoking, gender and co-medication but ethnicity (Asian vs non-Asian).", [["ADRs", "DISEASE", 40, 44], ["Clozapine", "CHEMICAL", 91, 100], ["metabolismClozapine", "CHEMICAL", 101, 120], ["Clozapine", "CHEMICAL", 91, 100], ["metabolismClozapine", "CHEMICAL", 101, 120], ["Clozapine", "SIMPLE_CHEMICAL", 91, 100], ["metabolismClozapine", "SIMPLE_CHEMICAL", 101, 120], ["daily ADRs", "TREATMENT", 34, 44], ["a single administration", "TREATMENT", 46, 69], ["Clozapine metabolismClozapine dosing", "TREATMENT", 91, 127]]], ["In 1997, Asian researchers first described Chinese patients as having serum concentrations similar to those of Caucasians with only half the clozapine dose used in the US.4 5 A meta-analytic review2 showed that Chinese and other East Asians have lower clozapine clearance than Caucasians.", [["serum", "ANATOMY", 70, 75], ["clozapine", "CHEMICAL", 141, 150], ["clozapine", "CHEMICAL", 252, 261], ["clozapine", "CHEMICAL", 141, 150], ["clozapine", "CHEMICAL", 252, 261], ["patients", "ORGANISM", 51, 59], ["serum", "ORGANISM_SUBSTANCE", 70, 75], ["clozapine", "SIMPLE_CHEMICAL", 141, 150], ["clozapine", "SIMPLE_CHEMICAL", 252, 261], ["patients", "SPECIES", 51, 59], ["serum concentrations", "PROBLEM", 70, 90], ["the clozapine dose", "TREATMENT", 137, 155], ["A meta-analytic review2", "TEST", 175, 198], ["lower clozapine clearance", "TREATMENT", 246, 271]]], ["The lower clozapine clearance, probably explained by lower CYP1A2 activity, appears to be present not only in Chinese patients but is also common to other Asians.6 The FDA describes Asians as those people whose ancestral origins range geographically from Pakistan to Japan.6 In Asians, to reach 350 ng/mL, a non-smoking female with average metabolism needs around 150 mg/day and a male smoker 300 mg/day, requiring typical doses in Asians from 150 to 300 mg/day.6 On the other hand, a non-smoking US Caucasian female with average clozapine metabolism needs around 300 mg/day while a US Caucasian male smoker needs 600 mg/day, requiring typical doses in the US from 300 to 600 mg/day.6Clozapine metabolismTo define clozapine poor metabolisers (PMs), it is necessary to stratify Asians versus non-Asians.", [["clozapine", "CHEMICAL", 10, 19], ["clozapine", "CHEMICAL", 530, 539], ["6Clozapine", "CHEMICAL", 683, 693], ["clozapine", "CHEMICAL", 714, 723], ["clozapine", "CHEMICAL", 10, 19], ["clozapine", "CHEMICAL", 530, 539], ["6Clozapine", "CHEMICAL", 683, 693], ["clozapine", "CHEMICAL", 714, 723], ["clozapine", "SIMPLE_CHEMICAL", 10, 19], ["CYP1A2", "GENE_OR_GENE_PRODUCT", 59, 65], ["patients", "ORGANISM", 118, 126], ["people", "ORGANISM", 198, 204], ["clozapine", "SIMPLE_CHEMICAL", 530, 539], ["6Clozapine", "SIMPLE_CHEMICAL", 683, 693], ["clozapine", "SIMPLE_CHEMICAL", 714, 723], ["PMs", "MULTI-TISSUE_STRUCTURE", 743, 746], ["CYP1A2", "PROTEIN", 59, 65], ["patients", "SPECIES", 118, 126], ["people", "SPECIES", 198, 204], ["The lower clozapine clearance", "TREATMENT", 0, 29], ["average clozapine metabolism", "TREATMENT", 522, 550], ["6Clozapine metabolismTo", "TREATMENT", 683, 706], ["clozapine poor metabolisers", "PROBLEM", 714, 741], ["non-Asians", "PROBLEM", 791, 801], ["lower", "OBSERVATION_MODIFIER", 4, 9], ["clozapine clearance", "OBSERVATION", 10, 29]]], ["Within the ethnic group, taking powerful clozapine inhibitors and/or being severely obese can be explained as being a phenotypic PM.", [["clozapine", "CHEMICAL", 41, 50], ["clozapine", "CHEMICAL", 41, 50], ["clozapine", "SIMPLE_CHEMICAL", 41, 50], ["powerful clozapine inhibitors", "TREATMENT", 32, 61], ["severely obese", "PROBLEM", 75, 89], ["obese", "OBSERVATION", 84, 89]]], ["In five Asian samples, around 7% of the patients (2%\u201313%) were phenotypic PMs, with no known cause, but four of the five studies were limited by not ruling out current inflammation, which can make a patient look temporarily like a clozapine PM.7 Thus, it is possible that around 7% (2%\u201313%) of Asians may have unknown genetic mutations possibly at the CYP1A2 gene associated with being a clozapine PM.7Clozapine metabolismUntil there is a better definition of clozapine PMs, we recommend considering Asian clozapine PMs as those who reach concentrations of 350 ng/mL with clozapine doses <150 mg/day.", [["samples", "ANATOMY", 14, 21], ["inflammation", "DISEASE", 168, 180], ["clozapine", "CHEMICAL", 231, 240], ["clozapine", "CHEMICAL", 388, 397], ["Clozapine", "CHEMICAL", 402, 411], ["clozapine", "CHEMICAL", 460, 469], ["clozapine", "CHEMICAL", 506, 515], ["clozapine", "CHEMICAL", 572, 581], ["clozapine", "CHEMICAL", 231, 240], ["clozapine", "CHEMICAL", 388, 397], ["Clozapine", "CHEMICAL", 402, 411], ["clozapine", "CHEMICAL", 460, 469], ["clozapine", "CHEMICAL", 506, 515], ["clozapine", "CHEMICAL", 572, 581], ["patients", "ORGANISM", 40, 48], ["PMs", "MULTI-TISSUE_STRUCTURE", 74, 77], ["patient", "ORGANISM", 199, 206], ["Asians", "ORGANISM", 294, 300], ["CYP1A2", "GENE_OR_GENE_PRODUCT", 352, 358], ["clozapine", "SIMPLE_CHEMICAL", 388, 397], ["Clozapine", "SIMPLE_CHEMICAL", 402, 411], ["clozapine", "SIMPLE_CHEMICAL", 460, 469], ["clozapine", "SIMPLE_CHEMICAL", 506, 515], ["clozapine", "SIMPLE_CHEMICAL", 572, 581], ["CYP1A2 gene", "DNA", 352, 363], ["patients", "SPECIES", 40, 48], ["patient", "SPECIES", 199, 206], ["phenotypic PMs", "PROBLEM", 63, 77], ["the five studies", "TEST", 112, 128], ["current inflammation", "PROBLEM", 160, 180], ["a clozapine PM", "TREATMENT", 229, 243], ["genetic mutations", "PROBLEM", 318, 335], ["a clozapine PM", "TREATMENT", 386, 400], ["Clozapine metabolismUntil", "TREATMENT", 402, 427], ["clozapine PMs", "TREATMENT", 460, 473], ["Asian clozapine PMs", "TREATMENT", 500, 519], ["clozapine doses", "TREATMENT", 572, 587], ["no known", "UNCERTAINTY", 84, 92], ["inflammation", "OBSERVATION", 168, 180]]], ["A more precise definition, including smoking and gender stratification, is provided in a review article.6 Asian female non-smokers who are PMs need a clozapine dose around 50 mg/day to reach 350 ng/mL, while Asian male smokers who are PMs need a clozapine dose around 125 mg/day.6 Until a better definition of clozapine PMs in non-Asians is established, we recommend considering non-Asian clozapine PMs as those who reach 350 ng/mL with clozapine doses <300 mg/day.2Inflammation can increase clozapine levelsThe US package insert for theophylline, a drug metabolised by CYP1A2, indicates that upper respiratory infections with fever increase serum theophylline concentrations.", [["respiratory", "ANATOMY", 599, 610], ["serum", "ANATOMY", 642, 647], ["clozapine", "CHEMICAL", 150, 159], ["clozapine", "CHEMICAL", 246, 255], ["clozapine", "CHEMICAL", 310, 319], ["clozapine", "CHEMICAL", 389, 398], ["clozapine", "CHEMICAL", 437, 446], ["2Inflammation", "DISEASE", 465, 478], ["clozapine", "CHEMICAL", 492, 501], ["theophylline", "CHEMICAL", 534, 546], ["respiratory infections", "DISEASE", 599, 621], ["fever", "DISEASE", 627, 632], ["theophylline", "CHEMICAL", 648, 660], ["clozapine", "CHEMICAL", 150, 159], ["clozapine", "CHEMICAL", 246, 255], ["clozapine", "CHEMICAL", 310, 319], ["clozapine", "CHEMICAL", 389, 398], ["clozapine", "CHEMICAL", 437, 446], ["clozapine", "CHEMICAL", 492, 501], ["theophylline", "CHEMICAL", 534, 546], ["theophylline", "CHEMICAL", 648, 660], ["non-smokers", "ORGANISM", 119, 130], ["PMs", "MULTI-TISSUE_STRUCTURE", 139, 142], ["clozapine", "SIMPLE_CHEMICAL", 150, 159], ["smokers", "ORGANISM", 219, 226], ["PMs", "MULTI-TISSUE_STRUCTURE", 235, 238], ["clozapine", "SIMPLE_CHEMICAL", 246, 255], ["clozapine", "SIMPLE_CHEMICAL", 310, 319], ["clozapine", "SIMPLE_CHEMICAL", 389, 398], ["clozapine", "SIMPLE_CHEMICAL", 437, 446], ["clozapine", "SIMPLE_CHEMICAL", 492, 501], ["theophylline", "SIMPLE_CHEMICAL", 534, 546], ["CYP1A2", "GENE_OR_GENE_PRODUCT", 570, 576], ["serum", "ORGANISM_SUBSTANCE", 642, 647], ["theophylline", "SIMPLE_CHEMICAL", 648, 660], ["CYP1A2", "PROTEIN", 570, 576], ["a clozapine dose", "TREATMENT", 148, 164], ["a clozapine dose", "TREATMENT", 244, 260], ["clozapine PMs", "TREATMENT", 310, 323], ["non-Asian clozapine PMs", "TREATMENT", 379, 402], ["clozapine doses", "TREATMENT", 437, 452], ["2Inflammation", "PROBLEM", 465, 478], ["clozapine levels", "TEST", 492, 508], ["The US package insert", "TREATMENT", 508, 529], ["theophylline", "TREATMENT", 534, 546], ["upper respiratory infections", "PROBLEM", 593, 621], ["fever", "PROBLEM", 627, 632], ["serum theophylline concentrations", "TREATMENT", 642, 675], ["upper", "ANATOMY_MODIFIER", 593, 598], ["respiratory", "ANATOMY", 599, 610], ["infections", "OBSERVATION", 611, 621]]], ["The release of cytokines during the infection decreases the activity and/or expression of CYP1A2.", [["infection", "DISEASE", 36, 45], ["CYP1A2", "GENE_OR_GENE_PRODUCT", 90, 96], ["cytokines", "PROTEIN", 15, 24], ["CYP1A2", "PROTEIN", 90, 96], ["cytokines", "TREATMENT", 15, 24], ["the infection", "PROBLEM", 32, 45], ["CYP1A2", "TEST", 90, 96], ["cytokines", "OBSERVATION", 15, 24], ["infection", "OBSERVATION", 36, 45]]], ["More relevant for clinicians, experts on theophylline8 recommended that the theophylline dose should be approximately halved to avoid intoxication during these infections.", [["theophylline8", "CHEMICAL", 41, 54], ["theophylline", "CHEMICAL", 76, 88], ["infections", "DISEASE", 160, 170], ["theophylline8", "CHEMICAL", 41, 54], ["theophylline", "CHEMICAL", 76, 88], ["theophylline8", "SIMPLE_CHEMICAL", 41, 54], ["theophylline", "SIMPLE_CHEMICAL", 76, 88], ["theophylline8", "TREATMENT", 41, 54], ["the theophylline dose", "TREATMENT", 72, 93], ["intoxication", "PROBLEM", 134, 146], ["these infections", "PROBLEM", 154, 170], ["infections", "OBSERVATION", 160, 170]]], ["Therefore, the first author reduced the clozapine dose by half8 when he first diagnosed a clozapine intoxication during an upper respiratory infection with fever in one of his patients.", [["respiratory", "ANATOMY", 129, 140], ["clozapine", "CHEMICAL", 40, 49], ["clozapine", "CHEMICAL", 90, 99], ["respiratory infection", "DISEASE", 129, 150], ["fever", "DISEASE", 156, 161], ["clozapine", "CHEMICAL", 40, 49], ["clozapine", "CHEMICAL", 90, 99], ["clozapine", "SIMPLE_CHEMICAL", 40, 49], ["clozapine", "SIMPLE_CHEMICAL", 90, 99], ["patients", "ORGANISM", 176, 184], ["patients", "SPECIES", 176, 184], ["the clozapine dose", "TREATMENT", 36, 54], ["a clozapine intoxication", "PROBLEM", 88, 112], ["an upper respiratory infection", "PROBLEM", 120, 150], ["fever", "PROBLEM", 156, 161], ["upper", "ANATOMY_MODIFIER", 123, 128], ["respiratory", "ANATOMY", 129, 140], ["infection", "OBSERVATION", 141, 150], ["fever", "OBSERVATION", 156, 161]]], ["The later arrival of the clozapine serum concentration level verified his diagnosis of clozapine intoxication.8 In 2004, based on this case9 and the available literature, he proposed that during severe inflammations/infections, including pneumonia, the clozapine dose should be halved until clozapine levels are available to better personalise clozapine dosing.9 Through 2016, there are 40 published cases of clozapine elevation during infections.10 There are also published clozapine intoxications during severe inflammation without infection.11Inflammation can increase clozapine levelsMore recently, in a Beijing hospital, three cases of clozapine intoxication we identified included ones with pneumonia,12 influenza11 and dermatitis in the absence of infection.11 In these three Chinese patients severe infections were associated with roughly double the serum concentrations,11 12 while the effects in relation to dermatitis depended more on its severity.", [["serum", "ANATOMY", 35, 40], ["serum", "ANATOMY", 858, 863], ["clozapine", "CHEMICAL", 25, 34], ["clozapine", "CHEMICAL", 87, 96], ["inflammations", "DISEASE", 202, 215], ["infections", "DISEASE", 216, 226], ["pneumonia", "DISEASE", 238, 247], ["clozapine", "CHEMICAL", 253, 262], ["clozapine", "CHEMICAL", 291, 300], ["clozapine", "CHEMICAL", 344, 353], ["clozapine", "CHEMICAL", 409, 418], ["infections", "DISEASE", 436, 446], ["clozapine", "CHEMICAL", 475, 484], ["inflammation", "DISEASE", 513, 525], ["infection", "DISEASE", 534, 543], ["clozapine", "CHEMICAL", 572, 581], ["clozapine", "CHEMICAL", 641, 650], ["pneumonia", "DISEASE", 697, 706], ["dermatitis", "DISEASE", 726, 736], ["infection", "DISEASE", 755, 764], ["infections", "DISEASE", 807, 817], ["dermatitis", "DISEASE", 918, 928], ["clozapine", "CHEMICAL", 25, 34], ["clozapine", "CHEMICAL", 87, 96], ["clozapine", "CHEMICAL", 253, 262], ["clozapine", "CHEMICAL", 291, 300], ["clozapine", "CHEMICAL", 344, 353], ["clozapine", "CHEMICAL", 409, 418], ["clozapine", "CHEMICAL", 475, 484], ["clozapine", "CHEMICAL", 572, 581], ["clozapine", "CHEMICAL", 641, 650], ["clozapine", "SIMPLE_CHEMICAL", 25, 34], ["serum", "ORGANISM_SUBSTANCE", 35, 40], ["clozapine", "SIMPLE_CHEMICAL", 87, 96], ["clozapine", "SIMPLE_CHEMICAL", 253, 262], ["clozapine", "SIMPLE_CHEMICAL", 291, 300], ["clozapine", "SIMPLE_CHEMICAL", 344, 353], ["clozapine", "SIMPLE_CHEMICAL", 409, 418], ["clozapine", "SIMPLE_CHEMICAL", 475, 484], ["clozapine", "SIMPLE_CHEMICAL", 572, 581], ["clozapine", "SIMPLE_CHEMICAL", 641, 650], ["patients", "ORGANISM", 791, 799], ["serum", "ORGANISM_SUBSTANCE", 858, 863], ["patients", "SPECIES", 791, 799], ["the clozapine serum concentration level", "TEST", 21, 60], ["clozapine intoxication", "PROBLEM", 87, 109], ["severe inflammations", "PROBLEM", 195, 215], ["infections", "PROBLEM", 216, 226], ["pneumonia", "PROBLEM", 238, 247], ["the clozapine dose", "TREATMENT", 249, 267], ["clozapine levels", "TEST", 291, 307], ["clozapine dosing", "TREATMENT", 344, 360], ["clozapine elevation during infections", "PROBLEM", 409, 446], ["published clozapine intoxications", "PROBLEM", 465, 498], ["severe inflammation", "PROBLEM", 506, 525], ["infection", "PROBLEM", 534, 543], ["clozapine levels", "TEST", 572, 588], ["clozapine intoxication", "PROBLEM", 641, 663], ["pneumonia", "PROBLEM", 697, 706], ["12 influenza11", "PROBLEM", 707, 721], ["dermatitis", "PROBLEM", 726, 736], ["infection", "PROBLEM", 755, 764], ["severe infections", "PROBLEM", 800, 817], ["the serum concentrations", "TEST", 854, 878], ["dermatitis", "PROBLEM", 918, 928], ["clozapine intoxication", "OBSERVATION", 87, 109], ["severe", "OBSERVATION_MODIFIER", 195, 201], ["inflammations", "OBSERVATION", 202, 215], ["infections", "OBSERVATION", 216, 226], ["pneumonia", "OBSERVATION", 238, 247], ["infections", "OBSERVATION", 436, 446], ["clozapine intoxications", "OBSERVATION", 475, 498], ["severe", "OBSERVATION_MODIFIER", 506, 512], ["inflammation", "OBSERVATION", 513, 525], ["without", "UNCERTAINTY", 526, 533], ["infection", "OBSERVATION", 534, 543], ["pneumonia", "OBSERVATION", 697, 706], ["dermatitis", "OBSERVATION", 726, 736], ["infection", "OBSERVATION", 755, 764], ["severe", "OBSERVATION_MODIFIER", 800, 806], ["infections", "OBSERVATION", 807, 817], ["dermatitis", "OBSERVATION", 918, 928]]], ["A doubling of the concentration was only observed when there was an elevation of the serum C-reactive protein (CRP) and widespread effect on the skin all over the body.11 In a recent retrospective review of 131 clozapine inpatients at Beijing Anding Hospital, we found 18 episodes of infections/inflammations in 16 patients.", [["serum", "ANATOMY", 85, 90], ["skin", "ANATOMY", 145, 149], ["body", "ANATOMY", 163, 167], ["clozapine", "CHEMICAL", 211, 220], ["infections", "DISEASE", 284, 294], ["inflammations", "DISEASE", 295, 308], ["clozapine", "CHEMICAL", 211, 220], ["serum", "ORGANISM_SUBSTANCE", 85, 90], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 91, 109], ["CRP", "GENE_OR_GENE_PRODUCT", 111, 114], ["skin", "ORGAN", 145, 149], ["body", "ORGANISM_SUBDIVISION", 163, 167], ["patients", "ORGANISM", 315, 323], ["serum C-reactive protein", "PROTEIN", 85, 109], ["CRP", "PROTEIN", 111, 114], ["patients", "SPECIES", 315, 323], ["an elevation", "PROBLEM", 65, 77], ["the serum C", "TEST", 81, 92], ["CRP", "TEST", 111, 114], ["widespread effect on the skin", "PROBLEM", 120, 149], ["clozapine", "TREATMENT", 211, 220], ["infections", "PROBLEM", 284, 294], ["inflammations", "PROBLEM", 295, 308], ["elevation", "OBSERVATION", 68, 77], ["reactive protein", "OBSERVATION", 93, 109], ["widespread", "OBSERVATION_MODIFIER", 120, 130], ["effect", "OBSERVATION_MODIFIER", 131, 137], ["skin", "ANATOMY", 145, 149], ["all", "ANATOMY_MODIFIER", 150, 153], ["body", "ANATOMY", 163, 167], ["infections", "OBSERVATION", 284, 294], ["inflammations", "OBSERVATION", 295, 308]]], ["At the total sample level, these episodes: (1) extended for 2% (482/24 789) of clozapine days and (2) contaminated 3% (46/1384) of trough steady-state serum concentrations of clozapine.", [["serum", "ANATOMY", 151, 156], ["clozapine", "CHEMICAL", 79, 88], ["clozapine", "CHEMICAL", 175, 184], ["clozapine", "CHEMICAL", 79, 88], ["clozapine", "CHEMICAL", 175, 184], ["serum", "ORGANISM_SUBSTANCE", 151, 156], ["clozapine", "SIMPLE_CHEMICAL", 175, 184], ["clozapine days", "TREATMENT", 79, 93], ["trough steady", "TEST", 131, 144], ["clozapine", "TREATMENT", 175, 184]]], ["At the individual level, we found: (1) no clinically relevant effects on the serum clozapine concentrations in the 11% of infection episodes which presented with no leukocytosis or CRP elevations; (2) halving the clozapine dose would be advisable in 61% of the infection episodes; and (3) reducing the clozapine dose to one-third would be advisable in 28% of infection episodes.13Inflammation can increase clozapine levelsTherefore, based on the US8 14 and Chinese experiences11\u201313 as well as on the literature,10 we proposed that clinicians need to be very alert regarding clozapine patients\u2019 risk of clozapine intoxications during any kind of systemic inflammation associated with fever and/or CRP elevations.", [["serum", "ANATOMY", 77, 82], ["clozapine", "CHEMICAL", 83, 92], ["infection", "DISEASE", 122, 131], ["leukocytosis", "DISEASE", 165, 177], ["clozapine", "CHEMICAL", 213, 222], ["infection", "DISEASE", 261, 270], ["clozapine", "CHEMICAL", 302, 311], ["infection", "DISEASE", 359, 368], ["clozapine", "CHEMICAL", 406, 415], ["clozapine", "CHEMICAL", 574, 583], ["clozapine", "CHEMICAL", 602, 611], ["inflammation", "DISEASE", 654, 666], ["fever", "DISEASE", 683, 688], ["clozapine", "CHEMICAL", 83, 92], ["clozapine", "CHEMICAL", 213, 222], ["clozapine", "CHEMICAL", 302, 311], ["clozapine", "CHEMICAL", 406, 415], ["clozapine", "CHEMICAL", 574, 583], ["clozapine", "CHEMICAL", 602, 611], ["serum", "ORGANISM_SUBSTANCE", 77, 82], ["clozapine", "SIMPLE_CHEMICAL", 83, 92], ["CRP", "GENE_OR_GENE_PRODUCT", 181, 184], ["clozapine", "SIMPLE_CHEMICAL", 213, 222], ["clozapine", "SIMPLE_CHEMICAL", 302, 311], ["clozapine", "SIMPLE_CHEMICAL", 406, 415], ["patients", "ORGANISM", 584, 592], ["clozapine", "SIMPLE_CHEMICAL", 602, 611], ["CRP", "GENE_OR_GENE_PRODUCT", 696, 699], ["CRP", "PROTEIN", 181, 184], ["CRP", "PROTEIN", 696, 699], ["patients", "SPECIES", 584, 592], ["the serum clozapine concentrations", "TREATMENT", 73, 107], ["infection episodes", "PROBLEM", 122, 140], ["leukocytosis", "PROBLEM", 165, 177], ["CRP elevations", "PROBLEM", 181, 195], ["the clozapine dose", "TREATMENT", 209, 227], ["the infection episodes", "PROBLEM", 257, 279], ["the clozapine dose", "TREATMENT", 298, 316], ["infection episodes", "PROBLEM", 359, 377], ["clozapine levels", "TEST", 406, 422], ["clozapine", "TREATMENT", 574, 583], ["clozapine intoxications", "PROBLEM", 602, 625], ["systemic inflammation", "PROBLEM", 645, 666], ["fever", "PROBLEM", 683, 688], ["CRP elevations", "PROBLEM", 696, 710], ["infection", "OBSERVATION", 122, 131], ["no", "UNCERTAINTY", 162, 164], ["leukocytosis", "OBSERVATION", 165, 177], ["infection", "OBSERVATION", 261, 270], ["infection", "OBSERVATION", 359, 368], ["inflammation", "OBSERVATION", 654, 666]]], ["Until better data is available, based on our experience in the US and China, we have developed three sets of recommendations regarding infection, based on timeframe: (1) prevention; (2) during the infection; and (3) after the infection.13Inflammation can increase clozapine levelsFor prevention, we recommend that psychiatrists using clozapine should educate their outpatients and families to be attentive to signs or symptoms of infection/inflammation or fever and to contact them immediately to prevent clozapine intoxications.", [["infection", "DISEASE", 135, 144], ["infection", "DISEASE", 197, 206], ["infection", "DISEASE", 226, 235], ["clozapine", "CHEMICAL", 264, 273], ["clozapine", "CHEMICAL", 334, 343], ["infection", "DISEASE", 430, 439], ["inflammation", "DISEASE", 440, 452], ["fever", "DISEASE", 456, 461], ["clozapine", "CHEMICAL", 505, 514], ["clozapine", "CHEMICAL", 264, 273], ["clozapine", "CHEMICAL", 334, 343], ["clozapine", "CHEMICAL", 505, 514], ["clozapine", "SIMPLE_CHEMICAL", 264, 273], ["clozapine", "SIMPLE_CHEMICAL", 334, 343], ["clozapine", "SIMPLE_CHEMICAL", 505, 514], ["infection", "PROBLEM", 135, 144], ["the infection", "PROBLEM", 193, 206], ["the infection", "PROBLEM", 222, 235], ["clozapine levels", "TREATMENT", 264, 280], ["clozapine", "TREATMENT", 334, 343], ["symptoms", "PROBLEM", 418, 426], ["infection", "PROBLEM", 430, 439], ["inflammation", "PROBLEM", 440, 452], ["fever", "PROBLEM", 456, 461], ["clozapine intoxications", "PROBLEM", 505, 528], ["infection", "OBSERVATION", 135, 144], ["infection", "OBSERVATION", 197, 206], ["infection", "OBSERVATION", 226, 235], ["infection", "OBSERVATION", 430, 439]]], ["Moreover, a careful clinician, after reaching a stable maintenance clozapine dose, should go ahead and measure two or three trough and steady-state serum clozapine concentrations.", [["serum", "ANATOMY", 148, 153], ["clozapine", "CHEMICAL", 67, 76], ["clozapine", "CHEMICAL", 154, 163], ["clozapine", "CHEMICAL", 67, 76], ["clozapine", "CHEMICAL", 154, 163], ["clozapine", "SIMPLE_CHEMICAL", 67, 76], ["serum", "ORGANISM_SUBSTANCE", 148, 153], ["clozapine", "SIMPLE_CHEMICAL", 154, 163], ["a stable maintenance clozapine dose", "TREATMENT", 46, 81], ["serum clozapine concentrations", "TREATMENT", 148, 178]]], ["By calculating the mean concentration and correcting by the clozapine dose,2 the clinician can establish a baseline for clozapine metabolism in that patient and the lowest clozapine dose providing a therapeutic serum concentration.", [["serum", "ANATOMY", 211, 216], ["clozapine", "CHEMICAL", 60, 69], ["clozapine", "CHEMICAL", 120, 129], ["clozapine", "CHEMICAL", 172, 181], ["clozapine", "CHEMICAL", 60, 69], ["clozapine", "CHEMICAL", 120, 129], ["clozapine", "CHEMICAL", 172, 181], ["clozapine", "SIMPLE_CHEMICAL", 60, 69], ["clozapine", "SIMPLE_CHEMICAL", 120, 129], ["patient", "ORGANISM", 149, 156], ["clozapine", "SIMPLE_CHEMICAL", 172, 181], ["serum", "ORGANISM_SUBSTANCE", 211, 216], ["patient", "SPECIES", 149, 156], ["the clozapine dose", "TREATMENT", 56, 74], ["clozapine metabolism", "TREATMENT", 120, 140], ["the lowest clozapine dose", "TREATMENT", 161, 186], ["a therapeutic serum concentration", "TREATMENT", 197, 230]]], ["In the unfortunate event that the patient develops a systemic infection or inflammation, this baseline clozapine metabolism can be compared with the decreased metabolism during the inflammation.Inflammation can increase clozapine levelsOnce an infection has developed, the psychiatrist should order a CRP level.", [["infection", "DISEASE", 62, 71], ["inflammation", "DISEASE", 75, 87], ["clozapine", "CHEMICAL", 103, 112], ["inflammation", "DISEASE", 181, 193], ["Inflammation", "DISEASE", 194, 206], ["clozapine", "CHEMICAL", 220, 229], ["infection", "DISEASE", 244, 253], ["clozapine", "CHEMICAL", 103, 112], ["clozapine", "CHEMICAL", 220, 229], ["patient", "ORGANISM", 34, 41], ["clozapine", "SIMPLE_CHEMICAL", 103, 112], ["clozapine", "SIMPLE_CHEMICAL", 220, 229], ["CRP", "GENE_OR_GENE_PRODUCT", 301, 304], ["CRP", "PROTEIN", 301, 304], ["patient", "SPECIES", 34, 41], ["a systemic infection", "PROBLEM", 51, 71], ["inflammation", "PROBLEM", 75, 87], ["this baseline clozapine metabolism", "PROBLEM", 89, 123], ["the decreased metabolism", "PROBLEM", 145, 169], ["the inflammation", "PROBLEM", 177, 193], ["Inflammation", "PROBLEM", 194, 206], ["clozapine levels", "TEST", 220, 236], ["an infection", "PROBLEM", 241, 253], ["a CRP level", "TEST", 299, 310], ["systemic", "OBSERVATION_MODIFIER", 53, 61], ["infection", "OBSERVATION", 62, 71], ["inflammation", "OBSERVATION", 75, 87], ["decreased", "OBSERVATION_MODIFIER", 149, 158], ["metabolism", "OBSERVATION_MODIFIER", 159, 169], ["inflammation", "OBSERVATION", 181, 193], ["infection", "OBSERVATION", 244, 253]]], ["When fever and/or CRP elevations develop, the psychiatrist should consider immediately halving the clozapine dose and monitor for signs of clozapine intoxication.", [["fever", "DISEASE", 5, 10], ["clozapine", "CHEMICAL", 99, 108], ["clozapine", "CHEMICAL", 139, 148], ["clozapine", "CHEMICAL", 99, 108], ["clozapine", "CHEMICAL", 139, 148], ["CRP", "GENE_OR_GENE_PRODUCT", 18, 21], ["clozapine", "SIMPLE_CHEMICAL", 99, 108], ["clozapine", "SIMPLE_CHEMICAL", 139, 148], ["CRP", "PROTEIN", 18, 21], ["fever", "PROBLEM", 5, 10], ["CRP elevations", "PROBLEM", 18, 32], ["the clozapine dose", "TREATMENT", 95, 113], ["clozapine intoxication", "PROBLEM", 139, 161]]], ["If the clinician has access to clozapine Therapeutic drug monotoring (TDM) when the lab returns the clozapine TDM, it will be possible to better adjust the dosage.", [["clozapine", "CHEMICAL", 31, 40], ["clozapine", "CHEMICAL", 100, 109], ["clozapine", "CHEMICAL", 31, 40], ["clozapine", "CHEMICAL", 100, 109], ["clozapine", "SIMPLE_CHEMICAL", 31, 40], ["clozapine", "SIMPLE_CHEMICAL", 100, 109], ["clozapine", "TREATMENT", 31, 40], ["Therapeutic drug monotoring", "TREATMENT", 41, 68], ["the clozapine TDM", "TREATMENT", 96, 113]]], ["If signs of clozapine intoxication are already present it may be safer to stop clozapine for 2\u20133 days or until the serum clozapine concentration report arrives.Inflammation can increase clozapine levelsAfter the infection/inflammation has resolved and the CRP has normalised, we recommend going back to the prior clozapine dose without uptitration, since half of the dose during infection will provide roughly the same concentration as the dose without infection.", [["serum", "ANATOMY", 115, 120], ["clozapine", "CHEMICAL", 12, 21], ["clozapine", "CHEMICAL", 79, 88], ["clozapine", "CHEMICAL", 121, 130], ["Inflammation", "DISEASE", 160, 172], ["clozapine", "CHEMICAL", 186, 195], ["infection", "DISEASE", 212, 221], ["inflammation", "DISEASE", 222, 234], ["clozapine", "CHEMICAL", 313, 322], ["infection", "DISEASE", 379, 388], ["infection", "DISEASE", 453, 462], ["clozapine", "CHEMICAL", 12, 21], ["clozapine", "CHEMICAL", 79, 88], ["clozapine", "CHEMICAL", 121, 130], ["clozapine", "CHEMICAL", 186, 195], ["clozapine", "CHEMICAL", 313, 322], ["clozapine", "SIMPLE_CHEMICAL", 12, 21], ["clozapine", "SIMPLE_CHEMICAL", 79, 88], ["serum", "ORGANISM_SUBSTANCE", 115, 120], ["clozapine", "SIMPLE_CHEMICAL", 121, 130], ["clozapine", "SIMPLE_CHEMICAL", 186, 195], ["CRP", "GENE_OR_GENE_PRODUCT", 256, 259], ["clozapine", "SIMPLE_CHEMICAL", 313, 322], ["CRP", "PROTEIN", 256, 259], ["clozapine intoxication", "PROBLEM", 12, 34], ["clozapine", "TREATMENT", 79, 88], ["the serum clozapine concentration", "TREATMENT", 111, 144], ["Inflammation", "PROBLEM", 160, 172], ["clozapine levels", "TEST", 186, 202], ["the infection", "PROBLEM", 208, 221], ["inflammation", "PROBLEM", 222, 234], ["the CRP", "TEST", 252, 259], ["the prior clozapine dose", "TREATMENT", 303, 327], ["uptitration", "TREATMENT", 336, 347], ["infection", "PROBLEM", 379, 388], ["infection", "PROBLEM", 453, 462], ["infection", "OBSERVATION", 212, 221], ["inflammation", "OBSERVATION", 222, 234], ["resolved", "OBSERVATION_MODIFIER", 239, 247], ["infection", "OBSERVATION", 379, 388], ["infection", "OBSERVATION", 453, 462]]], ["If the clinician did not measure clozapine concentrations before the infection, it may be wise to measure them after the infection to establish the lowest clozapine dose providing therapeutic serum concentrations and efficacy for maintenance treatment.Inflammation can increase clozapine levelsOther antipsychotics may be associated with elevations in serum concentrations during infections or inflammations, particularly those metabolised by CYP1A2 and CYP3A4.", [["serum", "ANATOMY", 192, 197], ["serum", "ANATOMY", 352, 357], ["clozapine", "CHEMICAL", 33, 42], ["infection", "DISEASE", 69, 78], ["infection", "DISEASE", 121, 130], ["clozapine", "CHEMICAL", 155, 164], ["Inflammation", "DISEASE", 252, 264], ["clozapine", "CHEMICAL", 278, 287], ["infections", "DISEASE", 380, 390], ["inflammations", "DISEASE", 394, 407], ["clozapine", "CHEMICAL", 33, 42], ["clozapine", "CHEMICAL", 155, 164], ["clozapine", "CHEMICAL", 278, 287], ["clozapine", "SIMPLE_CHEMICAL", 33, 42], ["clozapine", "SIMPLE_CHEMICAL", 155, 164], ["serum", "ORGANISM_SUBSTANCE", 192, 197], ["clozapine", "SIMPLE_CHEMICAL", 278, 287], ["serum", "ORGANISM_SUBSTANCE", 352, 357], ["CYP1A2", "GENE_OR_GENE_PRODUCT", 443, 449], ["CYP3A4", "GENE_OR_GENE_PRODUCT", 454, 460], ["CYP1A2", "PROTEIN", 443, 449], ["CYP3A4", "PROTEIN", 454, 460], ["clozapine concentrations", "TREATMENT", 33, 57], ["the infection", "PROBLEM", 65, 78], ["the infection", "PROBLEM", 117, 130], ["the lowest clozapine dose", "TREATMENT", 144, 169], ["therapeutic serum concentrations", "TREATMENT", 180, 212], ["maintenance treatment", "TREATMENT", 230, 251], ["Inflammation", "PROBLEM", 252, 264], ["clozapine levels", "TEST", 278, 294], ["Other antipsychotics", "PROBLEM", 294, 314], ["elevations in serum concentrations during infections", "PROBLEM", 338, 390], ["inflammations", "PROBLEM", 394, 407], ["CYP3A4", "TEST", 454, 460], ["infection", "OBSERVATION", 69, 78], ["inflammations", "OBSERVATION", 394, 407]]], ["Olanzapine is mainly metabolised by CYP1A2 and was associated with increases in serum concentrations during an upper respiratory infection in a case report8 but it has a wider therapeutic index than clozapine.", [["serum", "ANATOMY", 80, 85], ["respiratory", "ANATOMY", 117, 128], ["Olanzapine", "CHEMICAL", 0, 10], ["respiratory infection", "DISEASE", 117, 138], ["clozapine", "CHEMICAL", 199, 208], ["Olanzapine", "CHEMICAL", 0, 10], ["clozapine", "CHEMICAL", 199, 208], ["Olanzapine", "SIMPLE_CHEMICAL", 0, 10], ["CYP1A2", "GENE_OR_GENE_PRODUCT", 36, 42], ["serum", "ORGANISM_SUBSTANCE", 80, 85], ["clozapine", "SIMPLE_CHEMICAL", 199, 208], ["CYP1A2", "PROTEIN", 36, 42], ["Olanzapine", "TREATMENT", 0, 10], ["increases in serum concentrations", "PROBLEM", 67, 100], ["an upper respiratory infection", "PROBLEM", 108, 138], ["clozapine", "TREATMENT", 199, 208], ["increases", "OBSERVATION_MODIFIER", 67, 76], ["serum concentrations", "OBSERVATION_MODIFIER", 80, 100], ["upper", "ANATOMY_MODIFIER", 111, 116], ["respiratory", "ANATOMY", 117, 128], ["infection", "OBSERVATION", 129, 138]]], ["Some case reports and observational studies previously reviewed in another article11 suggest that infections can increase the serum concentrations of antipsychotics metabolised by CYP3A4.", [["serum", "ANATOMY", 126, 131], ["infections", "DISEASE", 98, 108], ["article11", "GENE_OR_GENE_PRODUCT", 75, 84], ["serum", "ORGANISM_SUBSTANCE", 126, 131], ["antipsychotics", "SIMPLE_CHEMICAL", 150, 164], ["CYP3A4", "GENE_OR_GENE_PRODUCT", 180, 186], ["CYP3A4", "PROTEIN", 180, 186], ["observational studies", "TEST", 22, 43], ["infections", "PROBLEM", 98, 108], ["the serum concentrations of antipsychotics", "TREATMENT", 122, 164], ["infections", "OBSERVATION", 98, 108]]], ["Three second-generation antipsychotics are mainly metabolised by CYP3A4: cariprazine, quetiapine and lurasidone.", [["cariprazine", "CHEMICAL", 73, 84], ["quetiapine", "CHEMICAL", 86, 96], ["lurasidone", "CHEMICAL", 101, 111], ["cariprazine", "CHEMICAL", 73, 84], ["quetiapine", "CHEMICAL", 86, 96], ["lurasidone", "CHEMICAL", 101, 111], ["CYP3A4", "SIMPLE_CHEMICAL", 65, 71], ["cariprazine", "SIMPLE_CHEMICAL", 73, 84], ["quetiapine", "SIMPLE_CHEMICAL", 86, 96], ["lurasidone", "SIMPLE_CHEMICAL", 101, 111], ["Three second-generation antipsychotics", "TREATMENT", 0, 38], ["cariprazine", "TREATMENT", 73, 84], ["quetiapine", "TREATMENT", 86, 96], ["lurasidone", "TREATMENT", 101, 111]]], ["Four second-generation antipsychotics are metabolised by CYP2D6 and CYP3A4: aripiprazole, brexpiprazole, iloperidone and risperidone.", [["aripiprazole", "CHEMICAL", 76, 88], ["brexpiprazole", "CHEMICAL", 90, 103], ["iloperidone", "CHEMICAL", 105, 116], ["risperidone", "CHEMICAL", 121, 132], ["aripiprazole", "CHEMICAL", 76, 88], ["brexpiprazole", "CHEMICAL", 90, 103], ["iloperidone", "CHEMICAL", 105, 116], ["risperidone", "CHEMICAL", 121, 132], ["CYP2D6", "GENE_OR_GENE_PRODUCT", 57, 63], ["CYP3A4", "SIMPLE_CHEMICAL", 68, 74], ["aripiprazole", "SIMPLE_CHEMICAL", 76, 88], ["brexpiprazole", "SIMPLE_CHEMICAL", 90, 103], ["iloperidone", "SIMPLE_CHEMICAL", 105, 116], ["risperidone", "SIMPLE_CHEMICAL", 121, 132], ["Four second-generation antipsychotics", "TREATMENT", 0, 37], ["aripiprazole", "TREATMENT", 76, 88], ["brexpiprazole", "TREATMENT", 90, 103], ["iloperidone", "TREATMENT", 105, 116], ["risperidone", "TREATMENT", 121, 132]]], ["Until better studies are available, we recommend that clinicians remain aware of this potential for increases in serum concentration levels during infections/inflammations and the wisdom of measuring the serum concentrations of these seven antipsychotics metabolised by CYP3A4 when possible.Clozapine can cause inflammationClozapine can also cause inflammation, although the mechanisms are not completely understood.", [["serum", "ANATOMY", 113, 118], ["serum", "ANATOMY", 204, 209], ["infections", "DISEASE", 147, 157], ["inflammations", "DISEASE", 158, 171], ["Clozapine", "CHEMICAL", 291, 300], ["inflammation", "DISEASE", 311, 323], ["Clozapine", "CHEMICAL", 323, 332], ["inflammation", "DISEASE", 348, 360], ["Clozapine", "CHEMICAL", 291, 300], ["Clozapine", "CHEMICAL", 323, 332], ["serum", "ORGANISM_SUBSTANCE", 113, 118], ["serum", "ORGANISM_SUBSTANCE", 204, 209], ["CYP3A4", "GENE_OR_GENE_PRODUCT", 270, 276], ["Clozapine", "SIMPLE_CHEMICAL", 291, 300], ["Clozapine", "SIMPLE_CHEMICAL", 323, 332], ["CYP3A4", "PROTEIN", 270, 276], ["increases in serum concentration levels", "PROBLEM", 100, 139], ["infections", "PROBLEM", 147, 157], ["inflammations", "PROBLEM", 158, 171], ["the serum concentrations", "TREATMENT", 200, 224], ["these seven antipsychotics", "TREATMENT", 228, 254], ["Clozapine", "TREATMENT", 291, 300], ["inflammation", "PROBLEM", 311, 323], ["Clozapine", "TREATMENT", 323, 332], ["inflammation", "PROBLEM", 348, 360], ["inflammations", "OBSERVATION", 158, 171], ["inflammation", "OBSERVATION", 311, 323], ["inflammation", "OBSERVATION", 348, 360]]], ["Most cases of clozapine-induced inflammation occur during titration and the most typical manifestations are CRP elevations, fever and/or myocarditis.15 Other rarer forms have been described and include serositis, pneumonitis/alveolitis, hepatitis, pancreatitis, nephritis, colitis and dermatological disorders.15Clozapine can cause inflammationAustralia appears to have almost 10\u2013100 times more clozapine-induced myocarditis than European countries.", [["clozapine", "CHEMICAL", 14, 23], ["inflammation", "DISEASE", 32, 44], ["fever", "DISEASE", 124, 129], ["myocarditis", "DISEASE", 137, 148], ["serositis", "DISEASE", 202, 211], ["pneumonitis", "DISEASE", 213, 224], ["alveolitis", "DISEASE", 225, 235], ["hepatitis", "DISEASE", 237, 246], ["pancreatitis", "DISEASE", 248, 260], ["nephritis", "DISEASE", 262, 271], ["colitis", "DISEASE", 273, 280], ["dermatological disorders", "DISEASE", 285, 309], ["Clozapine", "CHEMICAL", 312, 321], ["inflammationAustralia", "DISEASE", 332, 353], ["clozapine", "CHEMICAL", 395, 404], ["myocarditis", "DISEASE", 413, 424], ["clozapine", "CHEMICAL", 14, 23], ["Clozapine", "CHEMICAL", 312, 321], ["clozapine", "CHEMICAL", 395, 404], ["clozapine", "SIMPLE_CHEMICAL", 14, 23], ["CRP", "GENE_OR_GENE_PRODUCT", 108, 111], ["colitis", "PATHOLOGICAL_FORMATION", 273, 280], ["Clozapine", "SIMPLE_CHEMICAL", 312, 321], ["clozapine", "SIMPLE_CHEMICAL", 395, 404], ["CRP", "PROTEIN", 108, 111], ["clozapine", "TREATMENT", 14, 23], ["induced inflammation", "PROBLEM", 24, 44], ["CRP elevations", "PROBLEM", 108, 122], ["fever", "PROBLEM", 124, 129], ["myocarditis", "PROBLEM", 137, 148], ["serositis", "PROBLEM", 202, 211], ["pneumonitis", "PROBLEM", 213, 224], ["alveolitis", "PROBLEM", 225, 235], ["hepatitis", "PROBLEM", 237, 246], ["pancreatitis", "PROBLEM", 248, 260], ["nephritis", "PROBLEM", 262, 271], ["colitis", "PROBLEM", 273, 280], ["dermatological disorders", "PROBLEM", 285, 309], ["Clozapine", "TREATMENT", 312, 321], ["inflammationAustralia", "PROBLEM", 332, 353], ["clozapine", "TREATMENT", 395, 404], ["myocarditis", "PROBLEM", 413, 424], ["inflammation", "OBSERVATION", 32, 44], ["myocarditis", "OBSERVATION", 137, 148], ["serositis", "OBSERVATION", 202, 211], ["pneumonitis", "OBSERVATION", 213, 224], ["alveolitis", "OBSERVATION", 225, 235], ["hepatitis", "OBSERVATION", 237, 246], ["pancreatitis", "OBSERVATION", 248, 260], ["nephritis", "OBSERVATION", 262, 271], ["colitis", "OBSERVATION", 273, 280], ["myocarditis", "OBSERVATION", 413, 424]]], ["Drug agencies from various countries send their data to a WHO database called VigiBase.16 In July 2019, there were 3048 reports of myocarditis associated with clozapine, which resulted in 6% lethality (170 fatal outcomes).", [["myocarditis", "DISEASE", 131, 142], ["clozapine", "CHEMICAL", 159, 168], ["clozapine", "CHEMICAL", 159, 168], ["clozapine", "SIMPLE_CHEMICAL", 159, 168], ["myocarditis", "PROBLEM", 131, 142], ["clozapine", "TREATMENT", 159, 168], ["6% lethality", "PROBLEM", 188, 200], ["myocarditis", "OBSERVATION", 131, 142]]], ["In the view of Australian experts,17 a 3% incidence rate of clozapine-induced myocarditis in Australia is explained solely by their intensive cardiac monitoring during titration, which is not practiced in other countries.", [["cardiac", "ANATOMY", 142, 149], ["clozapine", "CHEMICAL", 60, 69], ["myocarditis", "DISEASE", 78, 89], ["clozapine", "CHEMICAL", 60, 69], ["clozapine", "SIMPLE_CHEMICAL", 60, 69], ["cardiac", "ORGAN", 142, 149], ["clozapine", "TREATMENT", 60, 69], ["myocarditis", "PROBLEM", 78, 89], ["myocarditis", "OBSERVATION", 78, 89]]], ["Psychiatrists in continental Europe, on the other hand, titrate their patients slowly and rarely diagnose clozapine-induced myocarditis.", [["clozapine", "CHEMICAL", 106, 115], ["myocarditis", "DISEASE", 124, 135], ["clozapine", "CHEMICAL", 106, 115], ["patients", "ORGANISM", 70, 78], ["clozapine", "SIMPLE_CHEMICAL", 106, 115], ["patients", "SPECIES", 70, 78], ["clozapine", "TREATMENT", 106, 115], ["myocarditis", "PROBLEM", 124, 135], ["myocarditis", "OBSERVATION", 124, 135]]], ["In a real-world study with 3262 clozapine patients from the Danish registry, Rohde et al18 found a 0.03% incidence of myocarditis within the first 2 months of treatment.", [["clozapine", "CHEMICAL", 32, 41], ["myocarditis", "DISEASE", 118, 129], ["clozapine", "CHEMICAL", 32, 41], ["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["clozapine", "TREATMENT", 32, 41], ["myocarditis", "PROBLEM", 118, 129], ["treatment", "TREATMENT", 159, 168], ["myocarditis", "OBSERVATION", 118, 129]]], ["Based on a 3% incidence of myocarditis according to Australian data and a 6% death rate due to lack of cardiac monitoring, six deaths (3% multiplied by 6% is 0.18% and 0.18% of 3262 is six deaths) were expected in that Danish study, but no myocarditis deaths were identified within the first 2 months of clozapine treatment.18Clozapine can cause inflammationTo understand the paradox of clozapine myocarditis, one needs to remember that inflammation decreases clozapine metabolism and then realise that clozapine can also cause inflammation.", [["cardiac", "ANATOMY", 103, 110], ["myocarditis", "DISEASE", 27, 38], ["death", "DISEASE", 77, 82], ["deaths", "DISEASE", 127, 133], ["deaths", "DISEASE", 189, 195], ["myocarditis", "DISEASE", 240, 251], ["deaths", "DISEASE", 252, 258], ["clozapine", "CHEMICAL", 304, 313], ["Clozapine", "CHEMICAL", 326, 335], ["inflammation", "DISEASE", 346, 358], ["clozapine", "CHEMICAL", 387, 396], ["myocarditis", "DISEASE", 397, 408], ["inflammation", "DISEASE", 437, 449], ["clozapine", "CHEMICAL", 460, 469], ["clozapine", "CHEMICAL", 503, 512], ["inflammation", "DISEASE", 528, 540], ["clozapine", "CHEMICAL", 304, 313], ["Clozapine", "CHEMICAL", 326, 335], ["clozapine", "CHEMICAL", 387, 396], ["clozapine", "CHEMICAL", 460, 469], ["clozapine", "CHEMICAL", 503, 512], ["cardiac", "ORGAN", 103, 110], ["clozapine", "SIMPLE_CHEMICAL", 304, 313], ["Clozapine", "SIMPLE_CHEMICAL", 326, 335], ["clozapine", "SIMPLE_CHEMICAL", 387, 396], ["clozapine", "SIMPLE_CHEMICAL", 460, 469], ["clozapine", "SIMPLE_CHEMICAL", 503, 512], ["myocarditis", "PROBLEM", 27, 38], ["Australian data", "TEST", 52, 67], ["a 6% death rate", "PROBLEM", 72, 87], ["cardiac monitoring", "TEST", 103, 121], ["Danish study", "TEST", 219, 231], ["myocarditis deaths", "PROBLEM", 240, 258], ["clozapine treatment", "TREATMENT", 304, 323], ["Clozapine", "TREATMENT", 326, 335], ["inflammation", "PROBLEM", 346, 358], ["clozapine myocarditis", "PROBLEM", 387, 408], ["inflammation decreases clozapine metabolism", "PROBLEM", 437, 480], ["clozapine", "TREATMENT", 503, 512], ["inflammation", "PROBLEM", 528, 540], ["myocarditis", "OBSERVATION", 27, 38], ["cardiac", "ANATOMY", 103, 110], ["no", "UNCERTAINTY", 237, 239], ["myocarditis", "OBSERVATION", 240, 251], ["inflammation", "OBSERVATION", 437, 449], ["inflammation", "OBSERVATION", 528, 540]]], ["The history of lamotrigine-induced Stevens-Johnson syndrome provides further understanding.19 Lamotrigine-induced Stevens-Johnson syndrome was associated with rapid dose escalation and/or normal titration in patients taking an inhibitor, such as valproic acid.", [["lamotrigine", "CHEMICAL", 15, 26], ["Stevens-Johnson syndrome", "DISEASE", 35, 59], ["Lamotrigine", "CHEMICAL", 94, 105], ["Stevens-Johnson syndrome", "DISEASE", 114, 138], ["valproic acid", "CHEMICAL", 246, 259], ["lamotrigine", "CHEMICAL", 15, 26], ["Lamotrigine", "CHEMICAL", 94, 105], ["valproic acid", "CHEMICAL", 246, 259], ["lamotrigine", "SIMPLE_CHEMICAL", 15, 26], ["Lamotrigine", "SIMPLE_CHEMICAL", 94, 105], ["patients", "ORGANISM", 208, 216], ["valproic acid", "SIMPLE_CHEMICAL", 246, 259], ["patients", "SPECIES", 208, 216], ["lamotrigine", "TREATMENT", 15, 26], ["Johnson syndrome", "PROBLEM", 43, 59], ["Lamotrigine", "TREATMENT", 94, 105], ["Johnson syndrome", "PROBLEM", 122, 138], ["rapid dose escalation", "TREATMENT", 159, 180], ["an inhibitor", "TREATMENT", 224, 236], ["valproic acid", "TREATMENT", 246, 259], ["Johnson syndrome", "OBSERVATION", 43, 59], ["Johnson syndrome", "OBSERVATION", 122, 138]]], ["The first sign that the titration is too fast for that patient is usually a skin rash.", [["skin", "ANATOMY", 76, 80], ["rash", "DISEASE", 81, 85], ["patient", "ORGANISM", 55, 62], ["skin", "ORGAN", 76, 80], ["patient", "SPECIES", 55, 62], ["a skin rash", "PROBLEM", 74, 85], ["skin", "ANATOMY", 76, 80], ["rash", "OBSERVATION", 81, 85]]], ["If the escalation continues, auto-antibodies develop, leading to full-blown Stevens-Johnson syndrome.", [["Stevens-Johnson syndrome", "DISEASE", 76, 100], ["auto-antibodies", "PROTEIN", 29, 44], ["the escalation", "PROBLEM", 3, 17], ["auto-antibodies", "TEST", 29, 44], ["Johnson syndrome", "PROBLEM", 84, 100], ["blown Stevens", "OBSERVATION", 70, 83], ["Johnson syndrome", "OBSERVATION", 84, 100]]], ["Therefore, after the first approval, the pharmaceutical company had to reformulate the lamotrigine titration by halving the dose during co-prescription of valproic acid.", [["lamotrigine", "CHEMICAL", 87, 98], ["valproic acid", "CHEMICAL", 155, 168], ["lamotrigine", "CHEMICAL", 87, 98], ["valproic acid", "CHEMICAL", 155, 168], ["lamotrigine", "SIMPLE_CHEMICAL", 87, 98], ["valproic acid", "SIMPLE_CHEMICAL", 155, 168], ["the lamotrigine titration", "TREATMENT", 83, 108], ["valproic acid", "TREATMENT", 155, 168], ["valproic acid", "OBSERVATION", 155, 168]]], ["Similarly, we propose that, first, a clozapine titration that is too fast leads to CRP elevations and/or fever; second, cytokine release decreases clozapine metabolism and this causes a positive feedback mechanism; Third, if the clozapine titration continues, the inflammation evolves into myocarditis, probably with the development of auto-antibodies.Clozapine can cause inflammationThis model was supported by five published cases of clozapine-induced myocarditis in New York.20 After their data was provided to the first author, four cases were found to have rapid titration and the other case could not tolerate a low clozapine dose of 25 mg/day, which is compatible with being a US clozapine PM.", [["clozapine", "CHEMICAL", 37, 46], ["fever", "DISEASE", 105, 110], ["clozapine", "CHEMICAL", 147, 156], ["clozapine", "CHEMICAL", 229, 238], ["inflammation", "DISEASE", 264, 276], ["myocarditis", "DISEASE", 290, 301], ["auto-antibodies", "DISEASE", 336, 351], ["Clozapine", "CHEMICAL", 352, 361], ["inflammation", "DISEASE", 372, 384], ["clozapine", "CHEMICAL", 436, 445], ["myocarditis", "DISEASE", 454, 465], ["clozapine", "CHEMICAL", 622, 631], ["clozapine", "CHEMICAL", 687, 696], ["clozapine", "CHEMICAL", 37, 46], ["clozapine", "CHEMICAL", 147, 156], ["clozapine", "CHEMICAL", 229, 238], ["Clozapine", "CHEMICAL", 352, 361], ["clozapine", "CHEMICAL", 436, 445], ["clozapine", "CHEMICAL", 622, 631], ["clozapine", "CHEMICAL", 687, 696], ["clozapine", "SIMPLE_CHEMICAL", 37, 46], ["CRP", "GENE_OR_GENE_PRODUCT", 83, 86], ["clozapine", "SIMPLE_CHEMICAL", 147, 156], ["clozapine", "SIMPLE_CHEMICAL", 229, 238], ["Clozapine", "SIMPLE_CHEMICAL", 352, 361], ["clozapine", "SIMPLE_CHEMICAL", 436, 445], ["clozapine", "SIMPLE_CHEMICAL", 622, 631], ["CRP", "PROTEIN", 83, 86], ["cytokine", "PROTEIN", 120, 128], ["auto-antibodies", "PROTEIN", 336, 351], ["a clozapine titration", "TREATMENT", 35, 56], ["CRP elevations", "PROBLEM", 83, 97], ["fever", "PROBLEM", 105, 110], ["cytokine release", "TREATMENT", 120, 136], ["clozapine metabolism", "TREATMENT", 147, 167], ["a positive feedback mechanism", "PROBLEM", 184, 213], ["the clozapine titration", "TREATMENT", 225, 248], ["the inflammation", "PROBLEM", 260, 276], ["myocarditis", "PROBLEM", 290, 301], ["auto-antibodies", "PROBLEM", 336, 351], ["Clozapine", "TREATMENT", 352, 361], ["inflammation", "PROBLEM", 372, 384], ["clozapine", "TREATMENT", 436, 445], ["myocarditis", "PROBLEM", 454, 465], ["rapid titration", "TREATMENT", 562, 577], ["a low clozapine dose", "TREATMENT", 616, 636], ["a US clozapine PM", "TREATMENT", 682, 699], ["inflammation", "OBSERVATION", 264, 276], ["myocarditis", "OBSERVATION", 290, 301], ["auto-antibodies", "OBSERVATION", 336, 351], ["inflammation", "OBSERVATION", 372, 384], ["myocarditis", "OBSERVATION", 454, 465], ["compatible with", "UNCERTAINTY", 660, 675]]], ["In two of the five patients clozapine levels were available and they were compatible with a decrease in clozapine clearance.20Clozapine can cause inflammationFollowing this model, clozapine-induced myocarditis can be prevented by using slow, personalised titration: (1) with further slowing for Asians treated by Western psychiatrists, including Australians, who were trained to use Caucasian-level titration in all their patients; (2) considering reversible cases of clozapine PM status by stopping the co-prescription of inhibitors, such as valproic acid and oral contraceptives, and requiring normal CRP before starting clozapine; and (3) considering extremely slow titration for cases of clozapine PMs in which the cause cannot be removed: extreme obesity or an absolutely needed co-prescribed inhibitor.", [["oral", "ANATOMY", 561, 565], ["clozapine", "CHEMICAL", 28, 37], ["clozapine", "CHEMICAL", 104, 113], ["Clozapine", "CHEMICAL", 126, 135], ["inflammation", "DISEASE", 146, 158], ["clozapine", "CHEMICAL", 180, 189], ["myocarditis", "DISEASE", 198, 209], ["clozapine", "CHEMICAL", 468, 477], ["valproic acid", "CHEMICAL", 543, 556], ["oral contraceptives", "CHEMICAL", 561, 580], ["clozapine", "CHEMICAL", 623, 632], ["clozapine", "CHEMICAL", 692, 701], ["obesity", "DISEASE", 752, 759], ["clozapine", "CHEMICAL", 28, 37], ["clozapine", "CHEMICAL", 104, 113], ["Clozapine", "CHEMICAL", 126, 135], ["clozapine", "CHEMICAL", 180, 189], ["clozapine", "CHEMICAL", 468, 477], ["valproic acid", "CHEMICAL", 543, 556], ["clozapine", "CHEMICAL", 623, 632], ["clozapine", "CHEMICAL", 692, 701], ["patients", "ORGANISM", 19, 27], ["clozapine", "SIMPLE_CHEMICAL", 28, 37], ["clozapine", "SIMPLE_CHEMICAL", 104, 113], ["Clozapine", "SIMPLE_CHEMICAL", 126, 135], ["clozapine", "SIMPLE_CHEMICAL", 180, 189], ["patients", "ORGANISM", 422, 430], ["clozapine", "SIMPLE_CHEMICAL", 468, 477], ["valproic acid", "SIMPLE_CHEMICAL", 543, 556], ["oral", "ORGANISM_SUBDIVISION", 561, 565], ["CRP", "GENE_OR_GENE_PRODUCT", 603, 606], ["clozapine", "SIMPLE_CHEMICAL", 623, 632], ["clozapine PMs", "SIMPLE_CHEMICAL", 692, 705], ["CRP", "PROTEIN", 603, 606], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 422, 430], ["clozapine levels", "TEST", 28, 44], ["a decrease in clozapine clearance", "TREATMENT", 90, 123], ["Clozapine", "TREATMENT", 126, 135], ["inflammation", "PROBLEM", 146, 158], ["clozapine", "TREATMENT", 180, 189], ["myocarditis", "PROBLEM", 198, 209], ["Caucasian-level titration", "TREATMENT", 383, 408], ["clozapine", "TREATMENT", 468, 477], ["the co-prescription of inhibitors", "TREATMENT", 500, 533], ["valproic acid", "TREATMENT", 543, 556], ["oral contraceptives", "TREATMENT", 561, 580], ["clozapine", "TREATMENT", 623, 632], ["extremely slow titration", "TREATMENT", 654, 678], ["clozapine PMs", "TREATMENT", 692, 705], ["extreme obesity", "PROBLEM", 744, 759], ["co-prescribed inhibitor", "TREATMENT", 784, 807], ["inflammation", "OBSERVATION", 146, 158], ["myocarditis", "OBSERVATION", 198, 209], ["obesity", "OBSERVATION", 752, 759]]], ["When clozapine dose escalation is associated with an abnormal CRP, cytokines are being released and the titration is too fast for that individual patient.", [["clozapine", "CHEMICAL", 5, 14], ["clozapine", "CHEMICAL", 5, 14], ["clozapine", "SIMPLE_CHEMICAL", 5, 14], ["CRP", "GENE_OR_GENE_PRODUCT", 62, 65], ["patient", "ORGANISM", 146, 153], ["CRP", "PROTEIN", 62, 65], ["cytokines", "PROTEIN", 67, 76], ["patient", "SPECIES", 146, 153], ["clozapine dose escalation", "TREATMENT", 5, 30], ["an abnormal CRP", "PROBLEM", 50, 65], ["cytokines", "TREATMENT", 67, 76], ["abnormal", "OBSERVATION_MODIFIER", 53, 61], ["CRP", "OBSERVATION", 62, 65]]], ["Clozapine dose escalation needs to be held until CRP is normal.Clozapine can cause inflammationTo avoid the risk of myocarditis in Asians, we recommend starting with 12.5 mg as the first dose, followed by targets of 50 mg/day on day 7, 100 mg/day on day 14 and 150 mg/day on day 21.", [["Clozapine", "CHEMICAL", 0, 9], ["Clozapine", "CHEMICAL", 63, 72], ["inflammation", "DISEASE", 83, 95], ["myocarditis", "DISEASE", 116, 127], ["Clozapine", "CHEMICAL", 0, 9], ["Clozapine", "CHEMICAL", 63, 72], ["Clozapine", "SIMPLE_CHEMICAL", 0, 9], ["CRP", "GENE_OR_GENE_PRODUCT", 49, 52], ["Clozapine", "SIMPLE_CHEMICAL", 63, 72], ["CRP", "PROTEIN", 49, 52], ["Clozapine dose escalation", "TREATMENT", 0, 25], ["CRP", "TEST", 49, 52], ["Clozapine", "TREATMENT", 63, 72], ["inflammation", "PROBLEM", 83, 95], ["myocarditis", "PROBLEM", 116, 127], ["normal", "OBSERVATION", 56, 62], ["myocarditis", "OBSERVATION", 116, 127]]], ["Moreover, Asian companies producing clozapine should consider developing tables of 5 or 10 mg to facilitate slower titrations for Asian clozapine PMs.6 In the absence of formulation with clozapine doses lower than 12.5 mg, for Asians with severe obesity or with co-prescription of a medication with potential to be a clinically-relevant inhibitor of clozapine metabolism (eg, valproic acid or an oral contraceptive), we recommend starting with 12.5 mg as the first dose, followed by targets of 25 mg/day on day 7, 50 mg/day on day 14 and 75 mg/day on day 21.Clozapine can cause inflammationIn summary, data from (1) the lamotrigine literature; (2) the clinical experience of the authors; (3) the review of TDM studies from the US, Europe and Asia; and (4) VigiBase has been used to reframe the myocarditis debate.", [["oral", "ANATOMY", 396, 400], ["clozapine", "CHEMICAL", 36, 45], ["clozapine", "CHEMICAL", 136, 145], ["clozapine", "CHEMICAL", 187, 196], ["obesity", "DISEASE", 246, 253], ["clozapine", "CHEMICAL", 350, 359], ["valproic acid", "CHEMICAL", 376, 389], ["oral contraceptive", "CHEMICAL", 396, 414], ["Clozapine", "CHEMICAL", 558, 567], ["inflammation", "DISEASE", 578, 590], ["lamotrigine", "CHEMICAL", 620, 631], ["myocarditis", "DISEASE", 794, 805], ["clozapine", "CHEMICAL", 36, 45], ["clozapine", "CHEMICAL", 136, 145], ["clozapine", "CHEMICAL", 187, 196], ["clozapine", "CHEMICAL", 350, 359], ["valproic acid", "CHEMICAL", 376, 389], ["Clozapine", "CHEMICAL", 558, 567], ["lamotrigine", "CHEMICAL", 620, 631], ["clozapine", "SIMPLE_CHEMICAL", 36, 45], ["clozapine", "SIMPLE_CHEMICAL", 187, 196], ["clozapine", "SIMPLE_CHEMICAL", 350, 359], ["valproic acid", "SIMPLE_CHEMICAL", 376, 389], ["oral", "ORGANISM_SUBDIVISION", 396, 400], ["Clozapine", "SIMPLE_CHEMICAL", 558, 567], ["clozapine", "TREATMENT", 36, 45], ["Asian clozapine PMs", "TREATMENT", 130, 149], ["clozapine doses", "TREATMENT", 187, 202], ["severe obesity", "PROBLEM", 239, 253], ["a medication", "TREATMENT", 281, 293], ["clozapine metabolism (eg", "TREATMENT", 350, 374], ["valproic acid", "TREATMENT", 376, 389], ["an oral contraceptive", "TREATMENT", 393, 414], ["Clozapine", "TREATMENT", 558, 567], ["inflammation", "PROBLEM", 578, 590], ["TDM studies", "TEST", 706, 717], ["the US", "TEST", 723, 729], ["the myocarditis debate", "PROBLEM", 790, 812], ["obesity", "OBSERVATION", 246, 253], ["inflammation", "OBSERVATION", 578, 590], ["myocarditis", "OBSERVATION", 794, 805]]], ["Myocarditis is extremely rare in non-Australian countries and can be avoided by slow, personalised titration.", [["Myocarditis", "DISEASE", 0, 11], ["Myocarditis", "PROBLEM", 0, 11]]], ["The high incidence of clozapine-induced myocarditis in Australia is probably explained by titration that may be fast for Caucasians and is risky for Asian patients or for Caucasians taking an inhibitor, such as valproic acid.Clozapine may be associated with increased risk OF infectionClinicians all over the world know that on rare occasions clozapine can cause agranulocytosis since this information is included in the clozapine package inserts and most drug agencies require white cell counts to start clozapine.", [["white cell", "ANATOMY", 478, 488], ["clozapine", "CHEMICAL", 22, 31], ["myocarditis", "DISEASE", 40, 51], ["valproic acid", "CHEMICAL", 211, 224], ["Clozapine", "CHEMICAL", 225, 234], ["infection", "DISEASE", 276, 285], ["clozapine", "CHEMICAL", 343, 352], ["agranulocytosis", "DISEASE", 363, 378], ["clozapine", "CHEMICAL", 421, 430], ["clozapine", "CHEMICAL", 505, 514], ["clozapine", "CHEMICAL", 22, 31], ["valproic acid", "CHEMICAL", 211, 224], ["Clozapine", "CHEMICAL", 225, 234], ["clozapine", "CHEMICAL", 343, 352], ["clozapine", "CHEMICAL", 421, 430], ["clozapine", "CHEMICAL", 505, 514], ["clozapine", "SIMPLE_CHEMICAL", 22, 31], ["patients", "ORGANISM", 155, 163], ["valproic acid", "SIMPLE_CHEMICAL", 211, 224], ["Clozapine", "SIMPLE_CHEMICAL", 225, 234], ["clozapine", "SIMPLE_CHEMICAL", 343, 352], ["clozapine", "SIMPLE_CHEMICAL", 421, 430], ["white cell", "CELL", 478, 488], ["clozapine", "SIMPLE_CHEMICAL", 505, 514], ["patients", "SPECIES", 155, 163], ["clozapine", "TREATMENT", 22, 31], ["myocarditis", "PROBLEM", 40, 51], ["Caucasians", "TREATMENT", 171, 181], ["an inhibitor", "TREATMENT", 189, 201], ["valproic acid", "TREATMENT", 211, 224], ["Clozapine", "TREATMENT", 225, 234], ["increased risk OF infection", "PROBLEM", 258, 285], ["clozapine", "TREATMENT", 343, 352], ["agranulocytosis", "PROBLEM", 363, 378], ["the clozapine package inserts", "TREATMENT", 417, 446], ["white cell counts", "TEST", 478, 495], ["clozapine", "TREATMENT", 505, 514], ["high", "OBSERVATION_MODIFIER", 4, 8], ["clozapine", "OBSERVATION", 22, 31], ["myocarditis", "OBSERVATION", 40, 51], ["probably explained", "UNCERTAINTY", 68, 86], ["infection", "OBSERVATION", 276, 285], ["agranulocytosis", "OBSERVATION", 363, 378]]], ["The mechanism is not well understood but it is believed that, in these patients, antibodies are developed against the neutrophils.", [["neutrophils", "ANATOMY", 118, 129], ["patients", "ORGANISM", 71, 79], ["neutrophils", "CELL", 118, 129], ["antibodies", "PROTEIN", 81, 91], ["neutrophils", "CELL_TYPE", 118, 129], ["patients", "SPECIES", 71, 79], ["the neutrophils", "PROBLEM", 114, 129]]], ["The peak incidence occurs at 1 month of exposure and declines to negligible levels after 1 year of treatment.21 A recent meta-analysis provided a prevalence of agranulocytosis of 0.4% (95% CI: 0.3% to 0.6%); deaths caused by agranulocytosis were 0.05% (CI: 0.03% to 0.09%).22 This widespread awareness by clinicians is reflected in the almost 35 000 reports of neutropenia in VigiBase with the number of fatal outcomes only in the 500s (2% relative lethality).16Clozapine may be associated with increased risk OF infectionMore importantly, clinicians may not be aware that even in the absence of neutropenia, clozapine has been associated with a possible increased infection risk.", [["agranulocytosis", "DISEASE", 160, 175], ["deaths", "DISEASE", 208, 214], ["agranulocytosis", "DISEASE", 225, 240], ["neutropenia", "DISEASE", 361, 372], ["Clozapine", "CHEMICAL", 462, 471], ["infection", "DISEASE", 513, 522], ["neutropenia", "DISEASE", 596, 607], ["clozapine", "CHEMICAL", 609, 618], ["infection", "DISEASE", 665, 674], ["Clozapine", "CHEMICAL", 462, 471], ["clozapine", "CHEMICAL", 609, 618], ["Clozapine", "SIMPLE_CHEMICAL", 462, 471], ["clozapine", "SIMPLE_CHEMICAL", 609, 618], ["treatment", "TREATMENT", 99, 108], ["agranulocytosis", "PROBLEM", 160, 175], ["CI", "TEST", 189, 191], ["agranulocytosis", "PROBLEM", 225, 240], ["CI", "TEST", 253, 255], ["neutropenia", "PROBLEM", 361, 372], ["Clozapine", "TREATMENT", 462, 471], ["infection", "PROBLEM", 513, 522], ["neutropenia", "PROBLEM", 596, 607], ["clozapine", "TREATMENT", 609, 618], ["increased infection risk", "PROBLEM", 655, 679], ["peak", "OBSERVATION_MODIFIER", 4, 8], ["agranulocytosis", "OBSERVATION", 160, 175], ["agranulocytosis", "OBSERVATION", 225, 240], ["neutropenia", "OBSERVATION", 361, 372], ["fatal", "OBSERVATION_MODIFIER", 404, 409], ["infection", "OBSERVATION", 513, 522], ["neutropenia", "OBSERVATION", 596, 607], ["possible", "UNCERTAINTY", 646, 654], ["increased", "OBSERVATION_MODIFIER", 655, 664], ["infection", "OBSERVATION", 665, 674]]], ["Landry et al,23 based on case reports, proposed that clozapine may increase the risk of tuberculosis and, based on a chart review in a Canadian hospital, may be associated with increased use of antibiotics.", [["clozapine", "CHEMICAL", 53, 62], ["tuberculosis", "DISEASE", 88, 100], ["clozapine", "CHEMICAL", 53, 62], ["clozapine", "SIMPLE_CHEMICAL", 53, 62], ["clozapine", "TREATMENT", 53, 62], ["tuberculosis", "PROBLEM", 88, 100], ["antibiotics", "TREATMENT", 194, 205], ["tuberculosis", "OBSERVATION", 88, 100]]], ["Large studies in clozapine patients using the registries of Taiwan24 and Denmark25 verified an increased risk of tuberculosis with an adjusted risk ratio of 1.63 (95% CI: 1.10 to 2.40; p = 0.014)24 and increased antibiotic use with a relative risk of 1.43 (95% CI: 1.26 to 1.61, p<0.001).25 In a British case-control study, a higher proportion of the clozapine-treated group reported taking more than five courses of antibiotics in the preceding year, 5.3% (5/123) vs 1% (1/111) in controls taking other antipsychotics, and this was associated with an increased percentage of patients with low values for all immunoglobulins.26 In an vitro study, clozapine increased the production of the interleukin-1 receptor antagonist.27Clozapine may be associated with increased risk OF infectionRegarding possible increased infection risk in the absence of agranulocytosis, we only recommend that clinicians tell clozapine patients to avoid close contact with contagious people.Clozapine may be more strongly associated with pneumonia than with other infectionsThe second section suggests that infection may be associated with clozapine intoxication and the fourth and prior section that clozapine may increase infection risk possibly by interfering with immunological defenses.", [["clozapine", "CHEMICAL", 17, 26], ["tuberculosis", "DISEASE", 113, 125], ["clozapine", "CHEMICAL", 351, 360], ["clozapine", "CHEMICAL", 647, 656], ["27Clozapine", "CHEMICAL", 723, 734], ["infection", "DISEASE", 776, 785], ["infection", "DISEASE", 814, 823], ["agranulocytosis", "DISEASE", 847, 862], ["clozapine", "CHEMICAL", 903, 912], ["Clozapine", "CHEMICAL", 968, 977], ["pneumonia", "DISEASE", 1015, 1024], ["infections", "DISEASE", 1041, 1051], ["infection", "DISEASE", 1084, 1093], ["clozapine", "CHEMICAL", 1117, 1126], ["clozapine", "CHEMICAL", 1178, 1187], ["infection", "DISEASE", 1201, 1210], ["clozapine", "CHEMICAL", 17, 26], ["clozapine", "CHEMICAL", 351, 360], ["clozapine", "CHEMICAL", 647, 656], ["27Clozapine", "CHEMICAL", 723, 734], ["clozapine", "CHEMICAL", 903, 912], ["Clozapine", "CHEMICAL", 968, 977], ["clozapine", "CHEMICAL", 1117, 1126], ["clozapine", "CHEMICAL", 1178, 1187], ["clozapine", "SIMPLE_CHEMICAL", 17, 26], ["patients", "ORGANISM", 27, 35], ["Taiwan24", "GENE_OR_GENE_PRODUCT", 60, 68], ["clozapine", "SIMPLE_CHEMICAL", 351, 360], ["patients", "ORGANISM", 576, 584], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 609, 624], ["clozapine", "SIMPLE_CHEMICAL", 647, 656], ["interleukin-1 receptor antagonist", "GENE_OR_GENE_PRODUCT", 689, 722], ["27Clozapine", "SIMPLE_CHEMICAL", 723, 734], ["patients", "ORGANISM", 913, 921], ["people", "ORGANISM", 961, 967], ["Clozapine", "SIMPLE_CHEMICAL", 968, 977], ["clozapine", "SIMPLE_CHEMICAL", 1117, 1126], ["clozapine", "SIMPLE_CHEMICAL", 1178, 1187], ["immunoglobulins", "PROTEIN", 609, 624], ["interleukin-1 receptor", "PROTEIN", 689, 711], ["patients", "SPECIES", 27, 35], ["patients", "SPECIES", 576, 584], ["patients", "SPECIES", 913, 921], ["people", "SPECIES", 961, 967], ["Large studies", "TEST", 0, 13], ["clozapine", "TREATMENT", 17, 26], ["the registries of Taiwan24", "TREATMENT", 42, 68], ["tuberculosis", "PROBLEM", 113, 125], ["an adjusted risk ratio", "TEST", 131, 153], ["CI", "TEST", 167, 169], ["p", "TEST", 185, 186], ["CI", "TEST", 261, 263], ["the clozapine", "TREATMENT", 347, 360], ["antibiotics", "TREATMENT", 417, 428], ["other antipsychotics", "TREATMENT", 498, 518], ["low values", "PROBLEM", 590, 600], ["all immunoglobulins", "TREATMENT", 605, 624], ["an vitro study", "TEST", 631, 645], ["clozapine", "TREATMENT", 647, 656], ["the interleukin-1 receptor antagonist", "TREATMENT", 685, 722], ["27Clozapine", "TREATMENT", 723, 734], ["increased risk OF infection", "PROBLEM", 758, 785], ["increased infection risk", "PROBLEM", 804, 828], ["agranulocytosis", "PROBLEM", 847, 862], ["clozapine", "TREATMENT", 903, 912], ["Clozapine", "TREATMENT", 968, 977], ["pneumonia", "PROBLEM", 1015, 1024], ["other infections", "PROBLEM", 1035, 1051], ["infection", "PROBLEM", 1084, 1093], ["clozapine intoxication", "PROBLEM", 1117, 1139], ["clozapine", "TREATMENT", 1178, 1187], ["infection risk", "PROBLEM", 1201, 1215], ["increased", "OBSERVATION_MODIFIER", 95, 104], ["tuberculosis", "OBSERVATION", 113, 125], ["increased", "OBSERVATION_MODIFIER", 552, 561], ["percentage", "OBSERVATION_MODIFIER", 562, 572], ["infection", "OBSERVATION", 776, 785], ["possible", "UNCERTAINTY", 795, 803], ["increased", "OBSERVATION_MODIFIER", 804, 813], ["infection", "OBSERVATION", 814, 823], ["agranulocytosis", "OBSERVATION", 847, 862], ["pneumonia", "OBSERVATION", 1015, 1024], ["infections", "OBSERVATION", 1041, 1051], ["infection", "OBSERVATION", 1084, 1093], ["may be associated with", "UNCERTAINTY", 1094, 1116], ["increase", "OBSERVATION_MODIFIER", 1192, 1200], ["infection", "OBSERVATION", 1201, 1210]]], ["As pneumonia is one of the most frequent infections, it is not surprising to find in the literature that pneumonia may be associated with clozapine intoxication and that clozapine, by interfering with immunological mechanisms, may increase the risk of pneumonia.", [["pneumonia", "DISEASE", 3, 12], ["infections", "DISEASE", 41, 51], ["pneumonia", "DISEASE", 105, 114], ["clozapine", "CHEMICAL", 138, 147], ["clozapine", "CHEMICAL", 170, 179], ["pneumonia", "DISEASE", 252, 261], ["clozapine", "CHEMICAL", 138, 147], ["clozapine", "CHEMICAL", 170, 179], ["clozapine", "SIMPLE_CHEMICAL", 138, 147], ["clozapine", "SIMPLE_CHEMICAL", 170, 179], ["pneumonia", "PROBLEM", 3, 12], ["the most frequent infections", "PROBLEM", 23, 51], ["pneumonia", "PROBLEM", 105, 114], ["clozapine intoxication", "PROBLEM", 138, 160], ["clozapine", "TREATMENT", 170, 179], ["pneumonia", "PROBLEM", 252, 261], ["pneumonia", "OBSERVATION", 3, 12], ["one of the most frequent", "OBSERVATION_MODIFIER", 16, 40], ["infections", "OBSERVATION", 41, 51], ["pneumonia", "OBSERVATION", 105, 114], ["pneumonia", "OBSERVATION", 252, 261]]], ["Moreover, attentive reading of the literature suggests that clozapine and pneumonia have strong bidirectional associations beyond what has been described in prior sections.Clozapine may be more strongly associated with pneumonia than with other infectionsIn 2005, after studying post-marketing surveillance data, the FDA proposed that, by interfering with swallowing, antipsychotics were associated with increases in pneumonia in the elderly and this contributed to mortality in this population.27 Although clozapine is rarely used in the elderly, its US package insert, as with other second-generation antipsychotics, was modified to include this warning.", [["sections", "ANATOMY", 163, 171], ["clozapine", "CHEMICAL", 60, 69], ["pneumonia", "DISEASE", 74, 83], ["Clozapine", "CHEMICAL", 172, 181], ["pneumonia", "DISEASE", 219, 228], ["infections", "DISEASE", 245, 255], ["pneumonia", "DISEASE", 417, 426], ["clozapine", "CHEMICAL", 507, 516], ["clozapine", "CHEMICAL", 60, 69], ["Clozapine", "CHEMICAL", 172, 181], ["clozapine", "CHEMICAL", 507, 516], ["clozapine", "SIMPLE_CHEMICAL", 60, 69], ["Clozapine", "SIMPLE_CHEMICAL", 172, 181], ["clozapine", "SIMPLE_CHEMICAL", 507, 516], ["clozapine", "TREATMENT", 60, 69], ["pneumonia", "PROBLEM", 74, 83], ["Clozapine", "TREATMENT", 172, 181], ["pneumonia", "PROBLEM", 219, 228], ["other infections", "PROBLEM", 239, 255], ["surveillance data", "TEST", 294, 311], ["antipsychotics", "TREATMENT", 368, 382], ["pneumonia", "PROBLEM", 417, 426], ["clozapine", "TREATMENT", 507, 516], ["its US package insert", "TREATMENT", 548, 569], ["other second-generation antipsychotics", "TREATMENT", 579, 617], ["pneumonia", "OBSERVATION", 74, 83], ["pneumonia", "OBSERVATION", 219, 228], ["infections", "OBSERVATION", 245, 255], ["pneumonia", "OBSERVATION", 417, 426]]], ["Then Kuo et al,28 using the Taiwanese registry, demonstrated that clozapine may be the antipsychotic most closely associated with pneumonia.", [["clozapine", "CHEMICAL", 66, 75], ["pneumonia", "DISEASE", 130, 139], ["clozapine", "CHEMICAL", 66, 75], ["clozapine", "SIMPLE_CHEMICAL", 66, 75], ["clozapine", "TREATMENT", 66, 75], ["the antipsychotic", "TREATMENT", 83, 100], ["pneumonia", "PROBLEM", 130, 139], ["pneumonia", "OBSERVATION", 130, 139]]], ["As a matter of fact, compared with other antipsychotics, clozapine may be associated with a greater number of pneumonia cases and greater mortality.16 More importantly, clinicians need to be aware that pneumonia may be among the greatest causes of mortality in clozapine patients.", [["clozapine", "CHEMICAL", 57, 66], ["pneumonia", "DISEASE", 110, 119], ["pneumonia", "DISEASE", 202, 211], ["clozapine", "CHEMICAL", 261, 270], ["clozapine", "CHEMICAL", 57, 66], ["clozapine", "CHEMICAL", 261, 270], ["clozapine", "SIMPLE_CHEMICAL", 57, 66], ["patients", "ORGANISM", 271, 279], ["patients", "SPECIES", 271, 279], ["antipsychotics", "TREATMENT", 41, 55], ["clozapine", "TREATMENT", 57, 66], ["pneumonia cases", "PROBLEM", 110, 125], ["pneumonia", "PROBLEM", 202, 211], ["clozapine patients", "TREATMENT", 261, 279], ["greater", "OBSERVATION_MODIFIER", 92, 99], ["pneumonia", "OBSERVATION", 110, 119], ["greater", "OBSERVATION_MODIFIER", 130, 137], ["pneumonia", "OBSERVATION", 202, 211]]], ["VigiBase had >6000 reports of broadly-defined pneumonia in clozapine patients with >2000 lethal outcomes.", [["pneumonia", "DISEASE", 46, 55], ["clozapine", "CHEMICAL", 59, 68], ["clozapine", "CHEMICAL", 59, 68], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["broadly-defined pneumonia in clozapine patients", "PROBLEM", 30, 77], ["pneumonia", "OBSERVATION", 46, 55]]], ["To get an accurate perspective, clinicians need to be aware that the broad definitions of agranulocytosis or myocarditis were associated with lethal outcomes in the 500s.16Clozapine may be more strongly associated with pneumonia than with other infectionsBefore describing which known mechanism can explain the strong association between clozapine and pneumonia, we have to acknowledge that in countries other than China clozapine is mainly used for treatment-resistant schizophrenia.", [["agranulocytosis", "DISEASE", 90, 105], ["myocarditis", "DISEASE", 109, 120], ["Clozapine", "CHEMICAL", 172, 181], ["pneumonia", "DISEASE", 219, 228], ["infections", "DISEASE", 245, 255], ["clozapine", "CHEMICAL", 338, 347], ["pneumonia", "DISEASE", 352, 361], ["clozapine", "CHEMICAL", 421, 430], ["schizophrenia", "DISEASE", 470, 483], ["Clozapine", "CHEMICAL", 172, 181], ["clozapine", "CHEMICAL", 338, 347], ["clozapine", "CHEMICAL", 421, 430], ["Clozapine", "SIMPLE_CHEMICAL", 172, 181], ["clozapine", "SIMPLE_CHEMICAL", 338, 347], ["clozapine", "SIMPLE_CHEMICAL", 421, 430], ["agranulocytosis", "PROBLEM", 90, 105], ["myocarditis", "PROBLEM", 109, 120], ["lethal outcomes", "PROBLEM", 142, 157], ["Clozapine", "TREATMENT", 172, 181], ["pneumonia", "PROBLEM", 219, 228], ["other infections", "PROBLEM", 239, 255], ["clozapine", "TREATMENT", 338, 347], ["pneumonia", "PROBLEM", 352, 361], ["China clozapine", "TREATMENT", 415, 430], ["treatment", "TREATMENT", 450, 459], ["resistant schizophrenia", "PROBLEM", 460, 483], ["agranulocytosis", "OBSERVATION", 90, 105], ["myocarditis", "OBSERVATION", 109, 120], ["pneumonia", "OBSERVATION", 219, 228], ["infections", "OBSERVATION", 245, 255], ["pneumonia", "OBSERVATION", 352, 361], ["resistant", "OBSERVATION_MODIFIER", 460, 469], ["schizophrenia", "OBSERVATION", 470, 483]]], ["Thus, in countries other than China, the association between clozapine and pneumonia may be partly explained by the greater severity of illness in clozapine patients, who are frequently the most treatment-refractory patients with relatively high rates of smoking.", [["clozapine", "CHEMICAL", 61, 70], ["pneumonia", "DISEASE", 75, 84], ["illness", "DISEASE", 136, 143], ["clozapine", "CHEMICAL", 147, 156], ["smoking", "CHEMICAL", 255, 262], ["clozapine", "CHEMICAL", 61, 70], ["clozapine", "CHEMICAL", 147, 156], ["clozapine", "SIMPLE_CHEMICAL", 61, 70], ["patients", "ORGANISM", 157, 165], ["patients", "ORGANISM", 216, 224], ["patients", "SPECIES", 157, 165], ["patients", "SPECIES", 216, 224], ["clozapine", "TREATMENT", 61, 70], ["pneumonia", "PROBLEM", 75, 84], ["pneumonia", "OBSERVATION", 75, 84]]], ["Therefore, the contributing effects of the severity level of mental illness on pneumonia needs to be further explored by future studies in clozapine patients.", [["illness", "DISEASE", 68, 75], ["pneumonia", "DISEASE", 79, 88], ["clozapine", "CHEMICAL", 139, 148], ["clozapine", "CHEMICAL", 139, 148], ["clozapine", "SIMPLE_CHEMICAL", 139, 148], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["mental illness", "PROBLEM", 61, 75], ["pneumonia", "PROBLEM", 79, 88], ["clozapine patients", "TREATMENT", 139, 157], ["pneumonia", "OBSERVATION", 79, 88]]], ["On the other hand, clozapine has specific effects independent of the greater severity of illness in the clozapine patients, since using mirror-image design in the Danish registry, Rhode et al.29Clozapine may be more strongly associated with pneumonia than with other infectionsRhode et al29 found that clozapine gave the largest absolute increase in pneumonia risk although it did not reach significance, probably due to the relatively small sample size.", [["clozapine", "CHEMICAL", 19, 28], ["illness", "DISEASE", 89, 96], ["clozapine", "CHEMICAL", 104, 113], ["Clozapine", "CHEMICAL", 194, 203], ["pneumonia", "DISEASE", 241, 250], ["infections", "DISEASE", 267, 277], ["clozapine", "CHEMICAL", 302, 311], ["pneumonia", "DISEASE", 350, 359], ["clozapine", "CHEMICAL", 19, 28], ["clozapine", "CHEMICAL", 104, 113], ["Clozapine", "CHEMICAL", 194, 203], ["clozapine", "CHEMICAL", 302, 311], ["clozapine", "SIMPLE_CHEMICAL", 19, 28], ["patients", "ORGANISM", 114, 122], ["Clozapine", "SIMPLE_CHEMICAL", 194, 203], ["clozapine", "SIMPLE_CHEMICAL", 302, 311], ["patients", "SPECIES", 114, 122], ["clozapine", "TREATMENT", 19, 28], ["Clozapine", "TREATMENT", 194, 203], ["pneumonia", "PROBLEM", 241, 250], ["other infections", "PROBLEM", 261, 277], ["clozapine", "TREATMENT", 302, 311], ["pneumonia risk", "PROBLEM", 350, 364], ["the relatively small sample size", "PROBLEM", 421, 453], ["pneumonia", "OBSERVATION", 241, 250], ["infections", "OBSERVATION", 267, 277], ["largest", "OBSERVATION_MODIFIER", 321, 328], ["absolute", "OBSERVATION_MODIFIER", 329, 337], ["increase", "OBSERVATION_MODIFIER", 338, 346], ["pneumonia", "OBSERVATION", 350, 359], ["probably due to", "UNCERTAINTY", 405, 420], ["relatively", "OBSERVATION_MODIFIER", 425, 435], ["small", "OBSERVATION_MODIFIER", 436, 441], ["sample", "OBSERVATION_MODIFIER", 442, 448], ["size", "OBSERVATION_MODIFIER", 449, 453]]], ["In the year before clozapine, there were 1.22% (23/1872) patients with pneumonia and in the first year 1.87% (35/1872).", [["clozapine", "CHEMICAL", 19, 28], ["pneumonia", "DISEASE", 71, 80], ["clozapine", "CHEMICAL", 19, 28], ["clozapine", "SIMPLE_CHEMICAL", 19, 28], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["clozapine", "TREATMENT", 19, 28], ["pneumonia", "PROBLEM", 71, 80], ["pneumonia", "OBSERVATION", 71, 80]]], ["This is an increase of 0.64% (12/1872) (p=0.10).Clozapine may be more strongly associated with pneumonia than with other infectionsClozapine, as with any other antipsychotic, can interfere with swallowing, increasing the potential for aspiration.27 The potential for aspiration and aspiration pneumonia during antipsychotic treatment may be further increased by sedation and hypersalivation.27 As clozapine is more prone to cause sedation and hypersalivation than other antipsychotics,27 it is not surprising that clozapine may be more strongly associated with aspiration pneumonia.", [["Clozapine", "CHEMICAL", 48, 57], ["pneumonia", "DISEASE", 95, 104], ["infections", "DISEASE", 121, 131], ["Clozapine", "CHEMICAL", 131, 140], ["pneumonia", "DISEASE", 293, 302], ["hypersalivation", "DISEASE", 375, 390], ["clozapine", "CHEMICAL", 397, 406], ["hypersalivation", "DISEASE", 443, 458], ["clozapine", "CHEMICAL", 514, 523], ["pneumonia", "DISEASE", 572, 581], ["Clozapine", "CHEMICAL", 48, 57], ["Clozapine", "CHEMICAL", 131, 140], ["clozapine", "CHEMICAL", 397, 406], ["clozapine", "CHEMICAL", 514, 523], ["Clozapine", "SIMPLE_CHEMICAL", 48, 57], ["Clozapine", "SIMPLE_CHEMICAL", 131, 140], ["clozapine", "SIMPLE_CHEMICAL", 397, 406], ["clozapine", "SIMPLE_CHEMICAL", 514, 523], ["Clozapine", "TREATMENT", 48, 57], ["pneumonia", "PROBLEM", 95, 104], ["other infections", "PROBLEM", 115, 131], ["Clozapine", "TREATMENT", 131, 140], ["any other antipsychotic", "TREATMENT", 150, 173], ["swallowing", "TREATMENT", 194, 204], ["aspiration", "PROBLEM", 235, 245], ["aspiration", "PROBLEM", 267, 277], ["aspiration pneumonia", "PROBLEM", 282, 302], ["antipsychotic treatment", "TREATMENT", 310, 333], ["sedation", "TREATMENT", 362, 370], ["hypersalivation", "PROBLEM", 375, 390], ["clozapine", "TREATMENT", 397, 406], ["sedation", "TREATMENT", 430, 438], ["hypersalivation", "PROBLEM", 443, 458], ["antipsychotics", "TREATMENT", 470, 484], ["clozapine", "TREATMENT", 514, 523], ["aspiration pneumonia", "PROBLEM", 561, 581], ["increase", "OBSERVATION_MODIFIER", 11, 19], ["pneumonia", "OBSERVATION", 95, 104], ["infections", "OBSERVATION", 121, 131], ["aspiration", "OBSERVATION", 235, 245], ["potential for", "UNCERTAINTY", 253, 266], ["aspiration", "OBSERVATION", 267, 277], ["aspiration", "OBSERVATION_MODIFIER", 282, 292], ["pneumonia", "OBSERVATION", 293, 302], ["increased", "OBSERVATION_MODIFIER", 349, 358], ["aspiration", "OBSERVATION", 561, 571]]], ["Assuming that clozapine is associated with immunological abnormalities, this may also explain an increased risk for other types of pneumonia not associated with aspiration.", [["clozapine", "CHEMICAL", 14, 23], ["pneumonia", "DISEASE", 131, 140], ["clozapine", "CHEMICAL", 14, 23], ["clozapine", "SIMPLE_CHEMICAL", 14, 23], ["clozapine", "TREATMENT", 14, 23], ["immunological abnormalities", "PROBLEM", 43, 70], ["pneumonia", "PROBLEM", 131, 140], ["aspiration", "PROBLEM", 161, 171], ["increased", "OBSERVATION_MODIFIER", 97, 106], ["pneumonia", "OBSERVATION", 131, 140], ["not associated with", "UNCERTAINTY", 141, 160], ["aspiration", "OBSERVATION", 161, 171]]], ["Rarely, other severe clozapine ADRs, such as severe constipation complicated with ileus, or myocarditis, can be complicated by pneumonia.", [["clozapine", "CHEMICAL", 21, 30], ["ADRs", "DISEASE", 31, 35], ["constipation", "DISEASE", 52, 64], ["ileus", "DISEASE", 82, 87], ["myocarditis", "DISEASE", 92, 103], ["pneumonia", "DISEASE", 127, 136], ["clozapine", "CHEMICAL", 21, 30], ["clozapine", "SIMPLE_CHEMICAL", 21, 30], ["other severe clozapine ADRs", "PROBLEM", 8, 35], ["severe constipation", "PROBLEM", 45, 64], ["ileus", "PROBLEM", 82, 87], ["myocarditis", "PROBLEM", 92, 103], ["pneumonia", "PROBLEM", 127, 136], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["clozapine", "OBSERVATION", 21, 30], ["ileus", "OBSERVATION", 82, 87], ["myocarditis", "OBSERVATION", 92, 103], ["pneumonia", "OBSERVATION", 127, 136]]], ["Once pneumonia develops, clozapine co-prescription may be particularly lethal and worse than other antipsychotics.", [["pneumonia", "DISEASE", 5, 14], ["clozapine", "CHEMICAL", 25, 34], ["clozapine", "CHEMICAL", 25, 34], ["clozapine", "SIMPLE_CHEMICAL", 25, 34], ["pneumonia", "PROBLEM", 5, 14], ["clozapine co-prescription", "TREATMENT", 25, 50], ["other antipsychotics", "TREATMENT", 93, 113], ["pneumonia", "OBSERVATION", 5, 14]]], ["Severe inflammation during pneumonia releases cytokines that inhibit CYP1A2 expression and/or activity and increase serum clozapine concentrations, further increasing the risk of concentration-related ADRs including hypersalivation, sedation, aspiration or even arrhythmia, creating very dangerous positive feedback.16Clozapine may be more strongly associated with pneumonia than with other infectionsOur three sets of recommendations for infections in clozapine patients apply to the most important infection, pneumonia.", [["serum", "ANATOMY", 116, 121], ["inflammation", "DISEASE", 7, 19], ["pneumonia", "DISEASE", 27, 36], ["clozapine", "CHEMICAL", 122, 131], ["ADRs", "DISEASE", 201, 205], ["hypersalivation", "DISEASE", 216, 231], ["arrhythmia", "DISEASE", 262, 272], ["Clozapine", "CHEMICAL", 318, 327], ["pneumonia", "DISEASE", 365, 374], ["infections", "DISEASE", 391, 401], ["infections", "DISEASE", 439, 449], ["clozapine", "CHEMICAL", 453, 462], ["infection", "DISEASE", 500, 509], ["pneumonia", "DISEASE", 511, 520], ["clozapine", "CHEMICAL", 122, 131], ["Clozapine", "CHEMICAL", 318, 327], ["clozapine", "CHEMICAL", 453, 462], ["CYP1A2", "GENE_OR_GENE_PRODUCT", 69, 75], ["serum", "ORGANISM_SUBSTANCE", 116, 121], ["clozapine", "SIMPLE_CHEMICAL", 122, 131], ["Clozapine", "SIMPLE_CHEMICAL", 318, 327], ["patients", "ORGANISM", 463, 471], ["cytokines", "PROTEIN", 46, 55], ["CYP1A2", "PROTEIN", 69, 75], ["patients", "SPECIES", 463, 471], ["Severe inflammation", "PROBLEM", 0, 19], ["pneumonia releases cytokines", "PROBLEM", 27, 55], ["CYP1A2 expression", "TEST", 69, 86], ["increase serum clozapine concentrations", "TREATMENT", 107, 146], ["ADRs", "PROBLEM", 201, 205], ["hypersalivation", "PROBLEM", 216, 231], ["sedation", "TREATMENT", 233, 241], ["aspiration", "PROBLEM", 243, 253], ["arrhythmia", "PROBLEM", 262, 272], ["creating very dangerous positive feedback", "PROBLEM", 274, 315], ["Clozapine", "TREATMENT", 318, 327], ["pneumonia", "PROBLEM", 365, 374], ["other infections", "PROBLEM", 385, 401], ["infections", "PROBLEM", 439, 449], ["clozapine", "TREATMENT", 453, 462], ["pneumonia", "PROBLEM", 511, 520], ["inflammation", "OBSERVATION", 7, 19], ["pneumonia", "OBSERVATION", 27, 36], ["pneumonia", "OBSERVATION", 365, 374], ["infections", "OBSERVATION", 391, 401], ["most important", "OBSERVATION_MODIFIER", 485, 499], ["infection", "OBSERVATION", 500, 509], ["pneumonia", "OBSERVATION", 511, 520]]], ["The general preventive measures related to infection apply, including patient/family education and use of the lowest possible dosage providing efficacious response.", [["infection", "DISEASE", 43, 52], ["patient", "ORGANISM", 70, 77], ["patient", "SPECIES", 70, 77], ["The general preventive measures", "TREATMENT", 0, 31], ["infection", "PROBLEM", 43, 52], ["infection", "OBSERVATION", 43, 52]]], ["Specific preventive measures for aspiration pneumonia are close monitoring of sedation and hypersalivation.", [["pneumonia", "DISEASE", 44, 53], ["hypersalivation", "DISEASE", 91, 106], ["Specific preventive measures", "TREATMENT", 0, 28], ["aspiration pneumonia", "PROBLEM", 33, 53], ["sedation", "TREATMENT", 78, 86], ["hypersalivation", "PROBLEM", 91, 106]]], ["Clozapine administration should be moved around to the most convenient times in order to increase adherence and decrease these ADRs; treat hypersalivation, preferably with local antimuscarinic treatments which may have less risk of increasing the risk of constipation than oral anticholinergic drugs, such as benztropine, or biperiden.", [["oral", "ANATOMY", 273, 277], ["Clozapine", "CHEMICAL", 0, 9], ["ADRs", "DISEASE", 127, 131], ["hypersalivation", "DISEASE", 139, 154], ["constipation", "DISEASE", 255, 267], ["benztropine", "CHEMICAL", 309, 320], ["biperiden", "CHEMICAL", 325, 334], ["Clozapine", "CHEMICAL", 0, 9], ["benztropine", "CHEMICAL", 309, 320], ["Clozapine", "SIMPLE_CHEMICAL", 0, 9], ["oral", "ORGANISM_SUBDIVISION", 273, 277], ["benztropine", "SIMPLE_CHEMICAL", 309, 320], ["Clozapine administration", "TREATMENT", 0, 24], ["these ADRs", "PROBLEM", 121, 131], ["hypersalivation", "PROBLEM", 139, 154], ["local antimuscarinic treatments", "TREATMENT", 172, 203], ["constipation", "PROBLEM", 255, 267], ["oral anticholinergic drugs", "TREATMENT", 273, 299], ["benztropine", "TREATMENT", 309, 320], ["biperiden", "TREATMENT", 325, 334]]], ["Discontinuation of other co-medications associated with sedation and/or pneumonia risk should be considered.", [["pneumonia", "DISEASE", 72, 81], ["other co-medications", "TREATMENT", 19, 39], ["sedation", "TREATMENT", 56, 64], ["pneumonia risk", "PROBLEM", 72, 86], ["pneumonia", "OBSERVATION", 72, 81]]], ["As benzodiazepines are associated with sedation, swallowing disturbances and pneumonia, clinicians may need to consider decreasing or discontinuing them to decrease the aspiration pneumonia risk.", [["benzodiazepines", "CHEMICAL", 3, 18], ["swallowing disturbances", "DISEASE", 49, 72], ["pneumonia", "DISEASE", 77, 86], ["pneumonia", "DISEASE", 180, 189], ["benzodiazepines", "CHEMICAL", 3, 18], ["benzodiazepines", "SIMPLE_CHEMICAL", 3, 18], ["benzodiazepines", "TREATMENT", 3, 18], ["sedation", "TREATMENT", 39, 47], ["swallowing disturbances", "PROBLEM", 49, 72], ["pneumonia", "PROBLEM", 77, 86], ["the aspiration pneumonia risk", "PROBLEM", 165, 194], ["pneumonia", "OBSERVATION", 77, 86], ["aspiration", "OBSERVATION_MODIFIER", 169, 179], ["pneumonia", "OBSERVATION", 180, 189]]], ["Although there is no data, it may not be unreasonable to give pneumonia vaccines to clozapine patients to decrease risk of pneumonia not associated with aspiration, but it cannot be ruled out that vaccines may not be as effective in clozapine patients due to clozapine effects on immunological mechanisms.Clozapine may be more strongly associated with pneumonia than with other infectionsBased on our experience with pneumonia,12\u201314 we recommend that clinicians measure trough serum clozapine concentrations to personalise dosing during pneumonia.", [["serum", "ANATOMY", 477, 482], ["pneumonia", "DISEASE", 62, 71], ["clozapine", "CHEMICAL", 84, 93], ["pneumonia", "DISEASE", 123, 132], ["clozapine", "CHEMICAL", 233, 242], ["clozapine", "CHEMICAL", 259, 268], ["Clozapine", "CHEMICAL", 305, 314], ["pneumonia", "DISEASE", 352, 361], ["infections", "DISEASE", 378, 388], ["pneumonia", "DISEASE", 417, 426], ["clozapine", "CHEMICAL", 483, 492], ["pneumonia", "DISEASE", 537, 546], ["clozapine", "CHEMICAL", 84, 93], ["clozapine", "CHEMICAL", 233, 242], ["clozapine", "CHEMICAL", 259, 268], ["Clozapine", "CHEMICAL", 305, 314], ["clozapine", "CHEMICAL", 483, 492], ["patients", "ORGANISM", 94, 102], ["patients", "ORGANISM", 243, 251], ["clozapine", "SIMPLE_CHEMICAL", 259, 268], ["Clozapine", "SIMPLE_CHEMICAL", 305, 314], ["serum", "ORGANISM_SUBSTANCE", 477, 482], ["clozapine", "SIMPLE_CHEMICAL", 483, 492], ["patients", "SPECIES", 94, 102], ["patients", "SPECIES", 243, 251], ["pneumonia vaccines", "TREATMENT", 62, 80], ["clozapine", "TREATMENT", 84, 93], ["pneumonia", "PROBLEM", 123, 132], ["aspiration", "PROBLEM", 153, 163], ["vaccines", "TREATMENT", 197, 205], ["clozapine", "TREATMENT", 233, 242], ["clozapine effects", "PROBLEM", 259, 276], ["immunological mechanisms", "TREATMENT", 280, 304], ["Clozapine", "TREATMENT", 305, 314], ["pneumonia", "PROBLEM", 352, 361], ["other infections", "PROBLEM", 372, 388], ["pneumonia", "PROBLEM", 417, 426], ["trough serum clozapine concentrations", "TREATMENT", 470, 507], ["personalise dosing", "TREATMENT", 511, 529], ["pneumonia", "PROBLEM", 537, 546], ["no", "UNCERTAINTY", 18, 20], ["pneumonia", "OBSERVATION", 123, 132], ["aspiration", "OBSERVATION", 153, 163], ["pneumonia", "OBSERVATION", 352, 361], ["infections", "OBSERVATION", 378, 388], ["pneumonia", "OBSERVATION", 417, 426], ["pneumonia", "OBSERVATION", 537, 546]]], ["As the clozapine levels may not be immediately available and due to high lethality, we are convinced that the clozapine dose should be cut in half in all patients with pneumonia.", [["clozapine", "CHEMICAL", 7, 16], ["clozapine", "CHEMICAL", 110, 119], ["pneumonia", "DISEASE", 168, 177], ["clozapine", "CHEMICAL", 7, 16], ["clozapine", "CHEMICAL", 110, 119], ["clozapine", "SIMPLE_CHEMICAL", 7, 16], ["clozapine", "SIMPLE_CHEMICAL", 110, 119], ["patients", "ORGANISM", 154, 162], ["patients", "SPECIES", 154, 162], ["the clozapine levels", "TEST", 3, 23], ["high lethality", "PROBLEM", 68, 82], ["the clozapine dose", "TREATMENT", 106, 124], ["pneumonia", "PROBLEM", 168, 177], ["pneumonia", "OBSERVATION", 168, 177]]], ["Regarding antibiotic treatment, those such as ciprofloxacin and norfloxacin, which are strong CYP1A2 inhibitors, should not be used.Clozapine may be more strongly associated with pneumonia than with other infectionsAfter the pneumonia has resolved, we make the same recommendation as after infections: return to the prior dose after the CRP has normalised and consider the lowest clozapine dose possible with the fewest ADRs in order to avoid the recurrence of pneumonia in the future.Clozapine may be more strongly associated with pneumonia than with other infectionsClozapine appears to be associated with significantly fewer deaths in patients continuously treated with clozapine compared with other antipsychotics.", [["ciprofloxacin", "CHEMICAL", 46, 59], ["norfloxacin", "CHEMICAL", 64, 75], ["Clozapine", "CHEMICAL", 132, 141], ["pneumonia", "DISEASE", 179, 188], ["infections", "DISEASE", 205, 215], ["pneumonia", "DISEASE", 225, 234], ["infections", "DISEASE", 290, 300], ["clozapine", "CHEMICAL", 380, 389], ["ADRs", "DISEASE", 420, 424], ["pneumonia", "DISEASE", 461, 470], ["Clozapine", "CHEMICAL", 485, 494], ["pneumonia", "DISEASE", 532, 541], ["infections", "DISEASE", 558, 568], ["Clozapine", "CHEMICAL", 568, 577], ["deaths", "DISEASE", 628, 634], ["clozapine", "CHEMICAL", 673, 682], ["ciprofloxacin", "CHEMICAL", 46, 59], ["norfloxacin", "CHEMICAL", 64, 75], ["Clozapine", "CHEMICAL", 132, 141], ["clozapine", "CHEMICAL", 380, 389], ["Clozapine", "CHEMICAL", 485, 494], ["Clozapine", "CHEMICAL", 568, 577], ["clozapine", "CHEMICAL", 673, 682], ["ciprofloxacin", "SIMPLE_CHEMICAL", 46, 59], ["norfloxacin", "SIMPLE_CHEMICAL", 64, 75], ["CYP1A2", "GENE_OR_GENE_PRODUCT", 94, 100], ["Clozapine", "SIMPLE_CHEMICAL", 132, 141], ["CRP", "GENE_OR_GENE_PRODUCT", 337, 340], ["clozapine", "SIMPLE_CHEMICAL", 380, 389], ["Clozapine", "SIMPLE_CHEMICAL", 485, 494], ["Clozapine", "SIMPLE_CHEMICAL", 568, 577], ["patients", "ORGANISM", 638, 646], ["clozapine", "SIMPLE_CHEMICAL", 673, 682], ["CRP", "PROTEIN", 337, 340], ["patients", "SPECIES", 638, 646], ["antibiotic treatment", "TREATMENT", 10, 30], ["ciprofloxacin", "TREATMENT", 46, 59], ["norfloxacin", "TREATMENT", 64, 75], ["strong CYP1A2 inhibitors", "TREATMENT", 87, 111], ["Clozapine", "TREATMENT", 132, 141], ["pneumonia", "PROBLEM", 179, 188], ["other infections", "PROBLEM", 199, 215], ["the pneumonia", "PROBLEM", 221, 234], ["the CRP", "TEST", 333, 340], ["the lowest clozapine dose", "TREATMENT", 369, 394], ["pneumonia", "PROBLEM", 461, 470], ["Clozapine", "TREATMENT", 485, 494], ["pneumonia", "PROBLEM", 532, 541], ["other infections", "PROBLEM", 552, 568], ["Clozapine", "TREATMENT", 568, 577], ["clozapine", "TREATMENT", 673, 682], ["other antipsychotics", "TREATMENT", 697, 717], ["pneumonia", "OBSERVATION", 179, 188], ["infections", "OBSERVATION", 205, 215], ["pneumonia", "OBSERVATION", 225, 234], ["pneumonia", "OBSERVATION", 461, 470], ["pneumonia", "OBSERVATION", 532, 541], ["infections", "OBSERVATION", 558, 568]]], ["In a meta-analysis of 24 studies, long-term, crude mortality rate ratios were not significantly lower in patients ever treated with clozapine during follow-up, but significantly lower in patients continuously treated with clozapine compared with patients using other antipsychotics (mortality rate ratio=0.56, 95% CI: 0.36 to 0.85, p =0.007).30 By being alert to the multifaceted association of clozapine with inflammation, clinicians may further decrease the mortality in clozapine patients.Clozapine may be more strongly associated with pneumonia than with other infectionsIn summary, clinicians need to remember that: (1) systemic inflammations can increase clozapine level; (2) clozapine, by itself, can cause inflammation, particularly during titration that is too rapid for that patient; (3) clozapine may increase the risk of infection; and (4) more specifically, clozapine may be particularly strongly associated with the risk of pneumonia.", [["clozapine", "CHEMICAL", 132, 141], ["clozapine", "CHEMICAL", 222, 231], ["clozapine", "CHEMICAL", 395, 404], ["inflammation", "DISEASE", 410, 422], ["clozapine", "CHEMICAL", 473, 482], ["Clozapine", "CHEMICAL", 492, 501], ["pneumonia", "DISEASE", 539, 548], ["infections", "DISEASE", 565, 575], ["inflammations", "DISEASE", 634, 647], ["clozapine", "CHEMICAL", 661, 670], ["clozapine", "CHEMICAL", 682, 691], ["inflammation", "DISEASE", 714, 726], ["clozapine", "CHEMICAL", 798, 807], ["infection", "DISEASE", 833, 842], ["clozapine", "CHEMICAL", 871, 880], ["pneumonia", "DISEASE", 938, 947], ["clozapine", "CHEMICAL", 132, 141], ["clozapine", "CHEMICAL", 222, 231], ["clozapine", "CHEMICAL", 395, 404], ["clozapine", "CHEMICAL", 473, 482], ["Clozapine", "CHEMICAL", 492, 501], ["clozapine", "CHEMICAL", 661, 670], ["clozapine", "CHEMICAL", 682, 691], ["clozapine", "CHEMICAL", 798, 807], ["clozapine", "CHEMICAL", 871, 880], ["patients", "ORGANISM", 105, 113], ["clozapine", "SIMPLE_CHEMICAL", 132, 141], ["patients", "ORGANISM", 187, 195], ["clozapine", "SIMPLE_CHEMICAL", 222, 231], ["patients", "ORGANISM", 246, 254], ["clozapine", "SIMPLE_CHEMICAL", 395, 404], ["patients", "ORGANISM", 483, 491], ["Clozapine", "SIMPLE_CHEMICAL", 492, 501], ["clozapine", "SIMPLE_CHEMICAL", 661, 670], ["clozapine", "SIMPLE_CHEMICAL", 682, 691], ["patient", "ORGANISM", 785, 792], ["clozapine", "SIMPLE_CHEMICAL", 798, 807], ["clozapine", "SIMPLE_CHEMICAL", 871, 880], ["patients", "SPECIES", 105, 113], ["patients", "SPECIES", 187, 195], ["patients", "SPECIES", 246, 254], ["patients", "SPECIES", 483, 491], ["patient", "SPECIES", 785, 792], ["crude mortality rate ratios", "TEST", 45, 72], ["clozapine", "TREATMENT", 132, 141], ["clozapine", "TREATMENT", 222, 231], ["other antipsychotics", "TREATMENT", 261, 281], ["mortality rate ratio", "TEST", 283, 303], ["CI", "TEST", 314, 316], ["clozapine", "TREATMENT", 395, 404], ["inflammation", "PROBLEM", 410, 422], ["clozapine patients", "TREATMENT", 473, 491], ["Clozapine", "TREATMENT", 492, 501], ["pneumonia", "PROBLEM", 539, 548], ["other infections", "PROBLEM", 559, 575], ["systemic inflammations", "PROBLEM", 625, 647], ["clozapine level", "TREATMENT", 661, 676], ["clozapine", "TREATMENT", 682, 691], ["inflammation", "PROBLEM", 714, 726], ["clozapine", "TREATMENT", 798, 807], ["infection", "PROBLEM", 833, 842], ["clozapine", "TREATMENT", 871, 880], ["pneumonia", "PROBLEM", 938, 947], ["pneumonia", "OBSERVATION", 539, 548], ["infections", "OBSERVATION", 565, 575], ["systemic", "ANATOMY", 625, 633], ["inflammations", "OBSERVATION", 634, 647], ["inflammation", "OBSERVATION", 714, 726], ["infection", "OBSERVATION", 833, 842], ["pneumonia", "OBSERVATION", 938, 947]]], ["Pneumonia appears to be associated with high mortality in clozapine patients around the world.", [["Pneumonia", "DISEASE", 0, 9], ["clozapine", "CHEMICAL", 58, 67], ["clozapine", "CHEMICAL", 58, 67], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["Pneumonia", "PROBLEM", 0, 9], ["clozapine", "TREATMENT", 58, 67], ["high", "OBSERVATION_MODIFIER", 40, 44], ["mortality", "OBSERVATION_MODIFIER", 45, 54]]], ["Clinicians who are alert to the risk of pneumonia in clozapine patients may significantly decrease mortality in clozapine patients.", [["pneumonia", "DISEASE", 40, 49], ["clozapine", "CHEMICAL", 53, 62], ["clozapine", "CHEMICAL", 112, 121], ["clozapine", "CHEMICAL", 53, 62], ["clozapine", "CHEMICAL", 112, 121], ["patients", "ORGANISM", 63, 71], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 63, 71], ["patients", "SPECIES", 122, 130], ["pneumonia", "PROBLEM", 40, 49], ["clozapine", "TREATMENT", 53, 62], ["clozapine patients", "TREATMENT", 112, 130], ["pneumonia", "OBSERVATION", 40, 49]]]], "3ee0be38c9320579bc3b906bb8133d39daf27024": [["Hippocrates, when writing of the occurrence of diseases, distinguished between the 'steady state', the 'endemic state' and the abrupt change in incidence, the 'epidemic'.", [["diseases", "PROBLEM", 47, 55], ["the abrupt change", "PROBLEM", 123, 140], ["diseases", "OBSERVATION", 47, 55], ["abrupt", "OBSERVATION_MODIFIER", 127, 133], ["change", "OBSERVATION_MODIFIER", 134, 140]]]]}